_unit_id,_created_at,_canary,_id,_started_at,_channel,_trust,_worker_id,_country,_region,_city,_ip,b1,b2,confirmids1,confirmids2,e1,e2,factor1,factor2,firstfactor,saveselectionids1,saveselectionids2,secondfactor,sentence,wordid1,wordid2,orig_b1,orig_b2,orig_e1,orig_e2,expertdecision,relation,sent_id,orig_sentence,term1,term2
502844709,7/13/2014 21:49:33,,1322179864,7/13/2014 21:49:16,clixsense,1,15189335,GBR,K3,Peterborough,81.156.166.189,71,0,,,84,7,HYPERGLYCEMIA,INSULIN,HYPERGLYCEMIA,71,0,INSULIN,Insulin and fluid and electrolyte therapy are initiated to control the hyperglycemia and prevent shock and further complications.,71,0,71,0,84,7,1,RO-may_treat,907972,Insulin and fluid and electrolyte therapy are initiated to control the hyperglycemia and prevent shock and further complications,hyperglycemia,Insulin
502844709,7/13/2014 21:53:57,,1322183451,7/13/2014 21:53:20,elite,1,28397222,GBR,,,31.49.231.211,71,0,,,84,7,HYPERGLYCEMIA,INSULIN,HYPERGLYCEMIA,71,0,INSULIN,Insulin and fluid and electrolyte therapy are initiated to control the hyperglycemia and prevent shock and further complications.,71,0,71,0,84,7,1,RO-may_treat,907972,Insulin and fluid and electrolyte therapy are initiated to control the hyperglycemia and prevent shock and further complications,hyperglycemia,Insulin
502844709,7/13/2014 21:55:34,,1322184831,7/13/2014 21:55:19,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,71,0,,,84,7,HYPERGLYCEMIA,INSULIN,HYPERGLYCEMIA,71,0,INSULIN,Insulin and fluid and electrolyte therapy are initiated to control the hyperglycemia and prevent shock and further complications.,71,0,71,0,84,7,1,RO-may_treat,907972,Insulin and fluid and electrolyte therapy are initiated to control the hyperglycemia and prevent shock and further complications,hyperglycemia,Insulin
502844709,7/13/2014 21:58:22,,1322187435,7/13/2014 21:58:12,elite,1,28503042,USA,OK,Oakwood,64.250.220.169,71,0,,,84,7,HYPERGLYCEMIA,INSULIN,HYPERGLYCEMIA,71,0,INSULIN,Insulin and fluid and electrolyte therapy are initiated to control the hyperglycemia and prevent shock and further complications.,71,0,71,0,84,7,1,RO-may_treat,907972,Insulin and fluid and electrolyte therapy are initiated to control the hyperglycemia and prevent shock and further complications,hyperglycemia,Insulin
502844709,7/13/2014 21:59:40,,1322188754,7/13/2014 21:59:35,clixsense,1,24763049,GBR,,,86.133.47.213,71,0,,,84,7,HYPERGLYCEMIA,INSULIN,to control the HYPERGLYCEMIA and prevent shock,56-59-67-71-85-89-97,0-8-12-18,INSULIN and fluid and,Insulin and fluid and electrolyte therapy are initiated to control the hyperglycemia and prevent shock and further complications.,71,0,71,0,84,7,1,RO-may_treat,907972,Insulin and fluid and electrolyte therapy are initiated to control the hyperglycemia and prevent shock and further complications,hyperglycemia,Insulin
502844709,7/13/2014 22:00:25,,1322189441,7/13/2014 21:59:52,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,71,0,,,84,7,HYPERGLYCEMIA,INSULIN,Insulin and fluid and electrolyte therapy HYPERGLYCEMIA prevent shock,0-8-12-18-22-34-71-89-97,0-8-12-18-22-71-89-97-34,INSULIN and fluid and electrolyte therapy hyperglycemia prevent shock,Insulin and fluid and electrolyte therapy are initiated to control the hyperglycemia and prevent shock and further complications.,71,0,71,0,84,7,1,RO-may_treat,907972,Insulin and fluid and electrolyte therapy are initiated to control the hyperglycemia and prevent shock and further complications,hyperglycemia,Insulin
502844709,7/13/2014 22:05:43,,1322193981,7/13/2014 22:05:33,bitcoinget,1,24792414,USA,IA,Independence,166.181.80.204,71,0,,,84,7,HYPERGLYCEMIA,INSULIN,HYPERGLYCEMIA,71,0,INSULIN,Insulin and fluid and electrolyte therapy are initiated to control the hyperglycemia and prevent shock and further complications.,71,0,71,0,84,7,1,RO-may_treat,907972,Insulin and fluid and electrolyte therapy are initiated to control the hyperglycemia and prevent shock and further complications,hyperglycemia,Insulin
502844709,7/13/2014 22:06:43,,1322194859,7/13/2014 22:06:21,prodege,1,28255346,GBR,L9,Sheffield,2.125.183.137,71,0,,,84,7,HYPERGLYCEMIA,INSULIN,HYPERGLYCEMIA,71,0-8-12-18-22-34,INSULIN and fluid and electrolyte therapy,Insulin and fluid and electrolyte therapy are initiated to control the hyperglycemia and prevent shock and further complications.,71,0,71,0,84,7,1,RO-may_treat,907972,Insulin and fluid and electrolyte therapy are initiated to control the hyperglycemia and prevent shock and further complications,hyperglycemia,Insulin
502844709,7/13/2014 22:15:51,,1322202184,7/13/2014 22:15:32,instagc,1,23149109,USA,NC,Durham,75.189.206.205,71,0,,,84,7,HYPERGLYCEMIA,INSULIN,HYPERGLYCEMIA,71,0,INSULIN,Insulin and fluid and electrolyte therapy are initiated to control the hyperglycemia and prevent shock and further complications.,71,0,71,0,84,7,1,RO-may_treat,907972,Insulin and fluid and electrolyte therapy are initiated to control the hyperglycemia and prevent shock and further complications,hyperglycemia,Insulin
502844709,7/13/2014 22:25:01,,1322210315,7/13/2014 22:24:46,gifthulk,1,22552178,AUS,5,Adelaide,14.2.7.227,71,0,,,84,7,HYPERGLYCEMIA,INSULIN,HYPERGLYCEMIA,71,0,INSULIN,Insulin and fluid and electrolyte therapy are initiated to control the hyperglycemia and prevent shock and further complications.,71,0,71,0,84,7,1,RO-may_treat,907972,Insulin and fluid and electrolyte therapy are initiated to control the hyperglycemia and prevent shock and further complications,hyperglycemia,Insulin
502844710,7/13/2014 22:01:43,,1322190812,7/13/2014 22:01:22,clixsense,1,25402344,CAN,ON,Wawa,24.109.124.45,99,66,,,103,79,BONE,OSTEOMYELITIS,/,-1,-1,/,"In a 5 1/2-year retrospective study of hospitalized children with osteomyelitis who had technetium bone scans, we found that 32 of 38 (84%) had increased radionuclide uptake, 4 (11%) had normal uptake and 2 (5%) had decreased uptake.",,,99,66,103,79,1,RO-disease_has_primary_anatomic_site,902221,"In a 5 1/2-year retrospective study of hospitalized children with osteomyelitis who had technetium bone scans, we found that 32 of 38 (84%) had increased radionuclide uptake, 4 (11%) had normal uptake and 2 (5%) had decreased uptake",bone,osteomyelitis
502844710,7/13/2014 22:07:34,,1322195511,7/13/2014 22:06:43,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,99,66,,,103,79,BONE,OSTEOMYELITIS,/,-1,,,"In a 5 1/2-year retrospective study of hospitalized children with osteomyelitis who had technetium bone scans, we found that 32 of 38 (84%) had increased radionuclide uptake, 4 (11%) had normal uptake and 2 (5%) had decreased uptake.",,,99,66,103,79,1,RO-disease_has_primary_anatomic_site,902221,"In a 5 1/2-year retrospective study of hospitalized children with osteomyelitis who had technetium bone scans, we found that 32 of 38 (84%) had increased radionuclide uptake, 4 (11%) had normal uptake and 2 (5%) had decreased uptake",bone,osteomyelitis
502844710,7/13/2014 22:08:55,,1322196507,7/13/2014 22:07:46,clixsense,1,15189335,GBR,K3,Peterborough,81.156.166.189,99,66,,,103,79,BONE,OSTEOMYELITIS,/,-1,-1,/,"In a 5 1/2-year retrospective study of hospitalized children with osteomyelitis who had technetium bone scans, we found that 32 of 38 (84%) had increased radionuclide uptake, 4 (11%) had normal uptake and 2 (5%) had decreased uptake.",,,99,66,103,79,1,RO-disease_has_primary_anatomic_site,902221,"In a 5 1/2-year retrospective study of hospitalized children with osteomyelitis who had technetium bone scans, we found that 32 of 38 (84%) had increased radionuclide uptake, 4 (11%) had normal uptake and 2 (5%) had decreased uptake",bone,osteomyelitis
502844710,7/13/2014 22:11:16,,1322198556,7/13/2014 22:09:48,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,99,66,,,103,79,BONE,OSTEOMYELITIS,/ had uptake,140-226--1,-1-140,/ had,"In a 5 1/2-year retrospective study of hospitalized children with osteomyelitis who had technetium bone scans, we found that 32 of 38 (84%) had increased radionuclide uptake, 4 (11%) had normal uptake and 2 (5%) had decreased uptake.",,,99,66,103,79,1,RO-disease_has_primary_anatomic_site,902221,"In a 5 1/2-year retrospective study of hospitalized children with osteomyelitis who had technetium bone scans, we found that 32 of 38 (84%) had increased radionuclide uptake, 4 (11%) had normal uptake and 2 (5%) had decreased uptake",bone,osteomyelitis
502844710,7/13/2014 22:14:31,,1322201199,7/13/2014 22:13:13,clixsense,1,8769423,AUS,6,Hobart,147.69.162.116,99,66,,,103,79,BONE,OSTEOMYELITIS,/,-1,,,"In a 5 1/2-year retrospective study of hospitalized children with osteomyelitis who had technetium bone scans, we found that 32 of 38 (84%) had increased radionuclide uptake, 4 (11%) had normal uptake and 2 (5%) had decreased uptake.",,,99,66,103,79,1,RO-disease_has_primary_anatomic_site,902221,"In a 5 1/2-year retrospective study of hospitalized children with osteomyelitis who had technetium bone scans, we found that 32 of 38 (84%) had increased radionuclide uptake, 4 (11%) had normal uptake and 2 (5%) had decreased uptake",bone,osteomyelitis
502844710,7/13/2014 22:22:54,,1322208331,7/13/2014 22:22:40,gifthulk,1,22552178,AUS,5,Adelaide,14.2.7.227,99,66,,,103,79,BONE,OSTEOMYELITIS,/,-1,-1,/,"In a 5 1/2-year retrospective study of hospitalized children with osteomyelitis who had technetium bone scans, we found that 32 of 38 (84%) had increased radionuclide uptake, 4 (11%) had normal uptake and 2 (5%) had decreased uptake.",,,99,66,103,79,1,RO-disease_has_primary_anatomic_site,902221,"In a 5 1/2-year retrospective study of hospitalized children with osteomyelitis who had technetium bone scans, we found that 32 of 38 (84%) had increased radionuclide uptake, 4 (11%) had normal uptake and 2 (5%) had decreased uptake",bone,osteomyelitis
502844710,7/13/2014 22:24:11,,1322209421,7/13/2014 22:23:44,clixsense,1,26889820,GBR,C3,Shelford,92.18.120.203,99,66,,,103,79,BONE,OSTEOMYELITIS,/,-1,-1,/,"In a 5 1/2-year retrospective study of hospitalized children with osteomyelitis who had technetium bone scans, we found that 32 of 38 (84%) had increased radionuclide uptake, 4 (11%) had normal uptake and 2 (5%) had decreased uptake.",,,99,66,103,79,1,RO-disease_has_primary_anatomic_site,902221,"In a 5 1/2-year retrospective study of hospitalized children with osteomyelitis who had technetium bone scans, we found that 32 of 38 (84%) had increased radionuclide uptake, 4 (11%) had normal uptake and 2 (5%) had decreased uptake",bone,osteomyelitis
502844710,7/13/2014 22:27:06,,1322212370,7/13/2014 22:26:46,prodege,1,2143114,CAN,BC,Vancouver,24.84.160.12,99,66,,,103,79,BONE,OSTEOMYELITIS,/,-1,-1,/,"In a 5 1/2-year retrospective study of hospitalized children with osteomyelitis who had technetium bone scans, we found that 32 of 38 (84%) had increased radionuclide uptake, 4 (11%) had normal uptake and 2 (5%) had decreased uptake.",,,99,66,103,79,1,RO-disease_has_primary_anatomic_site,902221,"In a 5 1/2-year retrospective study of hospitalized children with osteomyelitis who had technetium bone scans, we found that 32 of 38 (84%) had increased radionuclide uptake, 4 (11%) had normal uptake and 2 (5%) had decreased uptake",bone,osteomyelitis
502844710,7/13/2014 22:28:28,,1322213634,7/13/2014 22:27:47,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,99,66,,,103,79,BONE,OSTEOMYELITIS,/,-1,-1,/,"In a 5 1/2-year retrospective study of hospitalized children with osteomyelitis who had technetium bone scans, we found that 32 of 38 (84%) had increased radionuclide uptake, 4 (11%) had normal uptake and 2 (5%) had decreased uptake.",,,99,66,103,79,1,RO-disease_has_primary_anatomic_site,902221,"In a 5 1/2-year retrospective study of hospitalized children with osteomyelitis who had technetium bone scans, we found that 32 of 38 (84%) had increased radionuclide uptake, 4 (11%) had normal uptake and 2 (5%) had decreased uptake",bone,osteomyelitis
502844710,7/13/2014 22:29:50,,1322214966,7/13/2014 22:29:20,clixsense,1,21875134,GBR,,,91.125.61.83,99,66,,,103,79,BONE,OSTEOMYELITIS,/,-1,-1,/,"In a 5 1/2-year retrospective study of hospitalized children with osteomyelitis who had technetium bone scans, we found that 32 of 38 (84%) had increased radionuclide uptake, 4 (11%) had normal uptake and 2 (5%) had decreased uptake.",,,99,66,103,79,1,RO-disease_has_primary_anatomic_site,902221,"In a 5 1/2-year retrospective study of hospitalized children with osteomyelitis who had technetium bone scans, we found that 32 of 38 (84%) had increased radionuclide uptake, 4 (11%) had normal uptake and 2 (5%) had decreased uptake",bone,osteomyelitis
502844711,7/13/2014 21:53:02,,1322182616,7/13/2014 21:52:49,instagc,1,28301350,GBR,K4,Plymouth,89.242.63.62,36,66,,,48,82,HYPERTENSION,PHEOCHROMOCYTOMA,arterial HYPERTENSION,27-36,27-36-66,arterial hypertension PHEOCHROMOCYTOMA,2]  Dimopoulos C. [Cure of arterial hypertension by excision of a pheochromocytoma (2 cases.,36,66,36,66,48,82,-1,RO-disease_may_have_finding,902920,2]  Dimopoulos C. [Cure of arterial hypertension by excision of a pheochromocytoma (2 cases,hypertension,pheochromocytoma
502844711,7/13/2014 21:53:56,,1322183437,7/13/2014 21:53:45,elite,1,28503042,USA,OK,Oakwood,64.250.220.169,36,66,,,48,82,HYPERTENSION,PHEOCHROMOCYTOMA,arterial HYPERTENSION,27-36,66,PHEOCHROMOCYTOMA,2]  Dimopoulos C. [Cure of arterial hypertension by excision of a pheochromocytoma (2 cases.,36,66,36,66,48,82,-1,RO-disease_may_have_finding,902920,2]  Dimopoulos C. [Cure of arterial hypertension by excision of a pheochromocytoma (2 cases,hypertension,pheochromocytoma
502844711,7/13/2014 21:55:28,,1322184778,7/13/2014 21:55:06,clixsense,1,15189335,GBR,K3,Peterborough,81.156.166.189,36,66,,,48,82,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,36,66,PHEOCHROMOCYTOMA,2]  Dimopoulos C. [Cure of arterial hypertension by excision of a pheochromocytoma (2 cases.,36,66,36,66,48,82,-1,RO-disease_may_have_finding,902920,2]  Dimopoulos C. [Cure of arterial hypertension by excision of a pheochromocytoma (2 cases,hypertension,pheochromocytoma
502844711,7/13/2014 21:59:08,,1322188083,7/13/2014 21:59:03,clixsense,1,24763049,GBR,,,86.133.47.213,36,66,,,48,82,HYPERTENSION,PHEOCHROMOCYTOMA,[Cure of arterial HYPERTENSION by excision of,18-24-27-36-49-52-61,52-61-64-66-86,excision of a PHEOCHROMOCYTOMA cases.,2]  Dimopoulos C. [Cure of arterial hypertension by excision of a pheochromocytoma (2 cases.,36,66,36,66,48,82,-1,RO-disease_may_have_finding,902920,2]  Dimopoulos C. [Cure of arterial hypertension by excision of a pheochromocytoma (2 cases,hypertension,pheochromocytoma
502844711,7/13/2014 22:00:55,,1322190129,7/13/2014 22:00:41,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,36,66,,,48,82,HYPERTENSION,PHEOCHROMOCYTOMA,arterial HYPERTENSION,27-36,66,PHEOCHROMOCYTOMA,2]  Dimopoulos C. [Cure of arterial hypertension by excision of a pheochromocytoma (2 cases.,36,66,36,66,48,82,-1,RO-disease_may_have_finding,902920,2]  Dimopoulos C. [Cure of arterial hypertension by excision of a pheochromocytoma (2 cases,hypertension,pheochromocytoma
502844711,7/13/2014 22:02:23,,1322191442,7/13/2014 22:02:10,clixsense,1,25402344,CAN,ON,Wawa,24.109.124.45,36,66,,,48,82,HYPERTENSION,PHEOCHROMOCYTOMA,[Cure of arterial HYPERTENSION by excision of,18-24-27-36-49-52-61,52-61-64-66-86,excision of a PHEOCHROMOCYTOMA cases.,2]  Dimopoulos C. [Cure of arterial hypertension by excision of a pheochromocytoma (2 cases.,36,66,36,66,48,82,-1,RO-disease_may_have_finding,902920,2]  Dimopoulos C. [Cure of arterial hypertension by excision of a pheochromocytoma (2 cases,hypertension,pheochromocytoma
502844711,7/13/2014 22:02:39,,1322191612,7/13/2014 22:02:22,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,36,66,,,48,82,HYPERTENSION,PHEOCHROMOCYTOMA,arterial HYPERTENSION,27-36,66,PHEOCHROMOCYTOMA,2]  Dimopoulos C. [Cure of arterial hypertension by excision of a pheochromocytoma (2 cases.,36,66,36,66,48,82,-1,RO-disease_may_have_finding,902920,2]  Dimopoulos C. [Cure of arterial hypertension by excision of a pheochromocytoma (2 cases,hypertension,pheochromocytoma
502844711,7/13/2014 22:03:55,,1322192572,7/13/2014 22:03:29,elite,1,28397222,GBR,,,31.49.231.211,36,66,,,48,82,HYPERTENSION,PHEOCHROMOCYTOMA,arterial HYPERTENSION,27-36,66,PHEOCHROMOCYTOMA,2]  Dimopoulos C. [Cure of arterial hypertension by excision of a pheochromocytoma (2 cases.,36,66,36,66,48,82,-1,RO-disease_may_have_finding,902920,2]  Dimopoulos C. [Cure of arterial hypertension by excision of a pheochromocytoma (2 cases,hypertension,pheochromocytoma
502844711,7/13/2014 22:11:39,,1322198883,7/13/2014 22:11:04,prodege,1,17932518,GBR,Y2,Pwllheli,95.151.166.224,36,66,,,48,82,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,36,66,PHEOCHROMOCYTOMA,2]  Dimopoulos C. [Cure of arterial hypertension by excision of a pheochromocytoma (2 cases.,36,66,36,66,48,82,-1,RO-disease_may_have_finding,902920,2]  Dimopoulos C. [Cure of arterial hypertension by excision of a pheochromocytoma (2 cases,hypertension,pheochromocytoma
502844711,7/13/2014 22:14:52,,1322201477,7/13/2014 22:14:33,clixsense,1,8769423,AUS,6,Hobart,147.69.162.116,36,66,,,48,82,HYPERTENSION,PHEOCHROMOCYTOMA,HYPERTENSION,36,66,PHEOCHROMOCYTOMA,2]  Dimopoulos C. [Cure of arterial hypertension by excision of a pheochromocytoma (2 cases.,36,66,36,66,48,82,-1,RO-disease_may_have_finding,902920,2]  Dimopoulos C. [Cure of arterial hypertension by excision of a pheochromocytoma (2 cases,hypertension,pheochromocytoma
502844712,7/13/2014 21:50:09,,1322180342,7/13/2014 21:49:55,instagc,1,28301350,GBR,K4,Plymouth,89.242.63.62,4,46,,,22,59,EPSTEIN-BARR VIRUS,MONONUCLEOSIS,EPSTEIN BARR VIRUS,4-12-17,4-12-17-46,EPSTEIN BARR VIRUS MONONUCLEOSIS,41  EPSTEIN-BARR VIRUS  EBV causes infectious mononucleosis and has been implicated as a cause of nasopharyngeal carcinoma and Burkitt lymphoma.,4 12 17,46,4,46,22,59,1,RO-has_causative_agent,903618,41  EPSTEIN-BARR VIRUS  EBV causes infectious mononucleosis and has been implicated as a cause of nasopharyngeal carcinoma and Burkitt lymphoma,EPSTEIN-BARR VIRUS,mononucleosis
502844712,7/13/2014 21:59:27,,1322188480,7/13/2014 21:59:22,clixsense,1,24763049,GBR,,,86.133.47.213,4,46,,,22,59,EPSTEIN-BARR VIRUS,MONONUCLEOSIS,41 EPSTEIN BARR VIRUS EBV causes infectious,0-4-12-17-24-28-35,24-28-35-46-60-64-68,EBV causes infectious MONONUCLEOSIS and has been,41  EPSTEIN-BARR VIRUS  EBV causes infectious mononucleosis and has been implicated as a cause of nasopharyngeal carcinoma and Burkitt lymphoma.,4 12 17,46,4,46,22,59,1,RO-has_causative_agent,903618,41  EPSTEIN-BARR VIRUS  EBV causes infectious mononucleosis and has been implicated as a cause of nasopharyngeal carcinoma and Burkitt lymphoma,EPSTEIN-BARR VIRUS,mononucleosis
502844712,7/13/2014 22:00:21,,1322189339,7/13/2014 22:00:13,clixsense,1,25402344,CAN,ON,Wawa,24.109.124.45,4,46,,,22,59,EPSTEIN-BARR VIRUS,MONONUCLEOSIS,41 EPSTEIN BARR VIRUS EBV causes infectious,0-4-12-17-24-28-35,24-28-35-46-60-64-68,EBV causes infectious MONONUCLEOSIS and has been,41  EPSTEIN-BARR VIRUS  EBV causes infectious mononucleosis and has been implicated as a cause of nasopharyngeal carcinoma and Burkitt lymphoma.,4 12 17,46,4,46,22,59,1,RO-has_causative_agent,903618,41  EPSTEIN-BARR VIRUS  EBV causes infectious mononucleosis and has been implicated as a cause of nasopharyngeal carcinoma and Burkitt lymphoma,EPSTEIN-BARR VIRUS,mononucleosis
502844712,7/13/2014 22:01:35,,1322190713,7/13/2014 22:01:19,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,4,46,,,22,59,EPSTEIN-BARR VIRUS,MONONUCLEOSIS,EPSTEIN BARR VIRUS EBV,4-12-17-24,46,MONONUCLEOSIS,41  EPSTEIN-BARR VIRUS  EBV causes infectious mononucleosis and has been implicated as a cause of nasopharyngeal carcinoma and Burkitt lymphoma.,4 12 17,46,4,46,22,59,1,RO-has_causative_agent,903618,41  EPSTEIN-BARR VIRUS  EBV causes infectious mononucleosis and has been implicated as a cause of nasopharyngeal carcinoma and Burkitt lymphoma,EPSTEIN-BARR VIRUS,mononucleosis
502844712,7/13/2014 22:10:02,,1322197341,7/13/2014 22:09:35,clixsense,1,8769423,AUS,6,Hobart,147.69.162.116,4,46,,,22,59,EPSTEIN-BARR VIRUS,MONONUCLEOSIS,EPSTEIN BARR VIRUS,4-12-17,46,MONONUCLEOSIS,41  EPSTEIN-BARR VIRUS  EBV causes infectious mononucleosis and has been implicated as a cause of nasopharyngeal carcinoma and Burkitt lymphoma.,4 12 17,46,4,46,22,59,1,RO-has_causative_agent,903618,41  EPSTEIN-BARR VIRUS  EBV causes infectious mononucleosis and has been implicated as a cause of nasopharyngeal carcinoma and Burkitt lymphoma,EPSTEIN-BARR VIRUS,mononucleosis
502844712,7/13/2014 22:17:25,,1322203502,7/13/2014 22:17:09,instagc,1,23149109,USA,NC,Durham,75.189.206.205,4,46,,,22,59,EPSTEIN-BARR VIRUS,MONONUCLEOSIS,EPSTEIN BARR VIRUS EBV,4-12-17-24,35-46,infectious MONONUCLEOSIS,41  EPSTEIN-BARR VIRUS  EBV causes infectious mononucleosis and has been implicated as a cause of nasopharyngeal carcinoma and Burkitt lymphoma.,4 12 17,46,4,46,22,59,1,RO-has_causative_agent,903618,41  EPSTEIN-BARR VIRUS  EBV causes infectious mononucleosis and has been implicated as a cause of nasopharyngeal carcinoma and Burkitt lymphoma,EPSTEIN-BARR VIRUS,mononucleosis
502844712,7/13/2014 22:22:36,,1322208000,7/13/2014 22:22:20,clixsense,1,10842668,GBR,,,80.189.187.36,4,46,,,22,59,EPSTEIN-BARR VIRUS,MONONUCLEOSIS,EPSTEIN BARR VIRUS EBV,4-12-17-24,24-35-46,EBV infectious MONONUCLEOSIS,41  EPSTEIN-BARR VIRUS  EBV causes infectious mononucleosis and has been implicated as a cause of nasopharyngeal carcinoma and Burkitt lymphoma.,4 12 17,46,4,46,22,59,1,RO-has_causative_agent,903618,41  EPSTEIN-BARR VIRUS  EBV causes infectious mononucleosis and has been implicated as a cause of nasopharyngeal carcinoma and Burkitt lymphoma,EPSTEIN-BARR VIRUS,mononucleosis
502844712,7/13/2014 22:23:19,,1322208642,7/13/2014 22:21:55,instagc,1,27770607,USA,TX,El Paso,72.183.248.75,4,46,,,22,59,EPSTEIN-BARR VIRUS,MONONUCLEOSIS,41 EPSTEIN BARR VIRUS EBV,0-4-12-17-24,35-46,infectious MONONUCLEOSIS,41  EPSTEIN-BARR VIRUS  EBV causes infectious mononucleosis and has been implicated as a cause of nasopharyngeal carcinoma and Burkitt lymphoma.,4 12 17,46,4,46,22,59,1,RO-has_causative_agent,903618,41  EPSTEIN-BARR VIRUS  EBV causes infectious mononucleosis and has been implicated as a cause of nasopharyngeal carcinoma and Burkitt lymphoma,EPSTEIN-BARR VIRUS,mononucleosis
502844712,7/13/2014 22:23:46,,1322209013,7/13/2014 22:23:32,gifthulk,1,22552178,AUS,5,Adelaide,14.2.7.227,4,46,,,22,59,EPSTEIN-BARR VIRUS,MONONUCLEOSIS,EPSTEIN BARR VIRUS,4-12-17,46,MONONUCLEOSIS,41  EPSTEIN-BARR VIRUS  EBV causes infectious mononucleosis and has been implicated as a cause of nasopharyngeal carcinoma and Burkitt lymphoma.,4 12 17,46,4,46,22,59,1,RO-has_causative_agent,903618,41  EPSTEIN-BARR VIRUS  EBV causes infectious mononucleosis and has been implicated as a cause of nasopharyngeal carcinoma and Burkitt lymphoma,EPSTEIN-BARR VIRUS,mononucleosis
502844712,7/13/2014 22:27:20,,1322212547,7/13/2014 22:27:06,prodege,1,2143114,CAN,BC,Vancouver,24.84.160.12,4,46,,,22,59,EPSTEIN-BARR VIRUS,MONONUCLEOSIS,EPSTEIN BARR VIRUS EBV,4-12-17-24,46,MONONUCLEOSIS,41  EPSTEIN-BARR VIRUS  EBV causes infectious mononucleosis and has been implicated as a cause of nasopharyngeal carcinoma and Burkitt lymphoma.,4 12 17,46,4,46,22,59,1,RO-has_causative_agent,903618,41  EPSTEIN-BARR VIRUS  EBV causes infectious mononucleosis and has been implicated as a cause of nasopharyngeal carcinoma and Burkitt lymphoma,EPSTEIN-BARR VIRUS,mononucleosis
502844713,7/13/2014 21:53:48,,1322183311,7/13/2014 21:53:43,clixsense,1,24763049,GBR,,,86.133.47.213,6,70,,,10,96,LUNG,NON-SMALL CELL LUNG CANCER,Human LUNG cancers are divided,0-6-11-19-23,52-59-66-70-74-80-85-90-105-111,cancer (SCLC) and NON SMALL CELL LUNG CANCER based on,Human lung cancers are divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) based on established criteria.,6,70 74 80 85 90,6,70,10,96,1,RO-disease_has_primary_anatomic_site,902340,Human lung cancers are divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) based on established criteria,lung,non-small cell lung cancer
502844713,7/13/2014 21:56:37,,1322185866,7/13/2014 21:56:27,elite,1,28503042,USA,OK,Oakwood,64.250.220.169,6,70,,,10,96,LUNG,NON-SMALL CELL LUNG CANCER,Human LUNG cancers,0-6-11,70-74-80-85-90-97,NON SMALL CELL LUNG CANCER (NSCLC),Human lung cancers are divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) based on established criteria.,6,70 74 80 85 90,6,70,10,96,1,RO-disease_has_primary_anatomic_site,902340,Human lung cancers are divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) based on established criteria,lung,non-small cell lung cancer
502844713,7/13/2014 21:59:17,,1322188257,7/13/2014 21:58:51,clixsense,1,15189335,GBR,K3,Peterborough,81.156.166.189,6,70,,,10,96,LUNG,NON-SMALL CELL LUNG CANCER,LUNG,6,70-74-80-85-90,NON SMALL CELL LUNG CANCER,Human lung cancers are divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) based on established criteria.,6,70 74 80 85 90,6,70,10,96,1,RO-disease_has_primary_anatomic_site,902340,Human lung cancers are divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) based on established criteria,lung,non-small cell lung cancer
502844713,7/13/2014 22:05:23,,1322193725,7/13/2014 22:05:03,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,6,70,,,10,96,LUNG,NON-SMALL CELL LUNG CANCER,LUNG cancers,6-11,36-42-47-52-59-66-70-74-80-85-90-97,small cell lung cancer (SCLC) and NON SMALL CELL LUNG CANCER (NSCLC),Human lung cancers are divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) based on established criteria.,6,70 74 80 85 90,6,70,10,96,1,RO-disease_has_primary_anatomic_site,902340,Human lung cancers are divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) based on established criteria,lung,non-small cell lung cancer
502844713,7/13/2014 22:05:58,,1322194214,7/13/2014 22:04:54,prodege,1,17932518,GBR,Y2,Pwllheli,95.151.166.224,6,70,,,10,96,LUNG,NON-SMALL CELL LUNG CANCER,LUNG,6,70-74-80-85-90,NON SMALL CELL LUNG CANCER,Human lung cancers are divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) based on established criteria.,6,70 74 80 85 90,6,70,10,96,1,RO-disease_has_primary_anatomic_site,902340,Human lung cancers are divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) based on established criteria,lung,non-small cell lung cancer
502844713,7/13/2014 22:06:13,,1322194437,7/13/2014 22:06:00,bitcoinget,1,24792414,USA,IA,Independence,166.181.80.204,6,70,,,10,96,LUNG,NON-SMALL CELL LUNG CANCER,Human LUNG cancers,6-11-0,70-74-80-85-90,NON SMALL CELL LUNG CANCER,Human lung cancers are divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) based on established criteria.,6,70 74 80 85 90,6,70,10,96,1,RO-disease_has_primary_anatomic_site,902340,Human lung cancers are divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) based on established criteria,lung,non-small cell lung cancer
502844713,7/13/2014 22:07:01,,1322195069,7/13/2014 22:06:45,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,6,70,,,10,96,LUNG,NON-SMALL CELL LUNG CANCER,LUNG cancers,6-11,70-74-80-85-90,NON SMALL CELL LUNG CANCER,Human lung cancers are divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) based on established criteria.,6,70 74 80 85 90,6,70,10,96,1,RO-disease_has_primary_anatomic_site,902340,Human lung cancers are divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) based on established criteria,lung,non-small cell lung cancer
502844713,7/13/2014 22:08:50,,1322196474,7/13/2014 22:08:16,elite,1,28397222,GBR,,,31.49.231.211,6,70,,,10,96,LUNG,NON-SMALL CELL LUNG CANCER,LUNG cancers,6-11,70-74-80-85-90,NON SMALL CELL LUNG CANCER,Human lung cancers are divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) based on established criteria.,6,70 74 80 85 90,6,70,10,96,1,RO-disease_has_primary_anatomic_site,902340,Human lung cancers are divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) based on established criteria,lung,non-small cell lung cancer
502844713,7/13/2014 22:17:36,,1322203647,7/13/2014 22:17:15,gifthulk,1,22552178,AUS,5,Adelaide,14.2.7.227,6,70,,,10,96,LUNG,NON-SMALL CELL LUNG CANCER,LUNG,6,70-74-80-85-90,NON SMALL CELL LUNG CANCER,Human lung cancers are divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) based on established criteria.,6,70 74 80 85 90,6,70,10,96,1,RO-disease_has_primary_anatomic_site,902340,Human lung cancers are divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) based on established criteria,lung,non-small cell lung cancer
502844713,7/13/2014 22:18:51,,1322204762,7/13/2014 22:18:40,clixsense,1,10842668,GBR,,,80.189.187.36,6,70,,,10,96,LUNG,NON-SMALL CELL LUNG CANCER,LUNG,6,70-74-80-85-90-111,NON SMALL CELL LUNG CANCER on,Human lung cancers are divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) based on established criteria.,6,70 74 80 85 90,6,70,10,96,1,RO-disease_has_primary_anatomic_site,902340,Human lung cancers are divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) based on established criteria,lung,non-small cell lung cancer
502844714,7/13/2014 21:57:04,,1322186336,7/13/2014 21:56:50,elite,1,28503042,USA,OK,Oakwood,64.250.220.169,210,199,,,224,206,PSEUDO-ALLERGY,ALLERGY,allergy or PSEUDO ALLERGY.,199-210-217-207,199-207-210-217,ALLERGY or pseudo allergy.,"In a multicentric study by the European Study Group of Drug Allergy, 69 patients suffering from immediate type reaction after the intake of non-steroidal antiphlogistica were examined with regard to allergy or pseudo-allergy.",210 217,199,210,199,224,206,-1,RO-cause_of,900271,"In a multicentric study by the European Study Group of Drug Allergy, 69 patients suffering from immediate type reaction after the intake of non-steroidal antiphlogistica were examined with regard to allergy or pseudo-allergy",pseudo-allergy,allergy
502844714,7/13/2014 21:58:39,,1322187700,7/13/2014 21:58:25,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,210,199,,,224,206,PSEUDO-ALLERGY,ALLERGY,PSEUDO ALLERGY.,210-217,199,ALLERGY,"In a multicentric study by the European Study Group of Drug Allergy, 69 patients suffering from immediate type reaction after the intake of non-steroidal antiphlogistica were examined with regard to allergy or pseudo-allergy.",210 217,199,210,199,224,206,-1,RO-cause_of,900271,"In a multicentric study by the European Study Group of Drug Allergy, 69 patients suffering from immediate type reaction after the intake of non-steroidal antiphlogistica were examined with regard to allergy or pseudo-allergy",pseudo-allergy,allergy
502844714,7/13/2014 21:58:50,,1322187842,7/13/2014 21:58:20,clixsense,1,15189335,GBR,K3,Peterborough,81.156.166.189,210,199,,,224,206,PSEUDO-ALLERGY,ALLERGY,PSEUDO ALLERGY.,210-217,199,ALLERGY,"In a multicentric study by the European Study Group of Drug Allergy, 69 patients suffering from immediate type reaction after the intake of non-steroidal antiphlogistica were examined with regard to allergy or pseudo-allergy.",210 217,199,210,199,224,206,-1,RO-cause_of,900271,"In a multicentric study by the European Study Group of Drug Allergy, 69 patients suffering from immediate type reaction after the intake of non-steroidal antiphlogistica were examined with regard to allergy or pseudo-allergy",pseudo-allergy,allergy
502844714,7/13/2014 21:59:10,,1322188176,7/13/2014 21:58:56,bitcoinget,1,24792414,USA,IA,Independence,166.181.80.204,210,199,,,224,206,PSEUDO-ALLERGY,ALLERGY,PSEUDO ALLERGY.,210-217,199,ALLERGY,"In a multicentric study by the European Study Group of Drug Allergy, 69 patients suffering from immediate type reaction after the intake of non-steroidal antiphlogistica were examined with regard to allergy or pseudo-allergy.",210 217,199,210,199,224,206,-1,RO-cause_of,900271,"In a multicentric study by the European Study Group of Drug Allergy, 69 patients suffering from immediate type reaction after the intake of non-steroidal antiphlogistica were examined with regard to allergy or pseudo-allergy",pseudo-allergy,allergy
502844714,7/13/2014 22:00:22,,1322189375,7/13/2014 22:00:05,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,210,199,,,224,206,PSEUDO-ALLERGY,ALLERGY,PSEUDO ALLERGY.,210-217,199,ALLERGY,"In a multicentric study by the European Study Group of Drug Allergy, 69 patients suffering from immediate type reaction after the intake of non-steroidal antiphlogistica were examined with regard to allergy or pseudo-allergy.",210 217,199,210,199,224,206,-1,RO-cause_of,900271,"In a multicentric study by the European Study Group of Drug Allergy, 69 patients suffering from immediate type reaction after the intake of non-steroidal antiphlogistica were examined with regard to allergy or pseudo-allergy",pseudo-allergy,allergy
502844714,7/13/2014 22:00:38,,1322189657,7/13/2014 21:59:46,clixsense,1,8769423,AUS,6,Hobart,147.69.162.116,210,199,,,224,206,PSEUDO-ALLERGY,ALLERGY,PSEUDO ALLERGY.,210-217,199,ALLERGY,"In a multicentric study by the European Study Group of Drug Allergy, 69 patients suffering from immediate type reaction after the intake of non-steroidal antiphlogistica were examined with regard to allergy or pseudo-allergy.",210 217,199,210,199,224,206,-1,RO-cause_of,900271,"In a multicentric study by the European Study Group of Drug Allergy, 69 patients suffering from immediate type reaction after the intake of non-steroidal antiphlogistica were examined with regard to allergy or pseudo-allergy",pseudo-allergy,allergy
502844714,7/13/2014 22:20:04,,1322205895,7/13/2014 22:19:05,prodege,1,17932518,GBR,Y2,Pwllheli,95.151.166.224,210,199,,,224,206,PSEUDO-ALLERGY,ALLERGY,PSEUDO ALLERGY.,210-217,199,ALLERGY,"In a multicentric study by the European Study Group of Drug Allergy, 69 patients suffering from immediate type reaction after the intake of non-steroidal antiphlogistica were examined with regard to allergy or pseudo-allergy.",210 217,199,210,199,224,206,-1,RO-cause_of,900271,"In a multicentric study by the European Study Group of Drug Allergy, 69 patients suffering from immediate type reaction after the intake of non-steroidal antiphlogistica were examined with regard to allergy or pseudo-allergy",pseudo-allergy,allergy
502844714,7/13/2014 22:21:25,,1322207022,7/13/2014 22:21:11,gifthulk,1,22552178,AUS,5,Adelaide,14.2.7.227,210,199,,,224,206,PSEUDO-ALLERGY,ALLERGY,PSEUDO ALLERGY.,210-217,199,ALLERGY,"In a multicentric study by the European Study Group of Drug Allergy, 69 patients suffering from immediate type reaction after the intake of non-steroidal antiphlogistica were examined with regard to allergy or pseudo-allergy.",210 217,199,210,199,224,206,-1,RO-cause_of,900271,"In a multicentric study by the European Study Group of Drug Allergy, 69 patients suffering from immediate type reaction after the intake of non-steroidal antiphlogistica were examined with regard to allergy or pseudo-allergy",pseudo-allergy,allergy
502844714,7/13/2014 22:22:22,,1322207785,7/13/2014 22:22:05,instagc,1,23149109,USA,NC,Durham,75.189.206.205,210,199,,,224,206,PSEUDO-ALLERGY,ALLERGY,allergy or PSEUDO ALLERGY.,199-207-210-217,199-207-210-217,ALLERGY or pseudo allergy.,"In a multicentric study by the European Study Group of Drug Allergy, 69 patients suffering from immediate type reaction after the intake of non-steroidal antiphlogistica were examined with regard to allergy or pseudo-allergy.",210 217,199,210,199,224,206,-1,RO-cause_of,900271,"In a multicentric study by the European Study Group of Drug Allergy, 69 patients suffering from immediate type reaction after the intake of non-steroidal antiphlogistica were examined with regard to allergy or pseudo-allergy",pseudo-allergy,allergy
502844714,7/13/2014 22:26:43,,1322211934,7/13/2014 22:25:57,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,210,199,,,224,206,PSEUDO-ALLERGY,ALLERGY,PSEUDO ALLERGY.,210-217,199,ALLERGY,"In a multicentric study by the European Study Group of Drug Allergy, 69 patients suffering from immediate type reaction after the intake of non-steroidal antiphlogistica were examined with regard to allergy or pseudo-allergy.",210 217,199,210,199,224,206,-1,RO-cause_of,900271,"In a multicentric study by the European Study Group of Drug Allergy, 69 patients suffering from immediate type reaction after the intake of non-steroidal antiphlogistica were examined with regard to allergy or pseudo-allergy",pseudo-allergy,allergy
502844715,7/13/2014 21:52:00,,1322181748,7/13/2014 21:51:33,clixsense,1,15189335,GBR,K3,Peterborough,81.156.166.189,77,97,,,81,117,LUNG,SMALL CELL CARCINOMA,"LUNG,",77,97-103-108,SMALL CELL CARCINOMA,"In conclusion, NSE was considered to be very useful as a tumor marker of the lung, especially in small cell carcinoma for diagnosis and determination of disease extent and response to therapy, and also in non-small cell carcinoma for the evaluation of treatment effectiveness.",77,97 103 108,77,97,81,117,1,RO-disease_has_primary_anatomic_site,902099,"In conclusion, NSE was considered to be very useful as a tumor marker of the lung, especially in small cell carcinoma for diagnosis and determination of disease extent and response to therapy, and also in non-small cell carcinoma for the evaluation of treatment effectiveness",lung,small cell carcinoma
502844715,7/13/2014 22:06:27,,1322194622,7/13/2014 22:06:13,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,77,97,,,81,117,LUNG,SMALL CELL CARCINOMA,"LUNG,",77,97-103-108,SMALL CELL CARCINOMA,"In conclusion, NSE was considered to be very useful as a tumor marker of the lung, especially in small cell carcinoma for diagnosis and determination of disease extent and response to therapy, and also in non-small cell carcinoma for the evaluation of treatment effectiveness.",77,97 103 108,77,97,81,117,1,RO-disease_has_primary_anatomic_site,902099,"In conclusion, NSE was considered to be very useful as a tumor marker of the lung, especially in small cell carcinoma for diagnosis and determination of disease extent and response to therapy, and also in non-small cell carcinoma for the evaluation of treatment effectiveness",lung,small cell carcinoma
502844715,7/13/2014 22:06:41,,1322194846,7/13/2014 22:06:19,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,77,97,,,81,117,LUNG,SMALL CELL CARCINOMA,"marker of the LUNG,",63-70-73-77,97-103-108-118-122,SMALL CELL CARCINOMA for diagnosis,"In conclusion, NSE was considered to be very useful as a tumor marker of the lung, especially in small cell carcinoma for diagnosis and determination of disease extent and response to therapy, and also in non-small cell carcinoma for the evaluation of treatment effectiveness.",77,97 103 108,77,97,81,117,1,RO-disease_has_primary_anatomic_site,902099,"In conclusion, NSE was considered to be very useful as a tumor marker of the lung, especially in small cell carcinoma for diagnosis and determination of disease extent and response to therapy, and also in non-small cell carcinoma for the evaluation of treatment effectiveness",lung,small cell carcinoma
502844715,7/13/2014 22:09:47,,1322197113,7/13/2014 22:08:47,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,77,97,,,81,117,LUNG,SMALL CELL CARCINOMA,"NSE was considered to be useful as a tumor marker of the LUNG, especially in small cell carcinoma for diagnosis cell carcinoma",15-19-23-34-37-45-52-55-57-63-70-73-77-83-94-97-103-108-118-122-220-215,15-19-23-34-37-45-52-55-57-63-70-77-83-94-97-103-108-118-122-132-215-220-73,"NSE was considered to be useful as a tumor marker of the lung, especially in SMALL CELL CARCINOMA for diagnosis and cell carcinoma","In conclusion, NSE was considered to be very useful as a tumor marker of the lung, especially in small cell carcinoma for diagnosis and determination of disease extent and response to therapy, and also in non-small cell carcinoma for the evaluation of treatment effectiveness.",77,97 103 108,77,97,81,117,1,RO-disease_has_primary_anatomic_site,902099,"In conclusion, NSE was considered to be very useful as a tumor marker of the lung, especially in small cell carcinoma for diagnosis and determination of disease extent and response to therapy, and also in non-small cell carcinoma for the evaluation of treatment effectiveness",lung,small cell carcinoma
502844715,7/13/2014 22:16:21,,1322202663,7/13/2014 22:14:53,clixsense,1,8769423,AUS,6,Hobart,147.69.162.116,77,97,,,81,117,LUNG,SMALL CELL CARCINOMA,"LUNG,",77,97-103-108,SMALL CELL CARCINOMA,"In conclusion, NSE was considered to be very useful as a tumor marker of the lung, especially in small cell carcinoma for diagnosis and determination of disease extent and response to therapy, and also in non-small cell carcinoma for the evaluation of treatment effectiveness.",77,97 103 108,77,97,81,117,1,RO-disease_has_primary_anatomic_site,902099,"In conclusion, NSE was considered to be very useful as a tumor marker of the lung, especially in small cell carcinoma for diagnosis and determination of disease extent and response to therapy, and also in non-small cell carcinoma for the evaluation of treatment effectiveness",lung,small cell carcinoma
502844715,7/13/2014 22:18:02,,1322203996,7/13/2014 22:17:44,instagc,1,23149109,USA,NC,Durham,75.189.206.205,77,97,,,81,117,LUNG,SMALL CELL CARCINOMA,"tumor marker of the LUNG,",63-70-73-77-57,97-103-108-118-122,SMALL CELL CARCINOMA for diagnosis,"In conclusion, NSE was considered to be very useful as a tumor marker of the lung, especially in small cell carcinoma for diagnosis and determination of disease extent and response to therapy, and also in non-small cell carcinoma for the evaluation of treatment effectiveness.",77,97 103 108,77,97,81,117,1,RO-disease_has_primary_anatomic_site,902099,"In conclusion, NSE was considered to be very useful as a tumor marker of the lung, especially in small cell carcinoma for diagnosis and determination of disease extent and response to therapy, and also in non-small cell carcinoma for the evaluation of treatment effectiveness",lung,small cell carcinoma
502844715,7/13/2014 22:18:17,,1322204274,7/13/2014 22:17:45,prodege,1,28255346,GBR,L9,Sheffield,2.125.183.137,77,97,,,81,117,LUNG,SMALL CELL CARCINOMA,"tumor marker of the LUNG,",57-63-70-73-77,97-103-108,SMALL CELL CARCINOMA,"In conclusion, NSE was considered to be very useful as a tumor marker of the lung, especially in small cell carcinoma for diagnosis and determination of disease extent and response to therapy, and also in non-small cell carcinoma for the evaluation of treatment effectiveness.",77,97 103 108,77,97,81,117,1,RO-disease_has_primary_anatomic_site,902099,"In conclusion, NSE was considered to be very useful as a tumor marker of the lung, especially in small cell carcinoma for diagnosis and determination of disease extent and response to therapy, and also in non-small cell carcinoma for the evaluation of treatment effectiveness",lung,small cell carcinoma
502844715,7/13/2014 22:20:39,,1322206432,7/13/2014 22:20:28,clixsense,1,10842668,GBR,,,80.189.187.36,77,97,,,81,117,LUNG,SMALL CELL CARCINOMA,"LUNG,",77,97-103-108,SMALL CELL CARCINOMA,"In conclusion, NSE was considered to be very useful as a tumor marker of the lung, especially in small cell carcinoma for diagnosis and determination of disease extent and response to therapy, and also in non-small cell carcinoma for the evaluation of treatment effectiveness.",77,97 103 108,77,97,81,117,1,RO-disease_has_primary_anatomic_site,902099,"In conclusion, NSE was considered to be very useful as a tumor marker of the lung, especially in small cell carcinoma for diagnosis and determination of disease extent and response to therapy, and also in non-small cell carcinoma for the evaluation of treatment effectiveness",lung,small cell carcinoma
502844715,7/13/2014 22:21:11,,1322206878,7/13/2014 22:20:28,prodege,1,17932518,GBR,Y2,Pwllheli,95.151.166.224,77,97,,,81,117,LUNG,SMALL CELL CARCINOMA,"LUNG,",77,97-103-108,SMALL CELL CARCINOMA,"In conclusion, NSE was considered to be very useful as a tumor marker of the lung, especially in small cell carcinoma for diagnosis and determination of disease extent and response to therapy, and also in non-small cell carcinoma for the evaluation of treatment effectiveness.",77,97 103 108,77,97,81,117,1,RO-disease_has_primary_anatomic_site,902099,"In conclusion, NSE was considered to be very useful as a tumor marker of the lung, especially in small cell carcinoma for diagnosis and determination of disease extent and response to therapy, and also in non-small cell carcinoma for the evaluation of treatment effectiveness",lung,small cell carcinoma
502844715,7/13/2014 22:22:00,,1322207456,7/13/2014 22:21:18,clixsense,1,21875134,GBR,,,91.125.61.83,77,97,,,81,117,LUNG,SMALL CELL CARCINOMA,"tumor marker of the LUNG,",57-63-70-73-77,97-103-108,SMALL CELL CARCINOMA,"In conclusion, NSE was considered to be very useful as a tumor marker of the lung, especially in small cell carcinoma for diagnosis and determination of disease extent and response to therapy, and also in non-small cell carcinoma for the evaluation of treatment effectiveness.",77,97 103 108,77,97,81,117,1,RO-disease_has_primary_anatomic_site,902099,"In conclusion, NSE was considered to be very useful as a tumor marker of the lung, especially in small cell carcinoma for diagnosis and determination of disease extent and response to therapy, and also in non-small cell carcinoma for the evaluation of treatment effectiveness",lung,small cell carcinoma
502844716,7/13/2014 21:53:53,,1322183415,7/13/2014 21:53:10,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,435,414,,,443,433,AORTITIS,SPONDYLOARTHROPATHY,"AORTITIS,",435,414,"SPONDYLOARTHROPATHY,","Concurrent RF is rare and hard to detect Connective tissue diseases  Rheumatoid factor and antinuclear antibodies not found in RF  Serology helpful Rheumatoid arthritis  Chronicity, deformity  RA factor Juvenile arthritis  Chronicity Reiter's disease  Chronicity, urethritis, conjunctivitis  B27 antibodies Ankylosing spondylitis  Spondyloarthropathy, aortitis, uveitis  B27 antibodies Inflammatory bowel disease  Spondyloarthropathy, aortitis, uveitis, diarrhea  B27 antibodies Systemic lupus erythematosus  No pannus but chronic arthritis plus multiorgan disease; valvular disease (Libman-Sachs); chorea  Anti-DNA antibodies Carditis.",435,414,435,414,443,433,-1,RO-has_manifestation,906073,"Concurrent RF is rare and hard to detect Connective tissue diseases  Rheumatoid factor and antinuclear antibodies not found in RF  Serology helpful Rheumatoid arthritis  Chronicity, deformity  RA factor Juvenile arthritis  Chronicity Reiter's disease  Chronicity, urethritis, conjunctivitis  B27 antibodies Ankylosing spondylitis  Spondyloarthropathy, aortitis, uveitis  B27 antibodies Inflammatory bowel disease  Spondyloarthropathy, aortitis, uveitis, diarrhea  B27 antibodies Systemic lupus erythematosus  No pannus but chronic arthritis plus multiorgan disease; valvular disease (Libman-Sachs); chorea  Anti-DNA antibodies Carditis",aortitis,Spondyloarthropathy
502844716,7/13/2014 21:55:02,,1322184385,7/13/2014 21:54:46,instagc,1,28301350,GBR,K4,Plymouth,89.242.63.62,435,414,,,443,433,AORTITIS,SPONDYLOARTHROPATHY,"Inflammatory bowel disease Spondyloarthropathy, AORTITIS, uveitis, diarrhea",399-405-414-435-445-454-386,386-399-405-414-435-445-454,"Inflammatory bowel disease SPONDYLOARTHROPATHY, aortitis, uveitis, diarrhea","Concurrent RF is rare and hard to detect Connective tissue diseases  Rheumatoid factor and antinuclear antibodies not found in RF  Serology helpful Rheumatoid arthritis  Chronicity, deformity  RA factor Juvenile arthritis  Chronicity Reiter's disease  Chronicity, urethritis, conjunctivitis  B27 antibodies Ankylosing spondylitis  Spondyloarthropathy, aortitis, uveitis  B27 antibodies Inflammatory bowel disease  Spondyloarthropathy, aortitis, uveitis, diarrhea  B27 antibodies Systemic lupus erythematosus  No pannus but chronic arthritis plus multiorgan disease; valvular disease (Libman-Sachs); chorea  Anti-DNA antibodies Carditis.",435,414,435,414,443,433,-1,RO-has_manifestation,906073,"Concurrent RF is rare and hard to detect Connective tissue diseases  Rheumatoid factor and antinuclear antibodies not found in RF  Serology helpful Rheumatoid arthritis  Chronicity, deformity  RA factor Juvenile arthritis  Chronicity Reiter's disease  Chronicity, urethritis, conjunctivitis  B27 antibodies Ankylosing spondylitis  Spondyloarthropathy, aortitis, uveitis  B27 antibodies Inflammatory bowel disease  Spondyloarthropathy, aortitis, uveitis, diarrhea  B27 antibodies Systemic lupus erythematosus  No pannus but chronic arthritis plus multiorgan disease; valvular disease (Libman-Sachs); chorea  Anti-DNA antibodies Carditis",aortitis,Spondyloarthropathy
502844716,7/13/2014 21:59:51,,1322188981,7/13/2014 21:59:20,elite,1,28397222,GBR,,,31.49.231.211,435,414,,,443,433,AORTITIS,SPONDYLOARTHROPATHY,"AORTITIS,",435,414,"SPONDYLOARTHROPATHY,","Concurrent RF is rare and hard to detect Connective tissue diseases  Rheumatoid factor and antinuclear antibodies not found in RF  Serology helpful Rheumatoid arthritis  Chronicity, deformity  RA factor Juvenile arthritis  Chronicity Reiter's disease  Chronicity, urethritis, conjunctivitis  B27 antibodies Ankylosing spondylitis  Spondyloarthropathy, aortitis, uveitis  B27 antibodies Inflammatory bowel disease  Spondyloarthropathy, aortitis, uveitis, diarrhea  B27 antibodies Systemic lupus erythematosus  No pannus but chronic arthritis plus multiorgan disease; valvular disease (Libman-Sachs); chorea  Anti-DNA antibodies Carditis.",435,414,435,414,443,433,-1,RO-has_manifestation,906073,"Concurrent RF is rare and hard to detect Connective tissue diseases  Rheumatoid factor and antinuclear antibodies not found in RF  Serology helpful Rheumatoid arthritis  Chronicity, deformity  RA factor Juvenile arthritis  Chronicity Reiter's disease  Chronicity, urethritis, conjunctivitis  B27 antibodies Ankylosing spondylitis  Spondyloarthropathy, aortitis, uveitis  B27 antibodies Inflammatory bowel disease  Spondyloarthropathy, aortitis, uveitis, diarrhea  B27 antibodies Systemic lupus erythematosus  No pannus but chronic arthritis plus multiorgan disease; valvular disease (Libman-Sachs); chorea  Anti-DNA antibodies Carditis",aortitis,Spondyloarthropathy
502844716,7/13/2014 22:01:46,,1322190860,7/13/2014 22:01:32,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,435,414,,,443,433,AORTITIS,SPONDYLOARTHROPATHY,"AORTITIS,",435,414,"SPONDYLOARTHROPATHY,","Concurrent RF is rare and hard to detect Connective tissue diseases  Rheumatoid factor and antinuclear antibodies not found in RF  Serology helpful Rheumatoid arthritis  Chronicity, deformity  RA factor Juvenile arthritis  Chronicity Reiter's disease  Chronicity, urethritis, conjunctivitis  B27 antibodies Ankylosing spondylitis  Spondyloarthropathy, aortitis, uveitis  B27 antibodies Inflammatory bowel disease  Spondyloarthropathy, aortitis, uveitis, diarrhea  B27 antibodies Systemic lupus erythematosus  No pannus but chronic arthritis plus multiorgan disease; valvular disease (Libman-Sachs); chorea  Anti-DNA antibodies Carditis.",435,414,435,414,443,433,-1,RO-has_manifestation,906073,"Concurrent RF is rare and hard to detect Connective tissue diseases  Rheumatoid factor and antinuclear antibodies not found in RF  Serology helpful Rheumatoid arthritis  Chronicity, deformity  RA factor Juvenile arthritis  Chronicity Reiter's disease  Chronicity, urethritis, conjunctivitis  B27 antibodies Ankylosing spondylitis  Spondyloarthropathy, aortitis, uveitis  B27 antibodies Inflammatory bowel disease  Spondyloarthropathy, aortitis, uveitis, diarrhea  B27 antibodies Systemic lupus erythematosus  No pannus but chronic arthritis plus multiorgan disease; valvular disease (Libman-Sachs); chorea  Anti-DNA antibodies Carditis",aortitis,Spondyloarthropathy
502844716,7/13/2014 22:02:13,,1322191241,7/13/2014 22:01:33,neodev,1,28175665,CAN,ON,Brampton,99.228.31.59,435,414,,,443,433,AORTITIS,SPONDYLOARTHROPATHY,"AORTITIS,",435,362-371-375-386-399-405-414,"uveitis B27 antibodies Inflammatory bowel disease SPONDYLOARTHROPATHY,","Concurrent RF is rare and hard to detect Connective tissue diseases  Rheumatoid factor and antinuclear antibodies not found in RF  Serology helpful Rheumatoid arthritis  Chronicity, deformity  RA factor Juvenile arthritis  Chronicity Reiter's disease  Chronicity, urethritis, conjunctivitis  B27 antibodies Ankylosing spondylitis  Spondyloarthropathy, aortitis, uveitis  B27 antibodies Inflammatory bowel disease  Spondyloarthropathy, aortitis, uveitis, diarrhea  B27 antibodies Systemic lupus erythematosus  No pannus but chronic arthritis plus multiorgan disease; valvular disease (Libman-Sachs); chorea  Anti-DNA antibodies Carditis.",435,414,435,414,443,433,-1,RO-has_manifestation,906073,"Concurrent RF is rare and hard to detect Connective tissue diseases  Rheumatoid factor and antinuclear antibodies not found in RF  Serology helpful Rheumatoid arthritis  Chronicity, deformity  RA factor Juvenile arthritis  Chronicity Reiter's disease  Chronicity, urethritis, conjunctivitis  B27 antibodies Ankylosing spondylitis  Spondyloarthropathy, aortitis, uveitis  B27 antibodies Inflammatory bowel disease  Spondyloarthropathy, aortitis, uveitis, diarrhea  B27 antibodies Systemic lupus erythematosus  No pannus but chronic arthritis plus multiorgan disease; valvular disease (Libman-Sachs); chorea  Anti-DNA antibodies Carditis",aortitis,Spondyloarthropathy
502844716,7/13/2014 22:03:24,,1322192196,7/13/2014 22:01:40,clixsense,1,15189335,GBR,K3,Peterborough,81.156.166.189,435,414,,,443,433,AORTITIS,SPONDYLOARTHROPATHY,"AORTITIS,",435,414,"SPONDYLOARTHROPATHY,","Concurrent RF is rare and hard to detect Connective tissue diseases  Rheumatoid factor and antinuclear antibodies not found in RF  Serology helpful Rheumatoid arthritis  Chronicity, deformity  RA factor Juvenile arthritis  Chronicity Reiter's disease  Chronicity, urethritis, conjunctivitis  B27 antibodies Ankylosing spondylitis  Spondyloarthropathy, aortitis, uveitis  B27 antibodies Inflammatory bowel disease  Spondyloarthropathy, aortitis, uveitis, diarrhea  B27 antibodies Systemic lupus erythematosus  No pannus but chronic arthritis plus multiorgan disease; valvular disease (Libman-Sachs); chorea  Anti-DNA antibodies Carditis.",435,414,435,414,443,433,-1,RO-has_manifestation,906073,"Concurrent RF is rare and hard to detect Connective tissue diseases  Rheumatoid factor and antinuclear antibodies not found in RF  Serology helpful Rheumatoid arthritis  Chronicity, deformity  RA factor Juvenile arthritis  Chronicity Reiter's disease  Chronicity, urethritis, conjunctivitis  B27 antibodies Ankylosing spondylitis  Spondyloarthropathy, aortitis, uveitis  B27 antibodies Inflammatory bowel disease  Spondyloarthropathy, aortitis, uveitis, diarrhea  B27 antibodies Systemic lupus erythematosus  No pannus but chronic arthritis plus multiorgan disease; valvular disease (Libman-Sachs); chorea  Anti-DNA antibodies Carditis",aortitis,Spondyloarthropathy
502844716,7/13/2014 22:03:51,,1322192537,7/13/2014 22:03:31,bitcoinget,1,24792414,USA,IA,Independence,166.181.80.204,435,414,,,443,433,AORTITIS,SPONDYLOARTHROPATHY,"AORTITIS,",435,414,"SPONDYLOARTHROPATHY,","Concurrent RF is rare and hard to detect Connective tissue diseases  Rheumatoid factor and antinuclear antibodies not found in RF  Serology helpful Rheumatoid arthritis  Chronicity, deformity  RA factor Juvenile arthritis  Chronicity Reiter's disease  Chronicity, urethritis, conjunctivitis  B27 antibodies Ankylosing spondylitis  Spondyloarthropathy, aortitis, uveitis  B27 antibodies Inflammatory bowel disease  Spondyloarthropathy, aortitis, uveitis, diarrhea  B27 antibodies Systemic lupus erythematosus  No pannus but chronic arthritis plus multiorgan disease; valvular disease (Libman-Sachs); chorea  Anti-DNA antibodies Carditis.",435,414,435,414,443,433,-1,RO-has_manifestation,906073,"Concurrent RF is rare and hard to detect Connective tissue diseases  Rheumatoid factor and antinuclear antibodies not found in RF  Serology helpful Rheumatoid arthritis  Chronicity, deformity  RA factor Juvenile arthritis  Chronicity Reiter's disease  Chronicity, urethritis, conjunctivitis  B27 antibodies Ankylosing spondylitis  Spondyloarthropathy, aortitis, uveitis  B27 antibodies Inflammatory bowel disease  Spondyloarthropathy, aortitis, uveitis, diarrhea  B27 antibodies Systemic lupus erythematosus  No pannus but chronic arthritis plus multiorgan disease; valvular disease (Libman-Sachs); chorea  Anti-DNA antibodies Carditis",aortitis,Spondyloarthropathy
502844716,7/13/2014 22:05:05,,1322193524,7/13/2014 22:04:59,clixsense,1,24763049,GBR,,,86.133.47.213,435,414,,,443,433,AORTITIS,SPONDYLOARTHROPATHY,"bowel disease Spondyloarthropathy, AORTITIS, uveitis, diarrhea B27",399-405-414-435-445-454-464,386-399-405-414-435-445-454,"Inflammatory bowel disease SPONDYLOARTHROPATHY, aortitis, uveitis, diarrhea","Concurrent RF is rare and hard to detect Connective tissue diseases  Rheumatoid factor and antinuclear antibodies not found in RF  Serology helpful Rheumatoid arthritis  Chronicity, deformity  RA factor Juvenile arthritis  Chronicity Reiter's disease  Chronicity, urethritis, conjunctivitis  B27 antibodies Ankylosing spondylitis  Spondyloarthropathy, aortitis, uveitis  B27 antibodies Inflammatory bowel disease  Spondyloarthropathy, aortitis, uveitis, diarrhea  B27 antibodies Systemic lupus erythematosus  No pannus but chronic arthritis plus multiorgan disease; valvular disease (Libman-Sachs); chorea  Anti-DNA antibodies Carditis.",435,414,435,414,443,433,-1,RO-has_manifestation,906073,"Concurrent RF is rare and hard to detect Connective tissue diseases  Rheumatoid factor and antinuclear antibodies not found in RF  Serology helpful Rheumatoid arthritis  Chronicity, deformity  RA factor Juvenile arthritis  Chronicity Reiter's disease  Chronicity, urethritis, conjunctivitis  B27 antibodies Ankylosing spondylitis  Spondyloarthropathy, aortitis, uveitis  B27 antibodies Inflammatory bowel disease  Spondyloarthropathy, aortitis, uveitis, diarrhea  B27 antibodies Systemic lupus erythematosus  No pannus but chronic arthritis plus multiorgan disease; valvular disease (Libman-Sachs); chorea  Anti-DNA antibodies Carditis",aortitis,Spondyloarthropathy
502844716,7/13/2014 22:19:11,,1322205054,7/13/2014 22:18:51,clixsense,1,10842668,GBR,,,80.189.187.36,435,414,,,443,433,AORTITIS,SPONDYLOARTHROPATHY,"AORTITIS, uveitis, diarrhea",435-445-454,414-435-445-454,"SPONDYLOARTHROPATHY, aortitis, uveitis, diarrhea","Concurrent RF is rare and hard to detect Connective tissue diseases  Rheumatoid factor and antinuclear antibodies not found in RF  Serology helpful Rheumatoid arthritis  Chronicity, deformity  RA factor Juvenile arthritis  Chronicity Reiter's disease  Chronicity, urethritis, conjunctivitis  B27 antibodies Ankylosing spondylitis  Spondyloarthropathy, aortitis, uveitis  B27 antibodies Inflammatory bowel disease  Spondyloarthropathy, aortitis, uveitis, diarrhea  B27 antibodies Systemic lupus erythematosus  No pannus but chronic arthritis plus multiorgan disease; valvular disease (Libman-Sachs); chorea  Anti-DNA antibodies Carditis.",435,414,435,414,443,433,-1,RO-has_manifestation,906073,"Concurrent RF is rare and hard to detect Connective tissue diseases  Rheumatoid factor and antinuclear antibodies not found in RF  Serology helpful Rheumatoid arthritis  Chronicity, deformity  RA factor Juvenile arthritis  Chronicity Reiter's disease  Chronicity, urethritis, conjunctivitis  B27 antibodies Ankylosing spondylitis  Spondyloarthropathy, aortitis, uveitis  B27 antibodies Inflammatory bowel disease  Spondyloarthropathy, aortitis, uveitis, diarrhea  B27 antibodies Systemic lupus erythematosus  No pannus but chronic arthritis plus multiorgan disease; valvular disease (Libman-Sachs); chorea  Anti-DNA antibodies Carditis",aortitis,Spondyloarthropathy
502844716,7/13/2014 22:21:10,,1322206867,7/13/2014 22:20:48,instagc,1,23149109,USA,NC,Durham,75.189.206.205,435,414,,,443,433,AORTITIS,SPONDYLOARTHROPATHY,"Spondyloarthropathy, AORTITIS,",414-435,386-399-405-414,"Inflammatory bowel disease SPONDYLOARTHROPATHY,","Concurrent RF is rare and hard to detect Connective tissue diseases  Rheumatoid factor and antinuclear antibodies not found in RF  Serology helpful Rheumatoid arthritis  Chronicity, deformity  RA factor Juvenile arthritis  Chronicity Reiter's disease  Chronicity, urethritis, conjunctivitis  B27 antibodies Ankylosing spondylitis  Spondyloarthropathy, aortitis, uveitis  B27 antibodies Inflammatory bowel disease  Spondyloarthropathy, aortitis, uveitis, diarrhea  B27 antibodies Systemic lupus erythematosus  No pannus but chronic arthritis plus multiorgan disease; valvular disease (Libman-Sachs); chorea  Anti-DNA antibodies Carditis.",435,414,435,414,443,433,-1,RO-has_manifestation,906073,"Concurrent RF is rare and hard to detect Connective tissue diseases  Rheumatoid factor and antinuclear antibodies not found in RF  Serology helpful Rheumatoid arthritis  Chronicity, deformity  RA factor Juvenile arthritis  Chronicity Reiter's disease  Chronicity, urethritis, conjunctivitis  B27 antibodies Ankylosing spondylitis  Spondyloarthropathy, aortitis, uveitis  B27 antibodies Inflammatory bowel disease  Spondyloarthropathy, aortitis, uveitis, diarrhea  B27 antibodies Systemic lupus erythematosus  No pannus but chronic arthritis plus multiorgan disease; valvular disease (Libman-Sachs); chorea  Anti-DNA antibodies Carditis",aortitis,Spondyloarthropathy
502844717,7/13/2014 21:50:38,,1322180761,7/13/2014 21:49:53,clixsense,1,25402344,CAN,ON,Wawa,24.109.124.45,38,47,,,43,76,LUNGS,IDIOPATHIC PULMONARY FIBROSIS,HDGF was more highly expressed in the LUNGS,0-5-9-21-31-34-38-14,47-58-68-78-86-89-93-104,"IDIOPATHIC PULMONARY FIBROSIS, chiefly in the epithelial cells,","HDGF was more highly expressed in the lungs of idiopathic pulmonary fibrosis, chiefly in the epithelial cells, than in control nonfibrotic lungs.",38,47 58 68,38,47,43,76,1,RO-has_finding_site,905488,"HDGF was more highly expressed in the lungs of idiopathic pulmonary fibrosis, chiefly in the epithelial cells, than in control nonfibrotic lungs",lungs,idiopathic pulmonary fibrosis
502844717,7/13/2014 21:52:44,,1322182324,7/13/2014 21:52:19,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,38,47,,,43,76,LUNGS,IDIOPATHIC PULMONARY FIBROSIS,LUNGS,38,47-58-68,"IDIOPATHIC PULMONARY FIBROSIS,","HDGF was more highly expressed in the lungs of idiopathic pulmonary fibrosis, chiefly in the epithelial cells, than in control nonfibrotic lungs.",38,47 58 68,38,47,43,76,1,RO-has_finding_site,905488,"HDGF was more highly expressed in the lungs of idiopathic pulmonary fibrosis, chiefly in the epithelial cells, than in control nonfibrotic lungs",lungs,idiopathic pulmonary fibrosis
502844717,7/13/2014 21:55:04,,1322184416,7/13/2014 21:54:52,elite,1,28503042,USA,OK,Oakwood,64.250.220.169,38,47,,,43,76,LUNGS,IDIOPATHIC PULMONARY FIBROSIS,LUNGS,38,47-58-68,"IDIOPATHIC PULMONARY FIBROSIS,","HDGF was more highly expressed in the lungs of idiopathic pulmonary fibrosis, chiefly in the epithelial cells, than in control nonfibrotic lungs.",38,47 58 68,38,47,43,76,1,RO-has_finding_site,905488,"HDGF was more highly expressed in the lungs of idiopathic pulmonary fibrosis, chiefly in the epithelial cells, than in control nonfibrotic lungs",lungs,idiopathic pulmonary fibrosis
502844717,7/13/2014 21:59:31,,1322188676,7/13/2014 21:59:11,bitcoinget,1,24792414,USA,IA,Independence,166.181.80.204,38,47,,,43,76,LUNGS,IDIOPATHIC PULMONARY FIBROSIS,LUNGS,38,47-58-68,"IDIOPATHIC PULMONARY FIBROSIS,","HDGF was more highly expressed in the lungs of idiopathic pulmonary fibrosis, chiefly in the epithelial cells, than in control nonfibrotic lungs.",38,47 58 68,38,47,43,76,1,RO-has_finding_site,905488,"HDGF was more highly expressed in the lungs of idiopathic pulmonary fibrosis, chiefly in the epithelial cells, than in control nonfibrotic lungs",lungs,idiopathic pulmonary fibrosis
502844717,7/13/2014 22:01:54,,1322190964,7/13/2014 22:01:36,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,38,47,,,43,76,LUNGS,IDIOPATHIC PULMONARY FIBROSIS,LUNGS,38,47-58-68,"IDIOPATHIC PULMONARY FIBROSIS,","HDGF was more highly expressed in the lungs of idiopathic pulmonary fibrosis, chiefly in the epithelial cells, than in control nonfibrotic lungs.",38,47 58 68,38,47,43,76,1,RO-has_finding_site,905488,"HDGF was more highly expressed in the lungs of idiopathic pulmonary fibrosis, chiefly in the epithelial cells, than in control nonfibrotic lungs",lungs,idiopathic pulmonary fibrosis
502844717,7/13/2014 22:05:23,,1322193722,7/13/2014 22:05:00,neodev,1,28175665,CAN,ON,Brampton,99.228.31.59,38,47,,,43,76,LUNGS,IDIOPATHIC PULMONARY FIBROSIS,"HDGF was more highly expressed in the LUNGS of idiopathic pulmonary fibrosis,",5-9-14-21-31-34-38-44-47-58-68-0,47-58-68,"IDIOPATHIC PULMONARY FIBROSIS,","HDGF was more highly expressed in the lungs of idiopathic pulmonary fibrosis, chiefly in the epithelial cells, than in control nonfibrotic lungs.",38,47 58 68,38,47,43,76,1,RO-has_finding_site,905488,"HDGF was more highly expressed in the lungs of idiopathic pulmonary fibrosis, chiefly in the epithelial cells, than in control nonfibrotic lungs",lungs,idiopathic pulmonary fibrosis
502844717,7/13/2014 22:06:44,,1322194884,7/13/2014 22:06:17,clixsense,1,15189335,GBR,K3,Peterborough,81.156.166.189,38,47,,,43,76,LUNGS,IDIOPATHIC PULMONARY FIBROSIS,LUNGS,38,47-58-68,"IDIOPATHIC PULMONARY FIBROSIS,","HDGF was more highly expressed in the lungs of idiopathic pulmonary fibrosis, chiefly in the epithelial cells, than in control nonfibrotic lungs.",38,47 58 68,38,47,43,76,1,RO-has_finding_site,905488,"HDGF was more highly expressed in the lungs of idiopathic pulmonary fibrosis, chiefly in the epithelial cells, than in control nonfibrotic lungs",lungs,idiopathic pulmonary fibrosis
502844717,7/13/2014 22:09:20,,1322196822,7/13/2014 22:08:51,elite,1,28397222,GBR,,,31.49.231.211,38,47,,,43,76,LUNGS,IDIOPATHIC PULMONARY FIBROSIS,LUNGS,38,47-58-68,"IDIOPATHIC PULMONARY FIBROSIS,","HDGF was more highly expressed in the lungs of idiopathic pulmonary fibrosis, chiefly in the epithelial cells, than in control nonfibrotic lungs.",38,47 58 68,38,47,43,76,1,RO-has_finding_site,905488,"HDGF was more highly expressed in the lungs of idiopathic pulmonary fibrosis, chiefly in the epithelial cells, than in control nonfibrotic lungs",lungs,idiopathic pulmonary fibrosis
502844717,7/13/2014 22:16:52,,1322203125,7/13/2014 22:16:38,clixsense,1,10842668,GBR,,,80.189.187.36,38,47,,,43,76,LUNGS,IDIOPATHIC PULMONARY FIBROSIS,LUNGS,38,47-58-68,"IDIOPATHIC PULMONARY FIBROSIS,","HDGF was more highly expressed in the lungs of idiopathic pulmonary fibrosis, chiefly in the epithelial cells, than in control nonfibrotic lungs.",38,47 58 68,38,47,43,76,1,RO-has_finding_site,905488,"HDGF was more highly expressed in the lungs of idiopathic pulmonary fibrosis, chiefly in the epithelial cells, than in control nonfibrotic lungs",lungs,idiopathic pulmonary fibrosis
502844717,7/13/2014 22:16:52,,1322203131,7/13/2014 22:16:23,clixsense,1,8769423,AUS,6,Hobart,147.69.162.116,38,47,,,43,76,LUNGS,IDIOPATHIC PULMONARY FIBROSIS,LUNGS,38,47-58-68,"IDIOPATHIC PULMONARY FIBROSIS,","HDGF was more highly expressed in the lungs of idiopathic pulmonary fibrosis, chiefly in the epithelial cells, than in control nonfibrotic lungs.",38,47 58 68,38,47,43,76,1,RO-has_finding_site,905488,"HDGF was more highly expressed in the lungs of idiopathic pulmonary fibrosis, chiefly in the epithelial cells, than in control nonfibrotic lungs",lungs,idiopathic pulmonary fibrosis
502844718,7/13/2014 21:53:32,,1322183085,7/13/2014 21:51:53,clixsense,1,20614047,USA,WA,Deer Park,174.32.162.10,161,127,,,189,146,SUDDEN INFANT DEATH SYNDROME,SUDDEN INFANT DEATH,SUDDEN INFANT DEATH SYNDROME (SIDS) or infection.,161-168-175-181-190-197-200,127-134-141-161-168-175-181-190-197-200,SUDDEN INFANT DEATH sudden infant death syndrome (SIDS) or infection.,The purpose of this study was to elucidate the relationship between polymorphisms in the promoter region of the IL-10 gene and sudden infant death due to either sudden infant death syndrome (SIDS) or infection.,161 168 175 181,127 134 141,161,127,189,146,-1,RO-cause_of,900350,The purpose of this study was to elucidate the relationship between polymorphisms in the promoter region of the IL-10 gene and sudden infant death due to either sudden infant death syndrome (SIDS) or infection,sudden infant death syndrome,sudden infant death
502844718,7/13/2014 21:56:15,,1322185466,7/13/2014 21:55:17,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,161,127,,,189,146,SUDDEN INFANT DEATH SYNDROME,SUDDEN INFANT DEATH,polymorphisms promoter region of the IL 10 gene and sudden infant death due to either SUDDEN INFANT DEATH SYNDROME (SIDS) or infection.,68-89-98-105-108-112-115-118-127-134-141-147-151-154-161-168-175-181-190-197-200-123,68-89-98-105-108-115-118-123-127-134-141-147-151-154-161-168-175-181-190-197-200-112,polymorphisms promoter region of the IL 10 gene and SUDDEN INFANT DEATH due to either sudden infant death syndrome (SIDS) or infection.,The purpose of this study was to elucidate the relationship between polymorphisms in the promoter region of the IL-10 gene and sudden infant death due to either sudden infant death syndrome (SIDS) or infection.,161 168 175 181,127 134 141,161,127,189,146,-1,RO-cause_of,900350,The purpose of this study was to elucidate the relationship between polymorphisms in the promoter region of the IL-10 gene and sudden infant death due to either sudden infant death syndrome (SIDS) or infection,sudden infant death syndrome,sudden infant death
502844718,7/13/2014 21:57:36,,1322186749,7/13/2014 21:56:11,clixsense,1,15189335,GBR,K3,Peterborough,81.156.166.189,161,127,,,189,146,SUDDEN INFANT DEATH SYNDROME,SUDDEN INFANT DEATH,SUDDEN INFANT DEATH SYNDROME,161-168-175-181,127-134-141,SUDDEN INFANT DEATH,The purpose of this study was to elucidate the relationship between polymorphisms in the promoter region of the IL-10 gene and sudden infant death due to either sudden infant death syndrome (SIDS) or infection.,161 168 175 181,127 134 141,161,127,189,146,-1,RO-cause_of,900350,The purpose of this study was to elucidate the relationship between polymorphisms in the promoter region of the IL-10 gene and sudden infant death due to either sudden infant death syndrome (SIDS) or infection,sudden infant death syndrome,sudden infant death
502844718,7/13/2014 21:58:22,,1322187452,7/13/2014 21:58:01,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,161,127,,,189,146,SUDDEN INFANT DEATH SYNDROME,SUDDEN INFANT DEATH,SUDDEN INFANT DEATH SYNDROME (SIDS),161-168-175-181-190,127-134-141,SUDDEN INFANT DEATH,The purpose of this study was to elucidate the relationship between polymorphisms in the promoter region of the IL-10 gene and sudden infant death due to either sudden infant death syndrome (SIDS) or infection.,161 168 175 181,127 134 141,161,127,189,146,-1,RO-cause_of,900350,The purpose of this study was to elucidate the relationship between polymorphisms in the promoter region of the IL-10 gene and sudden infant death due to either sudden infant death syndrome (SIDS) or infection,sudden infant death syndrome,sudden infant death
502844718,7/13/2014 21:59:24,,1322188432,7/13/2014 21:59:08,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,161,127,,,189,146,SUDDEN INFANT DEATH SYNDROME,SUDDEN INFANT DEATH,SUDDEN INFANT DEATH SYNDROME,161-168-175-181,127-134-141,SUDDEN INFANT DEATH,The purpose of this study was to elucidate the relationship between polymorphisms in the promoter region of the IL-10 gene and sudden infant death due to either sudden infant death syndrome (SIDS) or infection.,161 168 175 181,127 134 141,161,127,189,146,-1,RO-cause_of,900350,The purpose of this study was to elucidate the relationship between polymorphisms in the promoter region of the IL-10 gene and sudden infant death due to either sudden infant death syndrome (SIDS) or infection,sudden infant death syndrome,sudden infant death
502844718,7/13/2014 22:00:01,,1322189077,7/13/2014 21:59:55,clixsense,1,25402344,CAN,ON,Wawa,24.109.124.45,161,127,,,189,146,SUDDEN INFANT DEATH SYNDROME,SUDDEN INFANT DEATH,due to either SUDDEN INFANT DEATH SYNDROME or infection.,147-151-154-161-168-175-181-197-200,115-118-123-127-134-141-147-151-154,10 gene and SUDDEN INFANT DEATH due to either,The purpose of this study was to elucidate the relationship between polymorphisms in the promoter region of the IL-10 gene and sudden infant death due to either sudden infant death syndrome (SIDS) or infection.,161 168 175 181,127 134 141,161,127,189,146,-1,RO-cause_of,900350,The purpose of this study was to elucidate the relationship between polymorphisms in the promoter region of the IL-10 gene and sudden infant death due to either sudden infant death syndrome (SIDS) or infection,sudden infant death syndrome,sudden infant death
502844718,7/13/2014 22:01:25,,1322190578,7/13/2014 22:01:09,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,161,127,,,189,146,SUDDEN INFANT DEATH SYNDROME,SUDDEN INFANT DEATH,SUDDEN INFANT DEATH SYNDROME,161-168-175-181,127-134-141,SUDDEN INFANT DEATH,The purpose of this study was to elucidate the relationship between polymorphisms in the promoter region of the IL-10 gene and sudden infant death due to either sudden infant death syndrome (SIDS) or infection.,161 168 175 181,127 134 141,161,127,189,146,-1,RO-cause_of,900350,The purpose of this study was to elucidate the relationship between polymorphisms in the promoter region of the IL-10 gene and sudden infant death due to either sudden infant death syndrome (SIDS) or infection,sudden infant death syndrome,sudden infant death
502844718,7/13/2014 22:05:32,,1322193828,7/13/2014 22:05:18,bitcoinget,1,24792414,USA,IA,Independence,166.181.80.204,161,127,,,189,146,SUDDEN INFANT DEATH SYNDROME,SUDDEN INFANT DEATH,SUDDEN INFANT DEATH SYNDROME,161-168-175-181,127-134-141,SUDDEN INFANT DEATH,The purpose of this study was to elucidate the relationship between polymorphisms in the promoter region of the IL-10 gene and sudden infant death due to either sudden infant death syndrome (SIDS) or infection.,161 168 175 181,127 134 141,161,127,189,146,-1,RO-cause_of,900350,The purpose of this study was to elucidate the relationship between polymorphisms in the promoter region of the IL-10 gene and sudden infant death due to either sudden infant death syndrome (SIDS) or infection,sudden infant death syndrome,sudden infant death
502844718,7/13/2014 22:11:44,,1322198975,7/13/2014 22:11:14,clixsense,1,8769423,AUS,6,Hobart,147.69.162.116,161,127,,,189,146,SUDDEN INFANT DEATH SYNDROME,SUDDEN INFANT DEATH,SUDDEN INFANT DEATH SYNDROME,161-168-175-181,127-134-141,SUDDEN INFANT DEATH,The purpose of this study was to elucidate the relationship between polymorphisms in the promoter region of the IL-10 gene and sudden infant death due to either sudden infant death syndrome (SIDS) or infection.,161 168 175 181,127 134 141,161,127,189,146,-1,RO-cause_of,900350,The purpose of this study was to elucidate the relationship between polymorphisms in the promoter region of the IL-10 gene and sudden infant death due to either sudden infant death syndrome (SIDS) or infection,sudden infant death syndrome,sudden infant death
502844718,7/13/2014 22:17:43,,1322203724,7/13/2014 22:17:16,prodege,1,28255346,GBR,L9,Sheffield,2.125.183.137,161,127,,,189,146,SUDDEN INFANT DEATH SYNDROME,SUDDEN INFANT DEATH,SUDDEN INFANT DEATH SYNDROME (SIDS),161-168-175-181-190,127-134-141,SUDDEN INFANT DEATH,The purpose of this study was to elucidate the relationship between polymorphisms in the promoter region of the IL-10 gene and sudden infant death due to either sudden infant death syndrome (SIDS) or infection.,161 168 175 181,127 134 141,161,127,189,146,-1,RO-cause_of,900350,The purpose of this study was to elucidate the relationship between polymorphisms in the promoter region of the IL-10 gene and sudden infant death due to either sudden infant death syndrome (SIDS) or infection,sudden infant death syndrome,sudden infant death
502844719,7/13/2014 21:52:34,,1322182163,7/13/2014 21:51:34,clixsense,1,25402344,CAN,ON,Wawa,24.109.124.45,468,450,,,489,466,RESPIRATORY ALKALOSIS,HYPERVENTILATION,pulmonary hyperventilation (RESPIRATORY ALKALOSIS);,450-467-480-440,429-436-440-450-480-492-467,"bases, and pulmonary HYPERVENTILATION (respiratory alkalosis); to","In order to investigate whether or not there is a causal relationship between the metabolic acidosis and the ocular hypotension induced by acetazolamide, we undertook to correlate over a period of time the blood-acidifying and ocular-hypotonizing effects of administering the lowest intravenous effective dose of acetazolamide; to treat the metabolic acidosis induced by acetazolamide by means of the intravenous introduction of bases, and pulmonary hyperventilation (respiratory alkalosis); to evaluate the effects on the intraocular pressure (IOP) by neutralizing the acetazolamide-induced metabolic acidosis by means of a continuous infusion of.",480,450,468,450,489,466,1,RO-cause_of,900447,"In order to investigate whether or not there is a causal relationship between the metabolic acidosis and the ocular hypotension induced by acetazolamide, we undertook to correlate over a period of time the blood-acidifying and ocular-hypotonizing effects of administering the lowest intravenous effective dose of acetazolamide; to treat the metabolic acidosis induced by acetazolamide by means of the intravenous introduction of bases, and pulmonary hyperventilation (respiratory alkalosis); to evaluate the effects on the intraocular pressure (IOP) by neutralizing the acetazolamide-induced metabolic acidosis by means of a continuous infusion of",respiratory alkalosis,hyperventilation
502844719,7/13/2014 21:59:45,,1322188871,7/13/2014 21:59:23,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,468,450,,,489,466,RESPIRATORY ALKALOSIS,HYPERVENTILATION,(RESPIRATORY ALKALOSIS);,467-480,440-450,pulmonary HYPERVENTILATION,"In order to investigate whether or not there is a causal relationship between the metabolic acidosis and the ocular hypotension induced by acetazolamide, we undertook to correlate over a period of time the blood-acidifying and ocular-hypotonizing effects of administering the lowest intravenous effective dose of acetazolamide; to treat the metabolic acidosis induced by acetazolamide by means of the intravenous introduction of bases, and pulmonary hyperventilation (respiratory alkalosis); to evaluate the effects on the intraocular pressure (IOP) by neutralizing the acetazolamide-induced metabolic acidosis by means of a continuous infusion of.",480,450,468,450,489,466,1,RO-cause_of,900447,"In order to investigate whether or not there is a causal relationship between the metabolic acidosis and the ocular hypotension induced by acetazolamide, we undertook to correlate over a period of time the blood-acidifying and ocular-hypotonizing effects of administering the lowest intravenous effective dose of acetazolamide; to treat the metabolic acidosis induced by acetazolamide by means of the intravenous introduction of bases, and pulmonary hyperventilation (respiratory alkalosis); to evaluate the effects on the intraocular pressure (IOP) by neutralizing the acetazolamide-induced metabolic acidosis by means of a continuous infusion of",respiratory alkalosis,hyperventilation
502844719,7/13/2014 22:06:15,,1322194477,7/13/2014 22:05:48,clixsense,1,15189335,GBR,K3,Peterborough,81.156.166.189,468,450,,,489,466,RESPIRATORY ALKALOSIS,HYPERVENTILATION,(RESPIRATORY ALKALOSIS);,467-480,450,HYPERVENTILATION,"In order to investigate whether or not there is a causal relationship between the metabolic acidosis and the ocular hypotension induced by acetazolamide, we undertook to correlate over a period of time the blood-acidifying and ocular-hypotonizing effects of administering the lowest intravenous effective dose of acetazolamide; to treat the metabolic acidosis induced by acetazolamide by means of the intravenous introduction of bases, and pulmonary hyperventilation (respiratory alkalosis); to evaluate the effects on the intraocular pressure (IOP) by neutralizing the acetazolamide-induced metabolic acidosis by means of a continuous infusion of.",480,450,468,450,489,466,1,RO-cause_of,900447,"In order to investigate whether or not there is a causal relationship between the metabolic acidosis and the ocular hypotension induced by acetazolamide, we undertook to correlate over a period of time the blood-acidifying and ocular-hypotonizing effects of administering the lowest intravenous effective dose of acetazolamide; to treat the metabolic acidosis induced by acetazolamide by means of the intravenous introduction of bases, and pulmonary hyperventilation (respiratory alkalosis); to evaluate the effects on the intraocular pressure (IOP) by neutralizing the acetazolamide-induced metabolic acidosis by means of a continuous infusion of",respiratory alkalosis,hyperventilation
502844719,7/13/2014 22:08:50,,1322196486,7/13/2014 22:08:13,clixsense,1,8769423,AUS,6,Hobart,147.69.162.116,468,450,,,489,466,RESPIRATORY ALKALOSIS,HYPERVENTILATION,(RESPIRATORY ALKALOSIS);,467-480,450,HYPERVENTILATION,"In order to investigate whether or not there is a causal relationship between the metabolic acidosis and the ocular hypotension induced by acetazolamide, we undertook to correlate over a period of time the blood-acidifying and ocular-hypotonizing effects of administering the lowest intravenous effective dose of acetazolamide; to treat the metabolic acidosis induced by acetazolamide by means of the intravenous introduction of bases, and pulmonary hyperventilation (respiratory alkalosis); to evaluate the effects on the intraocular pressure (IOP) by neutralizing the acetazolamide-induced metabolic acidosis by means of a continuous infusion of.",480,450,468,450,489,466,1,RO-cause_of,900447,"In order to investigate whether or not there is a causal relationship between the metabolic acidosis and the ocular hypotension induced by acetazolamide, we undertook to correlate over a period of time the blood-acidifying and ocular-hypotonizing effects of administering the lowest intravenous effective dose of acetazolamide; to treat the metabolic acidosis induced by acetazolamide by means of the intravenous introduction of bases, and pulmonary hyperventilation (respiratory alkalosis); to evaluate the effects on the intraocular pressure (IOP) by neutralizing the acetazolamide-induced metabolic acidosis by means of a continuous infusion of",respiratory alkalosis,hyperventilation
502844719,7/13/2014 22:08:51,,1322196490,7/13/2014 22:08:20,prodege,1,17932518,GBR,Y2,Pwllheli,95.151.166.224,468,450,,,489,466,RESPIRATORY ALKALOSIS,HYPERVENTILATION,ALKALOSIS);,480,440-450,pulmonary HYPERVENTILATION,"In order to investigate whether or not there is a causal relationship between the metabolic acidosis and the ocular hypotension induced by acetazolamide, we undertook to correlate over a period of time the blood-acidifying and ocular-hypotonizing effects of administering the lowest intravenous effective dose of acetazolamide; to treat the metabolic acidosis induced by acetazolamide by means of the intravenous introduction of bases, and pulmonary hyperventilation (respiratory alkalosis); to evaluate the effects on the intraocular pressure (IOP) by neutralizing the acetazolamide-induced metabolic acidosis by means of a continuous infusion of.",480,450,468,450,489,466,1,RO-cause_of,900447,"In order to investigate whether or not there is a causal relationship between the metabolic acidosis and the ocular hypotension induced by acetazolamide, we undertook to correlate over a period of time the blood-acidifying and ocular-hypotonizing effects of administering the lowest intravenous effective dose of acetazolamide; to treat the metabolic acidosis induced by acetazolamide by means of the intravenous introduction of bases, and pulmonary hyperventilation (respiratory alkalosis); to evaluate the effects on the intraocular pressure (IOP) by neutralizing the acetazolamide-induced metabolic acidosis by means of a continuous infusion of",respiratory alkalosis,hyperventilation
502844719,7/13/2014 22:14:07,,1322200821,7/13/2014 22:12:57,prodege,1,28255346,GBR,L9,Sheffield,2.125.183.137,468,450,,,489,466,RESPIRATORY ALKALOSIS,HYPERVENTILATION,(RESPIRATORY ALKALOSIS);,467-480,440-450,pulmonary HYPERVENTILATION,"In order to investigate whether or not there is a causal relationship between the metabolic acidosis and the ocular hypotension induced by acetazolamide, we undertook to correlate over a period of time the blood-acidifying and ocular-hypotonizing effects of administering the lowest intravenous effective dose of acetazolamide; to treat the metabolic acidosis induced by acetazolamide by means of the intravenous introduction of bases, and pulmonary hyperventilation (respiratory alkalosis); to evaluate the effects on the intraocular pressure (IOP) by neutralizing the acetazolamide-induced metabolic acidosis by means of a continuous infusion of.",480,450,468,450,489,466,1,RO-cause_of,900447,"In order to investigate whether or not there is a causal relationship between the metabolic acidosis and the ocular hypotension induced by acetazolamide, we undertook to correlate over a period of time the blood-acidifying and ocular-hypotonizing effects of administering the lowest intravenous effective dose of acetazolamide; to treat the metabolic acidosis induced by acetazolamide by means of the intravenous introduction of bases, and pulmonary hyperventilation (respiratory alkalosis); to evaluate the effects on the intraocular pressure (IOP) by neutralizing the acetazolamide-induced metabolic acidosis by means of a continuous infusion of",respiratory alkalosis,hyperventilation
502844719,7/13/2014 22:18:35,,1322204521,7/13/2014 22:18:11,gifthulk,1,22552178,AUS,5,Adelaide,14.2.7.227,468,450,,,489,466,RESPIRATORY ALKALOSIS,HYPERVENTILATION,(RESPIRATORY ALKALOSIS);,467-480,450,HYPERVENTILATION,"In order to investigate whether or not there is a causal relationship between the metabolic acidosis and the ocular hypotension induced by acetazolamide, we undertook to correlate over a period of time the blood-acidifying and ocular-hypotonizing effects of administering the lowest intravenous effective dose of acetazolamide; to treat the metabolic acidosis induced by acetazolamide by means of the intravenous introduction of bases, and pulmonary hyperventilation (respiratory alkalosis); to evaluate the effects on the intraocular pressure (IOP) by neutralizing the acetazolamide-induced metabolic acidosis by means of a continuous infusion of.",480,450,468,450,489,466,1,RO-cause_of,900447,"In order to investigate whether or not there is a causal relationship between the metabolic acidosis and the ocular hypotension induced by acetazolamide, we undertook to correlate over a period of time the blood-acidifying and ocular-hypotonizing effects of administering the lowest intravenous effective dose of acetazolamide; to treat the metabolic acidosis induced by acetazolamide by means of the intravenous introduction of bases, and pulmonary hyperventilation (respiratory alkalosis); to evaluate the effects on the intraocular pressure (IOP) by neutralizing the acetazolamide-induced metabolic acidosis by means of a continuous infusion of",respiratory alkalosis,hyperventilation
502844719,7/13/2014 22:21:00,,1322206712,7/13/2014 22:19:59,clixsense,1,26889820,GBR,C3,Shelford,92.18.120.203,468,450,,,489,466,RESPIRATORY ALKALOSIS,HYPERVENTILATION,(RESPIRATORY ALKALOSIS);,467-480,440-450,pulmonary HYPERVENTILATION,"In order to investigate whether or not there is a causal relationship between the metabolic acidosis and the ocular hypotension induced by acetazolamide, we undertook to correlate over a period of time the blood-acidifying and ocular-hypotonizing effects of administering the lowest intravenous effective dose of acetazolamide; to treat the metabolic acidosis induced by acetazolamide by means of the intravenous introduction of bases, and pulmonary hyperventilation (respiratory alkalosis); to evaluate the effects on the intraocular pressure (IOP) by neutralizing the acetazolamide-induced metabolic acidosis by means of a continuous infusion of.",480,450,468,450,489,466,1,RO-cause_of,900447,"In order to investigate whether or not there is a causal relationship between the metabolic acidosis and the ocular hypotension induced by acetazolamide, we undertook to correlate over a period of time the blood-acidifying and ocular-hypotonizing effects of administering the lowest intravenous effective dose of acetazolamide; to treat the metabolic acidosis induced by acetazolamide by means of the intravenous introduction of bases, and pulmonary hyperventilation (respiratory alkalosis); to evaluate the effects on the intraocular pressure (IOP) by neutralizing the acetazolamide-induced metabolic acidosis by means of a continuous infusion of",respiratory alkalosis,hyperventilation
502844719,7/13/2014 22:21:26,,1322207023,7/13/2014 22:21:11,clixsense,1,10842668,GBR,,,80.189.187.36,468,450,,,489,466,RESPIRATORY ALKALOSIS,HYPERVENTILATION,pulmonary hyperventilation (RESPIRATORY ALKALOSIS);,440-450-467-480,450,HYPERVENTILATION,"In order to investigate whether or not there is a causal relationship between the metabolic acidosis and the ocular hypotension induced by acetazolamide, we undertook to correlate over a period of time the blood-acidifying and ocular-hypotonizing effects of administering the lowest intravenous effective dose of acetazolamide; to treat the metabolic acidosis induced by acetazolamide by means of the intravenous introduction of bases, and pulmonary hyperventilation (respiratory alkalosis); to evaluate the effects on the intraocular pressure (IOP) by neutralizing the acetazolamide-induced metabolic acidosis by means of a continuous infusion of.",480,450,468,450,489,466,1,RO-cause_of,900447,"In order to investigate whether or not there is a causal relationship between the metabolic acidosis and the ocular hypotension induced by acetazolamide, we undertook to correlate over a period of time the blood-acidifying and ocular-hypotonizing effects of administering the lowest intravenous effective dose of acetazolamide; to treat the metabolic acidosis induced by acetazolamide by means of the intravenous introduction of bases, and pulmonary hyperventilation (respiratory alkalosis); to evaluate the effects on the intraocular pressure (IOP) by neutralizing the acetazolamide-induced metabolic acidosis by means of a continuous infusion of",respiratory alkalosis,hyperventilation
502844719,7/13/2014 22:21:31,,1322207120,7/13/2014 22:21:11,instagc,1,23149109,USA,NC,Durham,75.189.206.205,468,450,,,489,466,RESPIRATORY ALKALOSIS,HYPERVENTILATION,pulmonary hyperventilation (RESPIRATORY ALKALOSIS);,440-467-480-450,440-450,pulmonary HYPERVENTILATION,"In order to investigate whether or not there is a causal relationship between the metabolic acidosis and the ocular hypotension induced by acetazolamide, we undertook to correlate over a period of time the blood-acidifying and ocular-hypotonizing effects of administering the lowest intravenous effective dose of acetazolamide; to treat the metabolic acidosis induced by acetazolamide by means of the intravenous introduction of bases, and pulmonary hyperventilation (respiratory alkalosis); to evaluate the effects on the intraocular pressure (IOP) by neutralizing the acetazolamide-induced metabolic acidosis by means of a continuous infusion of.",480,450,468,450,489,466,1,RO-cause_of,900447,"In order to investigate whether or not there is a causal relationship between the metabolic acidosis and the ocular hypotension induced by acetazolamide, we undertook to correlate over a period of time the blood-acidifying and ocular-hypotonizing effects of administering the lowest intravenous effective dose of acetazolamide; to treat the metabolic acidosis induced by acetazolamide by means of the intravenous introduction of bases, and pulmonary hyperventilation (respiratory alkalosis); to evaluate the effects on the intraocular pressure (IOP) by neutralizing the acetazolamide-induced metabolic acidosis by means of a continuous infusion of",respiratory alkalosis,hyperventilation
502844720,7/13/2014 21:56:34,,1322185814,7/13/2014 21:56:15,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,269,294,,,273,305,LUNG,LUNG CANCER,LUNG,269,294-299,LUNG CANCER,"To determine whether concentrations of the primary airway immunoglobulins (SIgA, IgG) are altered in the uninvolved lung of patients with lung cancer, we determined concentrations of SIgA and IgG in bronchial washings recovered from a proximal airway of the uninvolved lung in 24 patients with lung cancer and in ten patients with benign lung disease.",269,294 299,269,294,273,305,1,RO-disease_has_primary_anatomic_site,902272,"To determine whether concentrations of the primary airway immunoglobulins (SIgA, IgG) are altered in the uninvolved lung of patients with lung cancer, we determined concentrations of SIgA and IgG in bronchial washings recovered from a proximal airway of the uninvolved lung in 24 patients with lung cancer and in ten patients with benign lung disease",lung,lung cancer
502844720,7/13/2014 21:57:45,,1322186905,7/13/2014 21:56:47,prodege,1,17932518,GBR,Y2,Pwllheli,95.151.166.224,269,294,,,273,305,LUNG,LUNG CANCER,LUNG,269,294-299,LUNG CANCER,"To determine whether concentrations of the primary airway immunoglobulins (SIgA, IgG) are altered in the uninvolved lung of patients with lung cancer, we determined concentrations of SIgA and IgG in bronchial washings recovered from a proximal airway of the uninvolved lung in 24 patients with lung cancer and in ten patients with benign lung disease.",269,294 299,269,294,273,305,1,RO-disease_has_primary_anatomic_site,902272,"To determine whether concentrations of the primary airway immunoglobulins (SIgA, IgG) are altered in the uninvolved lung of patients with lung cancer, we determined concentrations of SIgA and IgG in bronchial washings recovered from a proximal airway of the uninvolved lung in 24 patients with lung cancer and in ten patients with benign lung disease",lung,lung cancer
502844720,7/13/2014 21:59:26,,1322188484,7/13/2014 21:59:09,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,269,294,,,273,305,LUNG,LUNG CANCER,LUNG,269,294-299,LUNG CANCER,"To determine whether concentrations of the primary airway immunoglobulins (SIgA, IgG) are altered in the uninvolved lung of patients with lung cancer, we determined concentrations of SIgA and IgG in bronchial washings recovered from a proximal airway of the uninvolved lung in 24 patients with lung cancer and in ten patients with benign lung disease.",269,294 299,269,294,273,305,1,RO-disease_has_primary_anatomic_site,902272,"To determine whether concentrations of the primary airway immunoglobulins (SIgA, IgG) are altered in the uninvolved lung of patients with lung cancer, we determined concentrations of SIgA and IgG in bronchial washings recovered from a proximal airway of the uninvolved lung in 24 patients with lung cancer and in ten patients with benign lung disease",lung,lung cancer
502844720,7/13/2014 22:00:01,,1322189096,7/13/2014 21:59:40,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,269,294,,,273,305,LUNG,LUNG CANCER,uninvolved LUNG,258-269,294-299,LUNG CANCER,"To determine whether concentrations of the primary airway immunoglobulins (SIgA, IgG) are altered in the uninvolved lung of patients with lung cancer, we determined concentrations of SIgA and IgG in bronchial washings recovered from a proximal airway of the uninvolved lung in 24 patients with lung cancer and in ten patients with benign lung disease.",269,294 299,269,294,273,305,1,RO-disease_has_primary_anatomic_site,902272,"To determine whether concentrations of the primary airway immunoglobulins (SIgA, IgG) are altered in the uninvolved lung of patients with lung cancer, we determined concentrations of SIgA and IgG in bronchial washings recovered from a proximal airway of the uninvolved lung in 24 patients with lung cancer and in ten patients with benign lung disease",lung,lung cancer
502844720,7/13/2014 22:00:12,,1322189219,7/13/2014 22:00:07,clixsense,1,24763049,GBR,,,86.133.47.213,269,294,,,273,305,LUNG,LUNG CANCER,of the uninvolved LUNG in 24 patients,251-254-258-269-274-277-280,277-280-289-294-299-306-310-313,24 patients with LUNG CANCER and in ten,"To determine whether concentrations of the primary airway immunoglobulins (SIgA, IgG) are altered in the uninvolved lung of patients with lung cancer, we determined concentrations of SIgA and IgG in bronchial washings recovered from a proximal airway of the uninvolved lung in 24 patients with lung cancer and in ten patients with benign lung disease.",269,294 299,269,294,273,305,1,RO-disease_has_primary_anatomic_site,902272,"To determine whether concentrations of the primary airway immunoglobulins (SIgA, IgG) are altered in the uninvolved lung of patients with lung cancer, we determined concentrations of SIgA and IgG in bronchial washings recovered from a proximal airway of the uninvolved lung in 24 patients with lung cancer and in ten patients with benign lung disease",lung,lung cancer
502844720,7/13/2014 22:00:36,,1322189638,7/13/2014 21:59:53,superrewards,1,25748885,USA,PA,Bloomsburg,96.243.117.187,269,294,,,273,305,LUNG,LUNG CANCER,LUNG,269,294-299,LUNG CANCER,"To determine whether concentrations of the primary airway immunoglobulins (SIgA, IgG) are altered in the uninvolved lung of patients with lung cancer, we determined concentrations of SIgA and IgG in bronchial washings recovered from a proximal airway of the uninvolved lung in 24 patients with lung cancer and in ten patients with benign lung disease.",269,294 299,269,294,273,305,1,RO-disease_has_primary_anatomic_site,902272,"To determine whether concentrations of the primary airway immunoglobulins (SIgA, IgG) are altered in the uninvolved lung of patients with lung cancer, we determined concentrations of SIgA and IgG in bronchial washings recovered from a proximal airway of the uninvolved lung in 24 patients with lung cancer and in ten patients with benign lung disease",lung,lung cancer
502844720,7/13/2014 22:02:25,,1322191469,7/13/2014 22:02:09,bitcoinget,1,24792414,USA,IA,Independence,166.181.80.204,269,294,,,273,305,LUNG,LUNG CANCER,uninvolved LUNG,258-269,294-299,LUNG CANCER,"To determine whether concentrations of the primary airway immunoglobulins (SIgA, IgG) are altered in the uninvolved lung of patients with lung cancer, we determined concentrations of SIgA and IgG in bronchial washings recovered from a proximal airway of the uninvolved lung in 24 patients with lung cancer and in ten patients with benign lung disease.",269,294 299,269,294,273,305,1,RO-disease_has_primary_anatomic_site,902272,"To determine whether concentrations of the primary airway immunoglobulins (SIgA, IgG) are altered in the uninvolved lung of patients with lung cancer, we determined concentrations of SIgA and IgG in bronchial washings recovered from a proximal airway of the uninvolved lung in 24 patients with lung cancer and in ten patients with benign lung disease",lung,lung cancer
502844720,7/13/2014 22:04:52,,1322193400,7/13/2014 22:04:38,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,269,294,,,273,305,LUNG,LUNG CANCER,LUNG,269,294-299,LUNG CANCER,"To determine whether concentrations of the primary airway immunoglobulins (SIgA, IgG) are altered in the uninvolved lung of patients with lung cancer, we determined concentrations of SIgA and IgG in bronchial washings recovered from a proximal airway of the uninvolved lung in 24 patients with lung cancer and in ten patients with benign lung disease.",269,294 299,269,294,273,305,1,RO-disease_has_primary_anatomic_site,902272,"To determine whether concentrations of the primary airway immunoglobulins (SIgA, IgG) are altered in the uninvolved lung of patients with lung cancer, we determined concentrations of SIgA and IgG in bronchial washings recovered from a proximal airway of the uninvolved lung in 24 patients with lung cancer and in ten patients with benign lung disease",lung,lung cancer
502844720,7/13/2014 22:08:12,,1322195963,7/13/2014 22:07:44,clixsense,1,8769423,AUS,6,Hobart,147.69.162.116,269,294,,,273,305,LUNG,LUNG CANCER,LUNG,269,294-299,LUNG CANCER,"To determine whether concentrations of the primary airway immunoglobulins (SIgA, IgG) are altered in the uninvolved lung of patients with lung cancer, we determined concentrations of SIgA and IgG in bronchial washings recovered from a proximal airway of the uninvolved lung in 24 patients with lung cancer and in ten patients with benign lung disease.",269,294 299,269,294,273,305,1,RO-disease_has_primary_anatomic_site,902272,"To determine whether concentrations of the primary airway immunoglobulins (SIgA, IgG) are altered in the uninvolved lung of patients with lung cancer, we determined concentrations of SIgA and IgG in bronchial washings recovered from a proximal airway of the uninvolved lung in 24 patients with lung cancer and in ten patients with benign lung disease",lung,lung cancer
502844720,7/13/2014 22:09:52,,1322197209,7/13/2014 22:09:16,prodege,1,28255346,GBR,L9,Sheffield,2.125.183.137,269,294,,,273,305,LUNG,LUNG CANCER,proximal airway of the uninvolved LUNG,235-244-251-254-258-269,294-299,LUNG CANCER,"To determine whether concentrations of the primary airway immunoglobulins (SIgA, IgG) are altered in the uninvolved lung of patients with lung cancer, we determined concentrations of SIgA and IgG in bronchial washings recovered from a proximal airway of the uninvolved lung in 24 patients with lung cancer and in ten patients with benign lung disease.",269,294 299,269,294,273,305,1,RO-disease_has_primary_anatomic_site,902272,"To determine whether concentrations of the primary airway immunoglobulins (SIgA, IgG) are altered in the uninvolved lung of patients with lung cancer, we determined concentrations of SIgA and IgG in bronchial washings recovered from a proximal airway of the uninvolved lung in 24 patients with lung cancer and in ten patients with benign lung disease",lung,lung cancer
502844721,7/13/2014 21:49:34,,1322179865,7/13/2014 21:49:07,instagc,1,28301350,GBR,K4,Plymouth,89.242.63.62,123,66,,,136,77,TOXOPLASMOSIS,CLINDAMYCIN,TOXOPLASMOSIS):,123,66-123,CLINDAMYCIN toxoplasmosis):,161  For pyrimethamine dosages of 25-50 mg once daily (given with clindamycin or sulfadiazine for secondary prophylaxis of toxoplasmosis): 10-25 mg once daily.,123,66,123,66,136,77,1,RO-may_treat,907658,161  For pyrimethamine dosages of 25-50 mg once daily (given with clindamycin or sulfadiazine for secondary prophylaxis of toxoplasmosis): 10-25 mg once daily,toxoplasmosis,clindamycin
502844721,7/13/2014 21:53:54,,1322183420,7/13/2014 21:53:50,clixsense,1,24763049,GBR,,,86.133.47.213,123,66,,,136,77,TOXOPLASMOSIS,CLINDAMYCIN,secondary prophylaxis of TOXOPLASMOSIS): 10 25 mg,98-108-120-123-139-142-145,48-54-61-66-78-81-94,daily (given with CLINDAMYCIN or sulfadiazine for,161  For pyrimethamine dosages of 25-50 mg once daily (given with clindamycin or sulfadiazine for secondary prophylaxis of toxoplasmosis): 10-25 mg once daily.,123,66,123,66,136,77,1,RO-may_treat,907658,161  For pyrimethamine dosages of 25-50 mg once daily (given with clindamycin or sulfadiazine for secondary prophylaxis of toxoplasmosis): 10-25 mg once daily,toxoplasmosis,clindamycin
502844721,7/13/2014 21:55:18,,1322184615,7/13/2014 21:55:00,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,123,66,,,136,77,TOXOPLASMOSIS,CLINDAMYCIN,TOXOPLASMOSIS):,123,66,CLINDAMYCIN,161  For pyrimethamine dosages of 25-50 mg once daily (given with clindamycin or sulfadiazine for secondary prophylaxis of toxoplasmosis): 10-25 mg once daily.,123,66,123,66,136,77,1,RO-may_treat,907658,161  For pyrimethamine dosages of 25-50 mg once daily (given with clindamycin or sulfadiazine for secondary prophylaxis of toxoplasmosis): 10-25 mg once daily,toxoplasmosis,clindamycin
502844721,7/13/2014 21:57:34,,1322186731,7/13/2014 21:57:22,elite,1,28503042,USA,OK,Oakwood,64.250.220.169,123,66,,,136,77,TOXOPLASMOSIS,CLINDAMYCIN,secondary prophylaxis of TOXOPLASMOSIS):,98-108-120-123,66,CLINDAMYCIN,161  For pyrimethamine dosages of 25-50 mg once daily (given with clindamycin or sulfadiazine for secondary prophylaxis of toxoplasmosis): 10-25 mg once daily.,123,66,123,66,136,77,1,RO-may_treat,907658,161  For pyrimethamine dosages of 25-50 mg once daily (given with clindamycin or sulfadiazine for secondary prophylaxis of toxoplasmosis): 10-25 mg once daily,toxoplasmosis,clindamycin
502844721,7/13/2014 21:58:19,,1322187385,7/13/2014 21:57:36,clixsense,1,15189335,GBR,K3,Peterborough,81.156.166.189,123,66,,,136,77,TOXOPLASMOSIS,CLINDAMYCIN,TOXOPLASMOSIS):,123,66,CLINDAMYCIN,161  For pyrimethamine dosages of 25-50 mg once daily (given with clindamycin or sulfadiazine for secondary prophylaxis of toxoplasmosis): 10-25 mg once daily.,123,66,123,66,136,77,1,RO-may_treat,907658,161  For pyrimethamine dosages of 25-50 mg once daily (given with clindamycin or sulfadiazine for secondary prophylaxis of toxoplasmosis): 10-25 mg once daily,toxoplasmosis,clindamycin
502844721,7/13/2014 22:00:41,,1322189727,7/13/2014 22:00:31,clixsense,1,25402344,CAN,ON,Wawa,24.109.124.45,123,66,,,136,77,TOXOPLASMOSIS,CLINDAMYCIN,secondary prophylaxis of TOXOPLASMOSIS): 10 25 mg,98-108-120-123-139-142-145,48-54-61-66-78-81-94,daily (given with CLINDAMYCIN or sulfadiazine for,161  For pyrimethamine dosages of 25-50 mg once daily (given with clindamycin or sulfadiazine for secondary prophylaxis of toxoplasmosis): 10-25 mg once daily.,123,66,123,66,136,77,1,RO-may_treat,907658,161  For pyrimethamine dosages of 25-50 mg once daily (given with clindamycin or sulfadiazine for secondary prophylaxis of toxoplasmosis): 10-25 mg once daily,toxoplasmosis,clindamycin
502844721,7/13/2014 22:04:21,,1322192901,7/13/2014 22:04:00,neodev,1,28175665,CAN,ON,Brampton,99.228.31.59,123,66,,,136,77,TOXOPLASMOSIS,CLINDAMYCIN,secondary prophylaxis of TOXOPLASMOSIS): 10 25 mg once daily.,98-108-120-123-139-142-145-148-153,54-61-66-78-81-94-98-108-120-123,(given with CLINDAMYCIN or sulfadiazine for secondary prophylaxis of toxoplasmosis):,161  For pyrimethamine dosages of 25-50 mg once daily (given with clindamycin or sulfadiazine for secondary prophylaxis of toxoplasmosis): 10-25 mg once daily.,123,66,123,66,136,77,1,RO-may_treat,907658,161  For pyrimethamine dosages of 25-50 mg once daily (given with clindamycin or sulfadiazine for secondary prophylaxis of toxoplasmosis): 10-25 mg once daily,toxoplasmosis,clindamycin
502844721,7/13/2014 22:08:18,,1322196059,7/13/2014 22:08:02,bitcoinget,1,24792414,USA,IA,Independence,166.181.80.204,123,66,,,136,77,TOXOPLASMOSIS,CLINDAMYCIN,secondary prophylaxis of TOXOPLASMOSIS):,98-108-120-123,66,CLINDAMYCIN,161  For pyrimethamine dosages of 25-50 mg once daily (given with clindamycin or sulfadiazine for secondary prophylaxis of toxoplasmosis): 10-25 mg once daily.,123,66,123,66,136,77,1,RO-may_treat,907658,161  For pyrimethamine dosages of 25-50 mg once daily (given with clindamycin or sulfadiazine for secondary prophylaxis of toxoplasmosis): 10-25 mg once daily,toxoplasmosis,clindamycin
502844721,7/13/2014 22:08:45,,1322196372,7/13/2014 22:07:41,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,123,66,,,136,77,TOXOPLASMOSIS,CLINDAMYCIN,pyrimethamine dosages of 25 50 mg (given with clindamycin or sulfadiazine for secondary prophylaxis of TOXOPLASMOSIS): 10 25 mg,9-23-31-34-37-40-54-61-66-78-81-98-108-120-123-139-142-145-94,9-23-31-34-36-37-40-48-54-61-66-78-81-94-98-108-120-123-139-142-145,pyrimethamine dosages of 25 - 50 mg daily (given with CLINDAMYCIN or sulfadiazine for secondary prophylaxis of toxoplasmosis): 10 25 mg,161  For pyrimethamine dosages of 25-50 mg once daily (given with clindamycin or sulfadiazine for secondary prophylaxis of toxoplasmosis): 10-25 mg once daily.,123,66,123,66,136,77,1,RO-may_treat,907658,161  For pyrimethamine dosages of 25-50 mg once daily (given with clindamycin or sulfadiazine for secondary prophylaxis of toxoplasmosis): 10-25 mg once daily,toxoplasmosis,clindamycin
502844721,7/13/2014 22:09:33,,1322197024,7/13/2014 22:09:11,clixsense,1,8769423,AUS,6,Hobart,147.69.162.116,123,66,,,136,77,TOXOPLASMOSIS,CLINDAMYCIN,TOXOPLASMOSIS):,123,66,CLINDAMYCIN,161  For pyrimethamine dosages of 25-50 mg once daily (given with clindamycin or sulfadiazine for secondary prophylaxis of toxoplasmosis): 10-25 mg once daily.,123,66,123,66,136,77,1,RO-may_treat,907658,161  For pyrimethamine dosages of 25-50 mg once daily (given with clindamycin or sulfadiazine for secondary prophylaxis of toxoplasmosis): 10-25 mg once daily,toxoplasmosis,clindamycin
502844722,7/13/2014 21:54:45,,1322184143,7/13/2014 21:53:35,clixsense,1,20614047,USA,WA,Deer Park,174.32.162.10,75,125,,,79,143,LUNG,PULMONARY FIBROSIS,"LUNG disorders: chronic bronchitis (CB), pulmonary fibrosis (PF), old pulmonary tuberculosis (OPT), lung cancer (LC), bronchiectasis (BE),",75-80-91-99-110-125-135-144-159-163-173-186-202-207-214-234-249,75-80-91-99-110-116-118-125-135-144-159-163-173-186-202-207-214-234-249,"lung disorders: chronic bronchitis (CB), 7 cases; PULMONARY FIBROSIS (PF), old pulmonary tuberculosis (OPT), lung cancer (LC), bronchiectasis (BE),","Human subjects consisted of 18 normal volunteers (NV) and 47 patients with lung disorders: chronic bronchitis (CB), 7 cases; pulmonary fibrosis (PF), 8 cases; old pulmonary tuberculosis (OPT), 7 cases; lung cancer (LC), 20 cases; and bronchiectasis (BE), 5 cases.",75,125 135,75,125,79,143,1,RO-has_finding_site,905177,"Human subjects consisted of 18 normal volunteers (NV) and 47 patients with lung disorders: chronic bronchitis (CB), 7 cases; pulmonary fibrosis (PF), 8 cases; old pulmonary tuberculosis (OPT), 7 cases; lung cancer (LC), 20 cases; and bronchiectasis (BE), 5 cases",lung,pulmonary fibrosis
502844722,7/13/2014 22:04:17,,1322192863,7/13/2014 22:03:28,clixsense,1,25402344,CAN,ON,Wawa,24.109.124.45,75,125,,,79,143,LUNG,PULMONARY FIBROSIS,47 patients with LUNG disorders: chronic bronchitis,58-61-70-75-80-91-99,110-116-118-125-135-150-152,"(CB), 7 cases; PULMONARY FIBROSIS 8 cases;","Human subjects consisted of 18 normal volunteers (NV) and 47 patients with lung disorders: chronic bronchitis (CB), 7 cases; pulmonary fibrosis (PF), 8 cases; old pulmonary tuberculosis (OPT), 7 cases; lung cancer (LC), 20 cases; and bronchiectasis (BE), 5 cases.",75,125 135,75,125,79,143,1,RO-has_finding_site,905177,"Human subjects consisted of 18 normal volunteers (NV) and 47 patients with lung disorders: chronic bronchitis (CB), 7 cases; pulmonary fibrosis (PF), 8 cases; old pulmonary tuberculosis (OPT), 7 cases; lung cancer (LC), 20 cases; and bronchiectasis (BE), 5 cases",lung,pulmonary fibrosis
502844722,7/13/2014 22:07:14,,1322195229,7/13/2014 22:06:59,bitcoinget,1,24792414,USA,IA,Independence,166.181.80.204,75,125,,,79,143,LUNG,PULMONARY FIBROSIS,LUNG disorders:,75-80,125-135,PULMONARY FIBROSIS,"Human subjects consisted of 18 normal volunteers (NV) and 47 patients with lung disorders: chronic bronchitis (CB), 7 cases; pulmonary fibrosis (PF), 8 cases; old pulmonary tuberculosis (OPT), 7 cases; lung cancer (LC), 20 cases; and bronchiectasis (BE), 5 cases.",75,125 135,75,125,79,143,1,RO-has_finding_site,905177,"Human subjects consisted of 18 normal volunteers (NV) and 47 patients with lung disorders: chronic bronchitis (CB), 7 cases; pulmonary fibrosis (PF), 8 cases; old pulmonary tuberculosis (OPT), 7 cases; lung cancer (LC), 20 cases; and bronchiectasis (BE), 5 cases",lung,pulmonary fibrosis
502844722,7/13/2014 22:10:49,,1322198152,7/13/2014 22:10:44,clixsense,1,24763049,GBR,,,86.133.47.213,75,125,,,79,143,LUNG,PULMONARY FIBROSIS,47 patients with LUNG disorders: chronic bronchitis,58-61-70-75-80-91-99,110-116-118-125-135-150-152,"(CB), 7 cases; PULMONARY FIBROSIS 8 cases;","Human subjects consisted of 18 normal volunteers (NV) and 47 patients with lung disorders: chronic bronchitis (CB), 7 cases; pulmonary fibrosis (PF), 8 cases; old pulmonary tuberculosis (OPT), 7 cases; lung cancer (LC), 20 cases; and bronchiectasis (BE), 5 cases.",75,125 135,75,125,79,143,1,RO-has_finding_site,905177,"Human subjects consisted of 18 normal volunteers (NV) and 47 patients with lung disorders: chronic bronchitis (CB), 7 cases; pulmonary fibrosis (PF), 8 cases; old pulmonary tuberculosis (OPT), 7 cases; lung cancer (LC), 20 cases; and bronchiectasis (BE), 5 cases",lung,pulmonary fibrosis
502844722,7/13/2014 22:12:28,,1322199590,7/13/2014 22:11:50,prodege,1,28255346,GBR,L9,Sheffield,2.125.183.137,75,125,,,79,143,LUNG,PULMONARY FIBROSIS,LUNG disorders:,75-80,125-135,PULMONARY FIBROSIS,"Human subjects consisted of 18 normal volunteers (NV) and 47 patients with lung disorders: chronic bronchitis (CB), 7 cases; pulmonary fibrosis (PF), 8 cases; old pulmonary tuberculosis (OPT), 7 cases; lung cancer (LC), 20 cases; and bronchiectasis (BE), 5 cases.",75,125 135,75,125,79,143,1,RO-has_finding_site,905177,"Human subjects consisted of 18 normal volunteers (NV) and 47 patients with lung disorders: chronic bronchitis (CB), 7 cases; pulmonary fibrosis (PF), 8 cases; old pulmonary tuberculosis (OPT), 7 cases; lung cancer (LC), 20 cases; and bronchiectasis (BE), 5 cases",lung,pulmonary fibrosis
502844722,7/13/2014 22:13:22,,1322200259,7/13/2014 22:11:53,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,75,125,,,79,143,LUNG,PULMONARY FIBROSIS,"47 patients with LUNG disorders: chronic bronchitis (CB), 7 cases; pulmonary fibrosis (PF), 8 cases; old pulmonary tuberculosis (OPT), 7 cases; lung cancer (LC), 20 cases; and bronchiectasis (BE),",58-61-70-75-80-91-99-110-116-118-125-135-144-150-152-159-163-173-186-193-195-202-207-214-220-223-230-234-249,58-61-70-75-80-91-99-110-116-118-125-135-144-150-152-159-163-173-186-193-195-202-207-214-220-223-230-234-249,"47 patients with lung disorders: chronic bronchitis (CB), 7 cases; PULMONARY FIBROSIS (PF), 8 cases; old pulmonary tuberculosis (OPT), 7 cases; lung cancer (LC), 20 cases; and bronchiectasis (BE),","Human subjects consisted of 18 normal volunteers (NV) and 47 patients with lung disorders: chronic bronchitis (CB), 7 cases; pulmonary fibrosis (PF), 8 cases; old pulmonary tuberculosis (OPT), 7 cases; lung cancer (LC), 20 cases; and bronchiectasis (BE), 5 cases.",75,125 135,75,125,79,143,1,RO-has_finding_site,905177,"Human subjects consisted of 18 normal volunteers (NV) and 47 patients with lung disorders: chronic bronchitis (CB), 7 cases; pulmonary fibrosis (PF), 8 cases; old pulmonary tuberculosis (OPT), 7 cases; lung cancer (LC), 20 cases; and bronchiectasis (BE), 5 cases",lung,pulmonary fibrosis
502844722,7/13/2014 22:15:31,,1322201967,7/13/2014 22:15:09,instagc,1,23149109,USA,NC,Durham,75.189.206.205,75,125,,,79,143,LUNG,PULMONARY FIBROSIS,LUNG disorders: chronic bronchitis,75-80-91-99,125-135-144,"PULMONARY FIBROSIS (PF),","Human subjects consisted of 18 normal volunteers (NV) and 47 patients with lung disorders: chronic bronchitis (CB), 7 cases; pulmonary fibrosis (PF), 8 cases; old pulmonary tuberculosis (OPT), 7 cases; lung cancer (LC), 20 cases; and bronchiectasis (BE), 5 cases.",75,125 135,75,125,79,143,1,RO-has_finding_site,905177,"Human subjects consisted of 18 normal volunteers (NV) and 47 patients with lung disorders: chronic bronchitis (CB), 7 cases; pulmonary fibrosis (PF), 8 cases; old pulmonary tuberculosis (OPT), 7 cases; lung cancer (LC), 20 cases; and bronchiectasis (BE), 5 cases",lung,pulmonary fibrosis
502844722,7/13/2014 22:19:44,,1322205609,7/13/2014 22:19:23,clixsense,1,10842668,GBR,,,80.189.187.36,75,125,,,79,143,LUNG,PULMONARY FIBROSIS,LUNG disorders: chronic bronchitis,75-80-99-91,110-125-135,"(CB), PULMONARY FIBROSIS","Human subjects consisted of 18 normal volunteers (NV) and 47 patients with lung disorders: chronic bronchitis (CB), 7 cases; pulmonary fibrosis (PF), 8 cases; old pulmonary tuberculosis (OPT), 7 cases; lung cancer (LC), 20 cases; and bronchiectasis (BE), 5 cases.",75,125 135,75,125,79,143,1,RO-has_finding_site,905177,"Human subjects consisted of 18 normal volunteers (NV) and 47 patients with lung disorders: chronic bronchitis (CB), 7 cases; pulmonary fibrosis (PF), 8 cases; old pulmonary tuberculosis (OPT), 7 cases; lung cancer (LC), 20 cases; and bronchiectasis (BE), 5 cases",lung,pulmonary fibrosis
502844722,7/13/2014 22:19:58,,1322205837,7/13/2014 22:19:44,clixsense,1,26889820,GBR,C3,Shelford,92.18.120.203,75,125,,,79,143,LUNG,PULMONARY FIBROSIS,LUNG disorders:,75-80,125-135-144,"PULMONARY FIBROSIS (PF),","Human subjects consisted of 18 normal volunteers (NV) and 47 patients with lung disorders: chronic bronchitis (CB), 7 cases; pulmonary fibrosis (PF), 8 cases; old pulmonary tuberculosis (OPT), 7 cases; lung cancer (LC), 20 cases; and bronchiectasis (BE), 5 cases.",75,125 135,75,125,79,143,1,RO-has_finding_site,905177,"Human subjects consisted of 18 normal volunteers (NV) and 47 patients with lung disorders: chronic bronchitis (CB), 7 cases; pulmonary fibrosis (PF), 8 cases; old pulmonary tuberculosis (OPT), 7 cases; lung cancer (LC), 20 cases; and bronchiectasis (BE), 5 cases",lung,pulmonary fibrosis
502844722,7/13/2014 22:25:01,,1322210321,7/13/2014 22:24:29,clixsense,1,21875134,GBR,,,91.125.61.83,75,125,,,79,143,LUNG,PULMONARY FIBROSIS,LUNG disorders:,75-80,125-135,PULMONARY FIBROSIS,"Human subjects consisted of 18 normal volunteers (NV) and 47 patients with lung disorders: chronic bronchitis (CB), 7 cases; pulmonary fibrosis (PF), 8 cases; old pulmonary tuberculosis (OPT), 7 cases; lung cancer (LC), 20 cases; and bronchiectasis (BE), 5 cases.",75,125 135,75,125,79,143,1,RO-has_finding_site,905177,"Human subjects consisted of 18 normal volunteers (NV) and 47 patients with lung disorders: chronic bronchitis (CB), 7 cases; pulmonary fibrosis (PF), 8 cases; old pulmonary tuberculosis (OPT), 7 cases; lung cancer (LC), 20 cases; and bronchiectasis (BE), 5 cases",lung,pulmonary fibrosis
502844723,7/13/2014 21:51:19,,1322181214,7/13/2014 21:50:49,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,35,0,,,57,15,PATHOLOGICAL FRACTURES,BONE METASTASES,PATHOLOGICAL FRACTURES hypercalcaemia,35-48-62,0-5,BONE METASTASES,"Bone metastases cause severe pain, pathological fractures and hypercalcaemia and thus are a significant clinical problem.",35 48,0 5,35,0,57,15,1,RO-disease_may_have_finding,902703,"Bone metastases cause severe pain, pathological fractures and hypercalcaemia and thus are a significant clinical problem",pathological fractures,Bone metastases
502844723,7/13/2014 21:52:55,,1322182473,7/13/2014 21:52:27,clixsense,1,15189335,GBR,K3,Peterborough,81.156.166.189,35,0,,,57,15,PATHOLOGICAL FRACTURES,BONE METASTASES,PATHOLOGICAL FRACTURES,35-48,0-5,BONE METASTASES,"Bone metastases cause severe pain, pathological fractures and hypercalcaemia and thus are a significant clinical problem.",35 48,0 5,35,0,57,15,1,RO-disease_may_have_finding,902703,"Bone metastases cause severe pain, pathological fractures and hypercalcaemia and thus are a significant clinical problem",pathological fractures,Bone metastases
502844723,7/13/2014 21:56:11,,1322185438,7/13/2014 21:55:14,prodege,1,17932518,GBR,Y2,Pwllheli,95.151.166.224,35,0,,,57,15,PATHOLOGICAL FRACTURES,BONE METASTASES,PATHOLOGICAL FRACTURES,35-48,0-5,BONE METASTASES,"Bone metastases cause severe pain, pathological fractures and hypercalcaemia and thus are a significant clinical problem.",35 48,0 5,35,0,57,15,1,RO-disease_may_have_finding,902703,"Bone metastases cause severe pain, pathological fractures and hypercalcaemia and thus are a significant clinical problem",pathological fractures,Bone metastases
502844723,7/13/2014 21:57:41,,1322186839,7/13/2014 21:57:26,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,35,0,,,57,15,PATHOLOGICAL FRACTURES,BONE METASTASES,PATHOLOGICAL FRACTURES and hypercalcaemia,35-48-58-62,0-5,BONE METASTASES,"Bone metastases cause severe pain, pathological fractures and hypercalcaemia and thus are a significant clinical problem.",35 48,0 5,35,0,57,15,1,RO-disease_may_have_finding,902703,"Bone metastases cause severe pain, pathological fractures and hypercalcaemia and thus are a significant clinical problem",pathological fractures,Bone metastases
502844723,7/13/2014 22:00:52,,1322190006,7/13/2014 22:00:42,clixsense,1,25402344,CAN,ON,Wawa,24.109.124.45,35,0,,,57,15,PATHOLOGICAL FRACTURES,BONE METASTASES,"cause severe pain, PATHOLOGICAL FRACTURES and hypercalcaemia and",16-22-29-35-48-58-62-77,0-5-16-22-29,"BONE METASTASES cause severe pain,","Bone metastases cause severe pain, pathological fractures and hypercalcaemia and thus are a significant clinical problem.",35 48,0 5,35,0,57,15,1,RO-disease_may_have_finding,902703,"Bone metastases cause severe pain, pathological fractures and hypercalcaemia and thus are a significant clinical problem",pathological fractures,Bone metastases
502844723,7/13/2014 22:05:12,,1322193626,7/13/2014 22:05:07,clixsense,1,24763049,GBR,,,86.133.47.213,35,0,,,57,15,PATHOLOGICAL FRACTURES,BONE METASTASES,"cause severe pain, PATHOLOGICAL FRACTURES and hypercalcaemia and",16-22-29-35-48-58-62-77,0-5-16-22-29,"BONE METASTASES cause severe pain,","Bone metastases cause severe pain, pathological fractures and hypercalcaemia and thus are a significant clinical problem.",35 48,0 5,35,0,57,15,1,RO-disease_may_have_finding,902703,"Bone metastases cause severe pain, pathological fractures and hypercalcaemia and thus are a significant clinical problem",pathological fractures,Bone metastases
502844723,7/13/2014 22:12:05,,1322199273,7/13/2014 22:11:45,instagc,1,23149109,USA,NC,Durham,75.189.206.205,35,0,,,57,15,PATHOLOGICAL FRACTURES,BONE METASTASES,PATHOLOGICAL FRACTURES and hypercalcaemia,35-48-58-62,0-5,BONE METASTASES,"Bone metastases cause severe pain, pathological fractures and hypercalcaemia and thus are a significant clinical problem.",35 48,0 5,35,0,57,15,1,RO-disease_may_have_finding,902703,"Bone metastases cause severe pain, pathological fractures and hypercalcaemia and thus are a significant clinical problem",pathological fractures,Bone metastases
502844723,7/13/2014 22:15:25,,1322201917,7/13/2014 22:15:12,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,35,0,,,57,15,PATHOLOGICAL FRACTURES,BONE METASTASES,"Bone metastases cause severe pain, PATHOLOGICAL FRACTURES and hypercalcaemia",0-5-16-22-29-35-48-58-62,0-5-16-22-29-35-48-58-62,"BONE METASTASES cause severe pain, pathological fractures and hypercalcaemia","Bone metastases cause severe pain, pathological fractures and hypercalcaemia and thus are a significant clinical problem.",35 48,0 5,35,0,57,15,1,RO-disease_may_have_finding,902703,"Bone metastases cause severe pain, pathological fractures and hypercalcaemia and thus are a significant clinical problem",pathological fractures,Bone metastases
502844723,7/13/2014 22:21:53,,1322207401,7/13/2014 22:21:27,gifthulk,1,22552178,AUS,5,Adelaide,14.2.7.227,35,0,,,57,15,PATHOLOGICAL FRACTURES,BONE METASTASES,PATHOLOGICAL FRACTURES,35-48,0-5,BONE METASTASES,"Bone metastases cause severe pain, pathological fractures and hypercalcaemia and thus are a significant clinical problem.",35 48,0 5,35,0,57,15,1,RO-disease_may_have_finding,902703,"Bone metastases cause severe pain, pathological fractures and hypercalcaemia and thus are a significant clinical problem",pathological fractures,Bone metastases
502844723,7/13/2014 22:22:04,,1322207526,7/13/2014 22:21:53,clixsense,1,10842668,GBR,,,80.189.187.36,35,0,,,57,15,PATHOLOGICAL FRACTURES,BONE METASTASES,PATHOLOGICAL FRACTURES,35-48,0-5,BONE METASTASES,"Bone metastases cause severe pain, pathological fractures and hypercalcaemia and thus are a significant clinical problem.",35 48,0 5,35,0,57,15,1,RO-disease_may_have_finding,902703,"Bone metastases cause severe pain, pathological fractures and hypercalcaemia and thus are a significant clinical problem",pathological fractures,Bone metastases
502844724,7/13/2014 21:50:48,,1322180876,7/13/2014 21:50:22,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,188,205,,,196,221,SEIZURES,INFANTILE SPASMS,SEIZURES,188,205-215,INFANTILE SPASMS,The principal underlying concepts are (a) children with medically refractory infantile spasms may have an area of cortical defect (called the zone of cortical abnormality) that causes the seizures and (b) infantile spasms are usually generalized seizures.,188,205 215,188,205,196,221,-1,RO-has_definitional_manifestation,904788,The principal underlying concepts are (a) children with medically refractory infantile spasms may have an area of cortical defect (called the zone of cortical abnormality) that causes the seizures and (b) infantile spasms are usually generalized seizures,seizures,infantile spasms
502844724,7/13/2014 21:51:49,,1322181635,7/13/2014 21:51:29,instagc,1,28301350,GBR,K4,Plymouth,89.242.63.62,188,205,,,196,221,SEIZURES,INFANTILE SPASMS,medically refractory infantile spasms SEIZURES,56-66-77-87-188,56-66-77-87-205-215,medically refractory infantile spasms INFANTILE SPASMS,The principal underlying concepts are (a) children with medically refractory infantile spasms may have an area of cortical defect (called the zone of cortical abnormality) that causes the seizures and (b) infantile spasms are usually generalized seizures.,188,205 215,188,205,196,221,-1,RO-has_definitional_manifestation,904788,The principal underlying concepts are (a) children with medically refractory infantile spasms may have an area of cortical defect (called the zone of cortical abnormality) that causes the seizures and (b) infantile spasms are usually generalized seizures,seizures,infantile spasms
502844724,7/13/2014 21:59:19,,1322188333,7/13/2014 21:59:06,clixsense,1,25402344,CAN,ON,Wawa,24.109.124.45,188,205,,,196,221,SEIZURES,INFANTILE SPASMS,that causes the SEIZURES and infantile,172-177-184-188-197-205,188-197-201-205-215-222-226-234,seizures and (b) INFANTILE SPASMS are usually generalized,The principal underlying concepts are (a) children with medically refractory infantile spasms may have an area of cortical defect (called the zone of cortical abnormality) that causes the seizures and (b) infantile spasms are usually generalized seizures.,188,205 215,188,205,196,221,-1,RO-has_definitional_manifestation,904788,The principal underlying concepts are (a) children with medically refractory infantile spasms may have an area of cortical defect (called the zone of cortical abnormality) that causes the seizures and (b) infantile spasms are usually generalized seizures,seizures,infantile spasms
502844724,7/13/2014 22:00:56,,1322190151,7/13/2014 22:00:28,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,188,205,,,196,221,SEIZURES,INFANTILE SPASMS,SEIZURES and (b) infantile spasms,188-197-201-205-215,205-215-222-226-234-246,INFANTILE SPASMS are usually generalized seizures.,The principal underlying concepts are (a) children with medically refractory infantile spasms may have an area of cortical defect (called the zone of cortical abnormality) that causes the seizures and (b) infantile spasms are usually generalized seizures.,188,205 215,188,205,196,221,-1,RO-has_definitional_manifestation,904788,The principal underlying concepts are (a) children with medically refractory infantile spasms may have an area of cortical defect (called the zone of cortical abnormality) that causes the seizures and (b) infantile spasms are usually generalized seizures,seizures,infantile spasms
502844724,7/13/2014 22:05:51,,1322194077,7/13/2014 22:05:11,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,188,205,,,196,221,SEIZURES,INFANTILE SPASMS,children with medically refractory infantile spasms cortical defect cortical abnormality) that causes the SEIZURES and infantile spasms generalized seizures.,42-51-56-66-77-87-114-123-150-159-172-177-184-188-197-205-215-234-246,42-51-56-66-77-87-114-123-159-188-197-201-205-215-222-226-234-246-150,children with medically refractory infantile spasms cortical defect cortical abnormality) seizures and (b) INFANTILE SPASMS are usually generalized seizures.,The principal underlying concepts are (a) children with medically refractory infantile spasms may have an area of cortical defect (called the zone of cortical abnormality) that causes the seizures and (b) infantile spasms are usually generalized seizures.,188,205 215,188,205,196,221,-1,RO-has_definitional_manifestation,904788,The principal underlying concepts are (a) children with medically refractory infantile spasms may have an area of cortical defect (called the zone of cortical abnormality) that causes the seizures and (b) infantile spasms are usually generalized seizures,seizures,infantile spasms
502844724,7/13/2014 22:07:20,,1322195296,7/13/2014 22:06:52,prodege,1,17932518,GBR,Y2,Pwllheli,95.151.166.224,188,205,,,196,221,SEIZURES,INFANTILE SPASMS,SEIZURES,188,205-215,INFANTILE SPASMS,The principal underlying concepts are (a) children with medically refractory infantile spasms may have an area of cortical defect (called the zone of cortical abnormality) that causes the seizures and (b) infantile spasms are usually generalized seizures.,188,205 215,188,205,196,221,-1,RO-has_definitional_manifestation,904788,The principal underlying concepts are (a) children with medically refractory infantile spasms may have an area of cortical defect (called the zone of cortical abnormality) that causes the seizures and (b) infantile spasms are usually generalized seizures,seizures,infantile spasms
502844724,7/13/2014 22:18:48,,1322204681,7/13/2014 22:18:29,clixsense,1,8769423,AUS,6,Hobart,147.69.162.116,188,205,,,196,221,SEIZURES,INFANTILE SPASMS,SEIZURES,188,205-215,INFANTILE SPASMS,The principal underlying concepts are (a) children with medically refractory infantile spasms may have an area of cortical defect (called the zone of cortical abnormality) that causes the seizures and (b) infantile spasms are usually generalized seizures.,188,205 215,188,205,196,221,-1,RO-has_definitional_manifestation,904788,The principal underlying concepts are (a) children with medically refractory infantile spasms may have an area of cortical defect (called the zone of cortical abnormality) that causes the seizures and (b) infantile spasms are usually generalized seizures,seizures,infantile spasms
502844724,7/13/2014 22:23:13,,1322208531,7/13/2014 22:22:58,clixsense,1,10842668,GBR,,,80.189.187.36,188,205,,,196,221,SEIZURES,INFANTILE SPASMS,SEIZURES,188,205-215,INFANTILE SPASMS,The principal underlying concepts are (a) children with medically refractory infantile spasms may have an area of cortical defect (called the zone of cortical abnormality) that causes the seizures and (b) infantile spasms are usually generalized seizures.,188,205 215,188,205,196,221,-1,RO-has_definitional_manifestation,904788,The principal underlying concepts are (a) children with medically refractory infantile spasms may have an area of cortical defect (called the zone of cortical abnormality) that causes the seizures and (b) infantile spasms are usually generalized seizures,seizures,infantile spasms
502844724,7/13/2014 22:24:23,,1322209581,7/13/2014 22:24:12,clixsense,1,26889820,GBR,C3,Shelford,92.18.120.203,188,205,,,196,221,SEIZURES,INFANTILE SPASMS,SEIZURES,188,205-215,INFANTILE SPASMS,The principal underlying concepts are (a) children with medically refractory infantile spasms may have an area of cortical defect (called the zone of cortical abnormality) that causes the seizures and (b) infantile spasms are usually generalized seizures.,188,205 215,188,205,196,221,-1,RO-has_definitional_manifestation,904788,The principal underlying concepts are (a) children with medically refractory infantile spasms may have an area of cortical defect (called the zone of cortical abnormality) that causes the seizures and (b) infantile spasms are usually generalized seizures,seizures,infantile spasms
502844724,7/13/2014 22:26:31,,1322211714,7/13/2014 22:26:19,prodege,1,2143114,CAN,BC,Vancouver,24.84.160.12,188,205,,,196,221,SEIZURES,INFANTILE SPASMS,SEIZURES,188,205-215,INFANTILE SPASMS,The principal underlying concepts are (a) children with medically refractory infantile spasms may have an area of cortical defect (called the zone of cortical abnormality) that causes the seizures and (b) infantile spasms are usually generalized seizures.,188,205 215,188,205,196,221,-1,RO-has_definitional_manifestation,904788,The principal underlying concepts are (a) children with medically refractory infantile spasms may have an area of cortical defect (called the zone of cortical abnormality) that causes the seizures and (b) infantile spasms are usually generalized seizures,seizures,infantile spasms
502844725,7/13/2014 21:56:55,,1322186173,7/13/2014 21:56:35,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,74,43,,,83,48,DYSPLASIA,CIN 1,DYSPLASIA,74,43-47,"CIN 1,","Forty-one (30.1%) women had mild dysplasia/CIN 1, 21 (15.4%) had moderate dysplasia/CIN 2 and 17 (12.5%) had severe dysplasia/CIN 3.",74,43 47,74,43,83,48,-1,RO-disease_has_finding,901763,"Forty-one (30.1%) women had mild dysplasia/CIN 1, 21 (15.4%) had moderate dysplasia/CIN 2 and 17 (12.5%) had severe dysplasia/CIN 3",dysplasia,CIN 1
502844725,7/13/2014 21:59:34,,1322188658,7/13/2014 21:59:28,clixsense,1,24763049,GBR,,,86.133.47.213,74,43,,,83,48,DYSPLASIA,CIN 1,(15.4%) had moderate DYSPLASIA CIN 2 and,53-61-65-74-84-88-90,24-28-33-43-47-50-61,"had mild dysplasia CIN 1, 21 had","Forty-one (30.1%) women had mild dysplasia/CIN 1, 21 (15.4%) had moderate dysplasia/CIN 2 and 17 (12.5%) had severe dysplasia/CIN 3.",74,43 47,74,43,83,48,-1,RO-disease_has_finding,901763,"Forty-one (30.1%) women had mild dysplasia/CIN 1, 21 (15.4%) had moderate dysplasia/CIN 2 and 17 (12.5%) had severe dysplasia/CIN 3",dysplasia,CIN 1
502844725,7/13/2014 22:01:38,,1322190749,7/13/2014 22:00:32,clixsense,1,15189335,GBR,K3,Peterborough,81.156.166.189,74,43,,,83,48,DYSPLASIA,CIN 1,DYSPLASIA,74,43-47,"CIN 1,","Forty-one (30.1%) women had mild dysplasia/CIN 1, 21 (15.4%) had moderate dysplasia/CIN 2 and 17 (12.5%) had severe dysplasia/CIN 3.",74,43 47,74,43,83,48,-1,RO-disease_has_finding,901763,"Forty-one (30.1%) women had mild dysplasia/CIN 1, 21 (15.4%) had moderate dysplasia/CIN 2 and 17 (12.5%) had severe dysplasia/CIN 3",dysplasia,CIN 1
502844725,7/13/2014 22:01:59,,1322191019,7/13/2014 22:01:20,elite,1,28397222,GBR,,,31.49.231.211,74,43,,,83,48,DYSPLASIA,CIN 1,moderate DYSPLASIA CIN 2,74-84-88-65,28-33-43-47,"mild dysplasia CIN 1,","Forty-one (30.1%) women had mild dysplasia/CIN 1, 21 (15.4%) had moderate dysplasia/CIN 2 and 17 (12.5%) had severe dysplasia/CIN 3.",74,43 47,74,43,83,48,-1,RO-disease_has_finding,901763,"Forty-one (30.1%) women had mild dysplasia/CIN 1, 21 (15.4%) had moderate dysplasia/CIN 2 and 17 (12.5%) had severe dysplasia/CIN 3",dysplasia,CIN 1
502844725,7/13/2014 22:08:19,,1322196088,7/13/2014 22:07:35,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,74,43,,,83,48,DYSPLASIA,CIN 1,moderate DYSPLASIA CIN 2 and dysplasia CIN 3.,65-74-84-88-90-116-126-130,28-33-43-47-65-74-83-84-90-109-116-126-130,"mild dysplasia CIN 1, moderate dysplasia / CIN and severe dysplasia CIN 3.","Forty-one (30.1%) women had mild dysplasia/CIN 1, 21 (15.4%) had moderate dysplasia/CIN 2 and 17 (12.5%) had severe dysplasia/CIN 3.",74,43 47,74,43,83,48,-1,RO-disease_has_finding,901763,"Forty-one (30.1%) women had mild dysplasia/CIN 1, 21 (15.4%) had moderate dysplasia/CIN 2 and 17 (12.5%) had severe dysplasia/CIN 3",dysplasia,CIN 1
502844725,7/13/2014 22:16:39,,1322202933,7/13/2014 22:16:20,instagc,1,23149109,USA,NC,Durham,75.189.206.205,74,43,,,83,48,DYSPLASIA,CIN 1,moderate DYSPLASIA,65-74,28-33-43-47,"mild dysplasia CIN 1,","Forty-one (30.1%) women had mild dysplasia/CIN 1, 21 (15.4%) had moderate dysplasia/CIN 2 and 17 (12.5%) had severe dysplasia/CIN 3.",74,43 47,74,43,83,48,-1,RO-disease_has_finding,901763,"Forty-one (30.1%) women had mild dysplasia/CIN 1, 21 (15.4%) had moderate dysplasia/CIN 2 and 17 (12.5%) had severe dysplasia/CIN 3",dysplasia,CIN 1
502844725,7/13/2014 22:17:14,,1322203393,7/13/2014 22:16:25,prodege,1,28255346,GBR,L9,Sheffield,2.125.183.137,74,43,,,83,48,DYSPLASIA,CIN 1,moderate DYSPLASIA,65-74,24-28-33-43-47-50-53,"had mild dysplasia CIN 1, 21 (15.4%)","Forty-one (30.1%) women had mild dysplasia/CIN 1, 21 (15.4%) had moderate dysplasia/CIN 2 and 17 (12.5%) had severe dysplasia/CIN 3.",74,43 47,74,43,83,48,-1,RO-disease_has_finding,901763,"Forty-one (30.1%) women had mild dysplasia/CIN 1, 21 (15.4%) had moderate dysplasia/CIN 2 and 17 (12.5%) had severe dysplasia/CIN 3",dysplasia,CIN 1
502844725,7/13/2014 22:19:16,,1322205154,7/13/2014 22:18:50,clixsense,1,8769423,AUS,6,Hobart,147.69.162.116,74,43,,,83,48,DYSPLASIA,CIN 1,DYSPLASIA,74,43-47,"CIN 1,","Forty-one (30.1%) women had mild dysplasia/CIN 1, 21 (15.4%) had moderate dysplasia/CIN 2 and 17 (12.5%) had severe dysplasia/CIN 3.",74,43 47,74,43,83,48,-1,RO-disease_has_finding,901763,"Forty-one (30.1%) women had mild dysplasia/CIN 1, 21 (15.4%) had moderate dysplasia/CIN 2 and 17 (12.5%) had severe dysplasia/CIN 3",dysplasia,CIN 1
502844725,7/13/2014 22:20:30,,1322206259,7/13/2014 22:20:13,gifthulk,1,22552178,AUS,5,Adelaide,14.2.7.227,74,43,,,83,48,DYSPLASIA,CIN 1,DYSPLASIA,74,43-47,"CIN 1,","Forty-one (30.1%) women had mild dysplasia/CIN 1, 21 (15.4%) had moderate dysplasia/CIN 2 and 17 (12.5%) had severe dysplasia/CIN 3.",74,43 47,74,43,83,48,-1,RO-disease_has_finding,901763,"Forty-one (30.1%) women had mild dysplasia/CIN 1, 21 (15.4%) had moderate dysplasia/CIN 2 and 17 (12.5%) had severe dysplasia/CIN 3",dysplasia,CIN 1
502844725,7/13/2014 22:27:10,,1322212468,7/13/2014 22:25:57,clixsense,1,21875134,GBR,,,91.125.61.83,74,43,,,83,48,DYSPLASIA,CIN 1,moderate DYSPLASIA,65-74,43-47,"CIN 1,","Forty-one (30.1%) women had mild dysplasia/CIN 1, 21 (15.4%) had moderate dysplasia/CIN 2 and 17 (12.5%) had severe dysplasia/CIN 3.",74,43 47,74,43,83,48,-1,RO-disease_has_finding,901763,"Forty-one (30.1%) women had mild dysplasia/CIN 1, 21 (15.4%) had moderate dysplasia/CIN 2 and 17 (12.5%) had severe dysplasia/CIN 3",dysplasia,CIN 1
502844726,7/13/2014 21:53:57,,1322183459,7/13/2014 21:53:35,instagc,1,28301350,GBR,K4,Plymouth,89.242.63.62,126,162,,,147,179,VERTICAL GROWTH PHASE,NODULAR MELANOMAS,"melanomas VERTICAL GROWTH PHASE),",19-126-135-142,19-162-170,"melanomas NODULAR MELANOMAS,","Fifty non-selected melanomas comprising ten superficial spreading melanomas (five exhibiting a radial growth phase and five a vertical growth phase), ten primary nodular melanomas, 30 melanoma metastases, and 16 naevi were investigated by direct sequencing analysis of the AP-2alpha and c-kit genes and by immunohistochemistry for the respective proteins.",126 135 142,162 170,126,162,147,179,-1,RO-disease_has_finding,901610,"Fifty non-selected melanomas comprising ten superficial spreading melanomas (five exhibiting a radial growth phase and five a vertical growth phase), ten primary nodular melanomas, 30 melanoma metastases, and 16 naevi were investigated by direct sequencing analysis of the AP-2alpha and c-kit genes and by immunohistochemistry for the respective proteins",vertical growth phase,nodular melanomas
502844726,7/13/2014 21:54:13,,1322183684,7/13/2014 21:53:57,elite,1,28503042,USA,OK,Oakwood,64.250.220.169,126,162,,,147,179,VERTICAL GROWTH PHASE,NODULAR MELANOMAS,"VERTICAL GROWTH PHASE),",126-135-142,154-162-170,"primary NODULAR MELANOMAS,","Fifty non-selected melanomas comprising ten superficial spreading melanomas (five exhibiting a radial growth phase and five a vertical growth phase), ten primary nodular melanomas, 30 melanoma metastases, and 16 naevi were investigated by direct sequencing analysis of the AP-2alpha and c-kit genes and by immunohistochemistry for the respective proteins.",126 135 142,162 170,126,162,147,179,-1,RO-disease_has_finding,901610,"Fifty non-selected melanomas comprising ten superficial spreading melanomas (five exhibiting a radial growth phase and five a vertical growth phase), ten primary nodular melanomas, 30 melanoma metastases, and 16 naevi were investigated by direct sequencing analysis of the AP-2alpha and c-kit genes and by immunohistochemistry for the respective proteins",vertical growth phase,nodular melanomas
502844726,7/13/2014 21:54:41,,1322184042,7/13/2014 21:54:29,clixsense,1,25402344,CAN,ON,Wawa,24.109.124.45,126,162,,,147,179,VERTICAL GROWTH PHASE,NODULAR MELANOMAS,"and five a VERTICAL GROWTH PHASE), ten primary nodular",115-119-124-126-135-142-150-154-162,142-150-154-162-170-181-184-193,"phase), ten primary NODULAR MELANOMAS, 30 melanoma metastases,","Fifty non-selected melanomas comprising ten superficial spreading melanomas (five exhibiting a radial growth phase and five a vertical growth phase), ten primary nodular melanomas, 30 melanoma metastases, and 16 naevi were investigated by direct sequencing analysis of the AP-2alpha and c-kit genes and by immunohistochemistry for the respective proteins.",126 135 142,162 170,126,162,147,179,-1,RO-disease_has_finding,901610,"Fifty non-selected melanomas comprising ten superficial spreading melanomas (five exhibiting a radial growth phase and five a vertical growth phase), ten primary nodular melanomas, 30 melanoma metastases, and 16 naevi were investigated by direct sequencing analysis of the AP-2alpha and c-kit genes and by immunohistochemistry for the respective proteins",vertical growth phase,nodular melanomas
502844726,7/13/2014 21:55:06,,1322184451,7/13/2014 21:54:47,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,126,162,,,147,179,VERTICAL GROWTH PHASE,NODULAR MELANOMAS,"VERTICAL GROWTH PHASE),",126-135-142,162-170,"NODULAR MELANOMAS,","Fifty non-selected melanomas comprising ten superficial spreading melanomas (five exhibiting a radial growth phase and five a vertical growth phase), ten primary nodular melanomas, 30 melanoma metastases, and 16 naevi were investigated by direct sequencing analysis of the AP-2alpha and c-kit genes and by immunohistochemistry for the respective proteins.",126 135 142,162 170,126,162,147,179,-1,RO-disease_has_finding,901610,"Fifty non-selected melanomas comprising ten superficial spreading melanomas (five exhibiting a radial growth phase and five a vertical growth phase), ten primary nodular melanomas, 30 melanoma metastases, and 16 naevi were investigated by direct sequencing analysis of the AP-2alpha and c-kit genes and by immunohistochemistry for the respective proteins",vertical growth phase,nodular melanomas
502844726,7/13/2014 21:56:14,,1322185465,7/13/2014 21:55:54,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,126,162,,,147,179,VERTICAL GROWTH PHASE,NODULAR MELANOMAS,"VERTICAL GROWTH PHASE),",126-135-142,162-170,"NODULAR MELANOMAS,","Fifty non-selected melanomas comprising ten superficial spreading melanomas (five exhibiting a radial growth phase and five a vertical growth phase), ten primary nodular melanomas, 30 melanoma metastases, and 16 naevi were investigated by direct sequencing analysis of the AP-2alpha and c-kit genes and by immunohistochemistry for the respective proteins.",126 135 142,162 170,126,162,147,179,-1,RO-disease_has_finding,901610,"Fifty non-selected melanomas comprising ten superficial spreading melanomas (five exhibiting a radial growth phase and five a vertical growth phase), ten primary nodular melanomas, 30 melanoma metastases, and 16 naevi were investigated by direct sequencing analysis of the AP-2alpha and c-kit genes and by immunohistochemistry for the respective proteins",vertical growth phase,nodular melanomas
502844726,7/13/2014 21:56:41,,1322185947,7/13/2014 21:55:51,elite,1,28397222,GBR,,,31.49.231.211,126,162,,,147,179,VERTICAL GROWTH PHASE,NODULAR MELANOMAS,"VERTICAL GROWTH PHASE),",126-135-142,162-170,"NODULAR MELANOMAS,","Fifty non-selected melanomas comprising ten superficial spreading melanomas (five exhibiting a radial growth phase and five a vertical growth phase), ten primary nodular melanomas, 30 melanoma metastases, and 16 naevi were investigated by direct sequencing analysis of the AP-2alpha and c-kit genes and by immunohistochemistry for the respective proteins.",126 135 142,162 170,126,162,147,179,-1,RO-disease_has_finding,901610,"Fifty non-selected melanomas comprising ten superficial spreading melanomas (five exhibiting a radial growth phase and five a vertical growth phase), ten primary nodular melanomas, 30 melanoma metastases, and 16 naevi were investigated by direct sequencing analysis of the AP-2alpha and c-kit genes and by immunohistochemistry for the respective proteins",vertical growth phase,nodular melanomas
502844726,7/13/2014 21:59:38,,1322188705,7/13/2014 21:59:08,prodege,1,17932518,GBR,Y2,Pwllheli,95.151.166.224,126,162,,,147,179,VERTICAL GROWTH PHASE,NODULAR MELANOMAS,"VERTICAL GROWTH PHASE),",126-135-142,162-170,"NODULAR MELANOMAS,","Fifty non-selected melanomas comprising ten superficial spreading melanomas (five exhibiting a radial growth phase and five a vertical growth phase), ten primary nodular melanomas, 30 melanoma metastases, and 16 naevi were investigated by direct sequencing analysis of the AP-2alpha and c-kit genes and by immunohistochemistry for the respective proteins.",126 135 142,162 170,126,162,147,179,-1,RO-disease_has_finding,901610,"Fifty non-selected melanomas comprising ten superficial spreading melanomas (five exhibiting a radial growth phase and five a vertical growth phase), ten primary nodular melanomas, 30 melanoma metastases, and 16 naevi were investigated by direct sequencing analysis of the AP-2alpha and c-kit genes and by immunohistochemistry for the respective proteins",vertical growth phase,nodular melanomas
502844726,7/13/2014 22:03:27,,1322192219,7/13/2014 22:02:56,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,126,162,,,147,179,VERTICAL GROWTH PHASE,NODULAR MELANOMAS,"VERTICAL GROWTH PHASE),",126-135-142,162-170-184-193,"NODULAR MELANOMAS, melanoma metastases,","Fifty non-selected melanomas comprising ten superficial spreading melanomas (five exhibiting a radial growth phase and five a vertical growth phase), ten primary nodular melanomas, 30 melanoma metastases, and 16 naevi were investigated by direct sequencing analysis of the AP-2alpha and c-kit genes and by immunohistochemistry for the respective proteins.",126 135 142,162 170,126,162,147,179,-1,RO-disease_has_finding,901610,"Fifty non-selected melanomas comprising ten superficial spreading melanomas (five exhibiting a radial growth phase and five a vertical growth phase), ten primary nodular melanomas, 30 melanoma metastases, and 16 naevi were investigated by direct sequencing analysis of the AP-2alpha and c-kit genes and by immunohistochemistry for the respective proteins",vertical growth phase,nodular melanomas
502844726,7/13/2014 22:03:30,,1322192244,7/13/2014 22:03:11,bitcoinget,1,24792414,USA,IA,Independence,166.181.80.204,126,162,,,147,179,VERTICAL GROWTH PHASE,NODULAR MELANOMAS,"VERTICAL GROWTH PHASE),",126-135-142,154-162-170,"primary NODULAR MELANOMAS,","Fifty non-selected melanomas comprising ten superficial spreading melanomas (five exhibiting a radial growth phase and five a vertical growth phase), ten primary nodular melanomas, 30 melanoma metastases, and 16 naevi were investigated by direct sequencing analysis of the AP-2alpha and c-kit genes and by immunohistochemistry for the respective proteins.",126 135 142,162 170,126,162,147,179,-1,RO-disease_has_finding,901610,"Fifty non-selected melanomas comprising ten superficial spreading melanomas (five exhibiting a radial growth phase and five a vertical growth phase), ten primary nodular melanomas, 30 melanoma metastases, and 16 naevi were investigated by direct sequencing analysis of the AP-2alpha and c-kit genes and by immunohistochemistry for the respective proteins",vertical growth phase,nodular melanomas
502844726,7/13/2014 22:03:57,,1322192592,7/13/2014 22:03:39,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,126,162,,,147,179,VERTICAL GROWTH PHASE,NODULAR MELANOMAS,"VERTICAL GROWTH PHASE),",126-135-142,154-162-170,"primary NODULAR MELANOMAS,","Fifty non-selected melanomas comprising ten superficial spreading melanomas (five exhibiting a radial growth phase and five a vertical growth phase), ten primary nodular melanomas, 30 melanoma metastases, and 16 naevi were investigated by direct sequencing analysis of the AP-2alpha and c-kit genes and by immunohistochemistry for the respective proteins.",126 135 142,162 170,126,162,147,179,-1,RO-disease_has_finding,901610,"Fifty non-selected melanomas comprising ten superficial spreading melanomas (five exhibiting a radial growth phase and five a vertical growth phase), ten primary nodular melanomas, 30 melanoma metastases, and 16 naevi were investigated by direct sequencing analysis of the AP-2alpha and c-kit genes and by immunohistochemistry for the respective proteins",vertical growth phase,nodular melanomas
502844727,7/13/2014 21:50:35,,1322180781,7/13/2014 21:50:24,instagc,1,28301350,GBR,K4,Plymouth,89.242.63.62,46,0,,,52,12,KIDNEY,WILMS' TUMOR,Wilms' tumor KIDNEY.,0-7-46,0-7,WILMS' TUMOR,Wilms' tumor is a pediatric malignancy of the kidney.,46,0 7,46,0,52,12,1,RO-disease_has_primary_anatomic_site,902420,Wilms' tumor is a pediatric malignancy of the kidney,kidney,Wilms' tumor
502844727,7/13/2014 21:57:29,,1322186663,7/13/2014 21:57:14,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,46,0,,,52,12,KIDNEY,WILMS' TUMOR,malignancy of the KIDNEY.,28-39-42-46,0-7,WILMS' TUMOR,Wilms' tumor is a pediatric malignancy of the kidney.,46,0 7,46,0,52,12,1,RO-disease_has_primary_anatomic_site,902420,Wilms' tumor is a pediatric malignancy of the kidney,kidney,Wilms' tumor
502844727,7/13/2014 21:58:11,,1322187271,7/13/2014 21:57:38,elite,1,28397222,GBR,,,31.49.231.211,46,0,,,52,12,KIDNEY,WILMS' TUMOR,malignancy of the KIDNEY.,28-39-46-42,0-7,WILMS' TUMOR,Wilms' tumor is a pediatric malignancy of the kidney.,46,0 7,46,0,52,12,1,RO-disease_has_primary_anatomic_site,902420,Wilms' tumor is a pediatric malignancy of the kidney,kidney,Wilms' tumor
502844727,7/13/2014 21:59:39,,1322188787,7/13/2014 21:59:29,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,46,0,,,52,12,KIDNEY,WILMS' TUMOR,malignancy of the KIDNEY.,28-39-42-46,0-7-13-16-18-28-39-42-46,WILMS' TUMOR is a pediatric malignancy of the kidney.,Wilms' tumor is a pediatric malignancy of the kidney.,46,0 7,46,0,52,12,1,RO-disease_has_primary_anatomic_site,902420,Wilms' tumor is a pediatric malignancy of the kidney,kidney,Wilms' tumor
502844727,7/13/2014 22:00:24,,1322189464,7/13/2014 22:00:11,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,46,0,,,52,12,KIDNEY,WILMS' TUMOR,KIDNEY.,46,0-7,WILMS' TUMOR,Wilms' tumor is a pediatric malignancy of the kidney.,46,0 7,46,0,52,12,1,RO-disease_has_primary_anatomic_site,902420,Wilms' tumor is a pediatric malignancy of the kidney,kidney,Wilms' tumor
502844727,7/13/2014 22:01:58,,1322191009,7/13/2014 22:01:48,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,46,0,,,52,12,KIDNEY,WILMS' TUMOR,KIDNEY.,46,0-7,WILMS' TUMOR,Wilms' tumor is a pediatric malignancy of the kidney.,46,0 7,46,0,52,12,1,RO-disease_has_primary_anatomic_site,902420,Wilms' tumor is a pediatric malignancy of the kidney,kidney,Wilms' tumor
502844727,7/13/2014 22:05:51,,1322194088,7/13/2014 22:05:46,clixsense,1,24763049,GBR,,,86.133.47.213,46,0,,,52,12,KIDNEY,WILMS' TUMOR,malignancy of the KIDNEY.,28-39-42-46,0-7-13-16-18,WILMS' TUMOR is a pediatric,Wilms' tumor is a pediatric malignancy of the kidney.,46,0 7,46,0,52,12,1,RO-disease_has_primary_anatomic_site,902420,Wilms' tumor is a pediatric malignancy of the kidney,kidney,Wilms' tumor
502844727,7/13/2014 22:08:30,,1322196165,7/13/2014 22:08:20,bitcoinget,1,24792414,USA,IA,Independence,166.181.80.204,46,0,,,52,12,KIDNEY,WILMS' TUMOR,malignancy of the KIDNEY.,28-42-46-39,0-7,WILMS' TUMOR,Wilms' tumor is a pediatric malignancy of the kidney.,46,0 7,46,0,52,12,1,RO-disease_has_primary_anatomic_site,902420,Wilms' tumor is a pediatric malignancy of the kidney,kidney,Wilms' tumor
502844727,7/13/2014 22:09:37,,1322197064,7/13/2014 22:09:18,prodege,1,17932518,GBR,Y2,Pwllheli,95.151.166.224,46,0,,,52,12,KIDNEY,WILMS' TUMOR,KIDNEY.,46,0-7,WILMS' TUMOR,Wilms' tumor is a pediatric malignancy of the kidney.,46,0 7,46,0,52,12,1,RO-disease_has_primary_anatomic_site,902420,Wilms' tumor is a pediatric malignancy of the kidney,kidney,Wilms' tumor
502844727,7/13/2014 22:15:38,,1322202042,7/13/2014 22:15:17,prodege,1,28255346,GBR,L9,Sheffield,2.125.183.137,46,0,,,52,12,KIDNEY,WILMS' TUMOR,pediatric malignancy of the KIDNEY.,28-39-42-46-18,0-7,WILMS' TUMOR,Wilms' tumor is a pediatric malignancy of the kidney.,46,0 7,46,0,52,12,1,RO-disease_has_primary_anatomic_site,902420,Wilms' tumor is a pediatric malignancy of the kidney,kidney,Wilms' tumor
502844728,7/13/2014 21:52:17,,1322181920,7/13/2014 21:51:50,instagc,1,28301350,GBR,K4,Plymouth,89.242.63.62,139,157,,,147,163,PELLAGRA,NIACIN,keratomalacia PELLAGRA scurvy rickets osteomalacia pernicious anemia,48-139-166-194-206-240-251,48-157-166-194-206-240-251,keratomalacia NIACIN); scurvy rickets osteomalacia pernicious anemia,Deficiency diseases include night blindness and keratomalacia (caused by lack of vitamin A); beriberi and polyneuritis (lack of thiamine); pellagra (lack of niacin); scurvy (lack of vitamin C); rickets and osteomalacia (lack of vitamin D); pernicious anemia (lack of gastric intrinsic factor and vitamin B 12.,139,157,139,157,147,163,1,RO-may_treat,907665,Deficiency diseases include night blindness and keratomalacia (caused by lack of vitamin A); beriberi and polyneuritis (lack of thiamine); pellagra (lack of niacin); scurvy (lack of vitamin C); rickets and osteomalacia (lack of vitamin D); pernicious anemia (lack of gastric intrinsic factor and vitamin B 12,pellagra,niacin
502844728,7/13/2014 21:57:12,,1322186424,7/13/2014 21:56:31,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,139,157,,,147,163,PELLAGRA,NIACIN,PELLAGRA,139,139-148-154-157,pellagra (lack of NIACIN);,Deficiency diseases include night blindness and keratomalacia (caused by lack of vitamin A); beriberi and polyneuritis (lack of thiamine); pellagra (lack of niacin); scurvy (lack of vitamin C); rickets and osteomalacia (lack of vitamin D); pernicious anemia (lack of gastric intrinsic factor and vitamin B 12.,139,157,139,157,147,163,1,RO-may_treat,907665,Deficiency diseases include night blindness and keratomalacia (caused by lack of vitamin A); beriberi and polyneuritis (lack of thiamine); pellagra (lack of niacin); scurvy (lack of vitamin C); rickets and osteomalacia (lack of vitamin D); pernicious anemia (lack of gastric intrinsic factor and vitamin B 12,pellagra,niacin
502844728,7/13/2014 21:58:10,,1322187252,7/13/2014 21:58:00,elite,1,28503042,USA,OK,Oakwood,64.250.220.169,139,157,,,147,163,PELLAGRA,NIACIN,PELLAGRA (lack of niacin);,139-154-157-148,139-148-154-157,pellagra (lack of NIACIN);,Deficiency diseases include night blindness and keratomalacia (caused by lack of vitamin A); beriberi and polyneuritis (lack of thiamine); pellagra (lack of niacin); scurvy (lack of vitamin C); rickets and osteomalacia (lack of vitamin D); pernicious anemia (lack of gastric intrinsic factor and vitamin B 12.,139,157,139,157,147,163,1,RO-may_treat,907665,Deficiency diseases include night blindness and keratomalacia (caused by lack of vitamin A); beriberi and polyneuritis (lack of thiamine); pellagra (lack of niacin); scurvy (lack of vitamin C); rickets and osteomalacia (lack of vitamin D); pernicious anemia (lack of gastric intrinsic factor and vitamin B 12,pellagra,niacin
502844728,7/13/2014 22:12:55,,1322199922,7/13/2014 22:12:32,prodege,1,28255346,GBR,L9,Sheffield,2.125.183.137,139,157,,,147,163,PELLAGRA,NIACIN,PELLAGRA,139,148-154-157,(lack of NIACIN);,Deficiency diseases include night blindness and keratomalacia (caused by lack of vitamin A); beriberi and polyneuritis (lack of thiamine); pellagra (lack of niacin); scurvy (lack of vitamin C); rickets and osteomalacia (lack of vitamin D); pernicious anemia (lack of gastric intrinsic factor and vitamin B 12.,139,157,139,157,147,163,1,RO-may_treat,907665,Deficiency diseases include night blindness and keratomalacia (caused by lack of vitamin A); beriberi and polyneuritis (lack of thiamine); pellagra (lack of niacin); scurvy (lack of vitamin C); rickets and osteomalacia (lack of vitamin D); pernicious anemia (lack of gastric intrinsic factor and vitamin B 12,pellagra,niacin
502844728,7/13/2014 22:19:40,,1322205547,7/13/2014 22:19:22,gifthulk,1,22552178,AUS,5,Adelaide,14.2.7.227,139,157,,,147,163,PELLAGRA,NIACIN,PELLAGRA,139,157,NIACIN);,Deficiency diseases include night blindness and keratomalacia (caused by lack of vitamin A); beriberi and polyneuritis (lack of thiamine); pellagra (lack of niacin); scurvy (lack of vitamin C); rickets and osteomalacia (lack of vitamin D); pernicious anemia (lack of gastric intrinsic factor and vitamin B 12.,139,157,139,157,147,163,1,RO-may_treat,907665,Deficiency diseases include night blindness and keratomalacia (caused by lack of vitamin A); beriberi and polyneuritis (lack of thiamine); pellagra (lack of niacin); scurvy (lack of vitamin C); rickets and osteomalacia (lack of vitamin D); pernicious anemia (lack of gastric intrinsic factor and vitamin B 12,pellagra,niacin
502844728,7/13/2014 22:22:19,,1322207721,7/13/2014 22:22:06,clixsense,1,10842668,GBR,,,80.189.187.36,139,157,,,147,163,PELLAGRA,NIACIN,PELLAGRA,139,157,NIACIN);,Deficiency diseases include night blindness and keratomalacia (caused by lack of vitamin A); beriberi and polyneuritis (lack of thiamine); pellagra (lack of niacin); scurvy (lack of vitamin C); rickets and osteomalacia (lack of vitamin D); pernicious anemia (lack of gastric intrinsic factor and vitamin B 12.,139,157,139,157,147,163,1,RO-may_treat,907665,Deficiency diseases include night blindness and keratomalacia (caused by lack of vitamin A); beriberi and polyneuritis (lack of thiamine); pellagra (lack of niacin); scurvy (lack of vitamin C); rickets and osteomalacia (lack of vitamin D); pernicious anemia (lack of gastric intrinsic factor and vitamin B 12,pellagra,niacin
502844728,7/13/2014 22:25:34,,1322210779,7/13/2014 22:25:20,prodege,1,2143114,CAN,BC,Vancouver,24.84.160.12,139,157,,,147,163,PELLAGRA,NIACIN,PELLAGRA,139,157,NIACIN);,Deficiency diseases include night blindness and keratomalacia (caused by lack of vitamin A); beriberi and polyneuritis (lack of thiamine); pellagra (lack of niacin); scurvy (lack of vitamin C); rickets and osteomalacia (lack of vitamin D); pernicious anemia (lack of gastric intrinsic factor and vitamin B 12.,139,157,139,157,147,163,1,RO-may_treat,907665,Deficiency diseases include night blindness and keratomalacia (caused by lack of vitamin A); beriberi and polyneuritis (lack of thiamine); pellagra (lack of niacin); scurvy (lack of vitamin C); rickets and osteomalacia (lack of vitamin D); pernicious anemia (lack of gastric intrinsic factor and vitamin B 12,pellagra,niacin
502844728,7/13/2014 22:26:37,,1322211807,7/13/2014 22:26:14,clixsense,1,26889820,GBR,C3,Shelford,92.18.120.203,139,157,,,147,163,PELLAGRA,NIACIN,PELLAGRA,139,157,NIACIN);,Deficiency diseases include night blindness and keratomalacia (caused by lack of vitamin A); beriberi and polyneuritis (lack of thiamine); pellagra (lack of niacin); scurvy (lack of vitamin C); rickets and osteomalacia (lack of vitamin D); pernicious anemia (lack of gastric intrinsic factor and vitamin B 12.,139,157,139,157,147,163,1,RO-may_treat,907665,Deficiency diseases include night blindness and keratomalacia (caused by lack of vitamin A); beriberi and polyneuritis (lack of thiamine); pellagra (lack of niacin); scurvy (lack of vitamin C); rickets and osteomalacia (lack of vitamin D); pernicious anemia (lack of gastric intrinsic factor and vitamin B 12,pellagra,niacin
502844728,7/13/2014 22:27:46,,1322212947,7/13/2014 22:26:44,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,139,157,,,147,163,PELLAGRA,NIACIN,PELLAGRA,139,157,NIACIN);,Deficiency diseases include night blindness and keratomalacia (caused by lack of vitamin A); beriberi and polyneuritis (lack of thiamine); pellagra (lack of niacin); scurvy (lack of vitamin C); rickets and osteomalacia (lack of vitamin D); pernicious anemia (lack of gastric intrinsic factor and vitamin B 12.,139,157,139,157,147,163,1,RO-may_treat,907665,Deficiency diseases include night blindness and keratomalacia (caused by lack of vitamin A); beriberi and polyneuritis (lack of thiamine); pellagra (lack of niacin); scurvy (lack of vitamin C); rickets and osteomalacia (lack of vitamin D); pernicious anemia (lack of gastric intrinsic factor and vitamin B 12,pellagra,niacin
502844728,7/13/2014 22:35:49,,1322220463,7/13/2014 22:34:30,prodege,1,2374617,CAN,ON,Saint Catharines,216.121.166.67,139,157,,,147,163,PELLAGRA,NIACIN,PELLAGRA (lack of niacin);,139-148-154-157,139-148-154-157,pellagra (lack of NIACIN);,Deficiency diseases include night blindness and keratomalacia (caused by lack of vitamin A); beriberi and polyneuritis (lack of thiamine); pellagra (lack of niacin); scurvy (lack of vitamin C); rickets and osteomalacia (lack of vitamin D); pernicious anemia (lack of gastric intrinsic factor and vitamin B 12.,139,157,139,157,147,163,1,RO-may_treat,907665,Deficiency diseases include night blindness and keratomalacia (caused by lack of vitamin A); beriberi and polyneuritis (lack of thiamine); pellagra (lack of niacin); scurvy (lack of vitamin C); rickets and osteomalacia (lack of vitamin D); pernicious anemia (lack of gastric intrinsic factor and vitamin B 12,pellagra,niacin
502844729,7/13/2014 21:52:05,,1322181808,7/13/2014 21:51:40,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,0,52,,,39,68,ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS,HYPERSENSITIVITY,ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS,0-9-26,52-69-74,HYPERSENSITIVITY lung disease,Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity lung disease mediated by an allergic late-phase inflammatory response to Aspergillus fumigatus antigens.,0 9 26,52,0,52,39,68,1,RO-cause_of,900282,Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity lung disease mediated by an allergic late-phase inflammatory response to Aspergillus fumigatus antigens,Allergic bronchopulmonary aspergillosis,hypersensitivity
502844729,7/13/2014 21:53:58,,1322183452,7/13/2014 21:53:16,prodege,1,17932518,GBR,Y2,Pwllheli,95.151.166.224,0,52,,,39,68,ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS,HYPERSENSITIVITY,ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS is a,0-9-26-47-50,40-52,(ABPA) HYPERSENSITIVITY,Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity lung disease mediated by an allergic late-phase inflammatory response to Aspergillus fumigatus antigens.,0 9 26,52,0,52,39,68,1,RO-cause_of,900282,Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity lung disease mediated by an allergic late-phase inflammatory response to Aspergillus fumigatus antigens,Allergic bronchopulmonary aspergillosis,hypersensitivity
502844729,7/13/2014 21:54:50,,1322184235,7/13/2014 21:54:43,clixsense,1,25402344,CAN,ON,Wawa,24.109.124.45,0,52,,,39,68,ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS,HYPERSENSITIVITY,ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS is a,0-9-26-47-50,40-47-50-52-69-74-82,(ABPA) is a HYPERSENSITIVITY lung disease mediated,Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity lung disease mediated by an allergic late-phase inflammatory response to Aspergillus fumigatus antigens.,0 9 26,52,0,52,39,68,1,RO-cause_of,900282,Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity lung disease mediated by an allergic late-phase inflammatory response to Aspergillus fumigatus antigens,Allergic bronchopulmonary aspergillosis,hypersensitivity
502844729,7/13/2014 21:56:01,,1322185260,7/13/2014 21:55:41,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,0,52,,,39,68,ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS,HYPERSENSITIVITY,ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS,0-9-26,40-52,(ABPA) HYPERSENSITIVITY,Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity lung disease mediated by an allergic late-phase inflammatory response to Aspergillus fumigatus antigens.,0 9 26,52,0,52,39,68,1,RO-cause_of,900282,Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity lung disease mediated by an allergic late-phase inflammatory response to Aspergillus fumigatus antigens,Allergic bronchopulmonary aspergillosis,hypersensitivity
502844729,7/13/2014 21:56:54,,1322186153,7/13/2014 21:56:40,instagc,1,28301350,GBR,K4,Plymouth,89.242.63.62,0,52,,,39,68,ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS,HYPERSENSITIVITY,ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS,0-9-26,0-9-26-52,Allergic bronchopulmonary aspergillosis HYPERSENSITIVITY,Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity lung disease mediated by an allergic late-phase inflammatory response to Aspergillus fumigatus antigens.,0 9 26,52,0,52,39,68,1,RO-cause_of,900282,Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity lung disease mediated by an allergic late-phase inflammatory response to Aspergillus fumigatus antigens,Allergic bronchopulmonary aspergillosis,hypersensitivity
502844729,7/13/2014 21:57:43,,1322186887,7/13/2014 21:56:48,clixsense,1,20614047,USA,WA,Deer Park,174.32.162.10,0,52,,,39,68,ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS,HYPERSENSITIVITY,ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS (ABPA) is a hypersensitivity lung disease,0-9-26-40-47-50-52-69-74,0-9-26-40-47-50-52-69-74,Allergic bronchopulmonary aspergillosis (ABPA) is a HYPERSENSITIVITY lung disease,Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity lung disease mediated by an allergic late-phase inflammatory response to Aspergillus fumigatus antigens.,0 9 26,52,0,52,39,68,1,RO-cause_of,900282,Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity lung disease mediated by an allergic late-phase inflammatory response to Aspergillus fumigatus antigens,Allergic bronchopulmonary aspergillosis,hypersensitivity
502844729,7/13/2014 21:58:00,,1322187138,7/13/2014 21:57:42,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,0,52,,,39,68,ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS,HYPERSENSITIVITY,ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS (ABPA),0-9-26-40,40-47-50-52-69-74,(ABPA) is a HYPERSENSITIVITY lung disease,Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity lung disease mediated by an allergic late-phase inflammatory response to Aspergillus fumigatus antigens.,0 9 26,52,0,52,39,68,1,RO-cause_of,900282,Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity lung disease mediated by an allergic late-phase inflammatory response to Aspergillus fumigatus antigens,Allergic bronchopulmonary aspergillosis,hypersensitivity
502844729,7/13/2014 21:59:07,,1322188074,7/13/2014 21:58:42,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,0,52,,,39,68,ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS,HYPERSENSITIVITY,ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS,0-9-26,52-69-74,HYPERSENSITIVITY lung disease,Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity lung disease mediated by an allergic late-phase inflammatory response to Aspergillus fumigatus antigens.,0 9 26,52,0,52,39,68,1,RO-cause_of,900282,Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity lung disease mediated by an allergic late-phase inflammatory response to Aspergillus fumigatus antigens,Allergic bronchopulmonary aspergillosis,hypersensitivity
502844729,7/13/2014 21:59:58,,1322189050,7/13/2014 21:59:54,clixsense,1,24763049,GBR,,,86.133.47.213,0,52,,,39,68,ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS,HYPERSENSITIVITY,ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS is a,0-9-26-47-50,40-47-50-52-69-74-82,(ABPA) is a HYPERSENSITIVITY lung disease mediated,Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity lung disease mediated by an allergic late-phase inflammatory response to Aspergillus fumigatus antigens.,0 9 26,52,0,52,39,68,1,RO-cause_of,900282,Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity lung disease mediated by an allergic late-phase inflammatory response to Aspergillus fumigatus antigens,Allergic bronchopulmonary aspergillosis,hypersensitivity
502844729,7/13/2014 22:00:31,,1322189532,7/13/2014 22:00:01,clixsense,1,15189335,GBR,K3,Peterborough,81.156.166.189,0,52,,,39,68,ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS,HYPERSENSITIVITY,ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS,0-9-26,52,HYPERSENSITIVITY,Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity lung disease mediated by an allergic late-phase inflammatory response to Aspergillus fumigatus antigens.,0 9 26,52,0,52,39,68,1,RO-cause_of,900282,Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity lung disease mediated by an allergic late-phase inflammatory response to Aspergillus fumigatus antigens,Allergic bronchopulmonary aspergillosis,hypersensitivity
502844730,7/13/2014 21:52:24,,1322181984,7/13/2014 21:52:02,clixsense,1,15189335,GBR,K3,Peterborough,81.156.166.189,26,58,,,40,68,VARIANT ANGINA,ERGONOVINE,"VARIANT ANGINA,",26-34,58,ERGONOVINE,"However, in patients with variant angina, a small dose of ergonovine produced a percentage of change in diameter of 39.8 +/- 15.3% at the site of spastic occlusion included by a larger dose of ergonovine, compared with that of 7.0 +/- 11.9% in the remaining non-spastic coronary arteries (p less than 0.05.",26 34,58,26,58,40,68,1,RO-may_diagnose,906708,"However, in patients with variant angina, a small dose of ergonovine produced a percentage of change in diameter of 39.8 +/- 15.3% at the site of spastic occlusion included by a larger dose of ergonovine, compared with that of 7.0 +/- 11.9% in the remaining non-spastic coronary arteries (p less than 0.05",variant angina,ergonovine
502844730,7/13/2014 21:52:54,,1322182480,7/13/2014 21:51:44,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,26,58,,,40,68,VARIANT ANGINA,ERGONOVINE,"15.3% patients with VARIANT ANGINA, a small dose ergonovine of spastic",12-21-26-34-42-44-50-58-224-262--1,12-21-26-34-42-44-50-55-58-69-78-80-262--1,"15.3% patients with variant angina, a small dose of ERGONOVINE produced a percentage spastic","However, in patients with variant angina, a small dose of ergonovine produced a percentage of change in diameter of 39.8 +/- 15.3% at the site of spastic occlusion included by a larger dose of ergonovine, compared with that of 7.0 +/- 11.9% in the remaining non-spastic coronary arteries (p less than 0.05.",26 34,58,26,58,40,68,1,RO-may_diagnose,906708,"However, in patients with variant angina, a small dose of ergonovine produced a percentage of change in diameter of 39.8 +/- 15.3% at the site of spastic occlusion included by a larger dose of ergonovine, compared with that of 7.0 +/- 11.9% in the remaining non-spastic coronary arteries (p less than 0.05",variant angina,ergonovine
502844730,7/13/2014 21:53:09,,1322182713,7/13/2014 21:52:45,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,26,58,,,40,68,VARIANT ANGINA,ERGONOVINE,"VARIANT ANGINA,",26-34,58,ERGONOVINE,"However, in patients with variant angina, a small dose of ergonovine produced a percentage of change in diameter of 39.8 +/- 15.3% at the site of spastic occlusion included by a larger dose of ergonovine, compared with that of 7.0 +/- 11.9% in the remaining non-spastic coronary arteries (p less than 0.05.",26 34,58,26,58,40,68,1,RO-may_diagnose,906708,"However, in patients with variant angina, a small dose of ergonovine produced a percentage of change in diameter of 39.8 +/- 15.3% at the site of spastic occlusion included by a larger dose of ergonovine, compared with that of 7.0 +/- 11.9% in the remaining non-spastic coronary arteries (p less than 0.05",variant angina,ergonovine
502844730,7/13/2014 21:54:27,,1322183826,7/13/2014 21:53:59,prodege,1,17932518,GBR,Y2,Pwllheli,95.151.166.224,26,58,,,40,68,VARIANT ANGINA,ERGONOVINE,"VARIANT ANGINA,",26-34,58,ERGONOVINE,"However, in patients with variant angina, a small dose of ergonovine produced a percentage of change in diameter of 39.8 +/- 15.3% at the site of spastic occlusion included by a larger dose of ergonovine, compared with that of 7.0 +/- 11.9% in the remaining non-spastic coronary arteries (p less than 0.05.",26 34,58,26,58,40,68,1,RO-may_diagnose,906708,"However, in patients with variant angina, a small dose of ergonovine produced a percentage of change in diameter of 39.8 +/- 15.3% at the site of spastic occlusion included by a larger dose of ergonovine, compared with that of 7.0 +/- 11.9% in the remaining non-spastic coronary arteries (p less than 0.05",variant angina,ergonovine
502844730,7/13/2014 21:54:39,,1322183999,7/13/2014 21:54:29,elite,1,28503042,USA,OK,Oakwood,64.250.220.169,26,58,,,40,68,VARIANT ANGINA,ERGONOVINE,"VARIANT ANGINA,",26-34,58,ERGONOVINE,"However, in patients with variant angina, a small dose of ergonovine produced a percentage of change in diameter of 39.8 +/- 15.3% at the site of spastic occlusion included by a larger dose of ergonovine, compared with that of 7.0 +/- 11.9% in the remaining non-spastic coronary arteries (p less than 0.05.",26 34,58,26,58,40,68,1,RO-may_diagnose,906708,"However, in patients with variant angina, a small dose of ergonovine produced a percentage of change in diameter of 39.8 +/- 15.3% at the site of spastic occlusion included by a larger dose of ergonovine, compared with that of 7.0 +/- 11.9% in the remaining non-spastic coronary arteries (p less than 0.05",variant angina,ergonovine
502844730,7/13/2014 22:00:05,,1322189132,7/13/2014 22:00:00,clixsense,1,24763049,GBR,,,86.133.47.213,26,58,,,40,68,VARIANT ANGINA,ERGONOVINE,"in patients with VARIANT ANGINA, a small dose",9-12-21-26-34-42-44-50,44-50-55-58-69-78-80,small dose of ERGONOVINE produced a percentage,"However, in patients with variant angina, a small dose of ergonovine produced a percentage of change in diameter of 39.8 +/- 15.3% at the site of spastic occlusion included by a larger dose of ergonovine, compared with that of 7.0 +/- 11.9% in the remaining non-spastic coronary arteries (p less than 0.05.",26 34,58,26,58,40,68,1,RO-may_diagnose,906708,"However, in patients with variant angina, a small dose of ergonovine produced a percentage of change in diameter of 39.8 +/- 15.3% at the site of spastic occlusion included by a larger dose of ergonovine, compared with that of 7.0 +/- 11.9% in the remaining non-spastic coronary arteries (p less than 0.05",variant angina,ergonovine
502844730,7/13/2014 22:03:59,,1322192632,7/13/2014 22:03:35,neodev,1,28175665,CAN,ON,Brampton,99.228.31.59,26,58,,,40,68,VARIANT ANGINA,ERGONOVINE,"VARIANT ANGINA,",26-34,58,ERGONOVINE,"However, in patients with variant angina, a small dose of ergonovine produced a percentage of change in diameter of 39.8 +/- 15.3% at the site of spastic occlusion included by a larger dose of ergonovine, compared with that of 7.0 +/- 11.9% in the remaining non-spastic coronary arteries (p less than 0.05.",26 34,58,26,58,40,68,1,RO-may_diagnose,906708,"However, in patients with variant angina, a small dose of ergonovine produced a percentage of change in diameter of 39.8 +/- 15.3% at the site of spastic occlusion included by a larger dose of ergonovine, compared with that of 7.0 +/- 11.9% in the remaining non-spastic coronary arteries (p less than 0.05",variant angina,ergonovine
502844730,7/13/2014 22:04:15,,1322192826,7/13/2014 22:03:58,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,26,58,,,40,68,VARIANT ANGINA,ERGONOVINE,"VARIANT ANGINA,",26-34,58,ERGONOVINE,"However, in patients with variant angina, a small dose of ergonovine produced a percentage of change in diameter of 39.8 +/- 15.3% at the site of spastic occlusion included by a larger dose of ergonovine, compared with that of 7.0 +/- 11.9% in the remaining non-spastic coronary arteries (p less than 0.05.",26 34,58,26,58,40,68,1,RO-may_diagnose,906708,"However, in patients with variant angina, a small dose of ergonovine produced a percentage of change in diameter of 39.8 +/- 15.3% at the site of spastic occlusion included by a larger dose of ergonovine, compared with that of 7.0 +/- 11.9% in the remaining non-spastic coronary arteries (p less than 0.05",variant angina,ergonovine
502844730,7/13/2014 22:18:24,,1322204346,7/13/2014 22:18:11,clixsense,1,10842668,GBR,,,80.189.187.36,26,58,,,40,68,VARIANT ANGINA,ERGONOVINE,"VARIANT ANGINA,",26-34,58,ERGONOVINE,"However, in patients with variant angina, a small dose of ergonovine produced a percentage of change in diameter of 39.8 +/- 15.3% at the site of spastic occlusion included by a larger dose of ergonovine, compared with that of 7.0 +/- 11.9% in the remaining non-spastic coronary arteries (p less than 0.05.",26 34,58,26,58,40,68,1,RO-may_diagnose,906708,"However, in patients with variant angina, a small dose of ergonovine produced a percentage of change in diameter of 39.8 +/- 15.3% at the site of spastic occlusion included by a larger dose of ergonovine, compared with that of 7.0 +/- 11.9% in the remaining non-spastic coronary arteries (p less than 0.05",variant angina,ergonovine
502844730,7/13/2014 22:19:21,,1322205247,7/13/2014 22:19:00,gifthulk,1,22552178,AUS,5,Adelaide,14.2.7.227,26,58,,,40,68,VARIANT ANGINA,ERGONOVINE,"VARIANT ANGINA,",26-34,58,ERGONOVINE,"However, in patients with variant angina, a small dose of ergonovine produced a percentage of change in diameter of 39.8 +/- 15.3% at the site of spastic occlusion included by a larger dose of ergonovine, compared with that of 7.0 +/- 11.9% in the remaining non-spastic coronary arteries (p less than 0.05.",26 34,58,26,58,40,68,1,RO-may_diagnose,906708,"However, in patients with variant angina, a small dose of ergonovine produced a percentage of change in diameter of 39.8 +/- 15.3% at the site of spastic occlusion included by a larger dose of ergonovine, compared with that of 7.0 +/- 11.9% in the remaining non-spastic coronary arteries (p less than 0.05",variant angina,ergonovine
502844731,7/13/2014 21:50:20,,1322180494,7/13/2014 21:49:53,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,79,3,,,82,6,DIC,APL,DIC,79,3,APL,"In APL with the translocation t(15;17), all- trans- retinoic acid corrects the DIC in 2 to 5 days; combined with daunorubicin or idarubicin, this regimen can induce remission in 80 to 90% of patients, and long-term survival in 65 to 70%.",79,3,79,3,82,6,-1,RO-disease_may_have_finding,902646,"In APL with the translocation t(15;17), all- trans- retinoic acid corrects the DIC in 2 to 5 days; combined with daunorubicin or idarubicin, this regimen can induce remission in 80 to 90% of patients, and long-term survival in 65 to 70%",DIC,APL
502844731,7/13/2014 21:56:39,,1322185891,7/13/2014 21:56:16,instagc,1,28301350,GBR,K4,Plymouth,89.242.63.62,79,3,,,82,6,DIC,APL,APL DIC,3-79,3,APL,"In APL with the translocation t(15;17), all- trans- retinoic acid corrects the DIC in 2 to 5 days; combined with daunorubicin or idarubicin, this regimen can induce remission in 80 to 90% of patients, and long-term survival in 65 to 70%.",79,3,79,3,82,6,-1,RO-disease_may_have_finding,902646,"In APL with the translocation t(15;17), all- trans- retinoic acid corrects the DIC in 2 to 5 days; combined with daunorubicin or idarubicin, this regimen can induce remission in 80 to 90% of patients, and long-term survival in 65 to 70%",DIC,APL
502844731,7/13/2014 22:02:07,,1322191145,7/13/2014 22:01:54,bitcoinget,1,24792414,USA,IA,Independence,166.181.80.204,79,3,,,82,6,DIC,APL,DIC,79,3,APL,"In APL with the translocation t(15;17), all- trans- retinoic acid corrects the DIC in 2 to 5 days; combined with daunorubicin or idarubicin, this regimen can induce remission in 80 to 90% of patients, and long-term survival in 65 to 70%.",79,3,79,3,82,6,-1,RO-disease_may_have_finding,902646,"In APL with the translocation t(15;17), all- trans- retinoic acid corrects the DIC in 2 to 5 days; combined with daunorubicin or idarubicin, this regimen can induce remission in 80 to 90% of patients, and long-term survival in 65 to 70%",DIC,APL
502844731,7/13/2014 22:04:43,,1322193266,7/13/2014 22:04:11,clixsense,1,15189335,GBR,K3,Peterborough,81.156.166.189,79,3,,,82,6,DIC,APL,DIC,79,3,APL,"In APL with the translocation t(15;17), all- trans- retinoic acid corrects the DIC in 2 to 5 days; combined with daunorubicin or idarubicin, this regimen can induce remission in 80 to 90% of patients, and long-term survival in 65 to 70%.",79,3,79,3,82,6,-1,RO-disease_may_have_finding,902646,"In APL with the translocation t(15;17), all- trans- retinoic acid corrects the DIC in 2 to 5 days; combined with daunorubicin or idarubicin, this regimen can induce remission in 80 to 90% of patients, and long-term survival in 65 to 70%",DIC,APL
502844731,7/13/2014 22:05:32,,1322193839,7/13/2014 22:05:28,clixsense,1,24763049,GBR,,,86.133.47.213,79,3,,,82,6,DIC,APL,acid corrects the DIC in 2 to,61-66-75-79-83-86-88,0-3-7-12-16,In APL with the translocation,"In APL with the translocation t(15;17), all- trans- retinoic acid corrects the DIC in 2 to 5 days; combined with daunorubicin or idarubicin, this regimen can induce remission in 80 to 90% of patients, and long-term survival in 65 to 70%.",79,3,79,3,82,6,-1,RO-disease_may_have_finding,902646,"In APL with the translocation t(15;17), all- trans- retinoic acid corrects the DIC in 2 to 5 days; combined with daunorubicin or idarubicin, this regimen can induce remission in 80 to 90% of patients, and long-term survival in 65 to 70%",DIC,APL
502844731,7/13/2014 22:05:57,,1322194217,7/13/2014 22:05:33,elite,1,28397222,GBR,,,31.49.231.211,79,3,,,82,6,DIC,APL,DIC,79,3,APL,"In APL with the translocation t(15;17), all- trans- retinoic acid corrects the DIC in 2 to 5 days; combined with daunorubicin or idarubicin, this regimen can induce remission in 80 to 90% of patients, and long-term survival in 65 to 70%.",79,3,79,3,82,6,-1,RO-disease_may_have_finding,902646,"In APL with the translocation t(15;17), all- trans- retinoic acid corrects the DIC in 2 to 5 days; combined with daunorubicin or idarubicin, this regimen can induce remission in 80 to 90% of patients, and long-term survival in 65 to 70%",DIC,APL
502844731,7/13/2014 22:12:24,,1322199552,7/13/2014 22:12:06,instagc,1,23149109,USA,NC,Durham,75.189.206.205,79,3,,,82,6,DIC,APL,DIC,79,3-7-12-16,APL with the translocation,"In APL with the translocation t(15;17), all- trans- retinoic acid corrects the DIC in 2 to 5 days; combined with daunorubicin or idarubicin, this regimen can induce remission in 80 to 90% of patients, and long-term survival in 65 to 70%.",79,3,79,3,82,6,-1,RO-disease_may_have_finding,902646,"In APL with the translocation t(15;17), all- trans- retinoic acid corrects the DIC in 2 to 5 days; combined with daunorubicin or idarubicin, this regimen can induce remission in 80 to 90% of patients, and long-term survival in 65 to 70%",DIC,APL
502844731,7/13/2014 22:19:40,,1322205543,7/13/2014 22:19:17,clixsense,1,8769423,AUS,6,Hobart,147.69.162.116,79,3,,,82,6,DIC,APL,DIC,79,3,APL,"In APL with the translocation t(15;17), all- trans- retinoic acid corrects the DIC in 2 to 5 days; combined with daunorubicin or idarubicin, this regimen can induce remission in 80 to 90% of patients, and long-term survival in 65 to 70%.",79,3,79,3,82,6,-1,RO-disease_may_have_finding,902646,"In APL with the translocation t(15;17), all- trans- retinoic acid corrects the DIC in 2 to 5 days; combined with daunorubicin or idarubicin, this regimen can induce remission in 80 to 90% of patients, and long-term survival in 65 to 70%",DIC,APL
502844731,7/13/2014 22:20:12,,1322206007,7/13/2014 22:20:02,clixsense,1,10842668,GBR,,,80.189.187.36,79,3,,,82,6,DIC,APL,DIC,79,3,APL,"In APL with the translocation t(15;17), all- trans- retinoic acid corrects the DIC in 2 to 5 days; combined with daunorubicin or idarubicin, this regimen can induce remission in 80 to 90% of patients, and long-term survival in 65 to 70%.",79,3,79,3,82,6,-1,RO-disease_may_have_finding,902646,"In APL with the translocation t(15;17), all- trans- retinoic acid corrects the DIC in 2 to 5 days; combined with daunorubicin or idarubicin, this regimen can induce remission in 80 to 90% of patients, and long-term survival in 65 to 70%",DIC,APL
502844731,7/13/2014 22:24:15,,1322209470,7/13/2014 22:24:04,prodege,1,2143114,CAN,BC,Vancouver,24.84.160.12,79,3,,,82,6,DIC,APL,DIC,79,3,APL,"In APL with the translocation t(15;17), all- trans- retinoic acid corrects the DIC in 2 to 5 days; combined with daunorubicin or idarubicin, this regimen can induce remission in 80 to 90% of patients, and long-term survival in 65 to 70%.",79,3,79,3,82,6,-1,RO-disease_may_have_finding,902646,"In APL with the translocation t(15;17), all- trans- retinoic acid corrects the DIC in 2 to 5 days; combined with daunorubicin or idarubicin, this regimen can induce remission in 80 to 90% of patients, and long-term survival in 65 to 70%",DIC,APL
502844733,7/13/2014 21:55:26,,1322184758,7/13/2014 21:55:03,instagc,1,28301350,GBR,K4,Plymouth,89.242.63.62,200,256,,,223,273,MONOCLONAL GAMMAPATHIES,MACROGLOBULINEMIA,multiple myeloma MONOCLONAL GAMMAPATHIES,29-200-211-38,29-38,multiple myeloma,"115 (58%) were classified as multiple myeloma (MK), 34 (17%) as alpha heavy chain disease (MCL a), 34 (17%) as monoclonal gammapathy associated to various diseases (GMOD), 11 (6%) as benign essential monoclonal gammapathies (GMBE), 4 (2%) as Waldenstr macroglobulinemia (MW.",200 211,,200,256,223,273,-1,RO-disease_has_finding,901997,"115 (58%) were classified as multiple myeloma (MK), 34 (17%) as alpha heavy chain disease (MCL a), 34 (17%) as monoclonal gammapathy associated to various diseases (GMOD), 11 (6%) as benign essential monoclonal gammapathies (GMBE), 4 (2%) as Waldenstr macroglobulinemia (MW",monoclonal gammapathies,macroglobulinemia
502844733,7/13/2014 21:55:54,,1322185101,7/13/2014 21:55:36,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,200,256,,,223,273,MONOCLONAL GAMMAPATHIES,MACROGLOBULINEMIA,MONOCLONAL GAMMAPATHIES,200-211,270,MACroglobulinemia,"115 (58%) were classified as multiple myeloma (MK), 34 (17%) as alpha heavy chain disease (MCL a), 34 (17%) as monoclonal gammapathy associated to various diseases (GMOD), 11 (6%) as benign essential monoclonal gammapathies (GMBE), 4 (2%) as Waldenstr macroglobulinemia (MW.",200 211,,200,256,223,273,-1,RO-disease_has_finding,901997,"115 (58%) were classified as multiple myeloma (MK), 34 (17%) as alpha heavy chain disease (MCL a), 34 (17%) as monoclonal gammapathy associated to various diseases (GMOD), 11 (6%) as benign essential monoclonal gammapathies (GMBE), 4 (2%) as Waldenstr macroglobulinemia (MW",monoclonal gammapathies,macroglobulinemia
502844733,7/13/2014 21:55:53,,1322185117,7/13/2014 21:55:39,elite,1,28503042,USA,OK,Oakwood,64.250.220.169,200,256,,,223,273,MONOCLONAL GAMMAPATHIES,MACROGLOBULINEMIA,MONOCLONAL GAMMAPATHIES,200-211,270,MACroglobulinemia,"115 (58%) were classified as multiple myeloma (MK), 34 (17%) as alpha heavy chain disease (MCL a), 34 (17%) as monoclonal gammapathy associated to various diseases (GMOD), 11 (6%) as benign essential monoclonal gammapathies (GMBE), 4 (2%) as Waldenstr macroglobulinemia (MW.",200 211,,200,256,223,273,-1,RO-disease_has_finding,901997,"115 (58%) were classified as multiple myeloma (MK), 34 (17%) as alpha heavy chain disease (MCL a), 34 (17%) as monoclonal gammapathy associated to various diseases (GMOD), 11 (6%) as benign essential monoclonal gammapathies (GMBE), 4 (2%) as Waldenstr macroglobulinemia (MW",monoclonal gammapathies,macroglobulinemia
502844733,7/13/2014 21:56:30,,1322185755,7/13/2014 21:56:02,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,200,256,,,223,273,MONOCLONAL GAMMAPATHIES,MACROGLOBULINEMIA,MONOCLONAL GAMMAPATHIES,200-211,270,MACroglobulinemia,"115 (58%) were classified as multiple myeloma (MK), 34 (17%) as alpha heavy chain disease (MCL a), 34 (17%) as monoclonal gammapathy associated to various diseases (GMOD), 11 (6%) as benign essential monoclonal gammapathies (GMBE), 4 (2%) as Waldenstr macroglobulinemia (MW.",200 211,,200,256,223,273,-1,RO-disease_has_finding,901997,"115 (58%) were classified as multiple myeloma (MK), 34 (17%) as alpha heavy chain disease (MCL a), 34 (17%) as monoclonal gammapathy associated to various diseases (GMOD), 11 (6%) as benign essential monoclonal gammapathies (GMBE), 4 (2%) as Waldenstr macroglobulinemia (MW",monoclonal gammapathies,macroglobulinemia
502844733,7/13/2014 21:59:22,,1322188393,7/13/2014 21:58:00,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,200,256,,,223,273,MONOCLONAL GAMMAPATHIES,MACROGLOBULINEMIA,multiple myeloma alpha heavy chain disease monoclonal gammapathy associated to various diseases benign essential MONOCLONAL GAMMAPATHIES 4 macroglobulinemia,29-38-64-70-76-82-111-122-133-144-147-155-183-190-200-211-232-270,29-38-64-70-76-82-111-122-133-144-147-155-183-190-200-234-239-242-270-211,multiple myeloma alpha heavy chain disease monoclonal gammapathy associated to various diseases benign essential monoclonal gammapathies (2%) as Waldenstr MACroglobulinemia,"115 (58%) were classified as multiple myeloma (MK), 34 (17%) as alpha heavy chain disease (MCL a), 34 (17%) as monoclonal gammapathy associated to various diseases (GMOD), 11 (6%) as benign essential monoclonal gammapathies (GMBE), 4 (2%) as Waldenstr macroglobulinemia (MW.",200 211,,200,256,223,273,-1,RO-disease_has_finding,901997,"115 (58%) were classified as multiple myeloma (MK), 34 (17%) as alpha heavy chain disease (MCL a), 34 (17%) as monoclonal gammapathy associated to various diseases (GMOD), 11 (6%) as benign essential monoclonal gammapathies (GMBE), 4 (2%) as Waldenstr macroglobulinemia (MW",monoclonal gammapathies,macroglobulinemia
502844733,7/13/2014 22:03:55,,1322192565,7/13/2014 22:03:27,prodege,1,28255346,GBR,L9,Sheffield,2.125.183.137,200,256,,,223,273,MONOCLONAL GAMMAPATHIES,MACROGLOBULINEMIA,MONOCLONAL GAMMAPATHIES,200-211,242-270,Waldenstr MACroglobulinemia,"115 (58%) were classified as multiple myeloma (MK), 34 (17%) as alpha heavy chain disease (MCL a), 34 (17%) as monoclonal gammapathy associated to various diseases (GMOD), 11 (6%) as benign essential monoclonal gammapathies (GMBE), 4 (2%) as Waldenstr macroglobulinemia (MW.",200 211,,200,256,223,273,-1,RO-disease_has_finding,901997,"115 (58%) were classified as multiple myeloma (MK), 34 (17%) as alpha heavy chain disease (MCL a), 34 (17%) as monoclonal gammapathy associated to various diseases (GMOD), 11 (6%) as benign essential monoclonal gammapathies (GMBE), 4 (2%) as Waldenstr macroglobulinemia (MW",monoclonal gammapathies,macroglobulinemia
502844733,7/13/2014 22:05:37,,1322193901,7/13/2014 22:05:08,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,200,256,,,223,273,MONOCLONAL GAMMAPATHIES,MACROGLOBULINEMIA,benign essential MONOCLONAL GAMMAPATHIES,183-190-200-211,270,MACroglobulinemia,"115 (58%) were classified as multiple myeloma (MK), 34 (17%) as alpha heavy chain disease (MCL a), 34 (17%) as monoclonal gammapathy associated to various diseases (GMOD), 11 (6%) as benign essential monoclonal gammapathies (GMBE), 4 (2%) as Waldenstr macroglobulinemia (MW.",200 211,,200,256,223,273,-1,RO-disease_has_finding,901997,"115 (58%) were classified as multiple myeloma (MK), 34 (17%) as alpha heavy chain disease (MCL a), 34 (17%) as monoclonal gammapathy associated to various diseases (GMOD), 11 (6%) as benign essential monoclonal gammapathies (GMBE), 4 (2%) as Waldenstr macroglobulinemia (MW",monoclonal gammapathies,macroglobulinemia
502844733,7/13/2014 22:15:52,,1322202224,7/13/2014 22:14:46,clixsense,1,10842668,GBR,,,80.189.187.36,200,256,,,223,273,MONOCLONAL GAMMAPATHIES,MACROGLOBULINEMIA,MONOCLONAL GAMMAPATHIES,200-211,270,MACroglobulinemia,"115 (58%) were classified as multiple myeloma (MK), 34 (17%) as alpha heavy chain disease (MCL a), 34 (17%) as monoclonal gammapathy associated to various diseases (GMOD), 11 (6%) as benign essential monoclonal gammapathies (GMBE), 4 (2%) as Waldenstr macroglobulinemia (MW.",200 211,,200,256,223,273,-1,RO-disease_has_finding,901997,"115 (58%) were classified as multiple myeloma (MK), 34 (17%) as alpha heavy chain disease (MCL a), 34 (17%) as monoclonal gammapathy associated to various diseases (GMOD), 11 (6%) as benign essential monoclonal gammapathies (GMBE), 4 (2%) as Waldenstr macroglobulinemia (MW",monoclonal gammapathies,macroglobulinemia
502844733,7/13/2014 22:22:38,,1322208043,7/13/2014 22:22:13,gifthulk,1,22552178,AUS,5,Adelaide,14.2.7.227,200,256,,,223,273,MONOCLONAL GAMMAPATHIES,MACROGLOBULINEMIA,MONOCLONAL GAMMAPATHIES,200-211,270,MACroglobulinemia,"115 (58%) were classified as multiple myeloma (MK), 34 (17%) as alpha heavy chain disease (MCL a), 34 (17%) as monoclonal gammapathy associated to various diseases (GMOD), 11 (6%) as benign essential monoclonal gammapathies (GMBE), 4 (2%) as Waldenstr macroglobulinemia (MW.",200 211,,200,256,223,273,-1,RO-disease_has_finding,901997,"115 (58%) were classified as multiple myeloma (MK), 34 (17%) as alpha heavy chain disease (MCL a), 34 (17%) as monoclonal gammapathy associated to various diseases (GMOD), 11 (6%) as benign essential monoclonal gammapathies (GMBE), 4 (2%) as Waldenstr macroglobulinemia (MW",monoclonal gammapathies,macroglobulinemia
502844733,7/13/2014 22:22:57,,1322208334,7/13/2014 22:22:36,instagc,1,23149109,USA,NC,Durham,75.189.206.205,200,256,,,223,273,MONOCLONAL GAMMAPATHIES,MACROGLOBULINEMIA,benign essential MONOCLONAL GAMMAPATHIES,190-200-211-183,270,MACroglobulinemia,"115 (58%) were classified as multiple myeloma (MK), 34 (17%) as alpha heavy chain disease (MCL a), 34 (17%) as monoclonal gammapathy associated to various diseases (GMOD), 11 (6%) as benign essential monoclonal gammapathies (GMBE), 4 (2%) as Waldenstr macroglobulinemia (MW.",200 211,,200,256,223,273,-1,RO-disease_has_finding,901997,"115 (58%) were classified as multiple myeloma (MK), 34 (17%) as alpha heavy chain disease (MCL a), 34 (17%) as monoclonal gammapathy associated to various diseases (GMOD), 11 (6%) as benign essential monoclonal gammapathies (GMBE), 4 (2%) as Waldenstr macroglobulinemia (MW",monoclonal gammapathies,macroglobulinemia
502844734,7/13/2014 21:51:56,,1322181678,7/13/2014 21:49:13,elite,1,28397222,GBR,,,31.49.231.211,155,206,,,162,215,CADMIUM,ITAI-ITAI,CADMIUM,155,206-211-216,ITAI ITAI disease.,"In view of these data, the length of cadmium exposure and the life span of animals as well as epidemiological data published elsewhere, factors other than cadmium may also be involved in the development of Itai-Itai disease.",155,206 211,155,206,162,215,1,RO-has_causative_agent,903720,"In view of these data, the length of cadmium exposure and the life span of animals as well as epidemiological data published elsewhere, factors other than cadmium may also be involved in the development of Itai-Itai disease",cadmium,Itai-Itai
502844734,7/13/2014 21:53:32,,1322183097,7/13/2014 21:53:13,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,155,206,,,162,215,CADMIUM,ITAI-ITAI,CADMIUM,155,206-211-216,ITAI ITAI disease.,"In view of these data, the length of cadmium exposure and the life span of animals as well as epidemiological data published elsewhere, factors other than cadmium may also be involved in the development of Itai-Itai disease.",155,206 211,155,206,162,215,1,RO-has_causative_agent,903720,"In view of these data, the length of cadmium exposure and the life span of animals as well as epidemiological data published elsewhere, factors other than cadmium may also be involved in the development of Itai-Itai disease",cadmium,Itai-Itai
502844734,7/13/2014 22:03:37,,1322192331,7/13/2014 22:03:27,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,155,206,,,162,215,CADMIUM,ITAI-ITAI,CADMIUM,155,206-211-216,ITAI ITAI disease.,"In view of these data, the length of cadmium exposure and the life span of animals as well as epidemiological data published elsewhere, factors other than cadmium may also be involved in the development of Itai-Itai disease.",155,206 211,155,206,162,215,1,RO-has_causative_agent,903720,"In view of these data, the length of cadmium exposure and the life span of animals as well as epidemiological data published elsewhere, factors other than cadmium may also be involved in the development of Itai-Itai disease",cadmium,Itai-Itai
502844734,7/13/2014 22:10:29,,1322197816,7/13/2014 22:10:10,prodege,1,17932518,GBR,Y2,Pwllheli,95.151.166.224,155,206,,,162,215,CADMIUM,ITAI-ITAI,CADMIUM,155,206-211,ITAI ITAI,"In view of these data, the length of cadmium exposure and the life span of animals as well as epidemiological data published elsewhere, factors other than cadmium may also be involved in the development of Itai-Itai disease.",155,206 211,155,206,162,215,1,RO-has_causative_agent,903720,"In view of these data, the length of cadmium exposure and the life span of animals as well as epidemiological data published elsewhere, factors other than cadmium may also be involved in the development of Itai-Itai disease",cadmium,Itai-Itai
502844734,7/13/2014 22:12:15,,1322199388,7/13/2014 22:11:46,clixsense,1,8769423,AUS,6,Hobart,147.69.162.116,155,206,,,162,215,CADMIUM,ITAI-ITAI,CADMIUM,155,206-211-216,ITAI ITAI disease.,"In view of these data, the length of cadmium exposure and the life span of animals as well as epidemiological data published elsewhere, factors other than cadmium may also be involved in the development of Itai-Itai disease.",155,206 211,155,206,162,215,1,RO-has_causative_agent,903720,"In view of these data, the length of cadmium exposure and the life span of animals as well as epidemiological data published elsewhere, factors other than cadmium may also be involved in the development of Itai-Itai disease",cadmium,Itai-Itai
502844734,7/13/2014 22:15:08,,1322201663,7/13/2014 22:14:36,instagc,1,23149109,USA,NC,Durham,75.189.206.205,155,206,,,162,215,CADMIUM,ITAI-ITAI,CADMIUM in development of Itai Itai disease.,155-184-191-203-206-211-216,191-203-206-211-216,development of ITAI ITAI disease.,"In view of these data, the length of cadmium exposure and the life span of animals as well as epidemiological data published elsewhere, factors other than cadmium may also be involved in the development of Itai-Itai disease.",155,206 211,155,206,162,215,1,RO-has_causative_agent,903720,"In view of these data, the length of cadmium exposure and the life span of animals as well as epidemiological data published elsewhere, factors other than cadmium may also be involved in the development of Itai-Itai disease",cadmium,Itai-Itai
502844734,7/13/2014 22:17:13,,1322203359,7/13/2014 22:16:33,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,155,206,,,162,215,CADMIUM,ITAI-ITAI,cadmium exposure epidemiological data CADMIUM Itai Itai disease.,37-45-94-110-155-206-211-216,37-45-94-110-191-203-206-211-216-155,cadmium exposure epidemiological data cadmium development of ITAI ITAI disease.,"In view of these data, the length of cadmium exposure and the life span of animals as well as epidemiological data published elsewhere, factors other than cadmium may also be involved in the development of Itai-Itai disease.",155,206 211,155,206,162,215,1,RO-has_causative_agent,903720,"In view of these data, the length of cadmium exposure and the life span of animals as well as epidemiological data published elsewhere, factors other than cadmium may also be involved in the development of Itai-Itai disease",cadmium,Itai-Itai
502844734,7/13/2014 22:20:27,,1322206235,7/13/2014 22:20:13,clixsense,1,10842668,GBR,,,80.189.187.36,155,206,,,162,215,CADMIUM,ITAI-ITAI,CADMIUM,155,206-211-216,ITAI ITAI disease.,"In view of these data, the length of cadmium exposure and the life span of animals as well as epidemiological data published elsewhere, factors other than cadmium may also be involved in the development of Itai-Itai disease.",155,206 211,155,206,162,215,1,RO-has_causative_agent,903720,"In view of these data, the length of cadmium exposure and the life span of animals as well as epidemiological data published elsewhere, factors other than cadmium may also be involved in the development of Itai-Itai disease",cadmium,Itai-Itai
502844734,7/13/2014 22:21:09,,1322206824,7/13/2014 22:20:49,gifthulk,1,22552178,AUS,5,Adelaide,14.2.7.227,155,206,,,162,215,CADMIUM,ITAI-ITAI,CADMIUM,155,206-211,ITAI ITAI,"In view of these data, the length of cadmium exposure and the life span of animals as well as epidemiological data published elsewhere, factors other than cadmium may also be involved in the development of Itai-Itai disease.",155,206 211,155,206,162,215,1,RO-has_causative_agent,903720,"In view of these data, the length of cadmium exposure and the life span of animals as well as epidemiological data published elsewhere, factors other than cadmium may also be involved in the development of Itai-Itai disease",cadmium,Itai-Itai
502844734,7/13/2014 22:25:50,,1322211041,7/13/2014 22:25:35,prodege,1,2143114,CAN,BC,Vancouver,24.84.160.12,155,206,,,162,215,CADMIUM,ITAI-ITAI,CADMIUM,155,206-211-216,ITAI ITAI disease.,"In view of these data, the length of cadmium exposure and the life span of animals as well as epidemiological data published elsewhere, factors other than cadmium may also be involved in the development of Itai-Itai disease.",155,206 211,155,206,162,215,1,RO-has_causative_agent,903720,"In view of these data, the length of cadmium exposure and the life span of animals as well as epidemiological data published elsewhere, factors other than cadmium may also be involved in the development of Itai-Itai disease",cadmium,Itai-Itai
502844735,7/13/2014 21:51:32,,1322181394,7/13/2014 21:50:39,clixsense,1,25402344,CAN,ON,Wawa,24.109.124.45,37,0,,,41,7,IDDM,INSULIN,Insulin dependent diabetes mellitus (IDDM),0-8-18-27-36,0,INSULIN,Insulin-dependent diabetes mellitus (IDDM) is a disease that results from autoimmune destruction of the insulin-producing beta-cells in the pancreatic islets of Langerhans.,,0,37,0,41,7,1,RO-may_treat,907989,Insulin-dependent diabetes mellitus (IDDM) is a disease that results from autoimmune destruction of the insulin-producing beta-cells in the pancreatic islets of Langerhans,IDDM,Insulin
502844735,7/13/2014 21:51:50,,1322181652,7/13/2014 21:51:20,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,37,0,,,41,7,IDDM,INSULIN,diabetes mellitus (IDDM),18-27-36,0-8-18-27,INSULIN dependent diabetes mellitus,Insulin-dependent diabetes mellitus (IDDM) is a disease that results from autoimmune destruction of the insulin-producing beta-cells in the pancreatic islets of Langerhans.,,0,37,0,41,7,1,RO-may_treat,907989,Insulin-dependent diabetes mellitus (IDDM) is a disease that results from autoimmune destruction of the insulin-producing beta-cells in the pancreatic islets of Langerhans,IDDM,Insulin
502844735,7/13/2014 21:57:25,,1322186625,7/13/2014 21:57:02,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,37,0,,,41,7,IDDM,INSULIN,Insulin - dependent diabetes mellitus (IDDM),0-7-8-18-27-36,0-7-8-18-27-36,INSULIN - dependent diabetes mellitus (IDDM),Insulin-dependent diabetes mellitus (IDDM) is a disease that results from autoimmune destruction of the insulin-producing beta-cells in the pancreatic islets of Langerhans.,,0,37,0,41,7,1,RO-may_treat,907989,Insulin-dependent diabetes mellitus (IDDM) is a disease that results from autoimmune destruction of the insulin-producing beta-cells in the pancreatic islets of Langerhans,IDDM,Insulin
502844735,7/13/2014 21:59:03,,1322188033,7/13/2014 21:58:38,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,37,0,,,41,7,IDDM,INSULIN,Insulin dependent diabetes mellitus (IDDM),0-8-18-27-36,0,INSULIN,Insulin-dependent diabetes mellitus (IDDM) is a disease that results from autoimmune destruction of the insulin-producing beta-cells in the pancreatic islets of Langerhans.,,0,37,0,41,7,1,RO-may_treat,907989,Insulin-dependent diabetes mellitus (IDDM) is a disease that results from autoimmune destruction of the insulin-producing beta-cells in the pancreatic islets of Langerhans,IDDM,Insulin
502844735,7/13/2014 22:04:12,,1322192798,7/13/2014 22:03:52,bitcoinget,1,24792414,USA,IA,Independence,166.181.80.204,37,0,,,41,7,IDDM,INSULIN,Insulin dependent diabetes mellitus (IDDM),0-8-18-36-27,0-8-18-27,INSULIN dependent diabetes mellitus,Insulin-dependent diabetes mellitus (IDDM) is a disease that results from autoimmune destruction of the insulin-producing beta-cells in the pancreatic islets of Langerhans.,,0,37,0,41,7,1,RO-may_treat,907989,Insulin-dependent diabetes mellitus (IDDM) is a disease that results from autoimmune destruction of the insulin-producing beta-cells in the pancreatic islets of Langerhans,IDDM,Insulin
502844735,7/13/2014 22:05:58,,1322194223,7/13/2014 22:05:22,prodege,1,28255346,GBR,L9,Sheffield,2.125.183.137,37,0,,,41,7,IDDM,INSULIN,pancreatic islets of Langerhans.,140-151-161-158,0-8-18-27,INSULIN dependent diabetes mellitus,Insulin-dependent diabetes mellitus (IDDM) is a disease that results from autoimmune destruction of the insulin-producing beta-cells in the pancreatic islets of Langerhans.,,0,37,0,41,7,1,RO-may_treat,907989,Insulin-dependent diabetes mellitus (IDDM) is a disease that results from autoimmune destruction of the insulin-producing beta-cells in the pancreatic islets of Langerhans,IDDM,Insulin
502844735,7/13/2014 22:07:16,,1322195254,7/13/2014 22:07:01,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,37,0,,,41,7,IDDM,INSULIN,diabetes mellitus (IDDM),18-27-36,0-8-18-27,INSULIN dependent diabetes mellitus,Insulin-dependent diabetes mellitus (IDDM) is a disease that results from autoimmune destruction of the insulin-producing beta-cells in the pancreatic islets of Langerhans.,,0,37,0,41,7,1,RO-may_treat,907989,Insulin-dependent diabetes mellitus (IDDM) is a disease that results from autoimmune destruction of the insulin-producing beta-cells in the pancreatic islets of Langerhans,IDDM,Insulin
502844735,7/13/2014 22:09:24,,1322196871,7/13/2014 22:08:56,clixsense,1,15189335,GBR,K3,Peterborough,81.156.166.189,37,0,,,41,7,IDDM,INSULIN,(IDDM),36,0,INSULIN,Insulin-dependent diabetes mellitus (IDDM) is a disease that results from autoimmune destruction of the insulin-producing beta-cells in the pancreatic islets of Langerhans.,,0,37,0,41,7,1,RO-may_treat,907989,Insulin-dependent diabetes mellitus (IDDM) is a disease that results from autoimmune destruction of the insulin-producing beta-cells in the pancreatic islets of Langerhans,IDDM,Insulin
502844735,7/13/2014 22:17:08,,1322203303,7/13/2014 22:16:55,instagc,1,23149109,USA,NC,Durham,75.189.206.205,37,0,,,41,7,IDDM,INSULIN,Insulin dependent diabetes mellitus (IDDM),0-18-27-36-8,0-8-18-27-36,INSULIN dependent diabetes mellitus (IDDM),Insulin-dependent diabetes mellitus (IDDM) is a disease that results from autoimmune destruction of the insulin-producing beta-cells in the pancreatic islets of Langerhans.,,0,37,0,41,7,1,RO-may_treat,907989,Insulin-dependent diabetes mellitus (IDDM) is a disease that results from autoimmune destruction of the insulin-producing beta-cells in the pancreatic islets of Langerhans,IDDM,Insulin
502844735,7/13/2014 22:17:58,,1322203915,7/13/2014 22:17:32,clixsense,1,8769423,AUS,6,Hobart,147.69.162.116,37,0,,,41,7,IDDM,INSULIN,(IDDM) a,36-46,0,INSULIN,Insulin-dependent diabetes mellitus (IDDM) is a disease that results from autoimmune destruction of the insulin-producing beta-cells in the pancreatic islets of Langerhans.,,0,37,0,41,7,1,RO-may_treat,907989,Insulin-dependent diabetes mellitus (IDDM) is a disease that results from autoimmune destruction of the insulin-producing beta-cells in the pancreatic islets of Langerhans,IDDM,Insulin
502844736,7/13/2014 21:53:43,,1322183225,7/13/2014 21:53:26,elite,1,28503042,USA,OK,Oakwood,64.250.220.169,181,201,,,187,210,ASTHMA,ALBUTEROL,ASTHMA,181,201,ALBUTEROL,"CONCLUSION  In mild asthma, patients with the Gly/Gly genotype had better asthma control with albuterol than when it was withdrawn, and patients with the Arg/Arg genotype had worse asthma control with albuterol than when it was withdrawn.",181,201,181,201,187,210,1,RO-may_treat,907668,"CONCLUSION  In mild asthma, patients with the Gly/Gly genotype had better asthma control with albuterol than when it was withdrawn, and patients with the Arg/Arg genotype had worse asthma control with albuterol than when it was withdrawn",asthma,albuterol
502844736,7/13/2014 21:59:52,,1322188989,7/13/2014 21:59:47,clixsense,1,24763049,GBR,,,86.133.47.213,181,201,,,187,210,ASTHMA,ALBUTEROL,genotype had worse ASTHMA control with albuterol,162-171-175-181-188-196-201,181-188-196-201-211-216-221,asthma control with ALBUTEROL than when it,"CONCLUSION  In mild asthma, patients with the Gly/Gly genotype had better asthma control with albuterol than when it was withdrawn, and patients with the Arg/Arg genotype had worse asthma control with albuterol than when it was withdrawn.",181,201,181,201,187,210,1,RO-may_treat,907668,"CONCLUSION  In mild asthma, patients with the Gly/Gly genotype had better asthma control with albuterol than when it was withdrawn, and patients with the Arg/Arg genotype had worse asthma control with albuterol than when it was withdrawn",asthma,albuterol
502844736,7/13/2014 22:00:44,,1322189802,7/13/2014 22:00:25,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,181,201,,,187,210,ASTHMA,ALBUTEROL,ASTHMA,181,201,ALBUTEROL,"CONCLUSION  In mild asthma, patients with the Gly/Gly genotype had better asthma control with albuterol than when it was withdrawn, and patients with the Arg/Arg genotype had worse asthma control with albuterol than when it was withdrawn.",181,201,181,201,187,210,1,RO-may_treat,907668,"CONCLUSION  In mild asthma, patients with the Gly/Gly genotype had better asthma control with albuterol than when it was withdrawn, and patients with the Arg/Arg genotype had worse asthma control with albuterol than when it was withdrawn",asthma,albuterol
502844736,7/13/2014 22:01:56,,1322190996,7/13/2014 22:01:05,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,181,201,,,187,210,ASTHMA,ALBUTEROL,"mild asthma, patients with Gly Gly genotype asthma control albuterol Arg Arg genotype had worse ASTHMA control with albuterol",15-20-28-37-46-50-54-74-81-94-154-162-171-175-181-188-196-201-158,15-20-28-37-46-49-50-54-74-81-94-154-158-162-175-181-188-196-201-211-216-221-171,"mild asthma, patients with Gly / Gly genotype asthma control albuterol Arg Arg genotype had worse asthma control with ALBUTEROL than when it","CONCLUSION  In mild asthma, patients with the Gly/Gly genotype had better asthma control with albuterol than when it was withdrawn, and patients with the Arg/Arg genotype had worse asthma control with albuterol than when it was withdrawn.",181,201,181,201,187,210,1,RO-may_treat,907668,"CONCLUSION  In mild asthma, patients with the Gly/Gly genotype had better asthma control with albuterol than when it was withdrawn, and patients with the Arg/Arg genotype had worse asthma control with albuterol than when it was withdrawn",asthma,albuterol
502844736,7/13/2014 22:02:42,,1322191646,7/13/2014 22:01:36,prodege,1,17932518,GBR,Y2,Pwllheli,95.151.166.224,181,201,,,187,210,ASTHMA,ALBUTEROL,ASTHMA,181,201,ALBUTEROL,"CONCLUSION  In mild asthma, patients with the Gly/Gly genotype had better asthma control with albuterol than when it was withdrawn, and patients with the Arg/Arg genotype had worse asthma control with albuterol than when it was withdrawn.",181,201,181,201,187,210,1,RO-may_treat,907668,"CONCLUSION  In mild asthma, patients with the Gly/Gly genotype had better asthma control with albuterol than when it was withdrawn, and patients with the Arg/Arg genotype had worse asthma control with albuterol than when it was withdrawn",asthma,albuterol
502844736,7/13/2014 22:06:58,,1322195022,7/13/2014 22:06:47,bitcoinget,1,24792414,USA,IA,Independence,166.181.80.204,181,201,,,187,210,ASTHMA,ALBUTEROL,ASTHMA,181,201,ALBUTEROL,"CONCLUSION  In mild asthma, patients with the Gly/Gly genotype had better asthma control with albuterol than when it was withdrawn, and patients with the Arg/Arg genotype had worse asthma control with albuterol than when it was withdrawn.",181,201,181,201,187,210,1,RO-may_treat,907668,"CONCLUSION  In mild asthma, patients with the Gly/Gly genotype had better asthma control with albuterol than when it was withdrawn, and patients with the Arg/Arg genotype had worse asthma control with albuterol than when it was withdrawn",asthma,albuterol
502844736,7/13/2014 22:07:07,,1322195150,7/13/2014 22:06:43,clixsense,1,8769423,AUS,6,Hobart,147.69.162.116,181,201,,,187,210,ASTHMA,ALBUTEROL,ASTHMA,181,201,ALBUTEROL,"CONCLUSION  In mild asthma, patients with the Gly/Gly genotype had better asthma control with albuterol than when it was withdrawn, and patients with the Arg/Arg genotype had worse asthma control with albuterol than when it was withdrawn.",181,201,181,201,187,210,1,RO-may_treat,907668,"CONCLUSION  In mild asthma, patients with the Gly/Gly genotype had better asthma control with albuterol than when it was withdrawn, and patients with the Arg/Arg genotype had worse asthma control with albuterol than when it was withdrawn",asthma,albuterol
502844736,7/13/2014 22:08:37,,1322196268,7/13/2014 22:08:20,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,181,201,,,187,210,ASTHMA,ALBUTEROL,ASTHMA control with albuterol,181-188-196-201,181-188-196-201,asthma control with ALBUTEROL,"CONCLUSION  In mild asthma, patients with the Gly/Gly genotype had better asthma control with albuterol than when it was withdrawn, and patients with the Arg/Arg genotype had worse asthma control with albuterol than when it was withdrawn.",181,201,181,201,187,210,1,RO-may_treat,907668,"CONCLUSION  In mild asthma, patients with the Gly/Gly genotype had better asthma control with albuterol than when it was withdrawn, and patients with the Arg/Arg genotype had worse asthma control with albuterol than when it was withdrawn",asthma,albuterol
502844736,7/13/2014 22:21:56,,1322207423,7/13/2014 22:21:44,clixsense,1,26889820,GBR,C3,Shelford,92.18.120.203,181,201,,,187,210,ASTHMA,ALBUTEROL,ASTHMA,181,201,ALBUTEROL,"CONCLUSION  In mild asthma, patients with the Gly/Gly genotype had better asthma control with albuterol than when it was withdrawn, and patients with the Arg/Arg genotype had worse asthma control with albuterol than when it was withdrawn.",181,201,181,201,187,210,1,RO-may_treat,907668,"CONCLUSION  In mild asthma, patients with the Gly/Gly genotype had better asthma control with albuterol than when it was withdrawn, and patients with the Arg/Arg genotype had worse asthma control with albuterol than when it was withdrawn",asthma,albuterol
502844736,7/13/2014 22:22:57,,1322208335,7/13/2014 22:22:37,clixsense,1,10842668,GBR,,,80.189.187.36,181,201,,,187,210,ASTHMA,ALBUTEROL,ASTHMA,181,181-201,asthma ALBUTEROL,"CONCLUSION  In mild asthma, patients with the Gly/Gly genotype had better asthma control with albuterol than when it was withdrawn, and patients with the Arg/Arg genotype had worse asthma control with albuterol than when it was withdrawn.",181,201,181,201,187,210,1,RO-may_treat,907668,"CONCLUSION  In mild asthma, patients with the Gly/Gly genotype had better asthma control with albuterol than when it was withdrawn, and patients with the Arg/Arg genotype had worse asthma control with albuterol than when it was withdrawn",asthma,albuterol
502844737,7/13/2014 21:56:16,,1322185479,7/13/2014 21:55:41,instagc,1,28301350,GBR,K4,Plymouth,89.242.63.62,319,272,,,328,277,HAY FEVER,ATOPY,"flexural dermatitis facial dermatitis atopy, atopic dermatitis, asthma, HAY FEVER",121-130-192-199-272-296-308-319-323-289,121-130-192-199-272-289-296-308-319-323,"flexural dermatitis facial dermatitis ATOPY, atopic dermatitis, asthma, hay fever","There should be at least three out of four major diagnostic criteria including 1) itch; 2) appropriate distribution with flexural dermatitis in older children and adults and more extensor and facial dermatitis in infants; 3) waxing and waning course; 4) family history of atopy, including atopic dermatitis, asthma, or hay fever or seasonal allergies.",319 323,272,319,272,328,277,-1,RO-cause_of,900383,"There should be at least three out of four major diagnostic criteria including 1) itch; 2) appropriate distribution with flexural dermatitis in older children and adults and more extensor and facial dermatitis in infants; 3) waxing and waning course; 4) family history of atopy, including atopic dermatitis, asthma, or hay fever or seasonal allergies",hay fever,atopy
502844737,7/13/2014 21:56:44,,1322186002,7/13/2014 21:54:49,clixsense,1,20614047,USA,WA,Deer Park,174.32.162.10,319,272,,,328,277,HAY FEVER,ATOPY,"atopic dermatitis, asthma, or HAY FEVER or seasonal allergies.",289-296-308-316-319-323-329-332-341,254-261-269-272-279-289-296-308-319-323-329-332-341,"family history of ATOPY, including atopic dermatitis, asthma, hay fever or seasonal allergies.","There should be at least three out of four major diagnostic criteria including 1) itch; 2) appropriate distribution with flexural dermatitis in older children and adults and more extensor and facial dermatitis in infants; 3) waxing and waning course; 4) family history of atopy, including atopic dermatitis, asthma, or hay fever or seasonal allergies.",319 323,272,319,272,328,277,-1,RO-cause_of,900383,"There should be at least three out of four major diagnostic criteria including 1) itch; 2) appropriate distribution with flexural dermatitis in older children and adults and more extensor and facial dermatitis in infants; 3) waxing and waning course; 4) family history of atopy, including atopic dermatitis, asthma, or hay fever or seasonal allergies",hay fever,atopy
502844737,7/13/2014 21:57:41,,1322186857,7/13/2014 21:57:18,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,319,272,,,328,277,HAY FEVER,ATOPY,HAY FEVER,319-323,272,"ATOPY,","There should be at least three out of four major diagnostic criteria including 1) itch; 2) appropriate distribution with flexural dermatitis in older children and adults and more extensor and facial dermatitis in infants; 3) waxing and waning course; 4) family history of atopy, including atopic dermatitis, asthma, or hay fever or seasonal allergies.",319 323,272,319,272,328,277,-1,RO-cause_of,900383,"There should be at least three out of four major diagnostic criteria including 1) itch; 2) appropriate distribution with flexural dermatitis in older children and adults and more extensor and facial dermatitis in infants; 3) waxing and waning course; 4) family history of atopy, including atopic dermatitis, asthma, or hay fever or seasonal allergies",hay fever,atopy
502844737,7/13/2014 21:58:05,,1322187185,7/13/2014 21:57:49,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,319,272,,,328,277,HAY FEVER,ATOPY,HAY FEVER,319-323,272,"ATOPY,","There should be at least three out of four major diagnostic criteria including 1) itch; 2) appropriate distribution with flexural dermatitis in older children and adults and more extensor and facial dermatitis in infants; 3) waxing and waning course; 4) family history of atopy, including atopic dermatitis, asthma, or hay fever or seasonal allergies.",319 323,272,319,272,328,277,-1,RO-cause_of,900383,"There should be at least three out of four major diagnostic criteria including 1) itch; 2) appropriate distribution with flexural dermatitis in older children and adults and more extensor and facial dermatitis in infants; 3) waxing and waning course; 4) family history of atopy, including atopic dermatitis, asthma, or hay fever or seasonal allergies",hay fever,atopy
502844737,7/13/2014 22:00:12,,1322189221,7/13/2014 22:00:02,clixsense,1,25402344,CAN,ON,Wawa,24.109.124.45,319,272,,,328,277,HAY FEVER,ATOPY,"dermatitis, asthma, or HAY FEVER or seasonal allergies.",296-308-316-319-323-329-332-341,254-261-269-272-279-289-296,"family history of ATOPY, including atopic dermatitis,","There should be at least three out of four major diagnostic criteria including 1) itch; 2) appropriate distribution with flexural dermatitis in older children and adults and more extensor and facial dermatitis in infants; 3) waxing and waning course; 4) family history of atopy, including atopic dermatitis, asthma, or hay fever or seasonal allergies.",319 323,272,319,272,328,277,-1,RO-cause_of,900383,"There should be at least three out of four major diagnostic criteria including 1) itch; 2) appropriate distribution with flexural dermatitis in older children and adults and more extensor and facial dermatitis in infants; 3) waxing and waning course; 4) family history of atopy, including atopic dermatitis, asthma, or hay fever or seasonal allergies",hay fever,atopy
502844737,7/13/2014 22:00:27,,1322189491,7/13/2014 22:00:02,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,319,272,,,328,277,HAY FEVER,ATOPY,"atopic dermatitis, asthma, or HAY FEVER or seasonal allergies.",296-308-316-319-323-329-332-341-289,254-261-269-272-279-289-296-308-316-319-323-329-332-341,"family history of ATOPY, including atopic dermatitis, asthma, or hay fever or seasonal allergies.","There should be at least three out of four major diagnostic criteria including 1) itch; 2) appropriate distribution with flexural dermatitis in older children and adults and more extensor and facial dermatitis in infants; 3) waxing and waning course; 4) family history of atopy, including atopic dermatitis, asthma, or hay fever or seasonal allergies.",319 323,272,319,272,328,277,-1,RO-cause_of,900383,"There should be at least three out of four major diagnostic criteria including 1) itch; 2) appropriate distribution with flexural dermatitis in older children and adults and more extensor and facial dermatitis in infants; 3) waxing and waning course; 4) family history of atopy, including atopic dermatitis, asthma, or hay fever or seasonal allergies",hay fever,atopy
502844737,7/13/2014 22:04:48,,1322193333,7/13/2014 22:04:20,prodege,1,28255346,GBR,L9,Sheffield,2.125.183.137,319,272,,,328,277,HAY FEVER,ATOPY,HAY FEVER,319-323,272,"ATOPY,","There should be at least three out of four major diagnostic criteria including 1) itch; 2) appropriate distribution with flexural dermatitis in older children and adults and more extensor and facial dermatitis in infants; 3) waxing and waning course; 4) family history of atopy, including atopic dermatitis, asthma, or hay fever or seasonal allergies.",319 323,272,319,272,328,277,-1,RO-cause_of,900383,"There should be at least three out of four major diagnostic criteria including 1) itch; 2) appropriate distribution with flexural dermatitis in older children and adults and more extensor and facial dermatitis in infants; 3) waxing and waning course; 4) family history of atopy, including atopic dermatitis, asthma, or hay fever or seasonal allergies",hay fever,atopy
502844737,7/13/2014 22:04:51,,1322193371,7/13/2014 22:04:33,bitcoinget,1,24792414,USA,IA,Independence,166.181.80.204,319,272,,,328,277,HAY FEVER,ATOPY,HAY FEVER,319-323,272,"ATOPY,","There should be at least three out of four major diagnostic criteria including 1) itch; 2) appropriate distribution with flexural dermatitis in older children and adults and more extensor and facial dermatitis in infants; 3) waxing and waning course; 4) family history of atopy, including atopic dermatitis, asthma, or hay fever or seasonal allergies.",319 323,272,319,272,328,277,-1,RO-cause_of,900383,"There should be at least three out of four major diagnostic criteria including 1) itch; 2) appropriate distribution with flexural dermatitis in older children and adults and more extensor and facial dermatitis in infants; 3) waxing and waning course; 4) family history of atopy, including atopic dermatitis, asthma, or hay fever or seasonal allergies",hay fever,atopy
502844737,7/13/2014 22:06:20,,1322194518,7/13/2014 22:05:59,prodege,1,17932518,GBR,Y2,Pwllheli,95.151.166.224,319,272,,,328,277,HAY FEVER,ATOPY,HAY FEVER,319-323,272,"ATOPY,","There should be at least three out of four major diagnostic criteria including 1) itch; 2) appropriate distribution with flexural dermatitis in older children and adults and more extensor and facial dermatitis in infants; 3) waxing and waning course; 4) family history of atopy, including atopic dermatitis, asthma, or hay fever or seasonal allergies.",319 323,272,319,272,328,277,-1,RO-cause_of,900383,"There should be at least three out of four major diagnostic criteria including 1) itch; 2) appropriate distribution with flexural dermatitis in older children and adults and more extensor and facial dermatitis in infants; 3) waxing and waning course; 4) family history of atopy, including atopic dermatitis, asthma, or hay fever or seasonal allergies",hay fever,atopy
502844737,7/13/2014 22:17:48,,1322203749,7/13/2014 22:15:59,clixsense,1,21875134,GBR,,,91.125.61.83,319,272,,,328,277,HAY FEVER,ATOPY,HAY FEVER or seasonal allergies.,319-323-329-332-341,254-261-269-272,"family history of ATOPY,","There should be at least three out of four major diagnostic criteria including 1) itch; 2) appropriate distribution with flexural dermatitis in older children and adults and more extensor and facial dermatitis in infants; 3) waxing and waning course; 4) family history of atopy, including atopic dermatitis, asthma, or hay fever or seasonal allergies.",319 323,272,319,272,328,277,-1,RO-cause_of,900383,"There should be at least three out of four major diagnostic criteria including 1) itch; 2) appropriate distribution with flexural dermatitis in older children and adults and more extensor and facial dermatitis in infants; 3) waxing and waning course; 4) family history of atopy, including atopic dermatitis, asthma, or hay fever or seasonal allergies",hay fever,atopy
502844738,7/13/2014 21:50:18,,1322180453,7/13/2014 21:49:52,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,54,28,,,84,48,NEUROENDOCRINE DIFFERENTIATION,SMALL CELL CARCINOMA,Fine needle biopsy small cell carcinoma with NEUROENDOCRINE DIFFERENTIATION resembling small cell carcinoma of the lung.,0-5-12-28-34-39-49-54-69-85-96-102-107-117-124-120,0-5-12-28-34-39-49-54-69-85-96-102-107-117-120-124,Fine needle biopsy SMALL CELL CARCINOMA with neuroendocrine differentiation resembling small cell carcinoma of the lung.,Fine-needle biopsy revealed small cell carcinoma with neuroendocrine differentiation resembling small cell carcinoma of the lung.,54 69,28 34 39,54,28,84,48,1,RO-disease_has_finding,901823,Fine-needle biopsy revealed small cell carcinoma with neuroendocrine differentiation resembling small cell carcinoma of the lung,neuroendocrine differentiation,small cell carcinoma
502844738,7/13/2014 21:53:24,,1322182989,7/13/2014 21:53:04,elite,1,28503042,USA,OK,Oakwood,64.250.220.169,54,28,,,84,48,NEUROENDOCRINE DIFFERENTIATION,SMALL CELL CARCINOMA,NEUROENDOCRINE DIFFERENTIATION,54-69,28-34-39,SMALL CELL CARCINOMA,Fine-needle biopsy revealed small cell carcinoma with neuroendocrine differentiation resembling small cell carcinoma of the lung.,54 69,28 34 39,54,28,84,48,1,RO-disease_has_finding,901823,Fine-needle biopsy revealed small cell carcinoma with neuroendocrine differentiation resembling small cell carcinoma of the lung,neuroendocrine differentiation,small cell carcinoma
502844738,7/13/2014 21:53:37,,1322183152,7/13/2014 21:53:07,clixsense,1,25402344,CAN,ON,Wawa,24.109.124.45,54,28,,,84,48,NEUROENDOCRINE DIFFERENTIATION,SMALL CELL CARCINOMA,cell carcinoma with NEUROENDOCRINE DIFFERENTIATION,34-39-49-54-69,5-12-19-28-34-39-49-54-69-0,Fine needle biopsy revealed SMALL CELL CARCINOMA with neuroendocrine differentiation,Fine-needle biopsy revealed small cell carcinoma with neuroendocrine differentiation resembling small cell carcinoma of the lung.,54 69,28 34 39,54,28,84,48,1,RO-disease_has_finding,901823,Fine-needle biopsy revealed small cell carcinoma with neuroendocrine differentiation resembling small cell carcinoma of the lung,neuroendocrine differentiation,small cell carcinoma
502844738,7/13/2014 21:55:40,,1322184924,7/13/2014 21:55:27,instagc,1,28301350,GBR,K4,Plymouth,89.242.63.62,54,28,,,84,48,NEUROENDOCRINE DIFFERENTIATION,SMALL CELL CARCINOMA,small cell carcinoma with NEUROENDOCRINE DIFFERENTIATION,28-34-39-49-54-69,28-34-39-49-54-69,SMALL CELL CARCINOMA with neuroendocrine differentiation,Fine-needle biopsy revealed small cell carcinoma with neuroendocrine differentiation resembling small cell carcinoma of the lung.,54 69,28 34 39,54,28,84,48,1,RO-disease_has_finding,901823,Fine-needle biopsy revealed small cell carcinoma with neuroendocrine differentiation resembling small cell carcinoma of the lung,neuroendocrine differentiation,small cell carcinoma
502844738,7/13/2014 21:59:15,,1322188234,7/13/2014 21:59:09,clixsense,1,24763049,GBR,,,86.133.47.213,54,28,,,84,48,NEUROENDOCRINE DIFFERENTIATION,SMALL CELL CARCINOMA,cell carcinoma with NEUROENDOCRINE DIFFERENTIATION resembling small cell,34-39-49-54-69-85-96-102,5-12-19-28-34-39-49-54-69,needle biopsy revealed SMALL CELL CARCINOMA with neuroendocrine differentiation,Fine-needle biopsy revealed small cell carcinoma with neuroendocrine differentiation resembling small cell carcinoma of the lung.,54 69,28 34 39,54,28,84,48,1,RO-disease_has_finding,901823,Fine-needle biopsy revealed small cell carcinoma with neuroendocrine differentiation resembling small cell carcinoma of the lung,neuroendocrine differentiation,small cell carcinoma
502844738,7/13/2014 22:01:57,,1322191007,7/13/2014 22:01:26,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,54,28,,,84,48,NEUROENDOCRINE DIFFERENTIATION,SMALL CELL CARCINOMA,cell carcinoma with NEUROENDOCRINE DIFFERENTIATION,34-39-49-54-69,28-34-39-49-54-69,SMALL CELL CARCINOMA with neuroendocrine differentiation,Fine-needle biopsy revealed small cell carcinoma with neuroendocrine differentiation resembling small cell carcinoma of the lung.,54 69,28 34 39,54,28,84,48,1,RO-disease_has_finding,901823,Fine-needle biopsy revealed small cell carcinoma with neuroendocrine differentiation resembling small cell carcinoma of the lung,neuroendocrine differentiation,small cell carcinoma
502844738,7/13/2014 22:04:12,,1322192799,7/13/2014 22:03:53,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,54,28,,,84,48,NEUROENDOCRINE DIFFERENTIATION,SMALL CELL CARCINOMA,cell carcinoma with NEUROENDOCRINE DIFFERENTIATION,34-39-49-54-69,28-34-39-49-54-69,SMALL CELL CARCINOMA with neuroendocrine differentiation,Fine-needle biopsy revealed small cell carcinoma with neuroendocrine differentiation resembling small cell carcinoma of the lung.,54 69,28 34 39,54,28,84,48,1,RO-disease_has_finding,901823,Fine-needle biopsy revealed small cell carcinoma with neuroendocrine differentiation resembling small cell carcinoma of the lung,neuroendocrine differentiation,small cell carcinoma
502844738,7/13/2014 22:08:14,,1322195995,7/13/2014 22:07:43,elite,1,28397222,GBR,,,31.49.231.211,54,28,,,84,48,NEUROENDOCRINE DIFFERENTIATION,SMALL CELL CARCINOMA,NEUROENDOCRINE DIFFERENTIATION,54-69,28-34-39,SMALL CELL CARCINOMA,Fine-needle biopsy revealed small cell carcinoma with neuroendocrine differentiation resembling small cell carcinoma of the lung.,54 69,28 34 39,54,28,84,48,1,RO-disease_has_finding,901823,Fine-needle biopsy revealed small cell carcinoma with neuroendocrine differentiation resembling small cell carcinoma of the lung,neuroendocrine differentiation,small cell carcinoma
502844738,7/13/2014 22:09:16,,1322196798,7/13/2014 22:08:53,prodege,1,17932518,GBR,Y2,Pwllheli,95.151.166.224,54,28,,,84,48,NEUROENDOCRINE DIFFERENTIATION,SMALL CELL CARCINOMA,NEUROENDOCRINE DIFFERENTIATION,54-69,28-34-39,SMALL CELL CARCINOMA,Fine-needle biopsy revealed small cell carcinoma with neuroendocrine differentiation resembling small cell carcinoma of the lung.,54 69,28 34 39,54,28,84,48,1,RO-disease_has_finding,901823,Fine-needle biopsy revealed small cell carcinoma with neuroendocrine differentiation resembling small cell carcinoma of the lung,neuroendocrine differentiation,small cell carcinoma
502844738,7/13/2014 22:10:53,,1322198197,7/13/2014 22:10:22,prodege,1,28255346,GBR,L9,Sheffield,2.125.183.137,54,28,,,84,48,NEUROENDOCRINE DIFFERENTIATION,SMALL CELL CARCINOMA,NEUROENDOCRINE DIFFERENTIATION,54-69,28-34-39,SMALL CELL CARCINOMA,Fine-needle biopsy revealed small cell carcinoma with neuroendocrine differentiation resembling small cell carcinoma of the lung.,54 69,28 34 39,54,28,84,48,1,RO-disease_has_finding,901823,Fine-needle biopsy revealed small cell carcinoma with neuroendocrine differentiation resembling small cell carcinoma of the lung,neuroendocrine differentiation,small cell carcinoma
502844739,7/13/2014 21:55:17,,1322184614,7/13/2014 21:54:38,elite,1,28397222,GBR,,,31.49.231.211,44,90,,,60,113,PHOTOSENSITIVITY,PORPHYRIA CUTANEA TARDA,"cutaneous PHOTOSENSITIVITY,",44-34,90-100-108,PORPHYRIA CUTANEA TARDA,"The mutual clinical symptom was a cutaneous photosensitivity, which is a major symptom in porphyria cutanea tarda and a facultative one in porphyria variegata.",44,90 100 108,44,90,60,113,1,RO-has_manifestation,906439,"The mutual clinical symptom was a cutaneous photosensitivity, which is a major symptom in porphyria cutanea tarda and a facultative one in porphyria variegata",photosensitivity,porphyria cutanea tarda
502844739,7/13/2014 21:59:02,,1322188027,7/13/2014 21:58:55,clixsense,1,24763049,GBR,,,86.133.47.213,44,90,,,60,113,PHOTOSENSITIVITY,PORPHYRIA CUTANEA TARDA,"was a cutaneous PHOTOSENSITIVITY, which is a",28-32-34-44-62-68-71,73-79-87-90-100-108-114-118-120,major symptom in PORPHYRIA CUTANEA TARDA and a facultative,"The mutual clinical symptom was a cutaneous photosensitivity, which is a major symptom in porphyria cutanea tarda and a facultative one in porphyria variegata.",44,90 100 108,44,90,60,113,1,RO-has_manifestation,906439,"The mutual clinical symptom was a cutaneous photosensitivity, which is a major symptom in porphyria cutanea tarda and a facultative one in porphyria variegata",photosensitivity,porphyria cutanea tarda
502844739,7/13/2014 22:00:00,,1322189076,7/13/2014 21:59:48,elite,1,28503042,USA,OK,Oakwood,64.250.220.169,44,90,,,60,113,PHOTOSENSITIVITY,PORPHYRIA CUTANEA TARDA,"cutaneous PHOTOSENSITIVITY,",34-44,90-100-108,PORPHYRIA CUTANEA TARDA,"The mutual clinical symptom was a cutaneous photosensitivity, which is a major symptom in porphyria cutanea tarda and a facultative one in porphyria variegata.",44,90 100 108,44,90,60,113,1,RO-has_manifestation,906439,"The mutual clinical symptom was a cutaneous photosensitivity, which is a major symptom in porphyria cutanea tarda and a facultative one in porphyria variegata",photosensitivity,porphyria cutanea tarda
502844739,7/13/2014 22:00:04,,1322189130,7/13/2014 21:59:42,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,44,90,,,60,113,PHOTOSENSITIVITY,PORPHYRIA CUTANEA TARDA,"cutaneous PHOTOSENSITIVITY,",34-44,90-100-108,PORPHYRIA CUTANEA TARDA,"The mutual clinical symptom was a cutaneous photosensitivity, which is a major symptom in porphyria cutanea tarda and a facultative one in porphyria variegata.",44,90 100 108,44,90,60,113,1,RO-has_manifestation,906439,"The mutual clinical symptom was a cutaneous photosensitivity, which is a major symptom in porphyria cutanea tarda and a facultative one in porphyria variegata",photosensitivity,porphyria cutanea tarda
502844739,7/13/2014 22:00:55,,1322190135,7/13/2014 22:00:38,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,44,90,,,60,113,PHOTOSENSITIVITY,PORPHYRIA CUTANEA TARDA,"cutaneous PHOTOSENSITIVITY,",34-44,90-100-108,PORPHYRIA CUTANEA TARDA,"The mutual clinical symptom was a cutaneous photosensitivity, which is a major symptom in porphyria cutanea tarda and a facultative one in porphyria variegata.",44,90 100 108,44,90,60,113,1,RO-has_manifestation,906439,"The mutual clinical symptom was a cutaneous photosensitivity, which is a major symptom in porphyria cutanea tarda and a facultative one in porphyria variegata",photosensitivity,porphyria cutanea tarda
502844739,7/13/2014 22:02:54,,1322191792,7/13/2014 22:02:34,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,44,90,,,60,113,PHOTOSENSITIVITY,PORPHYRIA CUTANEA TARDA,"cutaneous PHOTOSENSITIVITY,",34-44,79-87-90-100-108,symptom in PORPHYRIA CUTANEA TARDA,"The mutual clinical symptom was a cutaneous photosensitivity, which is a major symptom in porphyria cutanea tarda and a facultative one in porphyria variegata.",44,90 100 108,44,90,60,113,1,RO-has_manifestation,906439,"The mutual clinical symptom was a cutaneous photosensitivity, which is a major symptom in porphyria cutanea tarda and a facultative one in porphyria variegata",photosensitivity,porphyria cutanea tarda
502844739,7/13/2014 22:04:30,,1322193050,7/13/2014 22:04:19,clixsense,1,25402344,CAN,ON,Wawa,24.109.124.45,44,90,,,60,113,PHOTOSENSITIVITY,PORPHYRIA CUTANEA TARDA,"was a cutaneous PHOTOSENSITIVITY, which is a",28-32-34-44-62-68-71,73-79-87-90-100-108-114-118-120,major symptom in PORPHYRIA CUTANEA TARDA and a facultative,"The mutual clinical symptom was a cutaneous photosensitivity, which is a major symptom in porphyria cutanea tarda and a facultative one in porphyria variegata.",44,90 100 108,44,90,60,113,1,RO-has_manifestation,906439,"The mutual clinical symptom was a cutaneous photosensitivity, which is a major symptom in porphyria cutanea tarda and a facultative one in porphyria variegata",photosensitivity,porphyria cutanea tarda
502844739,7/13/2014 22:11:23,,1322198618,7/13/2014 22:10:54,prodege,1,28255346,GBR,L9,Sheffield,2.125.183.137,44,90,,,60,113,PHOTOSENSITIVITY,PORPHYRIA CUTANEA TARDA,"cutaneous PHOTOSENSITIVITY,",34-44,90-100-108,PORPHYRIA CUTANEA TARDA,"The mutual clinical symptom was a cutaneous photosensitivity, which is a major symptom in porphyria cutanea tarda and a facultative one in porphyria variegata.",44,90 100 108,44,90,60,113,1,RO-has_manifestation,906439,"The mutual clinical symptom was a cutaneous photosensitivity, which is a major symptom in porphyria cutanea tarda and a facultative one in porphyria variegata",photosensitivity,porphyria cutanea tarda
502844739,7/13/2014 22:17:42,,1322203703,7/13/2014 22:17:24,clixsense,1,10842668,GBR,,,80.189.187.36,44,90,,,60,113,PHOTOSENSITIVITY,PORPHYRIA CUTANEA TARDA,"PHOTOSENSITIVITY,",44,90-100-108,PORPHYRIA CUTANEA TARDA,"The mutual clinical symptom was a cutaneous photosensitivity, which is a major symptom in porphyria cutanea tarda and a facultative one in porphyria variegata.",44,90 100 108,44,90,60,113,1,RO-has_manifestation,906439,"The mutual clinical symptom was a cutaneous photosensitivity, which is a major symptom in porphyria cutanea tarda and a facultative one in porphyria variegata",photosensitivity,porphyria cutanea tarda
502844739,7/13/2014 22:17:43,,1322203718,7/13/2014 22:17:26,instagc,1,23149109,USA,NC,Durham,75.189.206.205,44,90,,,60,113,PHOTOSENSITIVITY,PORPHYRIA CUTANEA TARDA,"cutaneous PHOTOSENSITIVITY,",34-44,90-100-108,PORPHYRIA CUTANEA TARDA,"The mutual clinical symptom was a cutaneous photosensitivity, which is a major symptom in porphyria cutanea tarda and a facultative one in porphyria variegata.",44,90 100 108,44,90,60,113,1,RO-has_manifestation,906439,"The mutual clinical symptom was a cutaneous photosensitivity, which is a major symptom in porphyria cutanea tarda and a facultative one in porphyria variegata",photosensitivity,porphyria cutanea tarda
502844740,7/13/2014 21:51:06,,1322181084,7/13/2014 21:50:47,clixsense,1,15189335,GBR,K3,Peterborough,81.156.166.189,91,163,,,99,187,SEIZURES,COMPLEX PARTIAL SEIZURES,SEIZURES,91,163-171-179,COMPLEX PARTIAL SEIZURES.,"The best results were obtained with astatic myoclonic and absence seizures, but control of seizures was improved in four children with tonic-clonic and three with complex partial seizures.",91,163 171 179,91,163,99,187,-1,RO-has_definitional_manifestation,904610,"The best results were obtained with astatic myoclonic and absence seizures, but control of seizures was improved in four children with tonic-clonic and three with complex partial seizures",seizures,complex partial seizures
502844740,7/13/2014 21:55:15,,1322184581,7/13/2014 21:55:06,elite,1,28503042,USA,OK,Oakwood,64.250.220.169,91,163,,,99,187,SEIZURES,COMPLEX PARTIAL SEIZURES,SEIZURES,91,163-171-179,COMPLEX PARTIAL SEIZURES.,"The best results were obtained with astatic myoclonic and absence seizures, but control of seizures was improved in four children with tonic-clonic and three with complex partial seizures.",91,163 171 179,91,163,99,187,-1,RO-has_definitional_manifestation,904610,"The best results were obtained with astatic myoclonic and absence seizures, but control of seizures was improved in four children with tonic-clonic and three with complex partial seizures",seizures,complex partial seizures
502844740,7/13/2014 21:57:29,,1322186647,7/13/2014 21:57:10,instagc,1,28301350,GBR,K4,Plymouth,89.242.63.62,91,163,,,99,187,SEIZURES,COMPLEX PARTIAL SEIZURES,SEIZURES complex partial seizures.,91-163-171-179,163-171-179,COMPLEX PARTIAL SEIZURES.,"The best results were obtained with astatic myoclonic and absence seizures, but control of seizures was improved in four children with tonic-clonic and three with complex partial seizures.",91,163 171 179,91,163,99,187,-1,RO-has_definitional_manifestation,904610,"The best results were obtained with astatic myoclonic and absence seizures, but control of seizures was improved in four children with tonic-clonic and three with complex partial seizures",seizures,complex partial seizures
502844740,7/13/2014 22:00:45,,1322189868,7/13/2014 22:00:15,elite,1,28397222,GBR,,,31.49.231.211,91,163,,,99,187,SEIZURES,COMPLEX PARTIAL SEIZURES,SEIZURES,91,163-171-179,COMPLEX PARTIAL SEIZURES.,"The best results were obtained with astatic myoclonic and absence seizures, but control of seizures was improved in four children with tonic-clonic and three with complex partial seizures.",91,163 171 179,91,163,99,187,-1,RO-has_definitional_manifestation,904610,"The best results were obtained with astatic myoclonic and absence seizures, but control of seizures was improved in four children with tonic-clonic and three with complex partial seizures",seizures,complex partial seizures
502844740,7/13/2014 22:01:09,,1322190398,7/13/2014 22:00:56,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,91,163,,,99,187,SEIZURES,COMPLEX PARTIAL SEIZURES,SEIZURES,91,163-171-179,COMPLEX PARTIAL SEIZURES.,"The best results were obtained with astatic myoclonic and absence seizures, but control of seizures was improved in four children with tonic-clonic and three with complex partial seizures.",91,163 171 179,91,163,99,187,-1,RO-has_definitional_manifestation,904610,"The best results were obtained with astatic myoclonic and absence seizures, but control of seizures was improved in four children with tonic-clonic and three with complex partial seizures",seizures,complex partial seizures
502844740,7/13/2014 22:01:12,,1322190423,7/13/2014 22:01:03,clixsense,1,25402344,CAN,ON,Wawa,24.109.124.45,91,163,,,99,187,SEIZURES,COMPLEX PARTIAL SEIZURES,but control of SEIZURES was improved in,76-80-88-91-100-104-113,148-152-158-163-171-179,and three with COMPLEX PARTIAL SEIZURES.,"The best results were obtained with astatic myoclonic and absence seizures, but control of seizures was improved in four children with tonic-clonic and three with complex partial seizures.",91,163 171 179,91,163,99,187,-1,RO-has_definitional_manifestation,904610,"The best results were obtained with astatic myoclonic and absence seizures, but control of seizures was improved in four children with tonic-clonic and three with complex partial seizures",seizures,complex partial seizures
502844740,7/13/2014 22:05:17,,1322193668,7/13/2014 22:04:52,bitcoinget,1,24792414,USA,IA,Independence,166.181.80.204,91,163,,,99,187,SEIZURES,COMPLEX PARTIAL SEIZURES,SEIZURES,91,163-171-179,COMPLEX PARTIAL SEIZURES.,"The best results were obtained with astatic myoclonic and absence seizures, but control of seizures was improved in four children with tonic-clonic and three with complex partial seizures.",91,163 171 179,91,163,99,187,-1,RO-has_definitional_manifestation,904610,"The best results were obtained with astatic myoclonic and absence seizures, but control of seizures was improved in four children with tonic-clonic and three with complex partial seizures",seizures,complex partial seizures
502844740,7/13/2014 22:05:19,,1322193684,7/13/2014 22:05:13,clixsense,1,24763049,GBR,,,86.133.47.213,91,163,,,99,187,SEIZURES,COMPLEX PARTIAL SEIZURES,but control of SEIZURES was improved in,76-80-88-91-100-104-113,148-152-158-163-171-179,and three with COMPLEX PARTIAL SEIZURES.,"The best results were obtained with astatic myoclonic and absence seizures, but control of seizures was improved in four children with tonic-clonic and three with complex partial seizures.",91,163 171 179,91,163,99,187,-1,RO-has_definitional_manifestation,904610,"The best results were obtained with astatic myoclonic and absence seizures, but control of seizures was improved in four children with tonic-clonic and three with complex partial seizures",seizures,complex partial seizures
502844740,7/13/2014 22:05:49,,1322194038,7/13/2014 22:05:38,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,91,163,,,99,187,SEIZURES,COMPLEX PARTIAL SEIZURES,SEIZURES,91,163-171-179,COMPLEX PARTIAL SEIZURES.,"The best results were obtained with astatic myoclonic and absence seizures, but control of seizures was improved in four children with tonic-clonic and three with complex partial seizures.",91,163 171 179,91,163,99,187,-1,RO-has_definitional_manifestation,904610,"The best results were obtained with astatic myoclonic and absence seizures, but control of seizures was improved in four children with tonic-clonic and three with complex partial seizures",seizures,complex partial seizures
502844740,7/13/2014 22:07:51,,1322195739,7/13/2014 22:07:22,prodege,1,17932518,GBR,Y2,Pwllheli,95.151.166.224,91,163,,,99,187,SEIZURES,COMPLEX PARTIAL SEIZURES,SEIZURES,91,163-171-179,COMPLEX PARTIAL SEIZURES.,"The best results were obtained with astatic myoclonic and absence seizures, but control of seizures was improved in four children with tonic-clonic and three with complex partial seizures.",91,163 171 179,91,163,99,187,-1,RO-has_definitional_manifestation,904610,"The best results were obtained with astatic myoclonic and absence seizures, but control of seizures was improved in four children with tonic-clonic and three with complex partial seizures",seizures,complex partial seizures
502844741,7/13/2014 21:49:31,,1322179849,7/13/2014 21:49:00,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,111,72,,,128,88,RECURRENT DISEASE,RECURRENT CANCER,recurrent cancer RECURRENT DISEASE.,82-111-121-72,72-82-111-121,RECURRENT CANCER recurrent disease.,"Three of the remaining seven have also died since the operation, one of recurrent cancer and two with no known recurrent disease.",111 121,72 82,111,72,128,88,-1,RO-disease_has_finding,901714,"Three of the remaining seven have also died since the operation, one of recurrent cancer and two with no known recurrent disease",recurrent disease,recurrent cancer
502844741,7/13/2014 21:50:24,,1322180584,7/13/2014 21:50:10,instagc,1,28301350,GBR,K4,Plymouth,89.242.63.62,111,72,,,128,88,RECURRENT DISEASE,RECURRENT CANCER,cancer RECURRENT DISEASE.,82-111-121,72-82,RECURRENT CANCER,"Three of the remaining seven have also died since the operation, one of recurrent cancer and two with no known recurrent disease.",111 121,72 82,111,72,128,88,-1,RO-disease_has_finding,901714,"Three of the remaining seven have also died since the operation, one of recurrent cancer and two with no known recurrent disease",recurrent disease,recurrent cancer
502844741,7/13/2014 21:54:35,,1322183954,7/13/2014 21:54:07,clixsense,1,15189335,GBR,K3,Peterborough,81.156.166.189,111,72,,,128,88,RECURRENT DISEASE,RECURRENT CANCER,RECURRENT DISEASE.,111-121,72-82,RECURRENT CANCER,"Three of the remaining seven have also died since the operation, one of recurrent cancer and two with no known recurrent disease.",111 121,72 82,111,72,128,88,-1,RO-disease_has_finding,901714,"Three of the remaining seven have also died since the operation, one of recurrent cancer and two with no known recurrent disease",recurrent disease,recurrent cancer
502844741,7/13/2014 21:58:33,,1322187646,7/13/2014 21:58:22,elite,1,28503042,USA,OK,Oakwood,64.250.220.169,111,72,,,128,88,RECURRENT DISEASE,RECURRENT CANCER,RECURRENT DISEASE.,111-121,72-82,RECURRENT CANCER,"Three of the remaining seven have also died since the operation, one of recurrent cancer and two with no known recurrent disease.",111 121,72 82,111,72,128,88,-1,RO-disease_has_finding,901714,"Three of the remaining seven have also died since the operation, one of recurrent cancer and two with no known recurrent disease",recurrent disease,recurrent cancer
502844741,7/13/2014 22:00:30,,1322189519,7/13/2014 22:00:22,clixsense,1,25402344,CAN,ON,Wawa,24.109.124.45,111,72,,,128,88,RECURRENT DISEASE,RECURRENT CANCER,with no known RECURRENT DISEASE.,97-102-105-111-121,54-65-69-72-82-89-93-97,"operation, one of RECURRENT CANCER and two with","Three of the remaining seven have also died since the operation, one of recurrent cancer and two with no known recurrent disease.",111 121,72 82,111,72,128,88,-1,RO-disease_has_finding,901714,"Three of the remaining seven have also died since the operation, one of recurrent cancer and two with no known recurrent disease",recurrent disease,recurrent cancer
502844741,7/13/2014 22:01:00,,1322190223,7/13/2014 22:00:44,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,111,72,,,128,88,RECURRENT DISEASE,RECURRENT CANCER,RECURRENT DISEASE.,111-121,72-82,RECURRENT CANCER,"Three of the remaining seven have also died since the operation, one of recurrent cancer and two with no known recurrent disease.",111 121,72 82,111,72,128,88,-1,RO-disease_has_finding,901714,"Three of the remaining seven have also died since the operation, one of recurrent cancer and two with no known recurrent disease",recurrent disease,recurrent cancer
502844741,7/13/2014 22:02:25,,1322191480,7/13/2014 22:02:14,neodev,1,28175665,CAN,ON,Brampton,99.228.31.59,111,72,,,128,88,RECURRENT DISEASE,RECURRENT CANCER,RECURRENT DISEASE.,111-121,72-82,RECURRENT CANCER,"Three of the remaining seven have also died since the operation, one of recurrent cancer and two with no known recurrent disease.",111 121,72 82,111,72,128,88,-1,RO-disease_has_finding,901714,"Three of the remaining seven have also died since the operation, one of recurrent cancer and two with no known recurrent disease",recurrent disease,recurrent cancer
502844741,7/13/2014 22:02:33,,1322191535,7/13/2014 22:02:17,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,111,72,,,128,88,RECURRENT DISEASE,RECURRENT CANCER,RECURRENT DISEASE.,111-121,72-82,RECURRENT CANCER,"Three of the remaining seven have also died since the operation, one of recurrent cancer and two with no known recurrent disease.",111 121,72 82,111,72,128,88,-1,RO-disease_has_finding,901714,"Three of the remaining seven have also died since the operation, one of recurrent cancer and two with no known recurrent disease",recurrent disease,recurrent cancer
502844741,7/13/2014 22:04:48,,1322193331,7/13/2014 22:04:21,elite,1,28397222,GBR,,,31.49.231.211,111,72,,,128,88,RECURRENT DISEASE,RECURRENT CANCER,RECURRENT DISEASE.,111-121,72-82,RECURRENT CANCER,"Three of the remaining seven have also died since the operation, one of recurrent cancer and two with no known recurrent disease.",111 121,72 82,111,72,128,88,-1,RO-disease_has_finding,901714,"Three of the remaining seven have also died since the operation, one of recurrent cancer and two with no known recurrent disease",recurrent disease,recurrent cancer
502844741,7/13/2014 22:07:45,,1322195662,7/13/2014 22:07:32,bitcoinget,1,24792414,USA,IA,Independence,166.181.80.204,111,72,,,128,88,RECURRENT DISEASE,RECURRENT CANCER,RECURRENT DISEASE.,111-121,72-82,RECURRENT CANCER,"Three of the remaining seven have also died since the operation, one of recurrent cancer and two with no known recurrent disease.",111 121,72 82,111,72,128,88,-1,RO-disease_has_finding,901714,"Three of the remaining seven have also died since the operation, one of recurrent cancer and two with no known recurrent disease",recurrent disease,recurrent cancer
502844742,7/13/2014 21:50:12,,1322180371,7/13/2014 21:49:34,clixsense,1,15189335,GBR,K3,Peterborough,81.156.166.189,2,12,,,8,38,NUMBER,HYPERSENSITIVITY REACTIONS,NUMBER,2,12-29,HYPERSENSITIVITY REACTIONS,A number of hypersensitivity reactions have been attributed to the presence of Cremophor((R)) EL in the current formulation for paclitaxel.,2,12 29,2,12,8,38,-1,RO-cause_of,900354,A number of hypersensitivity reactions have been attributed to the presence of Cremophor((R)) EL in the current formulation for paclitaxel,number,hypersensitivity reactions
502844742,7/13/2014 21:50:41,,1322180814,7/13/2014 21:50:19,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,2,12,,,8,38,NUMBER,HYPERSENSITIVITY REACTIONS,A NUMBER of hypersensitivity reactions Cremophor((R)) EL paclitaxel.,0-2-9-12-29-79-94-128,0-2-9-12-29-79-94-128,A number of HYPERSENSITIVITY REACTIONS Cremophor((R)) EL paclitaxel.,A number of hypersensitivity reactions have been attributed to the presence of Cremophor((R)) EL in the current formulation for paclitaxel.,2,12 29,2,12,8,38,-1,RO-cause_of,900354,A number of hypersensitivity reactions have been attributed to the presence of Cremophor((R)) EL in the current formulation for paclitaxel,number,hypersensitivity reactions
502844742,7/13/2014 21:54:15,,1322183699,7/13/2014 21:53:58,instagc,1,28301350,GBR,K4,Plymouth,89.242.63.62,2,12,,,8,38,NUMBER,HYPERSENSITIVITY REACTIONS,NUMBER hypersensitivity reactions,2-12-29,12-29,HYPERSENSITIVITY REACTIONS,A number of hypersensitivity reactions have been attributed to the presence of Cremophor((R)) EL in the current formulation for paclitaxel.,2,12 29,2,12,8,38,-1,RO-cause_of,900354,A number of hypersensitivity reactions have been attributed to the presence of Cremophor((R)) EL in the current formulation for paclitaxel,number,hypersensitivity reactions
502844742,7/13/2014 21:55:11,,1322184529,7/13/2014 21:54:31,prodege,1,17932518,GBR,Y2,Pwllheli,95.151.166.224,2,12,,,8,38,NUMBER,HYPERSENSITIVITY REACTIONS,NUMBER,2,12-29,HYPERSENSITIVITY REACTIONS,A number of hypersensitivity reactions have been attributed to the presence of Cremophor((R)) EL in the current formulation for paclitaxel.,2,12 29,2,12,8,38,-1,RO-cause_of,900354,A number of hypersensitivity reactions have been attributed to the presence of Cremophor((R)) EL in the current formulation for paclitaxel,number,hypersensitivity reactions
502844742,7/13/2014 21:59:08,,1322188082,7/13/2014 21:58:41,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,2,12,,,8,38,NUMBER,HYPERSENSITIVITY REACTIONS,NUMBER,2,12-29,HYPERSENSITIVITY REACTIONS,A number of hypersensitivity reactions have been attributed to the presence of Cremophor((R)) EL in the current formulation for paclitaxel.,2,12 29,2,12,8,38,-1,RO-cause_of,900354,A number of hypersensitivity reactions have been attributed to the presence of Cremophor((R)) EL in the current formulation for paclitaxel,number,hypersensitivity reactions
502844742,7/13/2014 22:01:58,,1322191008,7/13/2014 22:01:47,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,2,12,,,8,38,NUMBER,HYPERSENSITIVITY REACTIONS,A NUMBER of hypersensitivity reactions,0-2-9-12-29,0-2-9-12-29,A number of HYPERSENSITIVITY REACTIONS,A number of hypersensitivity reactions have been attributed to the presence of Cremophor((R)) EL in the current formulation for paclitaxel.,2,12 29,2,12,8,38,-1,RO-cause_of,900354,A number of hypersensitivity reactions have been attributed to the presence of Cremophor((R)) EL in the current formulation for paclitaxel,number,hypersensitivity reactions
502844742,7/13/2014 22:02:39,,1322191613,7/13/2014 22:02:26,bitcoinget,1,24792414,USA,IA,Independence,166.181.80.204,2,12,,,8,38,NUMBER,HYPERSENSITIVITY REACTIONS,NUMBER,2,12-29,HYPERSENSITIVITY REACTIONS,A number of hypersensitivity reactions have been attributed to the presence of Cremophor((R)) EL in the current formulation for paclitaxel.,2,12 29,2,12,8,38,-1,RO-cause_of,900354,A number of hypersensitivity reactions have been attributed to the presence of Cremophor((R)) EL in the current formulation for paclitaxel,number,hypersensitivity reactions
502844742,7/13/2014 22:04:19,,1322192907,7/13/2014 22:03:56,prodege,1,28255346,GBR,L9,Sheffield,2.125.183.137,2,12,,,8,38,NUMBER,HYPERSENSITIVITY REACTIONS,NUMBER of hypersensitivity reactions,2-9-12-29,12-29,HYPERSENSITIVITY REACTIONS,A number of hypersensitivity reactions have been attributed to the presence of Cremophor((R)) EL in the current formulation for paclitaxel.,2,12 29,2,12,8,38,-1,RO-cause_of,900354,A number of hypersensitivity reactions have been attributed to the presence of Cremophor((R)) EL in the current formulation for paclitaxel,number,hypersensitivity reactions
502844742,7/13/2014 22:07:41,,1322195594,7/13/2014 22:06:30,elite,1,28397222,GBR,,,31.49.231.211,2,12,,,8,38,NUMBER,HYPERSENSITIVITY REACTIONS,NUMBER,2,12-29,HYPERSENSITIVITY REACTIONS,A number of hypersensitivity reactions have been attributed to the presence of Cremophor((R)) EL in the current formulation for paclitaxel.,2,12 29,2,12,8,38,-1,RO-cause_of,900354,A number of hypersensitivity reactions have been attributed to the presence of Cremophor((R)) EL in the current formulation for paclitaxel,number,hypersensitivity reactions
502844742,7/13/2014 22:10:27,,1322197780,7/13/2014 22:10:21,clixsense,1,24763049,GBR,,,86.133.47.213,2,12,,,8,38,NUMBER,HYPERSENSITIVITY REACTIONS,A NUMBER of hypersensitivity reactions,0-2-9-12-29,0-2-9-12-29-39-44-49,A number of HYPERSENSITIVITY REACTIONS have been attributed,A number of hypersensitivity reactions have been attributed to the presence of Cremophor((R)) EL in the current formulation for paclitaxel.,2,12 29,2,12,8,38,-1,RO-cause_of,900354,A number of hypersensitivity reactions have been attributed to the presence of Cremophor((R)) EL in the current formulation for paclitaxel,number,hypersensitivity reactions
502844743,7/13/2014 21:54:59,,1322184337,7/13/2014 21:54:33,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,9,51,,,13,80,COLD,PSEUDOEPHEDRINE HYDROCHLORIDE,old,6,67-83,PSEUDOEPHEDRIne hydrochloride),Advil old & Sinus Liqui-Gels ibuprofen and pseudoephedrine hydrochloride) patient information.,,67,9,51,13,80,1,RO-may_treat,907896,Advil old & Sinus Liqui-Gels ibuprofen and pseudoephedrine hydrochloride) patient information,Cold,pseudoephedrine hydrochloride
502844743,7/13/2014 21:55:40,,1322184925,7/13/2014 21:55:07,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,9,51,,,13,80,COLD,PSEUDOEPHEDRINE HYDROCHLORIDE,old,6,67,PSEUDOEPHEDRIne,Advil old & Sinus Liqui-Gels ibuprofen and pseudoephedrine hydrochloride) patient information.,,67,9,51,13,80,1,RO-may_treat,907896,Advil old & Sinus Liqui-Gels ibuprofen and pseudoephedrine hydrochloride) patient information,Cold,pseudoephedrine hydrochloride
502844743,7/13/2014 22:06:03,,1322194298,7/13/2014 22:04:42,clixsense,1,8769423,AUS,6,Hobart,147.69.162.116,9,51,,,13,80,COLD,PSEUDOEPHEDRINE HYDROCHLORIDE,old,6,67-83,PSEUDOEPHEDRIne hydrochloride),Advil old & Sinus Liqui-Gels ibuprofen and pseudoephedrine hydrochloride) patient information.,,67,9,51,13,80,1,RO-may_treat,907896,Advil old & Sinus Liqui-Gels ibuprofen and pseudoephedrine hydrochloride) patient information,Cold,pseudoephedrine hydrochloride
502844743,7/13/2014 22:06:45,,1322194891,7/13/2014 22:06:14,bitcoinget,1,24792414,USA,IA,Independence,166.181.80.204,9,51,,,13,80,COLD,PSEUDOEPHEDRINE HYDROCHLORIDE,old,6,67-83,PSEUDOEPHEDRIne hydrochloride),Advil old & Sinus Liqui-Gels ibuprofen and pseudoephedrine hydrochloride) patient information.,,67,9,51,13,80,1,RO-may_treat,907896,Advil old & Sinus Liqui-Gels ibuprofen and pseudoephedrine hydrochloride) patient information,Cold,pseudoephedrine hydrochloride
502844743,7/13/2014 22:07:45,,1322195657,7/13/2014 22:06:46,clixsense,1,15189335,GBR,K3,Peterborough,81.156.166.189,9,51,,,13,80,COLD,PSEUDOEPHEDRINE HYDROCHLORIDE,old,6,67-83,PSEUDOEPHEDRIne hydrochloride),Advil old & Sinus Liqui-Gels ibuprofen and pseudoephedrine hydrochloride) patient information.,,67,9,51,13,80,1,RO-may_treat,907896,Advil old & Sinus Liqui-Gels ibuprofen and pseudoephedrine hydrochloride) patient information,Cold,pseudoephedrine hydrochloride
502844743,7/13/2014 22:14:21,,1322201029,7/13/2014 22:11:47,prodege,1,17932518,GBR,Y2,Pwllheli,95.151.166.224,9,51,,,13,80,COLD,PSEUDOEPHEDRINE HYDROCHLORIDE,Advil,0,67,PSEUDOEPHEDRIne,Advil old & Sinus Liqui-Gels ibuprofen and pseudoephedrine hydrochloride) patient information.,,67,9,51,13,80,1,RO-may_treat,907896,Advil old & Sinus Liqui-Gels ibuprofen and pseudoephedrine hydrochloride) patient information,Cold,pseudoephedrine hydrochloride
502844743,7/13/2014 22:18:50,,1322204742,7/13/2014 22:18:03,instagc,1,23149109,USA,NC,Durham,75.189.206.205,9,51,,,13,80,COLD,PSEUDOEPHEDRINE HYDROCHLORIDE,pseudoephedrine hydrochloride),67-83,35-67-83,- PSEUDOEPHEDRIne hydrochloride),Advil old & Sinus Liqui-Gels ibuprofen and pseudoephedrine hydrochloride) patient information.,,67,9,51,13,80,1,RO-may_treat,907896,Advil old & Sinus Liqui-Gels ibuprofen and pseudoephedrine hydrochloride) patient information,Cold,pseudoephedrine hydrochloride
502844743,7/13/2014 22:21:10,,1322206859,7/13/2014 22:20:41,clixsense,1,10842668,GBR,,,80.189.187.36,9,51,,,13,80,COLD,PSEUDOEPHEDRINE HYDROCHLORIDE,Sinus Liqui Gels,24-30-36,67,PSEUDOEPHEDRIne,Advil old & Sinus Liqui-Gels ibuprofen and pseudoephedrine hydrochloride) patient information.,,67,9,51,13,80,1,RO-may_treat,907896,Advil old & Sinus Liqui-Gels ibuprofen and pseudoephedrine hydrochloride) patient information,Cold,pseudoephedrine hydrochloride
502844743,7/13/2014 22:26:13,,1322211415,7/13/2014 22:25:26,clixsense,1,26889820,GBR,C3,Shelford,92.18.120.203,9,51,,,13,80,COLD,PSEUDOEPHEDRINE HYDROCHLORIDE,Advil,0,67-83,PSEUDOEPHEDRIne hydrochloride),Advil old & Sinus Liqui-Gels ibuprofen and pseudoephedrine hydrochloride) patient information.,,67,9,51,13,80,1,RO-may_treat,907896,Advil old & Sinus Liqui-Gels ibuprofen and pseudoephedrine hydrochloride) patient information,Cold,pseudoephedrine hydrochloride
502844743,7/13/2014 22:27:14,,1322212479,7/13/2014 22:25:03,gifthulk,1,22552178,AUS,5,Adelaide,14.2.7.227,9,51,,,13,80,COLD,PSEUDOEPHEDRINE HYDROCHLORIDE,old,6,67-83,PSEUDOEPHEDRIne hydrochloride),Advil old & Sinus Liqui-Gels ibuprofen and pseudoephedrine hydrochloride) patient information.,,67,9,51,13,80,1,RO-may_treat,907896,Advil old & Sinus Liqui-Gels ibuprofen and pseudoephedrine hydrochloride) patient information,Cold,pseudoephedrine hydrochloride
502844744,7/13/2014 21:49:51,,1322180070,7/13/2014 21:49:33,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,62,33,,,69,54,BREASTS,DUCTAL ADENOCARCINOMA,pathological diagnosis ductal adenocarcinoma of the BREASTS.,6-19-40-55-58-62-33,6-19-33-40-55-58-62,pathological diagnosis DUCTAL ADENOCARCINOMA of the breasts.,Final pathological diagnosis was ductal adenocarcinoma of the breasts.,62,33 40,62,33,69,54,1,RO-disease_has_primary_anatomic_site,902117,Final pathological diagnosis was ductal adenocarcinoma of the breasts,breasts,ductal adenocarcinoma
502844744,7/13/2014 21:50:47,,1322180873,7/13/2014 21:50:36,instagc,1,28301350,GBR,K4,Plymouth,89.242.63.62,62,33,,,69,54,BREASTS,DUCTAL ADENOCARCINOMA,ductal adenocarcinoma of the BREASTS.,40-55-58-62-33,33-40-55-58-62,DUCTAL ADENOCARCINOMA of the breasts.,Final pathological diagnosis was ductal adenocarcinoma of the breasts.,62,33 40,62,33,69,54,1,RO-disease_has_primary_anatomic_site,902117,Final pathological diagnosis was ductal adenocarcinoma of the breasts,breasts,ductal adenocarcinoma
502844744,7/13/2014 21:57:59,,1322187134,7/13/2014 21:57:51,elite,1,28503042,USA,OK,Oakwood,64.250.220.169,62,33,,,69,54,BREASTS,DUCTAL ADENOCARCINOMA,adenocarcinoma of the BREASTS.,40-55-58-62,33-40-55-58-62,DUCTAL ADENOCARCINOMA of the breasts.,Final pathological diagnosis was ductal adenocarcinoma of the breasts.,62,33 40,62,33,69,54,1,RO-disease_has_primary_anatomic_site,902117,Final pathological diagnosis was ductal adenocarcinoma of the breasts,breasts,ductal adenocarcinoma
502844744,7/13/2014 21:58:37,,1322187685,7/13/2014 21:58:23,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,62,33,,,69,54,BREASTS,DUCTAL ADENOCARCINOMA,BREASTS.,62,33-40,DUCTAL ADENOCARCINOMA,Final pathological diagnosis was ductal adenocarcinoma of the breasts.,62,33 40,62,33,69,54,1,RO-disease_has_primary_anatomic_site,902117,Final pathological diagnosis was ductal adenocarcinoma of the breasts,breasts,ductal adenocarcinoma
502844744,7/13/2014 22:01:21,,1322190531,7/13/2014 22:01:13,clixsense,1,25402344,CAN,ON,Wawa,24.109.124.45,62,33,,,69,54,BREASTS,DUCTAL ADENOCARCINOMA,adenocarcinoma of the BREASTS.,40-55-58-62,6-19-29-33-40-55-58-62,pathological diagnosis was DUCTAL ADENOCARCINOMA of the breasts.,Final pathological diagnosis was ductal adenocarcinoma of the breasts.,62,33 40,62,33,69,54,1,RO-disease_has_primary_anatomic_site,902117,Final pathological diagnosis was ductal adenocarcinoma of the breasts,breasts,ductal adenocarcinoma
502844744,7/13/2014 22:03:28,,1322192230,7/13/2014 22:02:51,elite,1,28397222,GBR,,,31.49.231.211,62,33,,,69,54,BREASTS,DUCTAL ADENOCARCINOMA,ductal adenocarcinoma of the BREASTS.,40-55-58-62-33,33-40,DUCTAL ADENOCARCINOMA,Final pathological diagnosis was ductal adenocarcinoma of the breasts.,62,33 40,62,33,69,54,1,RO-disease_has_primary_anatomic_site,902117,Final pathological diagnosis was ductal adenocarcinoma of the breasts,breasts,ductal adenocarcinoma
502844744,7/13/2014 22:05:26,,1322193772,7/13/2014 22:05:20,clixsense,1,24763049,GBR,,,86.133.47.213,62,33,,,69,54,BREASTS,DUCTAL ADENOCARCINOMA,adenocarcinoma of the BREASTS.,40-55-58-62,6-19-29-33-40-55-58-62,pathological diagnosis was DUCTAL ADENOCARCINOMA of the breasts.,Final pathological diagnosis was ductal adenocarcinoma of the breasts.,62,33 40,62,33,69,54,1,RO-disease_has_primary_anatomic_site,902117,Final pathological diagnosis was ductal adenocarcinoma of the breasts,breasts,ductal adenocarcinoma
502844744,7/13/2014 22:09:15,,1322196783,7/13/2014 22:08:41,prodege,1,28255346,GBR,L9,Sheffield,2.125.183.137,62,33,,,69,54,BREASTS,DUCTAL ADENOCARCINOMA,ductal adenocarcinoma of the BREASTS.,40-55-58-62-33,33-40-55-58-62,DUCTAL ADENOCARCINOMA of the breasts.,Final pathological diagnosis was ductal adenocarcinoma of the breasts.,62,33 40,62,33,69,54,1,RO-disease_has_primary_anatomic_site,902117,Final pathological diagnosis was ductal adenocarcinoma of the breasts,breasts,ductal adenocarcinoma
502844744,7/13/2014 22:13:12,,1322200151,7/13/2014 22:12:50,clixsense,1,8769423,AUS,6,Hobart,147.69.162.116,62,33,,,69,54,BREASTS,DUCTAL ADENOCARCINOMA,BREASTS.,62,33-40,DUCTAL ADENOCARCINOMA,Final pathological diagnosis was ductal adenocarcinoma of the breasts.,62,33 40,62,33,69,54,1,RO-disease_has_primary_anatomic_site,902117,Final pathological diagnosis was ductal adenocarcinoma of the breasts,breasts,ductal adenocarcinoma
502844744,7/13/2014 22:17:52,,1322203831,7/13/2014 22:17:37,gifthulk,1,22552178,AUS,5,Adelaide,14.2.7.227,62,33,,,69,54,BREASTS,DUCTAL ADENOCARCINOMA,BREASTS.,62,33-40,DUCTAL ADENOCARCINOMA,Final pathological diagnosis was ductal adenocarcinoma of the breasts.,62,33 40,62,33,69,54,1,RO-disease_has_primary_anatomic_site,902117,Final pathological diagnosis was ductal adenocarcinoma of the breasts,breasts,ductal adenocarcinoma
502844745,7/13/2014 21:51:09,,1322181096,7/13/2014 21:50:48,instagc,1,28301350,GBR,K4,Plymouth,89.242.63.62,185,222,,,190,231,LUNGS,PNEUMONIA,"LUNGS (uncomplicated, pyodestructive pneumonia,",185-191-207-222,191-207-222,"(uncomplicated, pyodestructive PNEUMONIA,","In young children with pneumonia the microflora of the upper respiratory tract was found to reflect the severity of acute pneumonia and the intensity of the pathological process in the lungs (uncomplicated, pyodestructive pneumonia, pyodestructive pneumonia with fatal termination, acute purulent pleurisy.",185,222,185,222,190,231,1,RO-has_finding_site,905371,"In young children with pneumonia the microflora of the upper respiratory tract was found to reflect the severity of acute pneumonia and the intensity of the pathological process in the lungs (uncomplicated, pyodestructive pneumonia, pyodestructive pneumonia with fatal termination, acute purulent pleurisy",lungs,pneumonia
502844745,7/13/2014 21:53:12,,1322182819,7/13/2014 21:52:47,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,185,222,,,190,231,LUNGS,PNEUMONIA,LUNGS,185,222,"PNEUMONIA,","In young children with pneumonia the microflora of the upper respiratory tract was found to reflect the severity of acute pneumonia and the intensity of the pathological process in the lungs (uncomplicated, pyodestructive pneumonia, pyodestructive pneumonia with fatal termination, acute purulent pleurisy.",185,222,185,222,190,231,1,RO-has_finding_site,905371,"In young children with pneumonia the microflora of the upper respiratory tract was found to reflect the severity of acute pneumonia and the intensity of the pathological process in the lungs (uncomplicated, pyodestructive pneumonia, pyodestructive pneumonia with fatal termination, acute purulent pleurisy",lungs,pneumonia
502844745,7/13/2014 22:01:46,,1322190830,7/13/2014 22:01:15,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,185,222,,,190,231,LUNGS,PNEUMONIA,"pathological process in the LUNGS pyodestructive pneumonia, pyodestructive pneumonia acute purulent pleurisy.",157-170-178-181-185-207-222-233-248-282-288-297,191-207-222-233-248-282-288-297,"(uncomplicated, pyodestructive PNEUMONIA, pyodestructive pneumonia acute purulent pleurisy.","In young children with pneumonia the microflora of the upper respiratory tract was found to reflect the severity of acute pneumonia and the intensity of the pathological process in the lungs (uncomplicated, pyodestructive pneumonia, pyodestructive pneumonia with fatal termination, acute purulent pleurisy.",185,222,185,222,190,231,1,RO-has_finding_site,905371,"In young children with pneumonia the microflora of the upper respiratory tract was found to reflect the severity of acute pneumonia and the intensity of the pathological process in the lungs (uncomplicated, pyodestructive pneumonia, pyodestructive pneumonia with fatal termination, acute purulent pleurisy",lungs,pneumonia
502844745,7/13/2014 22:01:54,,1322190991,7/13/2014 22:01:43,clixsense,1,25402344,CAN,ON,Wawa,24.109.124.45,185,222,,,190,231,LUNGS,PNEUMONIA,"process in the LUNGS pyodestructive pneumonia,",170-178-181-185-207-222,185-191-207-222-233-248-258,"lungs (uncomplicated, pyodestructive PNEUMONIA, pyodestructive pneumonia with","In young children with pneumonia the microflora of the upper respiratory tract was found to reflect the severity of acute pneumonia and the intensity of the pathological process in the lungs (uncomplicated, pyodestructive pneumonia, pyodestructive pneumonia with fatal termination, acute purulent pleurisy.",185,222,185,222,190,231,1,RO-has_finding_site,905371,"In young children with pneumonia the microflora of the upper respiratory tract was found to reflect the severity of acute pneumonia and the intensity of the pathological process in the lungs (uncomplicated, pyodestructive pneumonia, pyodestructive pneumonia with fatal termination, acute purulent pleurisy",lungs,pneumonia
502844745,7/13/2014 22:04:32,,1322193086,7/13/2014 22:04:13,bitcoinget,1,24792414,USA,IA,Independence,166.181.80.204,185,222,,,190,231,LUNGS,PNEUMONIA,LUNGS,185,207-222,"pyodestructive PNEUMONIA,","In young children with pneumonia the microflora of the upper respiratory tract was found to reflect the severity of acute pneumonia and the intensity of the pathological process in the lungs (uncomplicated, pyodestructive pneumonia, pyodestructive pneumonia with fatal termination, acute purulent pleurisy.",185,222,185,222,190,231,1,RO-has_finding_site,905371,"In young children with pneumonia the microflora of the upper respiratory tract was found to reflect the severity of acute pneumonia and the intensity of the pathological process in the lungs (uncomplicated, pyodestructive pneumonia, pyodestructive pneumonia with fatal termination, acute purulent pleurisy",lungs,pneumonia
502844745,7/13/2014 22:06:46,,1322194906,7/13/2014 22:06:21,prodege,1,17932518,GBR,Y2,Pwllheli,95.151.166.224,185,222,,,190,231,LUNGS,PNEUMONIA,LUNGS,185,222,"PNEUMONIA,","In young children with pneumonia the microflora of the upper respiratory tract was found to reflect the severity of acute pneumonia and the intensity of the pathological process in the lungs (uncomplicated, pyodestructive pneumonia, pyodestructive pneumonia with fatal termination, acute purulent pleurisy.",185,222,185,222,190,231,1,RO-has_finding_site,905371,"In young children with pneumonia the microflora of the upper respiratory tract was found to reflect the severity of acute pneumonia and the intensity of the pathological process in the lungs (uncomplicated, pyodestructive pneumonia, pyodestructive pneumonia with fatal termination, acute purulent pleurisy",lungs,pneumonia
502844745,7/13/2014 22:16:32,,1322202763,7/13/2014 22:15:41,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,185,222,,,190,231,LUNGS,PNEUMONIA,"pneumonia microflora upper respiratory tract acute pneumonia pathological process in the LUNGS pyodestructive pneumonia, pyodestructive pneumonia fatal termination, acute purulent pleurisy.",23-37-55-61-73-116-122-157-170-178-185-207-222-233-248-263-269-282-288-297-181,23-37-55-61-73-116-122-157-170-178-181-185-207-222-233-248-263-269-282-288-297,"pneumonia microflora upper respiratory tract acute pneumonia pathological process in the lungs pyodestructive PNEUMONIA, pyodestructive pneumonia fatal termination, acute purulent pleurisy.","In young children with pneumonia the microflora of the upper respiratory tract was found to reflect the severity of acute pneumonia and the intensity of the pathological process in the lungs (uncomplicated, pyodestructive pneumonia, pyodestructive pneumonia with fatal termination, acute purulent pleurisy.",185,222,185,222,190,231,1,RO-has_finding_site,905371,"In young children with pneumonia the microflora of the upper respiratory tract was found to reflect the severity of acute pneumonia and the intensity of the pathological process in the lungs (uncomplicated, pyodestructive pneumonia, pyodestructive pneumonia with fatal termination, acute purulent pleurisy",lungs,pneumonia
502844745,7/13/2014 22:18:46,,1322204638,7/13/2014 22:18:19,prodege,1,28255346,GBR,L9,Sheffield,2.125.183.137,185,222,,,190,231,LUNGS,PNEUMONIA,pathological process in the LUNGS,157-170-178-181-185,207-222,"pyodestructive PNEUMONIA,","In young children with pneumonia the microflora of the upper respiratory tract was found to reflect the severity of acute pneumonia and the intensity of the pathological process in the lungs (uncomplicated, pyodestructive pneumonia, pyodestructive pneumonia with fatal termination, acute purulent pleurisy.",185,222,185,222,190,231,1,RO-has_finding_site,905371,"In young children with pneumonia the microflora of the upper respiratory tract was found to reflect the severity of acute pneumonia and the intensity of the pathological process in the lungs (uncomplicated, pyodestructive pneumonia, pyodestructive pneumonia with fatal termination, acute purulent pleurisy",lungs,pneumonia
502844745,7/13/2014 22:21:53,,1322207386,7/13/2014 22:21:26,clixsense,1,10842668,GBR,,,80.189.187.36,185,222,,,190,231,LUNGS,PNEUMONIA,"LUNGS pyodestructive pneumonia,",185-222-207,222,"PNEUMONIA,","In young children with pneumonia the microflora of the upper respiratory tract was found to reflect the severity of acute pneumonia and the intensity of the pathological process in the lungs (uncomplicated, pyodestructive pneumonia, pyodestructive pneumonia with fatal termination, acute purulent pleurisy.",185,222,185,222,190,231,1,RO-has_finding_site,905371,"In young children with pneumonia the microflora of the upper respiratory tract was found to reflect the severity of acute pneumonia and the intensity of the pathological process in the lungs (uncomplicated, pyodestructive pneumonia, pyodestructive pneumonia with fatal termination, acute purulent pleurisy",lungs,pneumonia
502844745,7/13/2014 22:23:20,,1322208605,7/13/2014 22:22:35,clixsense,1,26889820,GBR,C3,Shelford,92.18.120.203,185,222,,,190,231,LUNGS,PNEUMONIA,LUNGS,185,207-222,"pyodestructive PNEUMONIA,","In young children with pneumonia the microflora of the upper respiratory tract was found to reflect the severity of acute pneumonia and the intensity of the pathological process in the lungs (uncomplicated, pyodestructive pneumonia, pyodestructive pneumonia with fatal termination, acute purulent pleurisy.",185,222,185,222,190,231,1,RO-has_finding_site,905371,"In young children with pneumonia the microflora of the upper respiratory tract was found to reflect the severity of acute pneumonia and the intensity of the pathological process in the lungs (uncomplicated, pyodestructive pneumonia, pyodestructive pneumonia with fatal termination, acute purulent pleurisy",lungs,pneumonia
502844746,7/13/2014 21:49:06,,1322179523,7/13/2014 21:48:46,instagc,1,28301350,GBR,K4,Plymouth,89.242.63.62,51,80,,,78,92,LYMPHOPLASMACYTOID LYMPHOMA,IMMUNOCYTOMA,"LYMPHOPLASMACYTOID LYMPHOMA (immunocytoma),",51-70-79,51-70-79,"lymphoplasmacytoid lymphoma (IMMUNOCYTOMA),","The main entities comprise marginal zone lymphoma, lymphoplasmacytoid lymphoma (immunocytoma), follicular center cell lymphoma, mantle cell lymphoma, large cell lymphoma (immunoblastic and anaplastic), intravascular lymphomatosis, plasmacytoma, and lymphoblastic lymphoma.",51 70,,51,80,78,92,-1,RO-cause_of,900433,"The main entities comprise marginal zone lymphoma, lymphoplasmacytoid lymphoma (immunocytoma), follicular center cell lymphoma, mantle cell lymphoma, large cell lymphoma (immunoblastic and anaplastic), intravascular lymphomatosis, plasmacytoma, and lymphoblastic lymphoma",lymphoplasmacytoid lymphoma,immunocytoma
502844746,7/13/2014 21:51:32,,1322181395,7/13/2014 21:51:08,clixsense,1,15189335,GBR,K3,Peterborough,81.156.166.189,51,80,,,78,92,LYMPHOPLASMACYTOID LYMPHOMA,IMMUNOCYTOMA,LYMPHOPLASMACYTOID LYMPHOMA,51-70,79,"(IMMUNOCYTOMA),","The main entities comprise marginal zone lymphoma, lymphoplasmacytoid lymphoma (immunocytoma), follicular center cell lymphoma, mantle cell lymphoma, large cell lymphoma (immunoblastic and anaplastic), intravascular lymphomatosis, plasmacytoma, and lymphoblastic lymphoma.",51 70,,51,80,78,92,-1,RO-cause_of,900433,"The main entities comprise marginal zone lymphoma, lymphoplasmacytoid lymphoma (immunocytoma), follicular center cell lymphoma, mantle cell lymphoma, large cell lymphoma (immunoblastic and anaplastic), intravascular lymphomatosis, plasmacytoma, and lymphoblastic lymphoma",lymphoplasmacytoid lymphoma,immunocytoma
502844746,7/13/2014 21:54:26,,1322183814,7/13/2014 21:54:06,clixsense,1,25402344,CAN,ON,Wawa,24.109.124.45,51,80,,,78,92,LYMPHOPLASMACYTOID LYMPHOMA,IMMUNOCYTOMA,"marginal zone lymphoma, LYMPHOPLASMACYTOID LYMPHOMA follicular center cell lymphoma,",27-36-41-51-70-95-106-113-118,51-70-95-106-113-79,"lymphoplasmacytoid lymphoma (IMMUNOCYTOMA), follicular center cell","The main entities comprise marginal zone lymphoma, lymphoplasmacytoid lymphoma (immunocytoma), follicular center cell lymphoma, mantle cell lymphoma, large cell lymphoma (immunoblastic and anaplastic), intravascular lymphomatosis, plasmacytoma, and lymphoblastic lymphoma.",51 70,,51,80,78,92,-1,RO-cause_of,900433,"The main entities comprise marginal zone lymphoma, lymphoplasmacytoid lymphoma (immunocytoma), follicular center cell lymphoma, mantle cell lymphoma, large cell lymphoma (immunoblastic and anaplastic), intravascular lymphomatosis, plasmacytoma, and lymphoblastic lymphoma",lymphoplasmacytoid lymphoma,immunocytoma
502844746,7/13/2014 21:57:13,,1322186421,7/13/2014 21:56:15,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,51,80,,,78,92,LYMPHOPLASMACYTOID LYMPHOMA,IMMUNOCYTOMA,"marginal zone lymphoma, LYMPHOPLASMACYTOID LYMPHOMA (immunocytoma), follicular center cell lymphoma, mantle cell lymphoma, cell lymphoma (immunoblastic and anaplastic), intravascular lymphomatosis, plasmacytoma, lymphoblastic lymphoma.",27-36-41-51-70-79-95-106-113-118-128-135-140-156-161-170-185-189-202-216-231-249-263,27-36-41-51-70-79-95-106-113-118-128-135-140-156-161-170-185-189-202-216-231-249-263,"marginal zone lymphoma, lymphoplasmacytoid lymphoma (IMMUNOCYTOMA), follicular center cell lymphoma, mantle cell lymphoma, cell lymphoma (immunoblastic and anaplastic), intravascular lymphomatosis, plasmacytoma, lymphoblastic lymphoma.","The main entities comprise marginal zone lymphoma, lymphoplasmacytoid lymphoma (immunocytoma), follicular center cell lymphoma, mantle cell lymphoma, large cell lymphoma (immunoblastic and anaplastic), intravascular lymphomatosis, plasmacytoma, and lymphoblastic lymphoma.",51 70,,51,80,78,92,-1,RO-cause_of,900433,"The main entities comprise marginal zone lymphoma, lymphoplasmacytoid lymphoma (immunocytoma), follicular center cell lymphoma, mantle cell lymphoma, large cell lymphoma (immunoblastic and anaplastic), intravascular lymphomatosis, plasmacytoma, and lymphoblastic lymphoma",lymphoplasmacytoid lymphoma,immunocytoma
502844746,7/13/2014 21:57:56,,1322187062,7/13/2014 21:57:32,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,51,80,,,78,92,LYMPHOPLASMACYTOID LYMPHOMA,IMMUNOCYTOMA,LYMPHOPLASMACYTOID LYMPHOMA,51-70,79,"(IMMUNOCYTOMA),","The main entities comprise marginal zone lymphoma, lymphoplasmacytoid lymphoma (immunocytoma), follicular center cell lymphoma, mantle cell lymphoma, large cell lymphoma (immunoblastic and anaplastic), intravascular lymphomatosis, plasmacytoma, and lymphoblastic lymphoma.",51 70,,51,80,78,92,-1,RO-cause_of,900433,"The main entities comprise marginal zone lymphoma, lymphoplasmacytoid lymphoma (immunocytoma), follicular center cell lymphoma, mantle cell lymphoma, large cell lymphoma (immunoblastic and anaplastic), intravascular lymphomatosis, plasmacytoma, and lymphoblastic lymphoma",lymphoplasmacytoid lymphoma,immunocytoma
502844746,7/13/2014 21:58:49,,1322187810,7/13/2014 21:58:34,elite,1,28503042,USA,OK,Oakwood,64.250.220.169,51,80,,,78,92,LYMPHOPLASMACYTOID LYMPHOMA,IMMUNOCYTOMA,"LYMPHOPLASMACYTOID LYMPHOMA (immunocytoma),",51-70-79,51-70-79,"lymphoplasmacytoid lymphoma (IMMUNOCYTOMA),","The main entities comprise marginal zone lymphoma, lymphoplasmacytoid lymphoma (immunocytoma), follicular center cell lymphoma, mantle cell lymphoma, large cell lymphoma (immunoblastic and anaplastic), intravascular lymphomatosis, plasmacytoma, and lymphoblastic lymphoma.",51 70,,51,80,78,92,-1,RO-cause_of,900433,"The main entities comprise marginal zone lymphoma, lymphoplasmacytoid lymphoma (immunocytoma), follicular center cell lymphoma, mantle cell lymphoma, large cell lymphoma (immunoblastic and anaplastic), intravascular lymphomatosis, plasmacytoma, and lymphoblastic lymphoma",lymphoplasmacytoid lymphoma,immunocytoma
502844746,7/13/2014 22:01:19,,1322190479,7/13/2014 22:00:46,elite,1,28397222,GBR,,,31.49.231.211,51,80,,,78,92,LYMPHOPLASMACYTOID LYMPHOMA,IMMUNOCYTOMA,LYMPHOPLASMACYTOID LYMPHOMA,51-70,79,"(IMMUNOCYTOMA),","The main entities comprise marginal zone lymphoma, lymphoplasmacytoid lymphoma (immunocytoma), follicular center cell lymphoma, mantle cell lymphoma, large cell lymphoma (immunoblastic and anaplastic), intravascular lymphomatosis, plasmacytoma, and lymphoblastic lymphoma.",51 70,,51,80,78,92,-1,RO-cause_of,900433,"The main entities comprise marginal zone lymphoma, lymphoplasmacytoid lymphoma (immunocytoma), follicular center cell lymphoma, mantle cell lymphoma, large cell lymphoma (immunoblastic and anaplastic), intravascular lymphomatosis, plasmacytoma, and lymphoblastic lymphoma",lymphoplasmacytoid lymphoma,immunocytoma
502844746,7/13/2014 22:05:03,,1322193468,7/13/2014 22:04:13,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,51,80,,,78,92,LYMPHOPLASMACYTOID LYMPHOMA,IMMUNOCYTOMA,"LYMPHOPLASMACYTOID LYMPHOMA (immunocytoma), follicular center cell lymphoma, mantle cell lymphoma, large cell lymphoma (immunoblastic anaplastic), intravascular lymphomatosis, plasmacytoma, lymphoblastic lymphoma.",51-70-79-95-106-113-118-128-135-140-150-156-161-170-189-202-216-231-249-263,51-70-79-95-106-113-118-128-135-140-150-156-161-170-189-202-216-231-249-263,"lymphoplasmacytoid lymphoma (IMMUNOCYTOMA), follicular center cell lymphoma, mantle cell lymphoma, large cell lymphoma (immunoblastic anaplastic), intravascular lymphomatosis, plasmacytoma, lymphoblastic lymphoma.","The main entities comprise marginal zone lymphoma, lymphoplasmacytoid lymphoma (immunocytoma), follicular center cell lymphoma, mantle cell lymphoma, large cell lymphoma (immunoblastic and anaplastic), intravascular lymphomatosis, plasmacytoma, and lymphoblastic lymphoma.",51 70,,51,80,78,92,-1,RO-cause_of,900433,"The main entities comprise marginal zone lymphoma, lymphoplasmacytoid lymphoma (immunocytoma), follicular center cell lymphoma, mantle cell lymphoma, large cell lymphoma (immunoblastic and anaplastic), intravascular lymphomatosis, plasmacytoma, and lymphoblastic lymphoma",lymphoplasmacytoid lymphoma,immunocytoma
502844746,7/13/2014 22:11:02,,1322198290,7/13/2014 22:10:35,prodege,1,17932518,GBR,Y2,Pwllheli,95.151.166.224,51,80,,,78,92,LYMPHOPLASMACYTOID LYMPHOMA,IMMUNOCYTOMA,LYMPHOPLASMACYTOID LYMPHOMA,51-70,51-79-70,"lymphoplasmacytoid lymphoma (IMMUNOCYTOMA),","The main entities comprise marginal zone lymphoma, lymphoplasmacytoid lymphoma (immunocytoma), follicular center cell lymphoma, mantle cell lymphoma, large cell lymphoma (immunoblastic and anaplastic), intravascular lymphomatosis, plasmacytoma, and lymphoblastic lymphoma.",51 70,,51,80,78,92,-1,RO-cause_of,900433,"The main entities comprise marginal zone lymphoma, lymphoplasmacytoid lymphoma (immunocytoma), follicular center cell lymphoma, mantle cell lymphoma, large cell lymphoma (immunoblastic and anaplastic), intravascular lymphomatosis, plasmacytoma, and lymphoblastic lymphoma",lymphoplasmacytoid lymphoma,immunocytoma
502844746,7/13/2014 22:17:30,,1322203602,7/13/2014 22:16:54,clixsense,1,8769423,AUS,6,Hobart,147.69.162.116,51,80,,,78,92,LYMPHOPLASMACYTOID LYMPHOMA,IMMUNOCYTOMA,LYMPHOPLASMACYTOID LYMPHOMA,51-70,79,"(IMMUNOCYTOMA),","The main entities comprise marginal zone lymphoma, lymphoplasmacytoid lymphoma (immunocytoma), follicular center cell lymphoma, mantle cell lymphoma, large cell lymphoma (immunoblastic and anaplastic), intravascular lymphomatosis, plasmacytoma, and lymphoblastic lymphoma.",51 70,,51,80,78,92,-1,RO-cause_of,900433,"The main entities comprise marginal zone lymphoma, lymphoplasmacytoid lymphoma (immunocytoma), follicular center cell lymphoma, mantle cell lymphoma, large cell lymphoma (immunoblastic and anaplastic), intravascular lymphomatosis, plasmacytoma, and lymphoblastic lymphoma",lymphoplasmacytoid lymphoma,immunocytoma
502844747,7/13/2014 21:52:48,,1322182413,7/13/2014 21:52:38,instagc,1,28301350,GBR,K4,Plymouth,89.242.63.62,21,82,,,25,91,PAIN,NEURALGIA,PAIN trigeminal neuralgia.,21-71-82,71-82,trigeminal NEURALGIA.,Predictive model for pain recurrence after posterior fossa surgery for trigeminal neuralgia.,21,82,21,82,25,91,-1,RO-has_definitional_manifestation,904802,Predictive model for pain recurrence after posterior fossa surgery for trigeminal neuralgia,pain,neuralgia
502844747,7/13/2014 21:54:37,,1322183990,7/13/2014 21:53:58,elite,1,28397222,GBR,,,31.49.231.211,21,82,,,25,91,PAIN,NEURALGIA,PAIN,21,71-82,trigeminal NEURALGIA.,Predictive model for pain recurrence after posterior fossa surgery for trigeminal neuralgia.,21,82,21,82,25,91,-1,RO-has_definitional_manifestation,904802,Predictive model for pain recurrence after posterior fossa surgery for trigeminal neuralgia,pain,neuralgia
502844747,7/13/2014 21:55:04,,1322184418,7/13/2014 21:54:36,clixsense,1,15189335,GBR,K3,Peterborough,81.156.166.189,21,82,,,25,91,PAIN,NEURALGIA,PAIN,21,82,NEURALGIA.,Predictive model for pain recurrence after posterior fossa surgery for trigeminal neuralgia.,21,82,21,82,25,91,-1,RO-has_definitional_manifestation,904802,Predictive model for pain recurrence after posterior fossa surgery for trigeminal neuralgia,pain,neuralgia
502844747,7/13/2014 21:59:41,,1322188791,7/13/2014 21:59:26,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,21,82,,,25,91,PAIN,NEURALGIA,PAIN,21,71-82,trigeminal NEURALGIA.,Predictive model for pain recurrence after posterior fossa surgery for trigeminal neuralgia.,21,82,21,82,25,91,-1,RO-has_definitional_manifestation,904802,Predictive model for pain recurrence after posterior fossa surgery for trigeminal neuralgia,pain,neuralgia
502844747,7/13/2014 22:02:15,,1322191290,7/13/2014 22:01:58,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,21,82,,,25,91,PAIN,NEURALGIA,PAIN recurrence after posterior fossa surgery,21-26-37-43-53-59,59-67-71-82,surgery for trigeminal NEURALGIA.,Predictive model for pain recurrence after posterior fossa surgery for trigeminal neuralgia.,21,82,21,82,25,91,-1,RO-has_definitional_manifestation,904802,Predictive model for pain recurrence after posterior fossa surgery for trigeminal neuralgia,pain,neuralgia
502844747,7/13/2014 22:07:09,,1322195176,7/13/2014 22:06:44,prodege,1,28255346,GBR,L9,Sheffield,2.125.183.137,21,82,,,25,91,PAIN,NEURALGIA,PAIN recurrence after posterior fossa surgery,21-26-37-43-53-59,71-82,trigeminal NEURALGIA.,Predictive model for pain recurrence after posterior fossa surgery for trigeminal neuralgia.,21,82,21,82,25,91,-1,RO-has_definitional_manifestation,904802,Predictive model for pain recurrence after posterior fossa surgery for trigeminal neuralgia,pain,neuralgia
502844747,7/13/2014 22:09:09,,1322196700,7/13/2014 22:08:52,clixsense,1,8769423,AUS,6,Hobart,147.69.162.116,21,82,,,25,91,PAIN,NEURALGIA,PAIN,21,82,NEURALGIA.,Predictive model for pain recurrence after posterior fossa surgery for trigeminal neuralgia.,21,82,21,82,25,91,-1,RO-has_definitional_manifestation,904802,Predictive model for pain recurrence after posterior fossa surgery for trigeminal neuralgia,pain,neuralgia
502844747,7/13/2014 22:13:44,,1322200549,7/13/2014 22:13:22,instagc,1,23149109,USA,NC,Durham,75.189.206.205,21,82,,,25,91,PAIN,NEURALGIA,PAIN recurrence after posterior fossa surgery,21-26-37-43-53-59,71-82,trigeminal NEURALGIA.,Predictive model for pain recurrence after posterior fossa surgery for trigeminal neuralgia.,21,82,21,82,25,91,-1,RO-has_definitional_manifestation,904802,Predictive model for pain recurrence after posterior fossa surgery for trigeminal neuralgia,pain,neuralgia
502844747,7/13/2014 22:17:23,,1322203460,7/13/2014 22:17:05,clixsense,1,10842668,GBR,,,80.189.187.36,21,82,,,25,91,PAIN,NEURALGIA,PAIN,21,82,NEURALGIA.,Predictive model for pain recurrence after posterior fossa surgery for trigeminal neuralgia.,21,82,21,82,25,91,-1,RO-has_definitional_manifestation,904802,Predictive model for pain recurrence after posterior fossa surgery for trigeminal neuralgia,pain,neuralgia
502844747,7/13/2014 22:24:01,,1322209197,7/13/2014 22:23:48,gifthulk,1,22552178,AUS,5,Adelaide,14.2.7.227,21,82,,,25,91,PAIN,NEURALGIA,PAIN,21,82,NEURALGIA.,Predictive model for pain recurrence after posterior fossa surgery for trigeminal neuralgia.,21,82,21,82,25,91,-1,RO-has_definitional_manifestation,904802,Predictive model for pain recurrence after posterior fossa surgery for trigeminal neuralgia,pain,neuralgia
502844748,7/13/2014 21:52:25,,1322182019,7/13/2014 21:52:06,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,73,17,,,86,29,ACNE VULGARIS,TETRACYCLINE,ACNE VULGARIS,73-78,17,TETRACYCLINE,Minocycline is a tetracycline derivative mainly used in the treatment of acne vulgaris in young persons.,73 78,17,73,17,86,29,1,RO-may_treat,907990,Minocycline is a tetracycline derivative mainly used in the treatment of acne vulgaris in young persons,acne vulgaris,tetracycline
502844748,7/13/2014 21:55:38,,1322184892,7/13/2014 21:55:27,elite,1,28503042,USA,OK,Oakwood,64.250.220.169,73,17,,,86,29,ACNE VULGARIS,TETRACYCLINE,ACNE VULGARIS,73-78,17-30,TETRACYCLINE derivative,Minocycline is a tetracycline derivative mainly used in the treatment of acne vulgaris in young persons.,73 78,17,73,17,86,29,1,RO-may_treat,907990,Minocycline is a tetracycline derivative mainly used in the treatment of acne vulgaris in young persons,acne vulgaris,tetracycline
502844748,7/13/2014 21:59:27,,1322188476,7/13/2014 21:59:11,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,73,17,,,86,29,ACNE VULGARIS,TETRACYCLINE,ACNE VULGARIS,73-78,0-12-15-17-30,Minocycline is a TETRACYCLINE derivative,Minocycline is a tetracycline derivative mainly used in the treatment of acne vulgaris in young persons.,73 78,17,73,17,86,29,1,RO-may_treat,907990,Minocycline is a tetracycline derivative mainly used in the treatment of acne vulgaris in young persons,acne vulgaris,tetracycline
502844748,7/13/2014 22:01:04,,1322190273,7/13/2014 22:00:48,bitcoinget,1,24792414,USA,IA,Independence,166.181.80.204,73,17,,,86,29,ACNE VULGARIS,TETRACYCLINE,ACNE VULGARIS,73-78,17-30,TETRACYCLINE derivative,Minocycline is a tetracycline derivative mainly used in the treatment of acne vulgaris in young persons.,73 78,17,73,17,86,29,1,RO-may_treat,907990,Minocycline is a tetracycline derivative mainly used in the treatment of acne vulgaris in young persons,acne vulgaris,tetracycline
502844748,7/13/2014 22:02:20,,1322191409,7/13/2014 22:01:59,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,73,17,,,86,29,ACNE VULGARIS,TETRACYCLINE,ACNE VULGARIS,73-78,17-30,TETRACYCLINE derivative,Minocycline is a tetracycline derivative mainly used in the treatment of acne vulgaris in young persons.,73 78,17,73,17,86,29,1,RO-may_treat,907990,Minocycline is a tetracycline derivative mainly used in the treatment of acne vulgaris in young persons,acne vulgaris,tetracycline
502844748,7/13/2014 22:03:34,,1322192296,7/13/2014 22:03:19,neodev,1,28175665,CAN,ON,Brampton,99.228.31.59,73,17,,,86,29,ACNE VULGARIS,TETRACYCLINE,ACNE VULGARIS,73-78,0-12-15-17-30,Minocycline is a TETRACYCLINE derivative,Minocycline is a tetracycline derivative mainly used in the treatment of acne vulgaris in young persons.,73 78,17,73,17,86,29,1,RO-may_treat,907990,Minocycline is a tetracycline derivative mainly used in the treatment of acne vulgaris in young persons,acne vulgaris,tetracycline
502844748,7/13/2014 22:04:20,,1322192897,7/13/2014 22:03:57,elite,1,28397222,GBR,,,31.49.231.211,73,17,,,86,29,ACNE VULGARIS,TETRACYCLINE,ACNE VULGARIS,73-78,17,TETRACYCLINE,Minocycline is a tetracycline derivative mainly used in the treatment of acne vulgaris in young persons.,73 78,17,73,17,86,29,1,RO-may_treat,907990,Minocycline is a tetracycline derivative mainly used in the treatment of acne vulgaris in young persons,acne vulgaris,tetracycline
502844748,7/13/2014 22:12:49,,1322199895,7/13/2014 22:12:16,clixsense,1,8769423,AUS,6,Hobart,147.69.162.116,73,17,,,86,29,ACNE VULGARIS,TETRACYCLINE,ACNE VULGARIS,73-78,17-30,TETRACYCLINE derivative,Minocycline is a tetracycline derivative mainly used in the treatment of acne vulgaris in young persons.,73 78,17,73,17,86,29,1,RO-may_treat,907990,Minocycline is a tetracycline derivative mainly used in the treatment of acne vulgaris in young persons,acne vulgaris,tetracycline
502844748,7/13/2014 22:14:48,,1322201426,7/13/2014 22:14:09,prodege,1,28255346,GBR,L9,Sheffield,2.125.183.137,73,17,,,86,29,ACNE VULGARIS,TETRACYCLINE,ACNE VULGARIS,73-78,17-30,TETRACYCLINE derivative,Minocycline is a tetracycline derivative mainly used in the treatment of acne vulgaris in young persons.,73 78,17,73,17,86,29,1,RO-may_treat,907990,Minocycline is a tetracycline derivative mainly used in the treatment of acne vulgaris in young persons,acne vulgaris,tetracycline
502844748,7/13/2014 22:15:58,,1322202313,7/13/2014 22:13:45,clixsense,1,21875134,GBR,,,91.125.61.83,73,17,,,86,29,ACNE VULGARIS,TETRACYCLINE,treatment of ACNE VULGARIS in young persons.,60-70-73-78-87-90-96,0-12-15-17-30,Minocycline is a TETRACYCLINE derivative,Minocycline is a tetracycline derivative mainly used in the treatment of acne vulgaris in young persons.,73 78,17,73,17,86,29,1,RO-may_treat,907990,Minocycline is a tetracycline derivative mainly used in the treatment of acne vulgaris in young persons,acne vulgaris,tetracycline
502844749,7/13/2014 21:48:46,,1322179214,7/13/2014 21:48:05,instagc,1,28301350,GBR,K4,Plymouth,89.242.63.62,145,177,,,150,205,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,systemic LUPUS erythematosus,136-145-151,177-186-192,SYSTEMIC LUPUS ERYTHEMATOSUS,"Neuropathies related to other connective tissue diseases   Peripheral neuropathy may occur in other connective tissue diseases, such as systemic lupus erythematosus [ see 15:IV Systemic Lupus Erythematosus ], although it can be difficult to ascertain whether the neuropathy is a direct complication of the connective tissue disease or a secondary effect of another complication (e.g., secondary to renal failure.",145,177 186 192,145,177,150,205,-1,RO-has_manifestation,906406,"Neuropathies related to other connective tissue diseases   Peripheral neuropathy may occur in other connective tissue diseases, such as systemic lupus erythematosus [ see 15:IV Systemic Lupus Erythematosus ], although it can be difficult to ascertain whether the neuropathy is a direct complication of the connective tissue disease or a secondary effect of another complication (e.g., secondary to renal failure",lupus,Systemic Lupus Erythematosus
502844749,7/13/2014 22:00:23,,1322189399,7/13/2014 22:00:01,elite,1,28503042,USA,OK,Oakwood,64.250.220.169,145,177,,,150,205,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,systemic LUPUS erythematosus Systemic Lupus Erythematosus,136-145-151-177-186-192,136-145-177-186-192-151,systemic lupus erythematosus SYSTEMIC LUPUS ERYTHEMATOSUS,"Neuropathies related to other connective tissue diseases   Peripheral neuropathy may occur in other connective tissue diseases, such as systemic lupus erythematosus [ see 15:IV Systemic Lupus Erythematosus ], although it can be difficult to ascertain whether the neuropathy is a direct complication of the connective tissue disease or a secondary effect of another complication (e.g., secondary to renal failure.",145,177 186 192,145,177,150,205,-1,RO-has_manifestation,906406,"Neuropathies related to other connective tissue diseases   Peripheral neuropathy may occur in other connective tissue diseases, such as systemic lupus erythematosus [ see 15:IV Systemic Lupus Erythematosus ], although it can be difficult to ascertain whether the neuropathy is a direct complication of the connective tissue disease or a secondary effect of another complication (e.g., secondary to renal failure",lupus,Systemic Lupus Erythematosus
502844749,7/13/2014 22:00:28,,1322189501,7/13/2014 22:00:05,bitcoinget,1,24792414,USA,IA,Independence,166.181.80.204,145,177,,,150,205,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,systemic LUPUS erythematosus,136-145-151,177-186-192,SYSTEMIC LUPUS ERYTHEMATOSUS,"Neuropathies related to other connective tissue diseases   Peripheral neuropathy may occur in other connective tissue diseases, such as systemic lupus erythematosus [ see 15:IV Systemic Lupus Erythematosus ], although it can be difficult to ascertain whether the neuropathy is a direct complication of the connective tissue disease or a secondary effect of another complication (e.g., secondary to renal failure.",145,177 186 192,145,177,150,205,-1,RO-has_manifestation,906406,"Neuropathies related to other connective tissue diseases   Peripheral neuropathy may occur in other connective tissue diseases, such as systemic lupus erythematosus [ see 15:IV Systemic Lupus Erythematosus ], although it can be difficult to ascertain whether the neuropathy is a direct complication of the connective tissue disease or a secondary effect of another complication (e.g., secondary to renal failure",lupus,Systemic Lupus Erythematosus
502844749,7/13/2014 22:02:09,,1322191165,7/13/2014 22:01:56,clixsense,1,25402344,CAN,ON,Wawa,24.109.124.45,145,177,,,150,205,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,such as systemic LUPUS erythematosus see 15:IV,128-133-136-145-151-167-171,165-167-171-177-186-192-209-218-221,[ see 15:IV SYSTEMIC LUPUS ERYTHEMATOSUS although it can,"Neuropathies related to other connective tissue diseases   Peripheral neuropathy may occur in other connective tissue diseases, such as systemic lupus erythematosus [ see 15:IV Systemic Lupus Erythematosus ], although it can be difficult to ascertain whether the neuropathy is a direct complication of the connective tissue disease or a secondary effect of another complication (e.g., secondary to renal failure.",145,177 186 192,145,177,150,205,-1,RO-has_manifestation,906406,"Neuropathies related to other connective tissue diseases   Peripheral neuropathy may occur in other connective tissue diseases, such as systemic lupus erythematosus [ see 15:IV Systemic Lupus Erythematosus ], although it can be difficult to ascertain whether the neuropathy is a direct complication of the connective tissue disease or a secondary effect of another complication (e.g., secondary to renal failure",lupus,Systemic Lupus Erythematosus
502844749,7/13/2014 22:04:37,,1322193177,7/13/2014 22:04:16,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,145,177,,,150,205,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,systemic LUPUS erythematosus,136-145-151,177-186-192,SYSTEMIC LUPUS ERYTHEMATOSUS,"Neuropathies related to other connective tissue diseases   Peripheral neuropathy may occur in other connective tissue diseases, such as systemic lupus erythematosus [ see 15:IV Systemic Lupus Erythematosus ], although it can be difficult to ascertain whether the neuropathy is a direct complication of the connective tissue disease or a secondary effect of another complication (e.g., secondary to renal failure.",145,177 186 192,145,177,150,205,-1,RO-has_manifestation,906406,"Neuropathies related to other connective tissue diseases   Peripheral neuropathy may occur in other connective tissue diseases, such as systemic lupus erythematosus [ see 15:IV Systemic Lupus Erythematosus ], although it can be difficult to ascertain whether the neuropathy is a direct complication of the connective tissue disease or a secondary effect of another complication (e.g., secondary to renal failure",lupus,Systemic Lupus Erythematosus
502844749,7/13/2014 22:10:42,,1322198048,7/13/2014 22:10:36,clixsense,1,24763049,GBR,,,86.133.47.213,145,177,,,150,205,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,such as systemic LUPUS erythematosus see 15:IV,128-133-136-145-151-167-171,165-167-171-177-186-192-209-218-221,[ see 15:IV SYSTEMIC LUPUS ERYTHEMATOSUS although it can,"Neuropathies related to other connective tissue diseases   Peripheral neuropathy may occur in other connective tissue diseases, such as systemic lupus erythematosus [ see 15:IV Systemic Lupus Erythematosus ], although it can be difficult to ascertain whether the neuropathy is a direct complication of the connective tissue disease or a secondary effect of another complication (e.g., secondary to renal failure.",145,177 186 192,145,177,150,205,-1,RO-has_manifestation,906406,"Neuropathies related to other connective tissue diseases   Peripheral neuropathy may occur in other connective tissue diseases, such as systemic lupus erythematosus [ see 15:IV Systemic Lupus Erythematosus ], although it can be difficult to ascertain whether the neuropathy is a direct complication of the connective tissue disease or a secondary effect of another complication (e.g., secondary to renal failure",lupus,Systemic Lupus Erythematosus
502844749,7/13/2014 22:11:48,,1322199051,7/13/2014 22:11:26,prodege,1,28255346,GBR,L9,Sheffield,2.125.183.137,145,177,,,150,205,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,systemic LUPUS erythematosus,136-145-151,177-186-192,SYSTEMIC LUPUS ERYTHEMATOSUS,"Neuropathies related to other connective tissue diseases   Peripheral neuropathy may occur in other connective tissue diseases, such as systemic lupus erythematosus [ see 15:IV Systemic Lupus Erythematosus ], although it can be difficult to ascertain whether the neuropathy is a direct complication of the connective tissue disease or a secondary effect of another complication (e.g., secondary to renal failure.",145,177 186 192,145,177,150,205,-1,RO-has_manifestation,906406,"Neuropathies related to other connective tissue diseases   Peripheral neuropathy may occur in other connective tissue diseases, such as systemic lupus erythematosus [ see 15:IV Systemic Lupus Erythematosus ], although it can be difficult to ascertain whether the neuropathy is a direct complication of the connective tissue disease or a secondary effect of another complication (e.g., secondary to renal failure",lupus,Systemic Lupus Erythematosus
502844749,7/13/2014 22:18:58,,1322204868,7/13/2014 22:18:37,gifthulk,1,22552178,AUS,5,Adelaide,14.2.7.227,145,177,,,150,205,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,LUPUS,145,177-186-192,SYSTEMIC LUPUS ERYTHEMATOSUS,"Neuropathies related to other connective tissue diseases   Peripheral neuropathy may occur in other connective tissue diseases, such as systemic lupus erythematosus [ see 15:IV Systemic Lupus Erythematosus ], although it can be difficult to ascertain whether the neuropathy is a direct complication of the connective tissue disease or a secondary effect of another complication (e.g., secondary to renal failure.",145,177 186 192,145,177,150,205,-1,RO-has_manifestation,906406,"Neuropathies related to other connective tissue diseases   Peripheral neuropathy may occur in other connective tissue diseases, such as systemic lupus erythematosus [ see 15:IV Systemic Lupus Erythematosus ], although it can be difficult to ascertain whether the neuropathy is a direct complication of the connective tissue disease or a secondary effect of another complication (e.g., secondary to renal failure",lupus,Systemic Lupus Erythematosus
502844749,7/13/2014 22:22:04,,1322207505,7/13/2014 22:21:47,instagc,1,23149109,USA,NC,Durham,75.189.206.205,145,177,,,150,205,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,systemic LUPUS erythematosus,136-145-151,165-167-171-177-186-192,[ see 15:IV SYSTEMIC LUPUS ERYTHEMATOSUS,"Neuropathies related to other connective tissue diseases   Peripheral neuropathy may occur in other connective tissue diseases, such as systemic lupus erythematosus [ see 15:IV Systemic Lupus Erythematosus ], although it can be difficult to ascertain whether the neuropathy is a direct complication of the connective tissue disease or a secondary effect of another complication (e.g., secondary to renal failure.",145,177 186 192,145,177,150,205,-1,RO-has_manifestation,906406,"Neuropathies related to other connective tissue diseases   Peripheral neuropathy may occur in other connective tissue diseases, such as systemic lupus erythematosus [ see 15:IV Systemic Lupus Erythematosus ], although it can be difficult to ascertain whether the neuropathy is a direct complication of the connective tissue disease or a secondary effect of another complication (e.g., secondary to renal failure",lupus,Systemic Lupus Erythematosus
502844749,7/13/2014 22:24:29,,1322209707,7/13/2014 22:24:16,prodege,1,2143114,CAN,BC,Vancouver,24.84.160.12,145,177,,,150,205,LUPUS,SYSTEMIC LUPUS ERYTHEMATOSUS,systemic LUPUS erythematosus,136-145-151,165-177-186-192,[ SYSTEMIC LUPUS ERYTHEMATOSUS,"Neuropathies related to other connective tissue diseases   Peripheral neuropathy may occur in other connective tissue diseases, such as systemic lupus erythematosus [ see 15:IV Systemic Lupus Erythematosus ], although it can be difficult to ascertain whether the neuropathy is a direct complication of the connective tissue disease or a secondary effect of another complication (e.g., secondary to renal failure.",145,177 186 192,145,177,150,205,-1,RO-has_manifestation,906406,"Neuropathies related to other connective tissue diseases   Peripheral neuropathy may occur in other connective tissue diseases, such as systemic lupus erythematosus [ see 15:IV Systemic Lupus Erythematosus ], although it can be difficult to ascertain whether the neuropathy is a direct complication of the connective tissue disease or a secondary effect of another complication (e.g., secondary to renal failure",lupus,Systemic Lupus Erythematosus
502844750,7/13/2014 21:53:34,,1322183141,7/13/2014 21:53:21,instagc,1,28301350,GBR,K4,Plymouth,89.242.63.62,263,234,,,269,248,JOINTS,OSTEOARTHRITIS,Osteoarthritis JOINTS,234-263,234,OSTEOARTHRITIS,C]  Specific recommendation: ? Consider referral to a rheumatologist for diagnostic consultation for CPPD disease/pseudogout in patients with: ? Inflammatory arthritis ? Osteoarthritis that appears to have an inflammatory component ? Osteoarthritis that involves joints that are not usually affected by osteoarthritis ? Consider referral to other specialists for patients with signs and symptoms of other underlying diseases such as: ? Hemochromatosis ? Hyperparathyroidism ? Acromegaly ? See module  Osteoarthritis.,263,234,263,234,269,248,1,RO-disease_has_primary_anatomic_site,902437,C]  Specific recommendation: ? Consider referral to a rheumatologist for diagnostic consultation for CPPD disease/pseudogout in patients with: ? Inflammatory arthritis ? Osteoarthritis that appears to have an inflammatory component ? Osteoarthritis that involves joints that are not usually affected by osteoarthritis ? Consider referral to other specialists for patients with signs and symptoms of other underlying diseases such as: ? Hemochromatosis ? Hyperparathyroidism ? Acromegaly ? See module  Osteoarthritis,joints,Osteoarthritis
502844750,7/13/2014 21:58:03,,1322187142,7/13/2014 21:57:42,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,263,234,,,269,248,JOINTS,OSTEOARTHRITIS,JOINTS,263,234,OSTEOARTHRITIS,C]  Specific recommendation: ? Consider referral to a rheumatologist for diagnostic consultation for CPPD disease/pseudogout in patients with: ? Inflammatory arthritis ? Osteoarthritis that appears to have an inflammatory component ? Osteoarthritis that involves joints that are not usually affected by osteoarthritis ? Consider referral to other specialists for patients with signs and symptoms of other underlying diseases such as: ? Hemochromatosis ? Hyperparathyroidism ? Acromegaly ? See module  Osteoarthritis.,263,234,263,234,269,248,1,RO-disease_has_primary_anatomic_site,902437,C]  Specific recommendation: ? Consider referral to a rheumatologist for diagnostic consultation for CPPD disease/pseudogout in patients with: ? Inflammatory arthritis ? Osteoarthritis that appears to have an inflammatory component ? Osteoarthritis that involves joints that are not usually affected by osteoarthritis ? Consider referral to other specialists for patients with signs and symptoms of other underlying diseases such as: ? Hemochromatosis ? Hyperparathyroidism ? Acromegaly ? See module  Osteoarthritis,joints,Osteoarthritis
502844750,7/13/2014 21:59:40,,1322188743,7/13/2014 21:59:26,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,263,234,,,269,248,JOINTS,OSTEOARTHRITIS,JOINTS,263,234,OSTEOARTHRITIS,C]  Specific recommendation: ? Consider referral to a rheumatologist for diagnostic consultation for CPPD disease/pseudogout in patients with: ? Inflammatory arthritis ? Osteoarthritis that appears to have an inflammatory component ? Osteoarthritis that involves joints that are not usually affected by osteoarthritis ? Consider referral to other specialists for patients with signs and symptoms of other underlying diseases such as: ? Hemochromatosis ? Hyperparathyroidism ? Acromegaly ? See module  Osteoarthritis.,263,234,263,234,269,248,1,RO-disease_has_primary_anatomic_site,902437,C]  Specific recommendation: ? Consider referral to a rheumatologist for diagnostic consultation for CPPD disease/pseudogout in patients with: ? Inflammatory arthritis ? Osteoarthritis that appears to have an inflammatory component ? Osteoarthritis that involves joints that are not usually affected by osteoarthritis ? Consider referral to other specialists for patients with signs and symptoms of other underlying diseases such as: ? Hemochromatosis ? Hyperparathyroidism ? Acromegaly ? See module  Osteoarthritis,joints,Osteoarthritis
502844750,7/13/2014 22:01:34,,1322190709,7/13/2014 22:01:07,prodege,1,17932518,GBR,Y2,Pwllheli,95.151.166.224,263,234,,,269,248,JOINTS,OSTEOARTHRITIS,JOINTS,263,234,OSTEOARTHRITIS,C]  Specific recommendation: ? Consider referral to a rheumatologist for diagnostic consultation for CPPD disease/pseudogout in patients with: ? Inflammatory arthritis ? Osteoarthritis that appears to have an inflammatory component ? Osteoarthritis that involves joints that are not usually affected by osteoarthritis ? Consider referral to other specialists for patients with signs and symptoms of other underlying diseases such as: ? Hemochromatosis ? Hyperparathyroidism ? Acromegaly ? See module  Osteoarthritis.,263,234,263,234,269,248,1,RO-disease_has_primary_anatomic_site,902437,C]  Specific recommendation: ? Consider referral to a rheumatologist for diagnostic consultation for CPPD disease/pseudogout in patients with: ? Inflammatory arthritis ? Osteoarthritis that appears to have an inflammatory component ? Osteoarthritis that involves joints that are not usually affected by osteoarthritis ? Consider referral to other specialists for patients with signs and symptoms of other underlying diseases such as: ? Hemochromatosis ? Hyperparathyroidism ? Acromegaly ? See module  Osteoarthritis,joints,Osteoarthritis
502844750,7/13/2014 22:05:31,,1322193823,7/13/2014 22:04:49,elite,1,28397222,GBR,,,31.49.231.211,263,234,,,269,248,JOINTS,OSTEOARTHRITIS,JOINTS,263,234,OSTEOARTHRITIS,C]  Specific recommendation: ? Consider referral to a rheumatologist for diagnostic consultation for CPPD disease/pseudogout in patients with: ? Inflammatory arthritis ? Osteoarthritis that appears to have an inflammatory component ? Osteoarthritis that involves joints that are not usually affected by osteoarthritis ? Consider referral to other specialists for patients with signs and symptoms of other underlying diseases such as: ? Hemochromatosis ? Hyperparathyroidism ? Acromegaly ? See module  Osteoarthritis.,263,234,263,234,269,248,1,RO-disease_has_primary_anatomic_site,902437,C]  Specific recommendation: ? Consider referral to a rheumatologist for diagnostic consultation for CPPD disease/pseudogout in patients with: ? Inflammatory arthritis ? Osteoarthritis that appears to have an inflammatory component ? Osteoarthritis that involves joints that are not usually affected by osteoarthritis ? Consider referral to other specialists for patients with signs and symptoms of other underlying diseases such as: ? Hemochromatosis ? Hyperparathyroidism ? Acromegaly ? See module  Osteoarthritis,joints,Osteoarthritis
502844750,7/13/2014 22:07:41,,1322195573,7/13/2014 22:05:52,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,263,234,,,269,248,JOINTS,OSTEOARTHRITIS,rheumatologist for diagnostic consultation CPPD disease pseudogout Inflammatory arthritis Osteoarthritis inflammatory component Osteoarthritis that involves JOINTS osteoarthritis Hemochromatosis Hyperparathyroidism Acromegaly Osteoarthritis.,54-69-73-84-101-106-114-145-158-170-209-222-234-249-254-263-303-436-454-476-501,54-69-73-84-101-106-114-145-158-170-209-222-232-234-249-254-263-303-436-476-501-454,rheumatologist for diagnostic consultation CPPD disease pseudogout Inflammatory arthritis Osteoarthritis inflammatory component ? OSTEOARTHRITIS that involves joints osteoarthritis Hemochromatosis Hyperparathyroidism Acromegaly Osteoarthritis.,C]  Specific recommendation: ? Consider referral to a rheumatologist for diagnostic consultation for CPPD disease/pseudogout in patients with: ? Inflammatory arthritis ? Osteoarthritis that appears to have an inflammatory component ? Osteoarthritis that involves joints that are not usually affected by osteoarthritis ? Consider referral to other specialists for patients with signs and symptoms of other underlying diseases such as: ? Hemochromatosis ? Hyperparathyroidism ? Acromegaly ? See module  Osteoarthritis.,263,234,263,234,269,248,1,RO-disease_has_primary_anatomic_site,902437,C]  Specific recommendation: ? Consider referral to a rheumatologist for diagnostic consultation for CPPD disease/pseudogout in patients with: ? Inflammatory arthritis ? Osteoarthritis that appears to have an inflammatory component ? Osteoarthritis that involves joints that are not usually affected by osteoarthritis ? Consider referral to other specialists for patients with signs and symptoms of other underlying diseases such as: ? Hemochromatosis ? Hyperparathyroidism ? Acromegaly ? See module  Osteoarthritis,joints,Osteoarthritis
502844750,7/13/2014 22:10:35,,1322197901,7/13/2014 22:10:29,clixsense,1,24763049,GBR,,,86.133.47.213,263,234,,,269,248,JOINTS,OSTEOARTHRITIS,Osteoarthritis that involves JOINTS that are not,234-249-254-263-270-275-279,209-222-232-234-249-254-263,inflammatory component ? OSTEOARTHRITIS that involves joints,C]  Specific recommendation: ? Consider referral to a rheumatologist for diagnostic consultation for CPPD disease/pseudogout in patients with: ? Inflammatory arthritis ? Osteoarthritis that appears to have an inflammatory component ? Osteoarthritis that involves joints that are not usually affected by osteoarthritis ? Consider referral to other specialists for patients with signs and symptoms of other underlying diseases such as: ? Hemochromatosis ? Hyperparathyroidism ? Acromegaly ? See module  Osteoarthritis.,263,234,263,234,269,248,1,RO-disease_has_primary_anatomic_site,902437,C]  Specific recommendation: ? Consider referral to a rheumatologist for diagnostic consultation for CPPD disease/pseudogout in patients with: ? Inflammatory arthritis ? Osteoarthritis that appears to have an inflammatory component ? Osteoarthritis that involves joints that are not usually affected by osteoarthritis ? Consider referral to other specialists for patients with signs and symptoms of other underlying diseases such as: ? Hemochromatosis ? Hyperparathyroidism ? Acromegaly ? See module  Osteoarthritis,joints,Osteoarthritis
502844750,7/13/2014 22:16:20,,1322202650,7/13/2014 22:15:51,instagc,1,23149109,USA,NC,Durham,75.189.206.205,263,234,,,269,248,JOINTS,OSTEOARTHRITIS,Osteoarthritis that involves JOINTS,234-249-263-254,234-249-254-263,OSTEOARTHRITIS that involves joints,C]  Specific recommendation: ? Consider referral to a rheumatologist for diagnostic consultation for CPPD disease/pseudogout in patients with: ? Inflammatory arthritis ? Osteoarthritis that appears to have an inflammatory component ? Osteoarthritis that involves joints that are not usually affected by osteoarthritis ? Consider referral to other specialists for patients with signs and symptoms of other underlying diseases such as: ? Hemochromatosis ? Hyperparathyroidism ? Acromegaly ? See module  Osteoarthritis.,263,234,263,234,269,248,1,RO-disease_has_primary_anatomic_site,902437,C]  Specific recommendation: ? Consider referral to a rheumatologist for diagnostic consultation for CPPD disease/pseudogout in patients with: ? Inflammatory arthritis ? Osteoarthritis that appears to have an inflammatory component ? Osteoarthritis that involves joints that are not usually affected by osteoarthritis ? Consider referral to other specialists for patients with signs and symptoms of other underlying diseases such as: ? Hemochromatosis ? Hyperparathyroidism ? Acromegaly ? See module  Osteoarthritis,joints,Osteoarthritis
502844750,7/13/2014 22:20:00,,1322205859,7/13/2014 22:19:45,clixsense,1,10842668,GBR,,,80.189.187.36,263,234,,,269,248,JOINTS,OSTEOARTHRITIS,Osteoarthritis JOINTS,234-263,234,OSTEOARTHRITIS,C]  Specific recommendation: ? Consider referral to a rheumatologist for diagnostic consultation for CPPD disease/pseudogout in patients with: ? Inflammatory arthritis ? Osteoarthritis that appears to have an inflammatory component ? Osteoarthritis that involves joints that are not usually affected by osteoarthritis ? Consider referral to other specialists for patients with signs and symptoms of other underlying diseases such as: ? Hemochromatosis ? Hyperparathyroidism ? Acromegaly ? See module  Osteoarthritis.,263,234,263,234,269,248,1,RO-disease_has_primary_anatomic_site,902437,C]  Specific recommendation: ? Consider referral to a rheumatologist for diagnostic consultation for CPPD disease/pseudogout in patients with: ? Inflammatory arthritis ? Osteoarthritis that appears to have an inflammatory component ? Osteoarthritis that involves joints that are not usually affected by osteoarthritis ? Consider referral to other specialists for patients with signs and symptoms of other underlying diseases such as: ? Hemochromatosis ? Hyperparathyroidism ? Acromegaly ? See module  Osteoarthritis,joints,Osteoarthritis
502844750,7/13/2014 22:23:24,,1322208742,7/13/2014 22:22:02,clixsense,1,21875134,GBR,,,91.125.61.83,263,234,,,269,248,JOINTS,OSTEOARTHRITIS,Osteoarthritis that involves JOINTS that are not usually affected by osteoarthritis,234-249-254-263-270-275-279-283-291-300-303,234,OSTEOARTHRITIS,C]  Specific recommendation: ? Consider referral to a rheumatologist for diagnostic consultation for CPPD disease/pseudogout in patients with: ? Inflammatory arthritis ? Osteoarthritis that appears to have an inflammatory component ? Osteoarthritis that involves joints that are not usually affected by osteoarthritis ? Consider referral to other specialists for patients with signs and symptoms of other underlying diseases such as: ? Hemochromatosis ? Hyperparathyroidism ? Acromegaly ? See module  Osteoarthritis.,263,234,263,234,269,248,1,RO-disease_has_primary_anatomic_site,902437,C]  Specific recommendation: ? Consider referral to a rheumatologist for diagnostic consultation for CPPD disease/pseudogout in patients with: ? Inflammatory arthritis ? Osteoarthritis that appears to have an inflammatory component ? Osteoarthritis that involves joints that are not usually affected by osteoarthritis ? Consider referral to other specialists for patients with signs and symptoms of other underlying diseases such as: ? Hemochromatosis ? Hyperparathyroidism ? Acromegaly ? See module  Osteoarthritis,joints,Osteoarthritis
502844751,7/13/2014 21:54:16,,1322183707,7/13/2014 21:53:53,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,205,251,,,221,258,BIPOLAR DISORDER,LITHIUM,BIPOLAR DISORDER,205-213,251,"LITHIUM,","30  Efficacy in the acute treatment of mood episodes has yet to be fully established,  31   but is considered a first-line agent by the APA for the management of acute depressive episodes in patients with bipolar disorder   +    and an alternative to lithium, valproic acid, or divalproex in the management of patients with rapid cycling bipolar disorder   +   , particularly in those with the bipolar 2 form of rapid cycling.",205 213,251,205,251,221,258,1,RO-may_treat,907591,"30  Efficacy in the acute treatment of mood episodes has yet to be fully established,  31   but is considered a first-line agent by the APA for the management of acute depressive episodes in patients with bipolar disorder   +    and an alternative to lithium, valproic acid, or divalproex in the management of patients with rapid cycling bipolar disorder   +   , particularly in those with the bipolar 2 form of rapid cycling",bipolar disorder,lithium
502844751,7/13/2014 21:57:47,,1322186907,7/13/2014 21:57:32,instagc,1,28301350,GBR,K4,Plymouth,89.242.63.62,205,251,,,221,258,BIPOLAR DISORDER,LITHIUM,BIPOLAR DISORDER,205-213,205-213-251,"bipolar disorder LITHIUM,","30  Efficacy in the acute treatment of mood episodes has yet to be fully established,  31   but is considered a first-line agent by the APA for the management of acute depressive episodes in patients with bipolar disorder   +    and an alternative to lithium, valproic acid, or divalproex in the management of patients with rapid cycling bipolar disorder   +   , particularly in those with the bipolar 2 form of rapid cycling.",205 213,251,205,251,221,258,1,RO-may_treat,907591,"30  Efficacy in the acute treatment of mood episodes has yet to be fully established,  31   but is considered a first-line agent by the APA for the management of acute depressive episodes in patients with bipolar disorder   +    and an alternative to lithium, valproic acid, or divalproex in the management of patients with rapid cycling bipolar disorder   +   , particularly in those with the bipolar 2 form of rapid cycling",bipolar disorder,lithium
502844751,7/13/2014 21:59:09,,1322188121,7/13/2014 21:58:50,elite,1,28503042,USA,OK,Oakwood,64.250.220.169,205,251,,,221,258,BIPOLAR DISORDER,LITHIUM,BIPOLAR DISORDER,205-213,236-248-251,"alternative to LITHIUM,","30  Efficacy in the acute treatment of mood episodes has yet to be fully established,  31   but is considered a first-line agent by the APA for the management of acute depressive episodes in patients with bipolar disorder   +    and an alternative to lithium, valproic acid, or divalproex in the management of patients with rapid cycling bipolar disorder   +   , particularly in those with the bipolar 2 form of rapid cycling.",205 213,251,205,251,221,258,1,RO-may_treat,907591,"30  Efficacy in the acute treatment of mood episodes has yet to be fully established,  31   but is considered a first-line agent by the APA for the management of acute depressive episodes in patients with bipolar disorder   +    and an alternative to lithium, valproic acid, or divalproex in the management of patients with rapid cycling bipolar disorder   +   , particularly in those with the bipolar 2 form of rapid cycling",bipolar disorder,lithium
502844751,7/13/2014 22:00:10,,1322189197,7/13/2014 21:59:46,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,205,251,,,221,258,BIPOLAR DISORDER,LITHIUM,BIPOLAR DISORDER,205-213,251,"LITHIUM,","30  Efficacy in the acute treatment of mood episodes has yet to be fully established,  31   but is considered a first-line agent by the APA for the management of acute depressive episodes in patients with bipolar disorder   +    and an alternative to lithium, valproic acid, or divalproex in the management of patients with rapid cycling bipolar disorder   +   , particularly in those with the bipolar 2 form of rapid cycling.",205 213,251,205,251,221,258,1,RO-may_treat,907591,"30  Efficacy in the acute treatment of mood episodes has yet to be fully established,  31   but is considered a first-line agent by the APA for the management of acute depressive episodes in patients with bipolar disorder   +    and an alternative to lithium, valproic acid, or divalproex in the management of patients with rapid cycling bipolar disorder   +   , particularly in those with the bipolar 2 form of rapid cycling",bipolar disorder,lithium
502844751,7/13/2014 22:00:13,,1322189254,7/13/2014 21:59:53,elite,1,28397222,GBR,,,31.49.231.211,205,251,,,221,258,BIPOLAR DISORDER,LITHIUM,BIPOLAR DISORDER,205-213,251,"LITHIUM,","30  Efficacy in the acute treatment of mood episodes has yet to be fully established,  31   but is considered a first-line agent by the APA for the management of acute depressive episodes in patients with bipolar disorder   +    and an alternative to lithium, valproic acid, or divalproex in the management of patients with rapid cycling bipolar disorder   +   , particularly in those with the bipolar 2 form of rapid cycling.",205 213,251,205,251,221,258,1,RO-may_treat,907591,"30  Efficacy in the acute treatment of mood episodes has yet to be fully established,  31   but is considered a first-line agent by the APA for the management of acute depressive episodes in patients with bipolar disorder   +    and an alternative to lithium, valproic acid, or divalproex in the management of patients with rapid cycling bipolar disorder   +   , particularly in those with the bipolar 2 form of rapid cycling",bipolar disorder,lithium
502844751,7/13/2014 22:01:02,,1322190231,7/13/2014 22:00:53,clixsense,1,25402344,CAN,ON,Wawa,24.109.124.45,205,251,,,221,258,BIPOLAR DISORDER,LITHIUM,in patients with BIPOLAR DISORDER and an alternative,188-191-200-205-213-229-233-236,233-236-248-251-260-269-275,"an alternative to LITHIUM, valproic acid, or","30  Efficacy in the acute treatment of mood episodes has yet to be fully established,  31   but is considered a first-line agent by the APA for the management of acute depressive episodes in patients with bipolar disorder   +    and an alternative to lithium, valproic acid, or divalproex in the management of patients with rapid cycling bipolar disorder   +   , particularly in those with the bipolar 2 form of rapid cycling.",205 213,251,205,251,221,258,1,RO-may_treat,907591,"30  Efficacy in the acute treatment of mood episodes has yet to be fully established,  31   but is considered a first-line agent by the APA for the management of acute depressive episodes in patients with bipolar disorder   +    and an alternative to lithium, valproic acid, or divalproex in the management of patients with rapid cycling bipolar disorder   +   , particularly in those with the bipolar 2 form of rapid cycling",bipolar disorder,lithium
502844751,7/13/2014 22:01:26,,1322190588,7/13/2014 22:00:39,clixsense,1,8769423,AUS,6,Hobart,147.69.162.116,205,251,,,221,258,BIPOLAR DISORDER,LITHIUM,BIPOLAR DISORDER,205-213,251,"LITHIUM,","30  Efficacy in the acute treatment of mood episodes has yet to be fully established,  31   but is considered a first-line agent by the APA for the management of acute depressive episodes in patients with bipolar disorder   +    and an alternative to lithium, valproic acid, or divalproex in the management of patients with rapid cycling bipolar disorder   +   , particularly in those with the bipolar 2 form of rapid cycling.",205 213,251,205,251,221,258,1,RO-may_treat,907591,"30  Efficacy in the acute treatment of mood episodes has yet to be fully established,  31   but is considered a first-line agent by the APA for the management of acute depressive episodes in patients with bipolar disorder   +    and an alternative to lithium, valproic acid, or divalproex in the management of patients with rapid cycling bipolar disorder   +   , particularly in those with the bipolar 2 form of rapid cycling",bipolar disorder,lithium
502844751,7/13/2014 22:07:31,,1322195438,7/13/2014 22:07:14,bitcoinget,1,24792414,USA,IA,Independence,166.181.80.204,205,251,,,221,258,BIPOLAR DISORDER,LITHIUM,BIPOLAR DISORDER,205-213,251,"LITHIUM,","30  Efficacy in the acute treatment of mood episodes has yet to be fully established,  31   but is considered a first-line agent by the APA for the management of acute depressive episodes in patients with bipolar disorder   +    and an alternative to lithium, valproic acid, or divalproex in the management of patients with rapid cycling bipolar disorder   +   , particularly in those with the bipolar 2 form of rapid cycling.",205 213,251,205,251,221,258,1,RO-may_treat,907591,"30  Efficacy in the acute treatment of mood episodes has yet to be fully established,  31   but is considered a first-line agent by the APA for the management of acute depressive episodes in patients with bipolar disorder   +    and an alternative to lithium, valproic acid, or divalproex in the management of patients with rapid cycling bipolar disorder   +   , particularly in those with the bipolar 2 form of rapid cycling",bipolar disorder,lithium
502844751,7/13/2014 22:10:08,,1322197470,7/13/2014 22:09:42,prodege,1,17932518,GBR,Y2,Pwllheli,95.151.166.224,205,251,,,221,258,BIPOLAR DISORDER,LITHIUM,BIPOLAR DISORDER,205-213,251,"LITHIUM,","30  Efficacy in the acute treatment of mood episodes has yet to be fully established,  31   but is considered a first-line agent by the APA for the management of acute depressive episodes in patients with bipolar disorder   +    and an alternative to lithium, valproic acid, or divalproex in the management of patients with rapid cycling bipolar disorder   +   , particularly in those with the bipolar 2 form of rapid cycling.",205 213,251,205,251,221,258,1,RO-may_treat,907591,"30  Efficacy in the acute treatment of mood episodes has yet to be fully established,  31   but is considered a first-line agent by the APA for the management of acute depressive episodes in patients with bipolar disorder   +    and an alternative to lithium, valproic acid, or divalproex in the management of patients with rapid cycling bipolar disorder   +   , particularly in those with the bipolar 2 form of rapid cycling",bipolar disorder,lithium
502844751,7/13/2014 22:12:53,,1322199913,7/13/2014 22:12:25,instagc,1,23149109,USA,NC,Durham,75.189.206.205,205,251,,,221,258,BIPOLAR DISORDER,LITHIUM,BIPOLAR DISORDER,205-213,251-260-269,"LITHIUM, valproic acid,","30  Efficacy in the acute treatment of mood episodes has yet to be fully established,  31   but is considered a first-line agent by the APA for the management of acute depressive episodes in patients with bipolar disorder   +    and an alternative to lithium, valproic acid, or divalproex in the management of patients with rapid cycling bipolar disorder   +   , particularly in those with the bipolar 2 form of rapid cycling.",205 213,251,205,251,221,258,1,RO-may_treat,907591,"30  Efficacy in the acute treatment of mood episodes has yet to be fully established,  31   but is considered a first-line agent by the APA for the management of acute depressive episodes in patients with bipolar disorder   +    and an alternative to lithium, valproic acid, or divalproex in the management of patients with rapid cycling bipolar disorder   +   , particularly in those with the bipolar 2 form of rapid cycling",bipolar disorder,lithium
502844752,7/13/2014 21:52:19,,1322181921,7/13/2014 21:51:51,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,144,175,,,148,186,HEAT,HEAT STROKE,HEAT,144,175-180,HEAT STROKE.,"Heat stress arising from the thermal environment is of concern to sports medicine and to sports administration because of the perceived risk of heat casualties, in particular heat stroke.",144,175 180,144,175,148,186,-1,RO-has_causative_agent,903691,"Heat stress arising from the thermal environment is of concern to sports medicine and to sports administration because of the perceived risk of heat casualties, in particular heat stroke",heat,heat stroke
502844752,7/13/2014 21:53:42,,1322183204,7/13/2014 21:53:34,clixsense,1,24763049,GBR,,,86.133.47.213,144,175,,,148,186,HEAT,HEAT STROKE,"perceived risk of HEAT casualties, in particular",126-136-141-144-149-161-164,149-161-164-175-180,"casualties, in particular HEAT STROKE.","Heat stress arising from the thermal environment is of concern to sports medicine and to sports administration because of the perceived risk of heat casualties, in particular heat stroke.",144,175 180,144,175,148,186,-1,RO-has_causative_agent,903691,"Heat stress arising from the thermal environment is of concern to sports medicine and to sports administration because of the perceived risk of heat casualties, in particular heat stroke",heat,heat stroke
502844752,7/13/2014 21:55:50,,1322185058,7/13/2014 21:55:19,elite,1,28397222,GBR,,,31.49.231.211,144,175,,,148,186,HEAT,HEAT STROKE,HEAT stroke.,144-180,175-180,HEAT STROKE.,"Heat stress arising from the thermal environment is of concern to sports medicine and to sports administration because of the perceived risk of heat casualties, in particular heat stroke.",144,175 180,144,175,148,186,-1,RO-has_causative_agent,903691,"Heat stress arising from the thermal environment is of concern to sports medicine and to sports administration because of the perceived risk of heat casualties, in particular heat stroke",heat,heat stroke
502844752,7/13/2014 21:57:50,,1322186997,7/13/2014 21:57:35,elite,1,28503042,USA,OK,Oakwood,64.250.220.169,144,175,,,148,186,HEAT,HEAT STROKE,"HEAT casualties,",144-149,175-180,HEAT STROKE.,"Heat stress arising from the thermal environment is of concern to sports medicine and to sports administration because of the perceived risk of heat casualties, in particular heat stroke.",144,175 180,144,175,148,186,-1,RO-has_causative_agent,903691,"Heat stress arising from the thermal environment is of concern to sports medicine and to sports administration because of the perceived risk of heat casualties, in particular heat stroke",heat,heat stroke
502844752,7/13/2014 22:03:26,,1322192198,7/13/2014 22:03:14,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,144,175,,,148,186,HEAT,HEAT STROKE,"HEAT casualties,",144-149,175-180,HEAT STROKE.,"Heat stress arising from the thermal environment is of concern to sports medicine and to sports administration because of the perceived risk of heat casualties, in particular heat stroke.",144,175 180,144,175,148,186,-1,RO-has_causative_agent,903691,"Heat stress arising from the thermal environment is of concern to sports medicine and to sports administration because of the perceived risk of heat casualties, in particular heat stroke",heat,heat stroke
502844752,7/13/2014 22:13:47,,1322200570,7/13/2014 22:13:23,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,144,175,,,148,186,HEAT,HEAT STROKE,"thermal environment perceived risk of HEAT casualties, in particular heat stroke.",29-37-126-136-141-144-149-161-164-175-180,29-37-126-136-141-149-161-164-175-180-144,"thermal environment perceived risk of heat casualties, in particular HEAT STROKE.","Heat stress arising from the thermal environment is of concern to sports medicine and to sports administration because of the perceived risk of heat casualties, in particular heat stroke.",144,175 180,144,175,148,186,-1,RO-has_causative_agent,903691,"Heat stress arising from the thermal environment is of concern to sports medicine and to sports administration because of the perceived risk of heat casualties, in particular heat stroke",heat,heat stroke
502844752,7/13/2014 22:18:10,,1322204100,7/13/2014 22:17:54,gifthulk,1,22552178,AUS,5,Adelaide,14.2.7.227,144,175,,,148,186,HEAT,HEAT STROKE,HEAT,144,175-180,HEAT STROKE.,"Heat stress arising from the thermal environment is of concern to sports medicine and to sports administration because of the perceived risk of heat casualties, in particular heat stroke.",144,175 180,144,175,148,186,-1,RO-has_causative_agent,903691,"Heat stress arising from the thermal environment is of concern to sports medicine and to sports administration because of the perceived risk of heat casualties, in particular heat stroke",heat,heat stroke
502844752,7/13/2014 22:21:42,,1322207289,7/13/2014 22:21:16,prodege,1,17932518,GBR,Y2,Pwllheli,95.151.166.224,144,175,,,148,186,HEAT,HEAT STROKE,HEAT,144,175-180,HEAT STROKE.,"Heat stress arising from the thermal environment is of concern to sports medicine and to sports administration because of the perceived risk of heat casualties, in particular heat stroke.",144,175 180,144,175,148,186,-1,RO-has_causative_agent,903691,"Heat stress arising from the thermal environment is of concern to sports medicine and to sports administration because of the perceived risk of heat casualties, in particular heat stroke",heat,heat stroke
502844752,7/13/2014 22:23:16,,1322208586,7/13/2014 22:22:57,instagc,1,23149109,USA,NC,Durham,75.189.206.205,144,175,,,148,186,HEAT,HEAT STROKE,"risk of HEAT casualties,",136-141-144-149,164-175-180,particular HEAT STROKE.,"Heat stress arising from the thermal environment is of concern to sports medicine and to sports administration because of the perceived risk of heat casualties, in particular heat stroke.",144,175 180,144,175,148,186,-1,RO-has_causative_agent,903691,"Heat stress arising from the thermal environment is of concern to sports medicine and to sports administration because of the perceived risk of heat casualties, in particular heat stroke",heat,heat stroke
502844752,7/13/2014 22:23:49,,1322209059,7/13/2014 22:23:35,clixsense,1,10842668,GBR,,,80.189.187.36,144,175,,,148,186,HEAT,HEAT STROKE,HEAT,144,175-180,HEAT STROKE.,"Heat stress arising from the thermal environment is of concern to sports medicine and to sports administration because of the perceived risk of heat casualties, in particular heat stroke.",144,175 180,144,175,148,186,-1,RO-has_causative_agent,903691,"Heat stress arising from the thermal environment is of concern to sports medicine and to sports administration because of the perceived risk of heat casualties, in particular heat stroke",heat,heat stroke
502844753,7/13/2014 21:51:28,,1322181354,7/13/2014 21:51:10,instagc,1,28301350,GBR,K4,Plymouth,89.242.63.62,82,147,,,90,159,VOMITING,PROMETHAZINE,uncomplicated nausea and VOMITING,57-71-78-82,57-71-78-82-147,uncomplicated nausea and vomiting PROMETHAZINE,"Prochlorperazine was more effective than promethazine in uncomplicated nausea and vomiting in the emergency department  Keywords: Prochlorperazine Promethazine Treatment, emergency.",82,147,82,147,90,159,1,RO-may_treat,907661,"Prochlorperazine was more effective than promethazine in uncomplicated nausea and vomiting in the emergency department  Keywords: Prochlorperazine Promethazine Treatment, emergency",vomiting,Promethazine
502844753,7/13/2014 21:54:04,,1322183563,7/13/2014 21:53:39,clixsense,1,25402344,CAN,ON,Wawa,24.109.124.45,82,147,,,90,159,VOMITING,PROMETHAZINE,uncomplicated nausea and VOMITING,57-71-78-82,147,PROMETHAZINE,"Prochlorperazine was more effective than promethazine in uncomplicated nausea and vomiting in the emergency department  Keywords: Prochlorperazine Promethazine Treatment, emergency.",82,147,82,147,90,159,1,RO-may_treat,907661,"Prochlorperazine was more effective than promethazine in uncomplicated nausea and vomiting in the emergency department  Keywords: Prochlorperazine Promethazine Treatment, emergency",vomiting,Promethazine
502844753,7/13/2014 21:56:49,,1322186060,7/13/2014 21:56:37,elite,1,28503042,USA,OK,Oakwood,64.250.220.169,82,147,,,90,159,VOMITING,PROMETHAZINE,VOMITING,82,130-147-160,"Prochlorperazine PROMETHAZINE Treatment,","Prochlorperazine was more effective than promethazine in uncomplicated nausea and vomiting in the emergency department  Keywords: Prochlorperazine Promethazine Treatment, emergency.",82,147,82,147,90,159,1,RO-may_treat,907661,"Prochlorperazine was more effective than promethazine in uncomplicated nausea and vomiting in the emergency department  Keywords: Prochlorperazine Promethazine Treatment, emergency",vomiting,Promethazine
502844753,7/13/2014 22:03:09,,1322191986,7/13/2014 22:02:40,bitcoinget,1,24792414,USA,IA,Independence,166.181.80.204,82,147,,,90,159,VOMITING,PROMETHAZINE,VOMITING,82,147-160-130,"Prochlorperazine PROMETHAZINE Treatment,","Prochlorperazine was more effective than promethazine in uncomplicated nausea and vomiting in the emergency department  Keywords: Prochlorperazine Promethazine Treatment, emergency.",82,147,82,147,90,159,1,RO-may_treat,907661,"Prochlorperazine was more effective than promethazine in uncomplicated nausea and vomiting in the emergency department  Keywords: Prochlorperazine Promethazine Treatment, emergency",vomiting,Promethazine
502844753,7/13/2014 22:04:09,,1322192760,7/13/2014 22:03:26,clixsense,1,15189335,GBR,K3,Peterborough,81.156.166.189,82,147,,,90,159,VOMITING,PROMETHAZINE,VOMITING,82,147,PROMETHAZINE,"Prochlorperazine was more effective than promethazine in uncomplicated nausea and vomiting in the emergency department  Keywords: Prochlorperazine Promethazine Treatment, emergency.",82,147,82,147,90,159,1,RO-may_treat,907661,"Prochlorperazine was more effective than promethazine in uncomplicated nausea and vomiting in the emergency department  Keywords: Prochlorperazine Promethazine Treatment, emergency",vomiting,Promethazine
502844753,7/13/2014 22:05:44,,1322193996,7/13/2014 22:05:40,clixsense,1,24763049,GBR,,,86.133.47.213,82,147,,,90,159,VOMITING,PROMETHAZINE,uncomplicated nausea and VOMITING in the emergency,57-71-78-82-91-94-98,108-120-130-147-160-171,"department Keywords: Prochlorperazine PROMETHAZINE Treatment, emergency.","Prochlorperazine was more effective than promethazine in uncomplicated nausea and vomiting in the emergency department  Keywords: Prochlorperazine Promethazine Treatment, emergency.",82,147,82,147,90,159,1,RO-may_treat,907661,"Prochlorperazine was more effective than promethazine in uncomplicated nausea and vomiting in the emergency department  Keywords: Prochlorperazine Promethazine Treatment, emergency",vomiting,Promethazine
502844753,7/13/2014 22:06:11,,1322194422,7/13/2014 22:05:50,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,82,147,,,90,159,VOMITING,PROMETHAZINE,VOMITING,82,147,PROMETHAZINE,"Prochlorperazine was more effective than promethazine in uncomplicated nausea and vomiting in the emergency department  Keywords: Prochlorperazine Promethazine Treatment, emergency.",82,147,82,147,90,159,1,RO-may_treat,907661,"Prochlorperazine was more effective than promethazine in uncomplicated nausea and vomiting in the emergency department  Keywords: Prochlorperazine Promethazine Treatment, emergency",vomiting,Promethazine
502844753,7/13/2014 22:06:41,,1322194841,7/13/2014 22:06:05,clixsense,1,8769423,AUS,6,Hobart,147.69.162.116,82,147,,,90,159,VOMITING,PROMETHAZINE,VOMITING,82,147,PROMETHAZINE,"Prochlorperazine was more effective than promethazine in uncomplicated nausea and vomiting in the emergency department  Keywords: Prochlorperazine Promethazine Treatment, emergency.",82,147,82,147,90,159,1,RO-may_treat,907661,"Prochlorperazine was more effective than promethazine in uncomplicated nausea and vomiting in the emergency department  Keywords: Prochlorperazine Promethazine Treatment, emergency",vomiting,Promethazine
502844753,7/13/2014 22:15:02,,1322201600,7/13/2014 22:14:23,prodege,1,17932518,GBR,Y2,Pwllheli,95.151.166.224,82,147,,,90,159,VOMITING,PROMETHAZINE,VOMITING,82,147,PROMETHAZINE,"Prochlorperazine was more effective than promethazine in uncomplicated nausea and vomiting in the emergency department  Keywords: Prochlorperazine Promethazine Treatment, emergency.",82,147,82,147,90,159,1,RO-may_treat,907661,"Prochlorperazine was more effective than promethazine in uncomplicated nausea and vomiting in the emergency department  Keywords: Prochlorperazine Promethazine Treatment, emergency",vomiting,Promethazine
502844753,7/13/2014 22:22:33,,1322207969,7/13/2014 22:21:57,clixsense,1,26889820,GBR,C3,Shelford,92.18.120.203,82,147,,,90,159,VOMITING,PROMETHAZINE,VOMITING,82,147,PROMETHAZINE,"Prochlorperazine was more effective than promethazine in uncomplicated nausea and vomiting in the emergency department  Keywords: Prochlorperazine Promethazine Treatment, emergency.",82,147,82,147,90,159,1,RO-may_treat,907661,"Prochlorperazine was more effective than promethazine in uncomplicated nausea and vomiting in the emergency department  Keywords: Prochlorperazine Promethazine Treatment, emergency",vomiting,Promethazine
502844754,7/13/2014 21:49:52,,1322180081,7/13/2014 21:48:06,clixsense,1,25402344,CAN,ON,Wawa,24.109.124.45,78,37,,,94,47,MULTIPLE MYELOMA,INTERFERON,naturl killer activity in MULTIPLE MYELOMA.,52-59-66-78-87-75,28-30-33-37,H et al. INTERFERON,"Einhorn S, Ahre A, Blomgren H et al. Interferon and naturl killer activity in multiple myeloma.",78 87,37,78,37,94,47,1,RO-may_treat,907872,"Einhorn S, Ahre A, Blomgren H et al. Interferon and naturl killer activity in multiple myeloma",multiple myeloma,Interferon
502844754,7/13/2014 21:49:52,,1322180082,7/13/2014 21:48:09,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,78,37,,,94,47,MULTIPLE MYELOMA,INTERFERON,MULTIPLE MYELOMA.,78-87,37,INTERFERON,"Einhorn S, Ahre A, Blomgren H et al. Interferon and naturl killer activity in multiple myeloma.",78 87,37,78,37,94,47,1,RO-may_treat,907872,"Einhorn S, Ahre A, Blomgren H et al. Interferon and naturl killer activity in multiple myeloma",multiple myeloma,Interferon
502844754,7/13/2014 21:54:06,,1322183596,7/13/2014 21:52:59,clixsense,1,15189335,GBR,K3,Peterborough,81.156.166.189,78,37,,,94,47,MULTIPLE MYELOMA,INTERFERON,MULTIPLE MYELOMA.,78-87,37,INTERFERON,"Einhorn S, Ahre A, Blomgren H et al. Interferon and naturl killer activity in multiple myeloma.",78 87,37,78,37,94,47,1,RO-may_treat,907872,"Einhorn S, Ahre A, Blomgren H et al. Interferon and naturl killer activity in multiple myeloma",multiple myeloma,Interferon
502844754,7/13/2014 21:54:29,,1322183843,7/13/2014 21:54:16,instagc,1,28301350,GBR,K4,Plymouth,89.242.63.62,78,37,,,94,47,MULTIPLE MYELOMA,INTERFERON,MULTIPLE MYELOMA.,78-87,37-78-87,INTERFERON multiple myeloma.,"Einhorn S, Ahre A, Blomgren H et al. Interferon and naturl killer activity in multiple myeloma.",78 87,37,78,37,94,47,1,RO-may_treat,907872,"Einhorn S, Ahre A, Blomgren H et al. Interferon and naturl killer activity in multiple myeloma",multiple myeloma,Interferon
502844754,7/13/2014 21:55:26,,1322184757,7/13/2014 21:55:16,elite,1,28503042,USA,OK,Oakwood,64.250.220.169,78,37,,,94,47,MULTIPLE MYELOMA,INTERFERON,MULTIPLE MYELOMA.,78-87,37,INTERFERON,"Einhorn S, Ahre A, Blomgren H et al. Interferon and naturl killer activity in multiple myeloma.",78 87,37,78,37,94,47,1,RO-may_treat,907872,"Einhorn S, Ahre A, Blomgren H et al. Interferon and naturl killer activity in multiple myeloma",multiple myeloma,Interferon
502844754,7/13/2014 21:57:38,,1322186789,7/13/2014 21:57:20,elite,1,28397222,GBR,,,31.49.231.211,78,37,,,94,47,MULTIPLE MYELOMA,INTERFERON,MULTIPLE MYELOMA.,78-87,37,INTERFERON,"Einhorn S, Ahre A, Blomgren H et al. Interferon and naturl killer activity in multiple myeloma.",78 87,37,78,37,94,47,1,RO-may_treat,907872,"Einhorn S, Ahre A, Blomgren H et al. Interferon and naturl killer activity in multiple myeloma",multiple myeloma,Interferon
502844754,7/13/2014 21:58:22,,1322187434,7/13/2014 21:58:03,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,78,37,,,94,47,MULTIPLE MYELOMA,INTERFERON,MULTIPLE MYELOMA.,78-87,37,INTERFERON,"Einhorn S, Ahre A, Blomgren H et al. Interferon and naturl killer activity in multiple myeloma.",78 87,37,78,37,94,47,1,RO-may_treat,907872,"Einhorn S, Ahre A, Blomgren H et al. Interferon and naturl killer activity in multiple myeloma",multiple myeloma,Interferon
502844754,7/13/2014 21:58:23,,1322187469,7/13/2014 21:58:07,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,78,37,,,94,47,MULTIPLE MYELOMA,INTERFERON,MULTIPLE MYELOMA.,78-87,37,INTERFERON,"Einhorn S, Ahre A, Blomgren H et al. Interferon and naturl killer activity in multiple myeloma.",78 87,37,78,37,94,47,1,RO-may_treat,907872,"Einhorn S, Ahre A, Blomgren H et al. Interferon and naturl killer activity in multiple myeloma",multiple myeloma,Interferon
502844754,7/13/2014 22:10:13,,1322197561,7/13/2014 22:10:08,clixsense,1,24763049,GBR,,,86.133.47.213,78,37,,,94,47,MULTIPLE MYELOMA,INTERFERON,killer activity in MULTIPLE MYELOMA.,59-66-75-78-87,28-30-33-37-48-52-59,H et al. INTERFERON and naturl killer,"Einhorn S, Ahre A, Blomgren H et al. Interferon and naturl killer activity in multiple myeloma.",78 87,37,78,37,94,47,1,RO-may_treat,907872,"Einhorn S, Ahre A, Blomgren H et al. Interferon and naturl killer activity in multiple myeloma",multiple myeloma,Interferon
502844754,7/13/2014 22:10:21,,1322197712,7/13/2014 22:09:53,prodege,1,28255346,GBR,L9,Sheffield,2.125.183.137,78,37,,,94,47,MULTIPLE MYELOMA,INTERFERON,MULTIPLE MYELOMA.,78-87,37,INTERFERON,"Einhorn S, Ahre A, Blomgren H et al. Interferon and naturl killer activity in multiple myeloma.",78 87,37,78,37,94,47,1,RO-may_treat,907872,"Einhorn S, Ahre A, Blomgren H et al. Interferon and naturl killer activity in multiple myeloma",multiple myeloma,Interferon
502844755,7/13/2014 21:48:59,,1322179455,7/13/2014 21:47:59,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,141,63,,,148,95,ASCITES,OVARIAN MUCINOUS ADENOCARCINOMAS,"cytology cancer cells ascites ovarian mucinous adenocarcinomas HNF4 alpha positive, tumor cells in ASCITES from other types ovarian carcinomas negative for HNF4 alpha.",3-30-37-50-63-71-80-101-106-112-126-132-138-141-149-154-160-169-177-193-206-211-202,3-30-37-46-50-58-63-71-80-96-101-106-112-126-132-138-141-149-169-177-193-211-206,"cytology cancer cells the ascites from OVARIAN MUCINOUS ADENOCARCINOMAS were HNF4 alpha positive, tumor cells in ascites from ovarian carcinomas negative HNF4 alpha.","On cytology it was found that cancer cells in the ascites from ovarian mucinous adenocarcinomas were HNF4 alpha positive, but tumor cells in ascites from other types of ovarian carcinomas were negative for HNF4 alpha.",141,63 71 80,141,63,148,95,-1,RO-disease_may_have_finding,902909,"On cytology it was found that cancer cells in the ascites from ovarian mucinous adenocarcinomas were HNF4 alpha positive, but tumor cells in ascites from other types of ovarian carcinomas were negative for HNF4 alpha",ascites,ovarian mucinous adenocarcinomas
502844755,7/13/2014 21:50:44,,1322180855,7/13/2014 21:50:15,clixsense,1,15189335,GBR,K3,Peterborough,81.156.166.189,141,63,,,148,95,ASCITES,OVARIAN MUCINOUS ADENOCARCINOMAS,ASCITES,141,63-71-80,OVARIAN MUCINOUS ADENOCARCINOMAS,"On cytology it was found that cancer cells in the ascites from ovarian mucinous adenocarcinomas were HNF4 alpha positive, but tumor cells in ascites from other types of ovarian carcinomas were negative for HNF4 alpha.",141,63 71 80,141,63,148,95,-1,RO-disease_may_have_finding,902909,"On cytology it was found that cancer cells in the ascites from ovarian mucinous adenocarcinomas were HNF4 alpha positive, but tumor cells in ascites from other types of ovarian carcinomas were negative for HNF4 alpha",ascites,ovarian mucinous adenocarcinomas
502844755,7/13/2014 22:02:30,,1322191516,7/13/2014 22:02:00,elite,1,28397222,GBR,,,31.49.231.211,141,63,,,148,95,ASCITES,OVARIAN MUCINOUS ADENOCARCINOMAS,ASCITES,141,63-71-80,OVARIAN MUCINOUS ADENOCARCINOMAS,"On cytology it was found that cancer cells in the ascites from ovarian mucinous adenocarcinomas were HNF4 alpha positive, but tumor cells in ascites from other types of ovarian carcinomas were negative for HNF4 alpha.",141,63 71 80,141,63,148,95,-1,RO-disease_may_have_finding,902909,"On cytology it was found that cancer cells in the ascites from ovarian mucinous adenocarcinomas were HNF4 alpha positive, but tumor cells in ascites from other types of ovarian carcinomas were negative for HNF4 alpha",ascites,ovarian mucinous adenocarcinomas
502844755,7/13/2014 22:05:07,,1322193551,7/13/2014 22:04:54,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,141,63,,,148,95,ASCITES,OVARIAN MUCINOUS ADENOCARCINOMAS,ASCITES,141,63-71-80,OVARIAN MUCINOUS ADENOCARCINOMAS,"On cytology it was found that cancer cells in the ascites from ovarian mucinous adenocarcinomas were HNF4 alpha positive, but tumor cells in ascites from other types of ovarian carcinomas were negative for HNF4 alpha.",141,63 71 80,141,63,148,95,-1,RO-disease_may_have_finding,902909,"On cytology it was found that cancer cells in the ascites from ovarian mucinous adenocarcinomas were HNF4 alpha positive, but tumor cells in ascites from other types of ovarian carcinomas were negative for HNF4 alpha",ascites,ovarian mucinous adenocarcinomas
502844755,7/13/2014 22:22:02,,1322207487,7/13/2014 22:21:44,prodege,1,17932518,GBR,Y2,Pwllheli,95.151.166.224,141,63,,,148,95,ASCITES,OVARIAN MUCINOUS ADENOCARCINOMAS,ASCITES,141,63-71-80,OVARIAN MUCINOUS ADENOCARCINOMAS,"On cytology it was found that cancer cells in the ascites from ovarian mucinous adenocarcinomas were HNF4 alpha positive, but tumor cells in ascites from other types of ovarian carcinomas were negative for HNF4 alpha.",141,63 71 80,141,63,148,95,-1,RO-disease_may_have_finding,902909,"On cytology it was found that cancer cells in the ascites from ovarian mucinous adenocarcinomas were HNF4 alpha positive, but tumor cells in ascites from other types of ovarian carcinomas were negative for HNF4 alpha",ascites,ovarian mucinous adenocarcinomas
502844755,7/13/2014 22:22:11,,1322207628,7/13/2014 22:21:55,gifthulk,1,22552178,AUS,5,Adelaide,14.2.7.227,141,63,,,148,95,ASCITES,OVARIAN MUCINOUS ADENOCARCINOMAS,ASCITES,141,63-71-80,OVARIAN MUCINOUS ADENOCARCINOMAS,"On cytology it was found that cancer cells in the ascites from ovarian mucinous adenocarcinomas were HNF4 alpha positive, but tumor cells in ascites from other types of ovarian carcinomas were negative for HNF4 alpha.",141,63 71 80,141,63,148,95,-1,RO-disease_may_have_finding,902909,"On cytology it was found that cancer cells in the ascites from ovarian mucinous adenocarcinomas were HNF4 alpha positive, but tumor cells in ascites from other types of ovarian carcinomas were negative for HNF4 alpha",ascites,ovarian mucinous adenocarcinomas
502844755,7/13/2014 22:23:33,,1322208866,7/13/2014 22:23:14,clixsense,1,10842668,GBR,,,80.189.187.36,141,63,,,148,95,ASCITES,OVARIAN MUCINOUS ADENOCARCINOMAS,tumor cells ASCITES,126-132-141,46-50-63-71-80-101-106,the ascites OVARIAN MUCINOUS ADENOCARCINOMAS HNF4 alpha,"On cytology it was found that cancer cells in the ascites from ovarian mucinous adenocarcinomas were HNF4 alpha positive, but tumor cells in ascites from other types of ovarian carcinomas were negative for HNF4 alpha.",141,63 71 80,141,63,148,95,-1,RO-disease_may_have_finding,902909,"On cytology it was found that cancer cells in the ascites from ovarian mucinous adenocarcinomas were HNF4 alpha positive, but tumor cells in ascites from other types of ovarian carcinomas were negative for HNF4 alpha",ascites,ovarian mucinous adenocarcinomas
502844755,7/13/2014 22:24:02,,1322209260,7/13/2014 22:23:51,prodege,1,2143114,CAN,BC,Vancouver,24.84.160.12,141,63,,,148,95,ASCITES,OVARIAN MUCINOUS ADENOCARCINOMAS,ASCITES,141,63-71-80,OVARIAN MUCINOUS ADENOCARCINOMAS,"On cytology it was found that cancer cells in the ascites from ovarian mucinous adenocarcinomas were HNF4 alpha positive, but tumor cells in ascites from other types of ovarian carcinomas were negative for HNF4 alpha.",141,63 71 80,141,63,148,95,-1,RO-disease_may_have_finding,902909,"On cytology it was found that cancer cells in the ascites from ovarian mucinous adenocarcinomas were HNF4 alpha positive, but tumor cells in ascites from other types of ovarian carcinomas were negative for HNF4 alpha",ascites,ovarian mucinous adenocarcinomas
502844755,7/13/2014 22:25:56,,1322211141,7/13/2014 22:25:24,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,141,63,,,148,95,ASCITES,OVARIAN MUCINOUS ADENOCARCINOMAS,ASCITES,141,63-71-80,OVARIAN MUCINOUS ADENOCARCINOMAS,"On cytology it was found that cancer cells in the ascites from ovarian mucinous adenocarcinomas were HNF4 alpha positive, but tumor cells in ascites from other types of ovarian carcinomas were negative for HNF4 alpha.",141,63 71 80,141,63,148,95,-1,RO-disease_may_have_finding,902909,"On cytology it was found that cancer cells in the ascites from ovarian mucinous adenocarcinomas were HNF4 alpha positive, but tumor cells in ascites from other types of ovarian carcinomas were negative for HNF4 alpha",ascites,ovarian mucinous adenocarcinomas
502844755,7/13/2014 22:26:51,,1322212090,7/13/2014 22:26:38,clixsense,1,26889820,GBR,C3,Shelford,92.18.120.203,141,63,,,148,95,ASCITES,OVARIAN MUCINOUS ADENOCARCINOMAS,ASCITES,141,63-71-80,OVARIAN MUCINOUS ADENOCARCINOMAS,"On cytology it was found that cancer cells in the ascites from ovarian mucinous adenocarcinomas were HNF4 alpha positive, but tumor cells in ascites from other types of ovarian carcinomas were negative for HNF4 alpha.",141,63 71 80,141,63,148,95,-1,RO-disease_may_have_finding,902909,"On cytology it was found that cancer cells in the ascites from ovarian mucinous adenocarcinomas were HNF4 alpha positive, but tumor cells in ascites from other types of ovarian carcinomas were negative for HNF4 alpha",ascites,ovarian mucinous adenocarcinomas
502844756,7/13/2014 21:53:06,,1322182650,7/13/2014 21:52:35,clixsense,1,25402344,CAN,ON,Wawa,24.109.124.45,77,152,,,89,177,PARKINSONISM,DEMENTIA WITH LEWY BODIES,the onset of PARKINSONISM,64-68-74-77,137-139-149-152-161-166-171-197-206,a diagnosis of DEMENTIA WITH LEWY BODIES Vascular parkinsonism,"Typically, but not invariably, dementia precedes or accompanies the onset of parkinsonism  Three or more major or minor criteria suggest a diagnosis of dementia with Lewy bodies (&gt;75% sensitivity) Vascular parkinsonism  Also known as lower-body parkinsonism.",77,152 161 166 171,77,152,89,177,1,RO-has_manifestation,906069,"Typically, but not invariably, dementia precedes or accompanies the onset of parkinsonism  Three or more major or minor criteria suggest a diagnosis of dementia with Lewy bodies (&gt;75% sensitivity) Vascular parkinsonism  Also known as lower-body parkinsonism",parkinsonism,dementia with Lewy bodies
502844756,7/13/2014 21:59:02,,1322188030,7/13/2014 21:57:47,clixsense,1,20614047,USA,WA,Deer Park,174.32.162.10,77,152,,,89,177,PARKINSONISM,DEMENTIA WITH LEWY BODIES,PARKINSONISM dementia with Lewy bodies,77-152-161-166-171,77-152-161-166-171,parkinsonism DEMENTIA WITH LEWY BODIES,"Typically, but not invariably, dementia precedes or accompanies the onset of parkinsonism  Three or more major or minor criteria suggest a diagnosis of dementia with Lewy bodies (&gt;75% sensitivity) Vascular parkinsonism  Also known as lower-body parkinsonism.",77,152 161 166 171,77,152,89,177,1,RO-has_manifestation,906069,"Typically, but not invariably, dementia precedes or accompanies the onset of parkinsonism  Three or more major or minor criteria suggest a diagnosis of dementia with Lewy bodies (&gt;75% sensitivity) Vascular parkinsonism  Also known as lower-body parkinsonism",parkinsonism,dementia with Lewy bodies
502844756,7/13/2014 22:00:36,,1322189614,7/13/2014 21:59:42,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,77,152,,,89,177,PARKINSONISM,DEMENTIA WITH LEWY BODIES,PARKINSONISM,77,152-161-166-171,DEMENTIA WITH LEWY BODIES,"Typically, but not invariably, dementia precedes or accompanies the onset of parkinsonism  Three or more major or minor criteria suggest a diagnosis of dementia with Lewy bodies (&gt;75% sensitivity) Vascular parkinsonism  Also known as lower-body parkinsonism.",77,152 161 166 171,77,152,89,177,1,RO-has_manifestation,906069,"Typically, but not invariably, dementia precedes or accompanies the onset of parkinsonism  Three or more major or minor criteria suggest a diagnosis of dementia with Lewy bodies (&gt;75% sensitivity) Vascular parkinsonism  Also known as lower-body parkinsonism",parkinsonism,dementia with Lewy bodies
502844756,7/13/2014 22:00:40,,1322189715,7/13/2014 22:00:23,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,77,152,,,89,177,PARKINSONISM,DEMENTIA WITH LEWY BODIES,PARKINSONISM,77,152-161-166-171,DEMENTIA WITH LEWY BODIES,"Typically, but not invariably, dementia precedes or accompanies the onset of parkinsonism  Three or more major or minor criteria suggest a diagnosis of dementia with Lewy bodies (&gt;75% sensitivity) Vascular parkinsonism  Also known as lower-body parkinsonism.",77,152 161 166 171,77,152,89,177,1,RO-has_manifestation,906069,"Typically, but not invariably, dementia precedes or accompanies the onset of parkinsonism  Three or more major or minor criteria suggest a diagnosis of dementia with Lewy bodies (&gt;75% sensitivity) Vascular parkinsonism  Also known as lower-body parkinsonism",parkinsonism,dementia with Lewy bodies
502844756,7/13/2014 22:05:38,,1322193918,7/13/2014 22:05:34,clixsense,1,24763049,GBR,,,86.133.47.213,77,152,,,89,177,PARKINSONISM,DEMENTIA WITH LEWY BODIES,the onset of PARKINSONISM Three or more,64-68-74-77-91-97-100,137-139-149-152-161-166-171-184-197,a diagnosis of DEMENTIA WITH LEWY BODIES sensitivity) Vascular,"Typically, but not invariably, dementia precedes or accompanies the onset of parkinsonism  Three or more major or minor criteria suggest a diagnosis of dementia with Lewy bodies (&gt;75% sensitivity) Vascular parkinsonism  Also known as lower-body parkinsonism.",77,152 161 166 171,77,152,89,177,1,RO-has_manifestation,906069,"Typically, but not invariably, dementia precedes or accompanies the onset of parkinsonism  Three or more major or minor criteria suggest a diagnosis of dementia with Lewy bodies (&gt;75% sensitivity) Vascular parkinsonism  Also known as lower-body parkinsonism",parkinsonism,dementia with Lewy bodies
502844756,7/13/2014 22:05:50,,1322194074,7/13/2014 22:05:24,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,77,152,,,89,177,PARKINSONISM,DEMENTIA WITH LEWY BODIES,PARKINSONISM,77,137-139-149-152-161-166-171-197-206-234-240-245,a diagnosis of DEMENTIA WITH LEWY BODIES Vascular parkinsonism lower body parkinsonism.,"Typically, but not invariably, dementia precedes or accompanies the onset of parkinsonism  Three or more major or minor criteria suggest a diagnosis of dementia with Lewy bodies (&gt;75% sensitivity) Vascular parkinsonism  Also known as lower-body parkinsonism.",77,152 161 166 171,77,152,89,177,1,RO-has_manifestation,906069,"Typically, but not invariably, dementia precedes or accompanies the onset of parkinsonism  Three or more major or minor criteria suggest a diagnosis of dementia with Lewy bodies (&gt;75% sensitivity) Vascular parkinsonism  Also known as lower-body parkinsonism",parkinsonism,dementia with Lewy bodies
502844756,7/13/2014 22:14:02,,1322200776,7/13/2014 22:13:45,instagc,1,23149109,USA,NC,Durham,75.189.206.205,77,152,,,89,177,PARKINSONISM,DEMENTIA WITH LEWY BODIES,PARKINSONISM,77,139-149-152-161-166-171,diagnosis of DEMENTIA WITH LEWY BODIES,"Typically, but not invariably, dementia precedes or accompanies the onset of parkinsonism  Three or more major or minor criteria suggest a diagnosis of dementia with Lewy bodies (&gt;75% sensitivity) Vascular parkinsonism  Also known as lower-body parkinsonism.",77,152 161 166 171,77,152,89,177,1,RO-has_manifestation,906069,"Typically, but not invariably, dementia precedes or accompanies the onset of parkinsonism  Three or more major or minor criteria suggest a diagnosis of dementia with Lewy bodies (&gt;75% sensitivity) Vascular parkinsonism  Also known as lower-body parkinsonism",parkinsonism,dementia with Lewy bodies
502844756,7/13/2014 22:17:04,,1322203269,7/13/2014 22:16:53,clixsense,1,10842668,GBR,,,80.189.187.36,77,152,,,89,177,PARKINSONISM,DEMENTIA WITH LEWY BODIES,PARKINSONISM,77,152-161-166-171,DEMENTIA WITH LEWY BODIES,"Typically, but not invariably, dementia precedes or accompanies the onset of parkinsonism  Three or more major or minor criteria suggest a diagnosis of dementia with Lewy bodies (&gt;75% sensitivity) Vascular parkinsonism  Also known as lower-body parkinsonism.",77,152 161 166 171,77,152,89,177,1,RO-has_manifestation,906069,"Typically, but not invariably, dementia precedes or accompanies the onset of parkinsonism  Three or more major or minor criteria suggest a diagnosis of dementia with Lewy bodies (&gt;75% sensitivity) Vascular parkinsonism  Also known as lower-body parkinsonism",parkinsonism,dementia with Lewy bodies
502844756,7/13/2014 22:18:28,,1322204396,7/13/2014 22:18:00,clixsense,1,8769423,AUS,6,Hobart,147.69.162.116,77,152,,,89,177,PARKINSONISM,DEMENTIA WITH LEWY BODIES,PARKINSONISM,77,152-161-166-171,DEMENTIA WITH LEWY BODIES,"Typically, but not invariably, dementia precedes or accompanies the onset of parkinsonism  Three or more major or minor criteria suggest a diagnosis of dementia with Lewy bodies (&gt;75% sensitivity) Vascular parkinsonism  Also known as lower-body parkinsonism.",77,152 161 166 171,77,152,89,177,1,RO-has_manifestation,906069,"Typically, but not invariably, dementia precedes or accompanies the onset of parkinsonism  Three or more major or minor criteria suggest a diagnosis of dementia with Lewy bodies (&gt;75% sensitivity) Vascular parkinsonism  Also known as lower-body parkinsonism",parkinsonism,dementia with Lewy bodies
502844756,7/13/2014 22:25:10,,1322210458,7/13/2014 22:24:41,clixsense,1,26889820,GBR,C3,Shelford,92.18.120.203,77,152,,,89,177,PARKINSONISM,DEMENTIA WITH LEWY BODIES,PARKINSONISM,77,152-161-166-171,DEMENTIA WITH LEWY BODIES,"Typically, but not invariably, dementia precedes or accompanies the onset of parkinsonism  Three or more major or minor criteria suggest a diagnosis of dementia with Lewy bodies (&gt;75% sensitivity) Vascular parkinsonism  Also known as lower-body parkinsonism.",77,152 161 166 171,77,152,89,177,1,RO-has_manifestation,906069,"Typically, but not invariably, dementia precedes or accompanies the onset of parkinsonism  Three or more major or minor criteria suggest a diagnosis of dementia with Lewy bodies (&gt;75% sensitivity) Vascular parkinsonism  Also known as lower-body parkinsonism",parkinsonism,dementia with Lewy bodies
502844757,7/13/2014 21:52:37,,1322182245,7/13/2014 21:52:18,instagc,1,28301350,GBR,K4,Plymouth,89.242.63.62,85,37,,,90,56,AORTA,DISSECTION OF AORTA,AORTA hemorrhage,85-95,37-48-51-95,DISSECTION OF AORTA hemorrhage,Cjest computerized tomography showed dissection of aorta from ascending to descendig aorta and hemorrhage around ascending aorta.,85,37 48 51,85,37,90,56,1,RO-has_finding_site,905375,Cjest computerized tomography showed dissection of aorta from ascending to descendig aorta and hemorrhage around ascending aorta,aorta,dissection of aorta
502844757,7/13/2014 21:52:46,,1322182356,7/13/2014 21:52:26,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,85,37,,,90,56,AORTA,DISSECTION OF AORTA,AORTA,85,37-48-51,DISSECTION OF AORTA,Cjest computerized tomography showed dissection of aorta from ascending to descendig aorta and hemorrhage around ascending aorta.,85,37 48 51,85,37,90,56,1,RO-has_finding_site,905375,Cjest computerized tomography showed dissection of aorta from ascending to descendig aorta and hemorrhage around ascending aorta,aorta,dissection of aorta
502844757,7/13/2014 21:59:51,,1322188914,7/13/2014 21:59:23,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,85,37,,,90,56,AORTA,DISSECTION OF AORTA,Cjest computerized tomography dissection of aorta ascending to descendig AORTA and hemorrhage around ascending aorta.,0-6-19-37-48-51-62-72-75-85-91-95-106-113-123,6-19-37-48-51-62-72-75-85-91-95-106-113-123,computerized tomography DISSECTION OF AORTA ascending to descendig aorta and hemorrhage around ascending aorta.,Cjest computerized tomography showed dissection of aorta from ascending to descendig aorta and hemorrhage around ascending aorta.,85,37 48 51,85,37,90,56,1,RO-has_finding_site,905375,Cjest computerized tomography showed dissection of aorta from ascending to descendig aorta and hemorrhage around ascending aorta,aorta,dissection of aorta
502844757,7/13/2014 21:59:59,,1322189056,7/13/2014 21:59:18,clixsense,1,15189335,GBR,K3,Peterborough,81.156.166.189,85,37,,,90,56,AORTA,DISSECTION OF AORTA,AORTA,85,37-48-51,DISSECTION OF AORTA,Cjest computerized tomography showed dissection of aorta from ascending to descendig aorta and hemorrhage around ascending aorta.,85,37 48 51,85,37,90,56,1,RO-has_finding_site,905375,Cjest computerized tomography showed dissection of aorta from ascending to descendig aorta and hemorrhage around ascending aorta,aorta,dissection of aorta
502844757,7/13/2014 22:06:44,,1322194883,7/13/2014 22:06:28,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,85,37,,,90,56,AORTA,DISSECTION OF AORTA,AORTA,85,37-48-51,DISSECTION OF AORTA,Cjest computerized tomography showed dissection of aorta from ascending to descendig aorta and hemorrhage around ascending aorta.,85,37 48 51,85,37,90,56,1,RO-has_finding_site,905375,Cjest computerized tomography showed dissection of aorta from ascending to descendig aorta and hemorrhage around ascending aorta,aorta,dissection of aorta
502844757,7/13/2014 22:08:40,,1322196332,7/13/2014 22:08:09,prodege,1,28255346,GBR,L9,Sheffield,2.125.183.137,85,37,,,90,56,AORTA,DISSECTION OF AORTA,ascending to descendig AORTA,72-75-85-62,6-19-30-37-48-51-0,Cjest computerized tomography showed DISSECTION OF AORTA,Cjest computerized tomography showed dissection of aorta from ascending to descendig aorta and hemorrhage around ascending aorta.,85,37 48 51,85,37,90,56,1,RO-has_finding_site,905375,Cjest computerized tomography showed dissection of aorta from ascending to descendig aorta and hemorrhage around ascending aorta,aorta,dissection of aorta
502844757,7/13/2014 22:18:10,,1322204107,7/13/2014 22:17:58,clixsense,1,10842668,GBR,,,80.189.187.36,85,37,,,90,56,AORTA,DISSECTION OF AORTA,AORTA,85,37-48-51,DISSECTION OF AORTA,Cjest computerized tomography showed dissection of aorta from ascending to descendig aorta and hemorrhage around ascending aorta.,85,37 48 51,85,37,90,56,1,RO-has_finding_site,905375,Cjest computerized tomography showed dissection of aorta from ascending to descendig aorta and hemorrhage around ascending aorta,aorta,dissection of aorta
502844757,7/13/2014 22:25:25,,1322210664,7/13/2014 22:25:11,clixsense,1,26889820,GBR,C3,Shelford,92.18.120.203,85,37,,,90,56,AORTA,DISSECTION OF AORTA,AORTA,85,37-48-51,DISSECTION OF AORTA,Cjest computerized tomography showed dissection of aorta from ascending to descendig aorta and hemorrhage around ascending aorta.,85,37 48 51,85,37,90,56,1,RO-has_finding_site,905375,Cjest computerized tomography showed dissection of aorta from ascending to descendig aorta and hemorrhage around ascending aorta,aorta,dissection of aorta
502844757,7/13/2014 22:25:56,,1322211142,7/13/2014 22:25:03,clixsense,1,21875134,GBR,,,91.125.61.83,85,37,,,90,56,AORTA,DISSECTION OF AORTA,AORTA,85,37-48-51,DISSECTION OF AORTA,Cjest computerized tomography showed dissection of aorta from ascending to descendig aorta and hemorrhage around ascending aorta.,85,37 48 51,85,37,90,56,1,RO-has_finding_site,905375,Cjest computerized tomography showed dissection of aorta from ascending to descendig aorta and hemorrhage around ascending aorta,aorta,dissection of aorta
502844757,7/13/2014 22:26:18,,1322211517,7/13/2014 22:26:06,prodege,1,2143114,CAN,BC,Vancouver,24.84.160.12,85,37,,,90,56,AORTA,DISSECTION OF AORTA,descendig AORTA,75-85,37-48-51,DISSECTION OF AORTA,Cjest computerized tomography showed dissection of aorta from ascending to descendig aorta and hemorrhage around ascending aorta.,85,37 48 51,85,37,90,56,1,RO-has_finding_site,905375,Cjest computerized tomography showed dissection of aorta from ascending to descendig aorta and hemorrhage around ascending aorta,aorta,dissection of aorta
502844758,7/13/2014 21:57:18,,1322186483,7/13/2014 21:56:42,elite,1,28397222,GBR,,,31.49.231.211,145,93,,,158,105,IRON OVERLOAD,DEFEROXAMINE,myocardial IRON OVERLOAD,134-145-150,93-106,DEFEROXAMINE (DFO),"Regarding iron chelation treatment, patients receiving combined therapy with deferiprone and deferoxamine (DFO) significantly reduced myocardial iron overload during the 4-yr study period, whilst patients in monotherapy with DFO showed a significant increase in LIC.",145 150,93,145,93,158,105,1,RO-may_prevent,907233,"Regarding iron chelation treatment, patients receiving combined therapy with deferiprone and deferoxamine (DFO) significantly reduced myocardial iron overload during the 4-yr study period, whilst patients in monotherapy with DFO showed a significant increase in LIC",iron overload,deferoxamine
502844758,7/13/2014 21:58:50,,1322187826,7/13/2014 21:58:24,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,145,93,,,158,105,IRON OVERLOAD,DEFEROXAMINE,myocardial IRON OVERLOAD,134-145-150,77-89-93-106,deferiprone and DEFEROXAMINE (DFO),"Regarding iron chelation treatment, patients receiving combined therapy with deferiprone and deferoxamine (DFO) significantly reduced myocardial iron overload during the 4-yr study period, whilst patients in monotherapy with DFO showed a significant increase in LIC.",145 150,93,145,93,158,105,1,RO-may_prevent,907233,"Regarding iron chelation treatment, patients receiving combined therapy with deferiprone and deferoxamine (DFO) significantly reduced myocardial iron overload during the 4-yr study period, whilst patients in monotherapy with DFO showed a significant increase in LIC",iron overload,deferoxamine
502844758,7/13/2014 21:59:46,,1322188883,7/13/2014 21:59:33,elite,1,28503042,USA,OK,Oakwood,64.250.220.169,145,93,,,158,105,IRON OVERLOAD,DEFEROXAMINE,myocardial IRON OVERLOAD,134-145-150,93-106,DEFEROXAMINE (DFO),"Regarding iron chelation treatment, patients receiving combined therapy with deferiprone and deferoxamine (DFO) significantly reduced myocardial iron overload during the 4-yr study period, whilst patients in monotherapy with DFO showed a significant increase in LIC.",145 150,93,145,93,158,105,1,RO-may_prevent,907233,"Regarding iron chelation treatment, patients receiving combined therapy with deferiprone and deferoxamine (DFO) significantly reduced myocardial iron overload during the 4-yr study period, whilst patients in monotherapy with DFO showed a significant increase in LIC",iron overload,deferoxamine
502844758,7/13/2014 22:01:53,,1322190947,7/13/2014 22:01:28,bitcoinget,1,24792414,USA,IA,Independence,166.181.80.204,145,93,,,158,105,IRON OVERLOAD,DEFEROXAMINE,myocardial IRON OVERLOAD,134-145-150,93,DEFEROXAMINE,"Regarding iron chelation treatment, patients receiving combined therapy with deferiprone and deferoxamine (DFO) significantly reduced myocardial iron overload during the 4-yr study period, whilst patients in monotherapy with DFO showed a significant increase in LIC.",145 150,93,145,93,158,105,1,RO-may_prevent,907233,"Regarding iron chelation treatment, patients receiving combined therapy with deferiprone and deferoxamine (DFO) significantly reduced myocardial iron overload during the 4-yr study period, whilst patients in monotherapy with DFO showed a significant increase in LIC",iron overload,deferoxamine
502844758,7/13/2014 22:04:36,,1322193174,7/13/2014 22:03:20,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,145,93,,,158,105,IRON OVERLOAD,DEFEROXAMINE,"iron chelation treatment, deferiprone and deferoxamine (DFO) significantly reduced myocardial IRON OVERLOAD patients in monotherapy with DFO showed significant increase in LIC.",10-15-25-77-89-93-106-112-126-134-145-150-196-205-208-220-225-229-238-250-259-262,10-15-25-36-45-55-64-72-77-89-93-106-112-126-134-145-196-205-208-220-225-229-238-250-259-262-150,"iron chelation treatment, patients receiving combined therapy with deferiprone and DEFEROXAMINE (DFO) significantly reduced myocardial iron overload patients in monotherapy with DFO showed significant increase in LIC.","Regarding iron chelation treatment, patients receiving combined therapy with deferiprone and deferoxamine (DFO) significantly reduced myocardial iron overload during the 4-yr study period, whilst patients in monotherapy with DFO showed a significant increase in LIC.",145 150,93,145,93,158,105,1,RO-may_prevent,907233,"Regarding iron chelation treatment, patients receiving combined therapy with deferiprone and deferoxamine (DFO) significantly reduced myocardial iron overload during the 4-yr study period, whilst patients in monotherapy with DFO showed a significant increase in LIC",iron overload,deferoxamine
502844758,7/13/2014 22:04:39,,1322193227,7/13/2014 22:03:41,clixsense,1,8769423,AUS,6,Hobart,147.69.162.116,145,93,,,158,105,IRON OVERLOAD,DEFEROXAMINE,IRON OVERLOAD 4,145-150-170,93,DEFEROXAMINE,"Regarding iron chelation treatment, patients receiving combined therapy with deferiprone and deferoxamine (DFO) significantly reduced myocardial iron overload during the 4-yr study period, whilst patients in monotherapy with DFO showed a significant increase in LIC.",145 150,93,145,93,158,105,1,RO-may_prevent,907233,"Regarding iron chelation treatment, patients receiving combined therapy with deferiprone and deferoxamine (DFO) significantly reduced myocardial iron overload during the 4-yr study period, whilst patients in monotherapy with DFO showed a significant increase in LIC",iron overload,deferoxamine
502844758,7/13/2014 22:05:46,,1322194020,7/13/2014 22:05:14,clixsense,1,15189335,GBR,K3,Peterborough,81.156.166.189,145,93,,,158,105,IRON OVERLOAD,DEFEROXAMINE,IRON OVERLOAD,145-150,93,DEFEROXAMINE,"Regarding iron chelation treatment, patients receiving combined therapy with deferiprone and deferoxamine (DFO) significantly reduced myocardial iron overload during the 4-yr study period, whilst patients in monotherapy with DFO showed a significant increase in LIC.",145 150,93,145,93,158,105,1,RO-may_prevent,907233,"Regarding iron chelation treatment, patients receiving combined therapy with deferiprone and deferoxamine (DFO) significantly reduced myocardial iron overload during the 4-yr study period, whilst patients in monotherapy with DFO showed a significant increase in LIC",iron overload,deferoxamine
502844758,7/13/2014 22:10:06,,1322197391,7/13/2014 22:10:01,clixsense,1,24763049,GBR,,,86.133.47.213,145,93,,,158,105,IRON OVERLOAD,DEFEROXAMINE,significantly reduced myocardial IRON OVERLOAD during the 4,112-126-134-145-150-159-166-170,72-77-89-93-112-126,with deferiprone and DEFEROXAMINE significantly reduced,"Regarding iron chelation treatment, patients receiving combined therapy with deferiprone and deferoxamine (DFO) significantly reduced myocardial iron overload during the 4-yr study period, whilst patients in monotherapy with DFO showed a significant increase in LIC.",145 150,93,145,93,158,105,1,RO-may_prevent,907233,"Regarding iron chelation treatment, patients receiving combined therapy with deferiprone and deferoxamine (DFO) significantly reduced myocardial iron overload during the 4-yr study period, whilst patients in monotherapy with DFO showed a significant increase in LIC",iron overload,deferoxamine
502844758,7/13/2014 22:14:35,,1322201233,7/13/2014 22:14:03,instagc,1,23149109,USA,NC,Durham,75.189.206.205,145,93,,,158,105,IRON OVERLOAD,DEFEROXAMINE,reduced myocardial IRON OVERLOAD,126-134-145-150,77-89-93-106,deferiprone and DEFEROXAMINE (DFO),"Regarding iron chelation treatment, patients receiving combined therapy with deferiprone and deferoxamine (DFO) significantly reduced myocardial iron overload during the 4-yr study period, whilst patients in monotherapy with DFO showed a significant increase in LIC.",145 150,93,145,93,158,105,1,RO-may_prevent,907233,"Regarding iron chelation treatment, patients receiving combined therapy with deferiprone and deferoxamine (DFO) significantly reduced myocardial iron overload during the 4-yr study period, whilst patients in monotherapy with DFO showed a significant increase in LIC",iron overload,deferoxamine
502844758,7/13/2014 22:21:16,,1322206938,7/13/2014 22:20:26,clixsense,1,21875134,GBR,,,91.125.61.83,145,93,,,158,105,IRON OVERLOAD,DEFEROXAMINE,myocardial IRON OVERLOAD,134-145-150,55-64-72-77-89-93,combined therapy with deferiprone and DEFEROXAMINE,"Regarding iron chelation treatment, patients receiving combined therapy with deferiprone and deferoxamine (DFO) significantly reduced myocardial iron overload during the 4-yr study period, whilst patients in monotherapy with DFO showed a significant increase in LIC.",145 150,93,145,93,158,105,1,RO-may_prevent,907233,"Regarding iron chelation treatment, patients receiving combined therapy with deferiprone and deferoxamine (DFO) significantly reduced myocardial iron overload during the 4-yr study period, whilst patients in monotherapy with DFO showed a significant increase in LIC",iron overload,deferoxamine
502844759,7/13/2014 21:54:28,,1322183834,7/13/2014 21:54:14,elite,1,28503042,USA,OK,Oakwood,64.250.220.169,49,127,,,82,155,HUMAN IMMUNODEFICIENCY VIRUS (HIV,HUMAN IMMUNODEFICIENCY VIRUS,"HUMAN IMMUNODEFICIENCY VIRUS (HIV),",49-55-72-78,127-133-150,"HUMAN IMMUNODEFICIENCY VIRUS,","Ten patients were positive for antibodies to the human immunodeficiency virus (HIV), three were negative for antibodies to the human immunodeficiency virus, and ten refused testing.",49 55 72 78,127 133 150,49,127,82,155,-1,RO-has_causative_agent,903805,"Ten patients were positive for antibodies to the human immunodeficiency virus (HIV), three were negative for antibodies to the human immunodeficiency virus, and ten refused testing",human immunodeficiency virus (HIV,human immunodeficiency virus
502844759,7/13/2014 21:56:44,,1322185973,7/13/2014 21:56:14,prodege,1,17932518,GBR,Y2,Pwllheli,95.151.166.224,49,127,,,82,155,HUMAN IMMUNODEFICIENCY VIRUS (HIV,HUMAN IMMUNODEFICIENCY VIRUS,"HUMAN IMMUNODEFICIENCY VIRUS (HIV),",49-55-72-78,127-133-150,"HUMAN IMMUNODEFICIENCY VIRUS,","Ten patients were positive for antibodies to the human immunodeficiency virus (HIV), three were negative for antibodies to the human immunodeficiency virus, and ten refused testing.",49 55 72 78,127 133 150,49,127,82,155,-1,RO-has_causative_agent,903805,"Ten patients were positive for antibodies to the human immunodeficiency virus (HIV), three were negative for antibodies to the human immunodeficiency virus, and ten refused testing",human immunodeficiency virus (HIV,human immunodeficiency virus
502844759,7/13/2014 21:57:01,,1322186257,7/13/2014 21:56:35,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,49,127,,,82,155,HUMAN IMMUNODEFICIENCY VIRUS (HIV,HUMAN IMMUNODEFICIENCY VIRUS,"HUMAN IMMUNODEFICIENCY VIRUS (HIV),",49-55-72-78,127-133-150,"HUMAN IMMUNODEFICIENCY VIRUS,","Ten patients were positive for antibodies to the human immunodeficiency virus (HIV), three were negative for antibodies to the human immunodeficiency virus, and ten refused testing.",49 55 72 78,127 133 150,49,127,82,155,-1,RO-has_causative_agent,903805,"Ten patients were positive for antibodies to the human immunodeficiency virus (HIV), three were negative for antibodies to the human immunodeficiency virus, and ten refused testing",human immunodeficiency virus (HIV,human immunodeficiency virus
502844759,7/13/2014 21:59:47,,1322188880,7/13/2014 21:59:42,clixsense,1,24763049,GBR,,,86.133.47.213,49,127,,,82,155,HUMAN IMMUNODEFICIENCY VIRUS (HIV,HUMAN IMMUNODEFICIENCY VIRUS,"antibodies to the HUMAN IMMUNODEFICIENCY VIRUS (HIV), three were negative",31-42-45-49-55-72-78-85-91-96,109-120-123-127-133-150-157-161-165,"antibodies to the HUMAN IMMUNODEFICIENCY VIRUS, and ten refused","Ten patients were positive for antibodies to the human immunodeficiency virus (HIV), three were negative for antibodies to the human immunodeficiency virus, and ten refused testing.",49 55 72 78,127 133 150,49,127,82,155,-1,RO-has_causative_agent,903805,"Ten patients were positive for antibodies to the human immunodeficiency virus (HIV), three were negative for antibodies to the human immunodeficiency virus, and ten refused testing",human immunodeficiency virus (HIV,human immunodeficiency virus
502844759,7/13/2014 22:07:43,,1322195612,7/13/2014 22:07:08,clixsense,1,8769423,AUS,6,Hobart,147.69.162.116,49,127,,,82,155,HUMAN IMMUNODEFICIENCY VIRUS (HIV,HUMAN IMMUNODEFICIENCY VIRUS,"HUMAN IMMUNODEFICIENCY VIRUS (HIV),",49-55-72-78,127-133-150,"HUMAN IMMUNODEFICIENCY VIRUS,","Ten patients were positive for antibodies to the human immunodeficiency virus (HIV), three were negative for antibodies to the human immunodeficiency virus, and ten refused testing.",49 55 72 78,127 133 150,49,127,82,155,-1,RO-has_causative_agent,903805,"Ten patients were positive for antibodies to the human immunodeficiency virus (HIV), three were negative for antibodies to the human immunodeficiency virus, and ten refused testing",human immunodeficiency virus (HIV,human immunodeficiency virus
502844759,7/13/2014 22:08:00,,1322195851,7/13/2014 22:07:46,bitcoinget,1,24792414,USA,IA,Independence,166.181.80.204,49,127,,,82,155,HUMAN IMMUNODEFICIENCY VIRUS (HIV,HUMAN IMMUNODEFICIENCY VIRUS,"HUMAN IMMUNODEFICIENCY VIRUS (HIV),",49-55-72-78,127-133-150,"HUMAN IMMUNODEFICIENCY VIRUS,","Ten patients were positive for antibodies to the human immunodeficiency virus (HIV), three were negative for antibodies to the human immunodeficiency virus, and ten refused testing.",49 55 72 78,127 133 150,49,127,82,155,-1,RO-has_causative_agent,903805,"Ten patients were positive for antibodies to the human immunodeficiency virus (HIV), three were negative for antibodies to the human immunodeficiency virus, and ten refused testing",human immunodeficiency virus (HIV,human immunodeficiency virus
502844759,7/13/2014 22:11:52,,1322199083,7/13/2014 22:11:17,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,49,127,,,82,155,HUMAN IMMUNODEFICIENCY VIRUS (HIV,HUMAN IMMUNODEFICIENCY VIRUS,"antibodies to the HUMAN IMMUNODEFICIENCY VIRUS (HIV), three were negative antibodies to the human immunodeficiency virus,",31-42-45-49-55-72-78-85-91-96-109-120-127-133-150-123,31-42-45-49-55-72-78-85-91-96-105-109-120-123-127-133-150,"antibodies to the human immunodeficiency virus (HIV), three were negative for antibodies to the HUMAN IMMUNODEFICIENCY VIRUS,","Ten patients were positive for antibodies to the human immunodeficiency virus (HIV), three were negative for antibodies to the human immunodeficiency virus, and ten refused testing.",49 55 72 78,127 133 150,49,127,82,155,-1,RO-has_causative_agent,903805,"Ten patients were positive for antibodies to the human immunodeficiency virus (HIV), three were negative for antibodies to the human immunodeficiency virus, and ten refused testing",human immunodeficiency virus (HIV,human immunodeficiency virus
502844759,7/13/2014 22:16:37,,1322202893,7/13/2014 22:16:23,clixsense,1,10842668,GBR,,,80.189.187.36,49,127,,,82,155,HUMAN IMMUNODEFICIENCY VIRUS (HIV,HUMAN IMMUNODEFICIENCY VIRUS,"HUMAN IMMUNODEFICIENCY VIRUS (HIV),",49-55-72-78,127-133-150,"HUMAN IMMUNODEFICIENCY VIRUS,","Ten patients were positive for antibodies to the human immunodeficiency virus (HIV), three were negative for antibodies to the human immunodeficiency virus, and ten refused testing.",49 55 72 78,127 133 150,49,127,82,155,-1,RO-has_causative_agent,903805,"Ten patients were positive for antibodies to the human immunodeficiency virus (HIV), three were negative for antibodies to the human immunodeficiency virus, and ten refused testing",human immunodeficiency virus (HIV,human immunodeficiency virus
502844759,7/13/2014 22:16:55,,1322203161,7/13/2014 22:16:40,instagc,1,23149109,USA,NC,Durham,75.189.206.205,49,127,,,82,155,HUMAN IMMUNODEFICIENCY VIRUS (HIV,HUMAN IMMUNODEFICIENCY VIRUS,"HUMAN IMMUNODEFICIENCY VIRUS (HIV),",49-55-72-78,109-120-123-127-133-150,"antibodies to the HUMAN IMMUNODEFICIENCY VIRUS,","Ten patients were positive for antibodies to the human immunodeficiency virus (HIV), three were negative for antibodies to the human immunodeficiency virus, and ten refused testing.",49 55 72 78,127 133 150,49,127,82,155,-1,RO-has_causative_agent,903805,"Ten patients were positive for antibodies to the human immunodeficiency virus (HIV), three were negative for antibodies to the human immunodeficiency virus, and ten refused testing",human immunodeficiency virus (HIV,human immunodeficiency virus
502844759,7/13/2014 22:20:11,,1322205984,7/13/2014 22:19:42,gifthulk,1,22552178,AUS,5,Adelaide,14.2.7.227,49,127,,,82,155,HUMAN IMMUNODEFICIENCY VIRUS (HIV,HUMAN IMMUNODEFICIENCY VIRUS,"HUMAN IMMUNODEFICIENCY VIRUS (HIV),",49-55-72-78,127-133-150,"HUMAN IMMUNODEFICIENCY VIRUS,","Ten patients were positive for antibodies to the human immunodeficiency virus (HIV), three were negative for antibodies to the human immunodeficiency virus, and ten refused testing.",49 55 72 78,127 133 150,49,127,82,155,-1,RO-has_causative_agent,903805,"Ten patients were positive for antibodies to the human immunodeficiency virus (HIV), three were negative for antibodies to the human immunodeficiency virus, and ten refused testing",human immunodeficiency virus (HIV,human immunodeficiency virus
502844760,7/13/2014 21:54:32,,1322183873,7/13/2014 21:54:11,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,196,136,,,200,148,PAIN,DYSMENORRHEA,PAIN,196,136,DYSMENORRHEA;,neosalpingostomy for symptomatic hydrosalpinx; 7) ovarian treatment for symptomatic ovarian pain; 8) uterosacral nerve vaporization for dysmenorrhea; 9) presacral neurectomy for disabling central pain primarily of uterine but also of bladder origin; 10) resection of endometriosis from all surfaces including removal from bladder and bowel as well as from the rectovaginal septal space.,196,136,196,136,200,148,-1,RO-has_definitional_manifestation,904857,neosalpingostomy for symptomatic hydrosalpinx; 7) ovarian treatment for symptomatic ovarian pain; 8) uterosacral nerve vaporization for dysmenorrhea; 9) presacral neurectomy for disabling central pain primarily of uterine but also of bladder origin; 10) resection of endometriosis from all surfaces including removal from bladder and bowel as well as from the rectovaginal septal space,pain,dysmenorrhea
502844760,7/13/2014 21:54:57,,1322184324,7/13/2014 21:54:51,clixsense,1,25402344,CAN,ON,Wawa,24.109.124.45,196,136,,,200,148,PAIN,DYSMENORRHEA,for disabling central PAIN primarily of uterine,174-178-188-196-201-211-214,113-119-132-136-150-153-163,nerve vaporization for DYSMENORRHEA; 9) presacral neurectomy,neosalpingostomy for symptomatic hydrosalpinx; 7) ovarian treatment for symptomatic ovarian pain; 8) uterosacral nerve vaporization for dysmenorrhea; 9) presacral neurectomy for disabling central pain primarily of uterine but also of bladder origin; 10) resection of endometriosis from all surfaces including removal from bladder and bowel as well as from the rectovaginal septal space.,196,136,196,136,200,148,-1,RO-has_definitional_manifestation,904857,neosalpingostomy for symptomatic hydrosalpinx; 7) ovarian treatment for symptomatic ovarian pain; 8) uterosacral nerve vaporization for dysmenorrhea; 9) presacral neurectomy for disabling central pain primarily of uterine but also of bladder origin; 10) resection of endometriosis from all surfaces including removal from bladder and bowel as well as from the rectovaginal septal space,pain,dysmenorrhea
502844760,7/13/2014 21:56:07,,1322185309,7/13/2014 21:55:31,clixsense,1,15189335,GBR,K3,Peterborough,81.156.166.189,196,136,,,200,148,PAIN,DYSMENORRHEA,PAIN,196,136,DYSMENORRHEA;,neosalpingostomy for symptomatic hydrosalpinx; 7) ovarian treatment for symptomatic ovarian pain; 8) uterosacral nerve vaporization for dysmenorrhea; 9) presacral neurectomy for disabling central pain primarily of uterine but also of bladder origin; 10) resection of endometriosis from all surfaces including removal from bladder and bowel as well as from the rectovaginal septal space.,196,136,196,136,200,148,-1,RO-has_definitional_manifestation,904857,neosalpingostomy for symptomatic hydrosalpinx; 7) ovarian treatment for symptomatic ovarian pain; 8) uterosacral nerve vaporization for dysmenorrhea; 9) presacral neurectomy for disabling central pain primarily of uterine but also of bladder origin; 10) resection of endometriosis from all surfaces including removal from bladder and bowel as well as from the rectovaginal septal space,pain,dysmenorrhea
502844760,7/13/2014 21:56:11,,1322185433,7/13/2014 21:55:54,elite,1,28503042,USA,OK,Oakwood,64.250.220.169,196,136,,,200,148,PAIN,DYSMENORRHEA,disabling central PAIN primarily of uterine,178-188-196-211-214-201,136,DYSMENORRHEA;,neosalpingostomy for symptomatic hydrosalpinx; 7) ovarian treatment for symptomatic ovarian pain; 8) uterosacral nerve vaporization for dysmenorrhea; 9) presacral neurectomy for disabling central pain primarily of uterine but also of bladder origin; 10) resection of endometriosis from all surfaces including removal from bladder and bowel as well as from the rectovaginal septal space.,196,136,196,136,200,148,-1,RO-has_definitional_manifestation,904857,neosalpingostomy for symptomatic hydrosalpinx; 7) ovarian treatment for symptomatic ovarian pain; 8) uterosacral nerve vaporization for dysmenorrhea; 9) presacral neurectomy for disabling central pain primarily of uterine but also of bladder origin; 10) resection of endometriosis from all surfaces including removal from bladder and bowel as well as from the rectovaginal septal space,pain,dysmenorrhea
502844760,7/13/2014 22:00:03,,1322189114,7/13/2014 21:59:32,bitcoinget,1,24792414,USA,IA,Independence,166.181.80.204,196,136,,,200,148,PAIN,DYSMENORRHEA,PAIN,196,136,DYSMENORRHEA;,neosalpingostomy for symptomatic hydrosalpinx; 7) ovarian treatment for symptomatic ovarian pain; 8) uterosacral nerve vaporization for dysmenorrhea; 9) presacral neurectomy for disabling central pain primarily of uterine but also of bladder origin; 10) resection of endometriosis from all surfaces including removal from bladder and bowel as well as from the rectovaginal septal space.,196,136,196,136,200,148,-1,RO-has_definitional_manifestation,904857,neosalpingostomy for symptomatic hydrosalpinx; 7) ovarian treatment for symptomatic ovarian pain; 8) uterosacral nerve vaporization for dysmenorrhea; 9) presacral neurectomy for disabling central pain primarily of uterine but also of bladder origin; 10) resection of endometriosis from all surfaces including removal from bladder and bowel as well as from the rectovaginal septal space,pain,dysmenorrhea
502844760,7/13/2014 22:03:13,,1322192006,7/13/2014 22:02:40,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,196,136,,,200,148,PAIN,DYSMENORRHEA,disabling central PAIN,178-188-196,136,DYSMENORRHEA;,neosalpingostomy for symptomatic hydrosalpinx; 7) ovarian treatment for symptomatic ovarian pain; 8) uterosacral nerve vaporization for dysmenorrhea; 9) presacral neurectomy for disabling central pain primarily of uterine but also of bladder origin; 10) resection of endometriosis from all surfaces including removal from bladder and bowel as well as from the rectovaginal septal space.,196,136,196,136,200,148,-1,RO-has_definitional_manifestation,904857,neosalpingostomy for symptomatic hydrosalpinx; 7) ovarian treatment for symptomatic ovarian pain; 8) uterosacral nerve vaporization for dysmenorrhea; 9) presacral neurectomy for disabling central pain primarily of uterine but also of bladder origin; 10) resection of endometriosis from all surfaces including removal from bladder and bowel as well as from the rectovaginal septal space,pain,dysmenorrhea
502844760,7/13/2014 22:04:59,,1322193464,7/13/2014 22:04:42,neodev,1,28175665,CAN,ON,Brampton,99.228.31.59,196,136,,,200,148,PAIN,DYSMENORRHEA,PAIN,196,113-119-132-136,nerve vaporization for DYSMENORRHEA;,neosalpingostomy for symptomatic hydrosalpinx; 7) ovarian treatment for symptomatic ovarian pain; 8) uterosacral nerve vaporization for dysmenorrhea; 9) presacral neurectomy for disabling central pain primarily of uterine but also of bladder origin; 10) resection of endometriosis from all surfaces including removal from bladder and bowel as well as from the rectovaginal septal space.,196,136,196,136,200,148,-1,RO-has_definitional_manifestation,904857,neosalpingostomy for symptomatic hydrosalpinx; 7) ovarian treatment for symptomatic ovarian pain; 8) uterosacral nerve vaporization for dysmenorrhea; 9) presacral neurectomy for disabling central pain primarily of uterine but also of bladder origin; 10) resection of endometriosis from all surfaces including removal from bladder and bowel as well as from the rectovaginal septal space,pain,dysmenorrhea
502844760,7/13/2014 22:06:28,,1322194675,7/13/2014 22:05:58,elite,1,28397222,GBR,,,31.49.231.211,196,136,,,200,148,PAIN,DYSMENORRHEA,central PAIN,188-196,136,DYSMENORRHEA;,neosalpingostomy for symptomatic hydrosalpinx; 7) ovarian treatment for symptomatic ovarian pain; 8) uterosacral nerve vaporization for dysmenorrhea; 9) presacral neurectomy for disabling central pain primarily of uterine but also of bladder origin; 10) resection of endometriosis from all surfaces including removal from bladder and bowel as well as from the rectovaginal septal space.,196,136,196,136,200,148,-1,RO-has_definitional_manifestation,904857,neosalpingostomy for symptomatic hydrosalpinx; 7) ovarian treatment for symptomatic ovarian pain; 8) uterosacral nerve vaporization for dysmenorrhea; 9) presacral neurectomy for disabling central pain primarily of uterine but also of bladder origin; 10) resection of endometriosis from all surfaces including removal from bladder and bowel as well as from the rectovaginal septal space,pain,dysmenorrhea
502844760,7/13/2014 22:11:12,,1322198456,7/13/2014 22:10:03,clixsense,1,8769423,AUS,6,Hobart,147.69.162.116,196,136,,,200,148,PAIN,DYSMENORRHEA,PAIN,196,136-322,DYSMENORRHEA; bladder,neosalpingostomy for symptomatic hydrosalpinx; 7) ovarian treatment for symptomatic ovarian pain; 8) uterosacral nerve vaporization for dysmenorrhea; 9) presacral neurectomy for disabling central pain primarily of uterine but also of bladder origin; 10) resection of endometriosis from all surfaces including removal from bladder and bowel as well as from the rectovaginal septal space.,196,136,196,136,200,148,-1,RO-has_definitional_manifestation,904857,neosalpingostomy for symptomatic hydrosalpinx; 7) ovarian treatment for symptomatic ovarian pain; 8) uterosacral nerve vaporization for dysmenorrhea; 9) presacral neurectomy for disabling central pain primarily of uterine but also of bladder origin; 10) resection of endometriosis from all surfaces including removal from bladder and bowel as well as from the rectovaginal septal space,pain,dysmenorrhea
502844760,7/13/2014 22:13:21,,1322200263,7/13/2014 22:12:54,instagc,1,23149109,USA,NC,Durham,75.189.206.205,196,136,,,200,148,PAIN,DYSMENORRHEA,central PAIN of uterine,188-196-211-214,113-119-132-136,nerve vaporization for DYSMENORRHEA;,neosalpingostomy for symptomatic hydrosalpinx; 7) ovarian treatment for symptomatic ovarian pain; 8) uterosacral nerve vaporization for dysmenorrhea; 9) presacral neurectomy for disabling central pain primarily of uterine but also of bladder origin; 10) resection of endometriosis from all surfaces including removal from bladder and bowel as well as from the rectovaginal septal space.,196,136,196,136,200,148,-1,RO-has_definitional_manifestation,904857,neosalpingostomy for symptomatic hydrosalpinx; 7) ovarian treatment for symptomatic ovarian pain; 8) uterosacral nerve vaporization for dysmenorrhea; 9) presacral neurectomy for disabling central pain primarily of uterine but also of bladder origin; 10) resection of endometriosis from all surfaces including removal from bladder and bowel as well as from the rectovaginal septal space,pain,dysmenorrhea
502844761,7/13/2014 21:54:45,,1322184137,7/13/2014 21:54:31,instagc,1,28301350,GBR,K4,Plymouth,89.242.63.62,94,27,,,104,45,MIDDLE EAR,ACUTE OTITIS MEDIA,acute otitis media MIDDLE EAR.,27-33-40-94-101,27-33-40,ACUTE OTITIS MEDIA,The role of antibiotics in acute otitis media is to eradicate the causative pathogen from the middle ear.,94 101,27 33 40,94,27,104,45,1,RO-has_finding_site,905496,The role of antibiotics in acute otitis media is to eradicate the causative pathogen from the middle ear,middle ear,acute otitis media
502844761,7/13/2014 22:01:17,,1322190450,7/13/2014 22:01:01,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,94,27,,,104,45,MIDDLE EAR,ACUTE OTITIS MEDIA,MIDDLE EAR.,94-101,27-33-40,ACUTE OTITIS MEDIA,The role of antibiotics in acute otitis media is to eradicate the causative pathogen from the middle ear.,94 101,27 33 40,94,27,104,45,1,RO-has_finding_site,905496,The role of antibiotics in acute otitis media is to eradicate the causative pathogen from the middle ear,middle ear,acute otitis media
502844761,7/13/2014 22:01:55,,1322190976,7/13/2014 22:01:29,clixsense,1,8769423,AUS,6,Hobart,147.69.162.116,94,27,,,104,45,MIDDLE EAR,ACUTE OTITIS MEDIA,MIDDLE EAR.,94-101,27-33-40,ACUTE OTITIS MEDIA,The role of antibiotics in acute otitis media is to eradicate the causative pathogen from the middle ear.,94 101,27 33 40,94,27,104,45,1,RO-has_finding_site,905496,The role of antibiotics in acute otitis media is to eradicate the causative pathogen from the middle ear,middle ear,acute otitis media
502844761,7/13/2014 22:02:35,,1322191585,7/13/2014 22:02:24,clixsense,1,25402344,CAN,ON,Wawa,24.109.124.45,94,27,,,104,45,MIDDLE EAR,ACUTE OTITIS MEDIA,pathogen from the MIDDLE EAR.,76-85-90-94-101,9-12-24-27-33-40-46-49-52,of antibiotics in ACUTE OTITIS MEDIA is to eradicate,The role of antibiotics in acute otitis media is to eradicate the causative pathogen from the middle ear.,94 101,27 33 40,94,27,104,45,1,RO-has_finding_site,905496,The role of antibiotics in acute otitis media is to eradicate the causative pathogen from the middle ear,middle ear,acute otitis media
502844761,7/13/2014 22:19:22,,1322205274,7/13/2014 22:19:11,clixsense,1,10842668,GBR,,,80.189.187.36,94,27,,,104,45,MIDDLE EAR,ACUTE OTITIS MEDIA,MIDDLE EAR.,94-101,27-33-40,ACUTE OTITIS MEDIA,The role of antibiotics in acute otitis media is to eradicate the causative pathogen from the middle ear.,94 101,27 33 40,94,27,104,45,1,RO-has_finding_site,905496,The role of antibiotics in acute otitis media is to eradicate the causative pathogen from the middle ear,middle ear,acute otitis media
502844761,7/13/2014 22:20:24,,1322206163,7/13/2014 22:17:49,clixsense,1,21875134,GBR,,,91.125.61.83,94,27,,,104,45,MIDDLE EAR,ACUTE OTITIS MEDIA,eradicate the causative pathogen from the MIDDLE EAR.,52-62-76-85-90-94-101-66,4-9-12-24-27-33-40,role of antibiotics in ACUTE OTITIS MEDIA,The role of antibiotics in acute otitis media is to eradicate the causative pathogen from the middle ear.,94 101,27 33 40,94,27,104,45,1,RO-has_finding_site,905496,The role of antibiotics in acute otitis media is to eradicate the causative pathogen from the middle ear,middle ear,acute otitis media
502844761,7/13/2014 22:23:31,,1322208830,7/13/2014 22:23:14,gifthulk,1,22552178,AUS,5,Adelaide,14.2.7.227,94,27,,,104,45,MIDDLE EAR,ACUTE OTITIS MEDIA,MIDDLE EAR.,94-101,27-33-40,ACUTE OTITIS MEDIA,The role of antibiotics in acute otitis media is to eradicate the causative pathogen from the middle ear.,94 101,27 33 40,94,27,104,45,1,RO-has_finding_site,905496,The role of antibiotics in acute otitis media is to eradicate the causative pathogen from the middle ear,middle ear,acute otitis media
502844761,7/13/2014 22:23:36,,1322208874,7/13/2014 22:23:17,instagc,1,23149109,USA,NC,Durham,75.189.206.205,94,27,,,104,45,MIDDLE EAR,ACUTE OTITIS MEDIA,causative pathogen from the MIDDLE EAR.,76-85-90-94-101-66,27-33-40,ACUTE OTITIS MEDIA,The role of antibiotics in acute otitis media is to eradicate the causative pathogen from the middle ear.,94 101,27 33 40,94,27,104,45,1,RO-has_finding_site,905496,The role of antibiotics in acute otitis media is to eradicate the causative pathogen from the middle ear,middle ear,acute otitis media
502844761,7/13/2014 22:23:43,,1322209007,7/13/2014 22:23:21,clixsense,1,26889820,GBR,C3,Shelford,92.18.120.203,94,27,,,104,45,MIDDLE EAR,ACUTE OTITIS MEDIA,MIDDLE EAR.,94-101,27-33-40,ACUTE OTITIS MEDIA,The role of antibiotics in acute otitis media is to eradicate the causative pathogen from the middle ear.,94 101,27 33 40,94,27,104,45,1,RO-has_finding_site,905496,The role of antibiotics in acute otitis media is to eradicate the causative pathogen from the middle ear,middle ear,acute otitis media
502844761,7/13/2014 22:25:18,,1322210582,7/13/2014 22:25:07,prodege,1,2143114,CAN,BC,Vancouver,24.84.160.12,94,27,,,104,45,MIDDLE EAR,ACUTE OTITIS MEDIA,MIDDLE EAR.,94-101,27-33-40,ACUTE OTITIS MEDIA,The role of antibiotics in acute otitis media is to eradicate the causative pathogen from the middle ear.,94 101,27 33 40,94,27,104,45,1,RO-has_finding_site,905496,The role of antibiotics in acute otitis media is to eradicate the causative pathogen from the middle ear,middle ear,acute otitis media
502844762,7/13/2014 21:53:20,,1322182956,7/13/2014 21:53:03,instagc,1,28301350,GBR,K4,Plymouth,89.242.63.62,579,626,,,585,639,BREAST,BREAST CANCER,early stage BREAST cancer,567-573-579-586,567-573-579-586-626-633,early stage breast cancer BREAST CANCER,"Follow-up of patients with early breast cancer  Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations  HER2 and response to paclitaxel in node-positive breast cancer  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer  Breast-cancer stromal cells with TP53 mutations and nodal metastases  Weekly paclitaxel in the adjuvant treatment of breast cancer  Polygenes, risk prediction, and targeted prevention of breast cancer  Single reading with computer-aided detection for screening mammography  Radiation therapy for early-stage breast cancer after breast-conserving surgery  Breast cancer after use of estrogen.",579,626 633,579,626,585,639,1,RO-disease_has_primary_anatomic_site,902208,"Follow-up of patients with early breast cancer  Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations  HER2 and response to paclitaxel in node-positive breast cancer  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer  Breast-cancer stromal cells with TP53 mutations and nodal metastases  Weekly paclitaxel in the adjuvant treatment of breast cancer  Polygenes, risk prediction, and targeted prevention of breast cancer  Single reading with computer-aided detection for screening mammography  Radiation therapy for early-stage breast cancer after breast-conserving surgery  Breast cancer after use of estrogen",breast,Breast cancer
502844762,7/13/2014 21:57:17,,1322186478,7/13/2014 21:56:56,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,579,626,,,585,639,BREAST,BREAST CANCER,BREAST cancer,579-586,626-633,BREAST CANCER,"Follow-up of patients with early breast cancer  Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations  HER2 and response to paclitaxel in node-positive breast cancer  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer  Breast-cancer stromal cells with TP53 mutations and nodal metastases  Weekly paclitaxel in the adjuvant treatment of breast cancer  Polygenes, risk prediction, and targeted prevention of breast cancer  Single reading with computer-aided detection for screening mammography  Radiation therapy for early-stage breast cancer after breast-conserving surgery  Breast cancer after use of estrogen.",579,626 633,579,626,585,639,1,RO-disease_has_primary_anatomic_site,902208,"Follow-up of patients with early breast cancer  Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations  HER2 and response to paclitaxel in node-positive breast cancer  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer  Breast-cancer stromal cells with TP53 mutations and nodal metastases  Weekly paclitaxel in the adjuvant treatment of breast cancer  Polygenes, risk prediction, and targeted prevention of breast cancer  Single reading with computer-aided detection for screening mammography  Radiation therapy for early-stage breast cancer after breast-conserving surgery  Breast cancer after use of estrogen",breast,Breast cancer
502844762,7/13/2014 21:59:32,,1322188583,7/13/2014 21:59:10,elite,1,28503042,USA,OK,Oakwood,64.250.220.169,579,626,,,585,639,BREAST,BREAST CANCER,for early stage BREAST cancer,563-567-573-579-586,599-606-617-626-633-640-646-650-653,breast conserving surgery BREAST CANCER after use of estrogen.,"Follow-up of patients with early breast cancer  Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations  HER2 and response to paclitaxel in node-positive breast cancer  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer  Breast-cancer stromal cells with TP53 mutations and nodal metastases  Weekly paclitaxel in the adjuvant treatment of breast cancer  Polygenes, risk prediction, and targeted prevention of breast cancer  Single reading with computer-aided detection for screening mammography  Radiation therapy for early-stage breast cancer after breast-conserving surgery  Breast cancer after use of estrogen.",579,626 633,579,626,585,639,1,RO-disease_has_primary_anatomic_site,902208,"Follow-up of patients with early breast cancer  Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations  HER2 and response to paclitaxel in node-positive breast cancer  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer  Breast-cancer stromal cells with TP53 mutations and nodal metastases  Weekly paclitaxel in the adjuvant treatment of breast cancer  Polygenes, risk prediction, and targeted prevention of breast cancer  Single reading with computer-aided detection for screening mammography  Radiation therapy for early-stage breast cancer after breast-conserving surgery  Breast cancer after use of estrogen",breast,Breast cancer
502844762,7/13/2014 22:02:50,,1322191775,7/13/2014 22:02:27,neodev,1,28175665,CAN,ON,Brampton,99.228.31.59,579,626,,,585,639,BREAST,BREAST CANCER,early stage BREAST cancer,567-573-579-586,599-606-617-626-633,breast conserving surgery BREAST CANCER,"Follow-up of patients with early breast cancer  Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations  HER2 and response to paclitaxel in node-positive breast cancer  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer  Breast-cancer stromal cells with TP53 mutations and nodal metastases  Weekly paclitaxel in the adjuvant treatment of breast cancer  Polygenes, risk prediction, and targeted prevention of breast cancer  Single reading with computer-aided detection for screening mammography  Radiation therapy for early-stage breast cancer after breast-conserving surgery  Breast cancer after use of estrogen.",579,626 633,579,626,585,639,1,RO-disease_has_primary_anatomic_site,902208,"Follow-up of patients with early breast cancer  Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations  HER2 and response to paclitaxel in node-positive breast cancer  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer  Breast-cancer stromal cells with TP53 mutations and nodal metastases  Weekly paclitaxel in the adjuvant treatment of breast cancer  Polygenes, risk prediction, and targeted prevention of breast cancer  Single reading with computer-aided detection for screening mammography  Radiation therapy for early-stage breast cancer after breast-conserving surgery  Breast cancer after use of estrogen",breast,Breast cancer
502844762,7/13/2014 22:03:39,,1322192332,7/13/2014 22:02:45,clixsense,1,8769423,AUS,6,Hobart,147.69.162.116,579,626,,,585,639,BREAST,BREAST CANCER,BREAST,579,626-633-646-650,BREAST CANCER use of,"Follow-up of patients with early breast cancer  Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations  HER2 and response to paclitaxel in node-positive breast cancer  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer  Breast-cancer stromal cells with TP53 mutations and nodal metastases  Weekly paclitaxel in the adjuvant treatment of breast cancer  Polygenes, risk prediction, and targeted prevention of breast cancer  Single reading with computer-aided detection for screening mammography  Radiation therapy for early-stage breast cancer after breast-conserving surgery  Breast cancer after use of estrogen.",579,626 633,579,626,585,639,1,RO-disease_has_primary_anatomic_site,902208,"Follow-up of patients with early breast cancer  Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations  HER2 and response to paclitaxel in node-positive breast cancer  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer  Breast-cancer stromal cells with TP53 mutations and nodal metastases  Weekly paclitaxel in the adjuvant treatment of breast cancer  Polygenes, risk prediction, and targeted prevention of breast cancer  Single reading with computer-aided detection for screening mammography  Radiation therapy for early-stage breast cancer after breast-conserving surgery  Breast cancer after use of estrogen",breast,Breast cancer
502844762,7/13/2014 22:04:52,,1322193386,7/13/2014 22:04:30,clixsense,1,25402344,CAN,ON,Wawa,24.109.124.45,579,626,,,585,639,BREAST,BREAST CANCER,for early stage BREAST cancer after breast,563-567-573-579-586-593-599,599-606-617-626-633-640-646-650,breast conserving surgery BREAST CANCER after use of,"Follow-up of patients with early breast cancer  Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations  HER2 and response to paclitaxel in node-positive breast cancer  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer  Breast-cancer stromal cells with TP53 mutations and nodal metastases  Weekly paclitaxel in the adjuvant treatment of breast cancer  Polygenes, risk prediction, and targeted prevention of breast cancer  Single reading with computer-aided detection for screening mammography  Radiation therapy for early-stage breast cancer after breast-conserving surgery  Breast cancer after use of estrogen.",579,626 633,579,626,585,639,1,RO-disease_has_primary_anatomic_site,902208,"Follow-up of patients with early breast cancer  Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations  HER2 and response to paclitaxel in node-positive breast cancer  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer  Breast-cancer stromal cells with TP53 mutations and nodal metastases  Weekly paclitaxel in the adjuvant treatment of breast cancer  Polygenes, risk prediction, and targeted prevention of breast cancer  Single reading with computer-aided detection for screening mammography  Radiation therapy for early-stage breast cancer after breast-conserving surgery  Breast cancer after use of estrogen",breast,Breast cancer
502844762,7/13/2014 22:05:58,,1322194222,7/13/2014 22:05:44,bitcoinget,1,24792414,USA,IA,Independence,166.181.80.204,579,626,,,585,639,BREAST,BREAST CANCER,BREAST cancer,579-586,626-633,BREAST CANCER,"Follow-up of patients with early breast cancer  Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations  HER2 and response to paclitaxel in node-positive breast cancer  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer  Breast-cancer stromal cells with TP53 mutations and nodal metastases  Weekly paclitaxel in the adjuvant treatment of breast cancer  Polygenes, risk prediction, and targeted prevention of breast cancer  Single reading with computer-aided detection for screening mammography  Radiation therapy for early-stage breast cancer after breast-conserving surgery  Breast cancer after use of estrogen.",579,626 633,579,626,585,639,1,RO-disease_has_primary_anatomic_site,902208,"Follow-up of patients with early breast cancer  Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations  HER2 and response to paclitaxel in node-positive breast cancer  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer  Breast-cancer stromal cells with TP53 mutations and nodal metastases  Weekly paclitaxel in the adjuvant treatment of breast cancer  Polygenes, risk prediction, and targeted prevention of breast cancer  Single reading with computer-aided detection for screening mammography  Radiation therapy for early-stage breast cancer after breast-conserving surgery  Breast cancer after use of estrogen",breast,Breast cancer
502844762,7/13/2014 22:09:46,,1322197111,7/13/2014 22:09:21,elite,1,28397222,GBR,,,31.49.231.211,579,626,,,585,639,BREAST,BREAST CANCER,BREAST cancer,579-586,626-633,BREAST CANCER,"Follow-up of patients with early breast cancer  Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations  HER2 and response to paclitaxel in node-positive breast cancer  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer  Breast-cancer stromal cells with TP53 mutations and nodal metastases  Weekly paclitaxel in the adjuvant treatment of breast cancer  Polygenes, risk prediction, and targeted prevention of breast cancer  Single reading with computer-aided detection for screening mammography  Radiation therapy for early-stage breast cancer after breast-conserving surgery  Breast cancer after use of estrogen.",579,626 633,579,626,585,639,1,RO-disease_has_primary_anatomic_site,902208,"Follow-up of patients with early breast cancer  Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations  HER2 and response to paclitaxel in node-positive breast cancer  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer  Breast-cancer stromal cells with TP53 mutations and nodal metastases  Weekly paclitaxel in the adjuvant treatment of breast cancer  Polygenes, risk prediction, and targeted prevention of breast cancer  Single reading with computer-aided detection for screening mammography  Radiation therapy for early-stage breast cancer after breast-conserving surgery  Breast cancer after use of estrogen",breast,Breast cancer
502844762,7/13/2014 22:16:24,,1322202699,7/13/2014 22:15:40,prodege,1,28255346,GBR,L9,Sheffield,2.125.183.137,579,626,,,585,639,BREAST,BREAST CANCER,early stage BREAST cancer,567-573-579-586,626-633,BREAST CANCER,"Follow-up of patients with early breast cancer  Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations  HER2 and response to paclitaxel in node-positive breast cancer  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer  Breast-cancer stromal cells with TP53 mutations and nodal metastases  Weekly paclitaxel in the adjuvant treatment of breast cancer  Polygenes, risk prediction, and targeted prevention of breast cancer  Single reading with computer-aided detection for screening mammography  Radiation therapy for early-stage breast cancer after breast-conserving surgery  Breast cancer after use of estrogen.",579,626 633,579,626,585,639,1,RO-disease_has_primary_anatomic_site,902208,"Follow-up of patients with early breast cancer  Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations  HER2 and response to paclitaxel in node-positive breast cancer  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer  Breast-cancer stromal cells with TP53 mutations and nodal metastases  Weekly paclitaxel in the adjuvant treatment of breast cancer  Polygenes, risk prediction, and targeted prevention of breast cancer  Single reading with computer-aided detection for screening mammography  Radiation therapy for early-stage breast cancer after breast-conserving surgery  Breast cancer after use of estrogen",breast,Breast cancer
502844762,7/13/2014 22:20:14,,1322206016,7/13/2014 22:18:51,instagc,1,23149109,USA,NC,Durham,75.189.206.205,579,626,,,585,639,BREAST,BREAST CANCER,early stage BREAST cancer,567-573-579-586,599-606-617-626-633,breast conserving surgery BREAST CANCER,"Follow-up of patients with early breast cancer  Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations  HER2 and response to paclitaxel in node-positive breast cancer  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer  Breast-cancer stromal cells with TP53 mutations and nodal metastases  Weekly paclitaxel in the adjuvant treatment of breast cancer  Polygenes, risk prediction, and targeted prevention of breast cancer  Single reading with computer-aided detection for screening mammography  Radiation therapy for early-stage breast cancer after breast-conserving surgery  Breast cancer after use of estrogen.",579,626 633,579,626,585,639,1,RO-disease_has_primary_anatomic_site,902208,"Follow-up of patients with early breast cancer  Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations  HER2 and response to paclitaxel in node-positive breast cancer  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer  Breast-cancer stromal cells with TP53 mutations and nodal metastases  Weekly paclitaxel in the adjuvant treatment of breast cancer  Polygenes, risk prediction, and targeted prevention of breast cancer  Single reading with computer-aided detection for screening mammography  Radiation therapy for early-stage breast cancer after breast-conserving surgery  Breast cancer after use of estrogen",breast,Breast cancer
502844763,7/13/2014 21:55:16,,1322184587,7/13/2014 21:54:31,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,59,133,,,63,148,PAIN,OSTEOID OSTEOMA,"persistent unexplained PAIN of the wrist clinical symptoms tenosynovitis, osteoid osteoma styloid process radius carpal bones differential diagnosis.",36-47-59-64-67-71-80-89-118-133-141-156-164-179-196-203-240-253,36-47-59-64-67-71-80-89-109-115-118-133-141-149-152-156-179-203-240-253-196,"persistent unexplained pain of the wrist clinical symptoms those of tenosynovitis, OSTEOID OSTEOMA of the styloid radius carpal bones differential diagnosis.","It is suggested that in any case of persistent unexplained pain of the wrist or clinical symptoms resembling those of tenosynovitis, osteoid osteoma of the styloid process of the radius or of the carpal bones should also be included in the differential diagnosis.",59,133 141,59,133,63,148,1,RO-disease_has_finding,901842,"It is suggested that in any case of persistent unexplained pain of the wrist or clinical symptoms resembling those of tenosynovitis, osteoid osteoma of the styloid process of the radius or of the carpal bones should also be included in the differential diagnosis",pain,osteoid osteoma
502844763,7/13/2014 21:58:40,,1322187722,7/13/2014 21:58:17,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,59,133,,,63,148,PAIN,OSTEOID OSTEOMA,PAIN,59,133-141,OSTEOID OSTEOMA,"It is suggested that in any case of persistent unexplained pain of the wrist or clinical symptoms resembling those of tenosynovitis, osteoid osteoma of the styloid process of the radius or of the carpal bones should also be included in the differential diagnosis.",59,133 141,59,133,63,148,1,RO-disease_has_finding,901842,"It is suggested that in any case of persistent unexplained pain of the wrist or clinical symptoms resembling those of tenosynovitis, osteoid osteoma of the styloid process of the radius or of the carpal bones should also be included in the differential diagnosis",pain,osteoid osteoma
502844763,7/13/2014 21:59:21,,1322188396,7/13/2014 21:59:16,clixsense,1,24763049,GBR,,,86.133.47.213,59,133,,,63,148,PAIN,OSTEOID OSTEOMA,of persistent unexplained PAIN of the wrist,33-36-47-59-64-67-71,109-115-118-133-141-149-152-156,"those of tenosynovitis, OSTEOID OSTEOMA of the styloid","It is suggested that in any case of persistent unexplained pain of the wrist or clinical symptoms resembling those of tenosynovitis, osteoid osteoma of the styloid process of the radius or of the carpal bones should also be included in the differential diagnosis.",59,133 141,59,133,63,148,1,RO-disease_has_finding,901842,"It is suggested that in any case of persistent unexplained pain of the wrist or clinical symptoms resembling those of tenosynovitis, osteoid osteoma of the styloid process of the radius or of the carpal bones should also be included in the differential diagnosis",pain,osteoid osteoma
502844763,7/13/2014 22:00:47,,1322189886,7/13/2014 22:00:29,bitcoinget,1,24792414,USA,IA,Independence,166.181.80.204,59,133,,,63,148,PAIN,OSTEOID OSTEOMA,PAIN,59,133-141,OSTEOID OSTEOMA,"It is suggested that in any case of persistent unexplained pain of the wrist or clinical symptoms resembling those of tenosynovitis, osteoid osteoma of the styloid process of the radius or of the carpal bones should also be included in the differential diagnosis.",59,133 141,59,133,63,148,1,RO-disease_has_finding,901842,"It is suggested that in any case of persistent unexplained pain of the wrist or clinical symptoms resembling those of tenosynovitis, osteoid osteoma of the styloid process of the radius or of the carpal bones should also be included in the differential diagnosis",pain,osteoid osteoma
502844763,7/13/2014 22:01:30,,1322190645,7/13/2014 22:01:13,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,59,133,,,63,148,PAIN,OSTEOID OSTEOMA,persistent unexplained PAIN,36-47-59,133-141,OSTEOID OSTEOMA,"It is suggested that in any case of persistent unexplained pain of the wrist or clinical symptoms resembling those of tenosynovitis, osteoid osteoma of the styloid process of the radius or of the carpal bones should also be included in the differential diagnosis.",59,133 141,59,133,63,148,1,RO-disease_has_finding,901842,"It is suggested that in any case of persistent unexplained pain of the wrist or clinical symptoms resembling those of tenosynovitis, osteoid osteoma of the styloid process of the radius or of the carpal bones should also be included in the differential diagnosis",pain,osteoid osteoma
502844763,7/13/2014 22:09:05,,1322196658,7/13/2014 22:08:38,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,59,133,,,63,148,PAIN,OSTEOID OSTEOMA,persistent unexplained PAIN,36-47-59,133-141-149-152-156-164,OSTEOID OSTEOMA of the styloid process,"It is suggested that in any case of persistent unexplained pain of the wrist or clinical symptoms resembling those of tenosynovitis, osteoid osteoma of the styloid process of the radius or of the carpal bones should also be included in the differential diagnosis.",59,133 141,59,133,63,148,1,RO-disease_has_finding,901842,"It is suggested that in any case of persistent unexplained pain of the wrist or clinical symptoms resembling those of tenosynovitis, osteoid osteoma of the styloid process of the radius or of the carpal bones should also be included in the differential diagnosis",pain,osteoid osteoma
502844763,7/13/2014 22:19:33,,1322205430,7/13/2014 22:19:12,prodege,1,28255346,GBR,L9,Sheffield,2.125.183.137,59,133,,,63,148,PAIN,OSTEOID OSTEOMA,persistent unexplained PAIN,36-47-59,133-141-149-152-156,OSTEOID OSTEOMA of the styloid,"It is suggested that in any case of persistent unexplained pain of the wrist or clinical symptoms resembling those of tenosynovitis, osteoid osteoma of the styloid process of the radius or of the carpal bones should also be included in the differential diagnosis.",59,133 141,59,133,63,148,1,RO-disease_has_finding,901842,"It is suggested that in any case of persistent unexplained pain of the wrist or clinical symptoms resembling those of tenosynovitis, osteoid osteoma of the styloid process of the radius or of the carpal bones should also be included in the differential diagnosis",pain,osteoid osteoma
502844763,7/13/2014 22:22:35,,1322208035,7/13/2014 22:22:22,instagc,1,23149109,USA,NC,Durham,75.189.206.205,59,133,,,63,148,PAIN,OSTEOID OSTEOMA,PAIN of the wrist,59-64-67-71,118-133-141-149-152-156,"tenosynovitis, OSTEOID OSTEOMA of the styloid","It is suggested that in any case of persistent unexplained pain of the wrist or clinical symptoms resembling those of tenosynovitis, osteoid osteoma of the styloid process of the radius or of the carpal bones should also be included in the differential diagnosis.",59,133 141,59,133,63,148,1,RO-disease_has_finding,901842,"It is suggested that in any case of persistent unexplained pain of the wrist or clinical symptoms resembling those of tenosynovitis, osteoid osteoma of the styloid process of the radius or of the carpal bones should also be included in the differential diagnosis",pain,osteoid osteoma
502844763,7/13/2014 22:25:06,,1322210388,7/13/2014 22:24:30,prodege,1,2143114,CAN,BC,Vancouver,24.84.160.12,59,133,,,63,148,PAIN,OSTEOID OSTEOMA,persistent unexplained PAIN,36-59-47,133-141,OSTEOID OSTEOMA,"It is suggested that in any case of persistent unexplained pain of the wrist or clinical symptoms resembling those of tenosynovitis, osteoid osteoma of the styloid process of the radius or of the carpal bones should also be included in the differential diagnosis.",59,133 141,59,133,63,148,1,RO-disease_has_finding,901842,"It is suggested that in any case of persistent unexplained pain of the wrist or clinical symptoms resembling those of tenosynovitis, osteoid osteoma of the styloid process of the radius or of the carpal bones should also be included in the differential diagnosis",pain,osteoid osteoma
502844763,7/13/2014 22:27:26,,1322212650,7/13/2014 22:27:08,clixsense,1,26889820,GBR,C3,Shelford,92.18.120.203,59,133,,,63,148,PAIN,OSTEOID OSTEOMA,PAIN,59,133-141-149-152-156,OSTEOID OSTEOMA of the styloid,"It is suggested that in any case of persistent unexplained pain of the wrist or clinical symptoms resembling those of tenosynovitis, osteoid osteoma of the styloid process of the radius or of the carpal bones should also be included in the differential diagnosis.",59,133 141,59,133,63,148,1,RO-disease_has_finding,901842,"It is suggested that in any case of persistent unexplained pain of the wrist or clinical symptoms resembling those of tenosynovitis, osteoid osteoma of the styloid process of the radius or of the carpal bones should also be included in the differential diagnosis",pain,osteoid osteoma
502844764,7/13/2014 21:57:20,,1322186532,7/13/2014 21:57:05,elite,1,28503042,USA,OK,Oakwood,64.250.220.169,107,177,,,127,190,RENAL OSTEODYSTROPHY,RENAL DISEASE,RENAL OSTEODYSTROPHY,107-113,167-171-177-183-198-191,end stage RENAL DISEASE (ESRD) patients.,The purpose of the present study is to investigate whether an ethnic difference exists in the incidence of renal osteodystrophy between Asian and Western countries in end-stage renal disease (ESRD) patients.,107 113,177 183,107,177,127,190,1,RO-cause_of,900407,The purpose of the present study is to investigate whether an ethnic difference exists in the incidence of renal osteodystrophy between Asian and Western countries in end-stage renal disease (ESRD) patients,renal osteodystrophy,renal disease
502844764,7/13/2014 21:59:10,,1322188174,7/13/2014 21:58:51,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,107,177,,,127,190,RENAL OSTEODYSTROPHY,RENAL DISEASE,RENAL OSTEODYSTROPHY,107-113,177-183-191,RENAL DISEASE (ESRD),The purpose of the present study is to investigate whether an ethnic difference exists in the incidence of renal osteodystrophy between Asian and Western countries in end-stage renal disease (ESRD) patients.,107 113,177 183,107,177,127,190,1,RO-cause_of,900407,The purpose of the present study is to investigate whether an ethnic difference exists in the incidence of renal osteodystrophy between Asian and Western countries in end-stage renal disease (ESRD) patients,renal osteodystrophy,renal disease
502844764,7/13/2014 22:01:05,,1322190254,7/13/2014 22:00:26,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,107,177,,,127,190,RENAL OSTEODYSTROPHY,RENAL DISEASE,RENAL OSTEODYSTROPHY end stage renal disease (ESRD) patients.,107-113-167-171-177-183-191-198,107-167-171-177-183-191-198-113,renal osteodystrophy end stage RENAL DISEASE (ESRD) patients.,The purpose of the present study is to investigate whether an ethnic difference exists in the incidence of renal osteodystrophy between Asian and Western countries in end-stage renal disease (ESRD) patients.,107 113,177 183,107,177,127,190,1,RO-cause_of,900407,The purpose of the present study is to investigate whether an ethnic difference exists in the incidence of renal osteodystrophy between Asian and Western countries in end-stage renal disease (ESRD) patients,renal osteodystrophy,renal disease
502844764,7/13/2014 22:06:20,,1322194498,7/13/2014 22:06:00,prodege,1,28255346,GBR,L9,Sheffield,2.125.183.137,107,177,,,127,190,RENAL OSTEODYSTROPHY,RENAL DISEASE,RENAL OSTEODYSTROPHY,107-113,167-171-177-183-191,end stage RENAL DISEASE (ESRD),The purpose of the present study is to investigate whether an ethnic difference exists in the incidence of renal osteodystrophy between Asian and Western countries in end-stage renal disease (ESRD) patients.,107 113,177 183,107,177,127,190,1,RO-cause_of,900407,The purpose of the present study is to investigate whether an ethnic difference exists in the incidence of renal osteodystrophy between Asian and Western countries in end-stage renal disease (ESRD) patients,renal osteodystrophy,renal disease
502844764,7/13/2014 22:08:19,,1322196095,7/13/2014 22:07:55,prodege,1,17932518,GBR,Y2,Pwllheli,95.151.166.224,107,177,,,127,190,RENAL OSTEODYSTROPHY,RENAL DISEASE,RENAL OSTEODYSTROPHY,107-113,177-183,RENAL DISEASE,The purpose of the present study is to investigate whether an ethnic difference exists in the incidence of renal osteodystrophy between Asian and Western countries in end-stage renal disease (ESRD) patients.,107 113,177 183,107,177,127,190,1,RO-cause_of,900407,The purpose of the present study is to investigate whether an ethnic difference exists in the incidence of renal osteodystrophy between Asian and Western countries in end-stage renal disease (ESRD) patients,renal osteodystrophy,renal disease
502844764,7/13/2014 22:10:07,,1322197402,7/13/2014 22:09:48,elite,1,28397222,GBR,,,31.49.231.211,107,177,,,127,190,RENAL OSTEODYSTROPHY,RENAL DISEASE,RENAL OSTEODYSTROPHY,107-113,177-183,RENAL DISEASE,The purpose of the present study is to investigate whether an ethnic difference exists in the incidence of renal osteodystrophy between Asian and Western countries in end-stage renal disease (ESRD) patients.,107 113,177 183,107,177,127,190,1,RO-cause_of,900407,The purpose of the present study is to investigate whether an ethnic difference exists in the incidence of renal osteodystrophy between Asian and Western countries in end-stage renal disease (ESRD) patients,renal osteodystrophy,renal disease
502844764,7/13/2014 22:18:39,,1322204538,7/13/2014 22:18:25,clixsense,1,10842668,GBR,,,80.189.187.36,107,177,,,127,190,RENAL OSTEODYSTROPHY,RENAL DISEASE,RENAL OSTEODYSTROPHY,107-113,177-183,RENAL DISEASE,The purpose of the present study is to investigate whether an ethnic difference exists in the incidence of renal osteodystrophy between Asian and Western countries in end-stage renal disease (ESRD) patients.,107 113,177 183,107,177,127,190,1,RO-cause_of,900407,The purpose of the present study is to investigate whether an ethnic difference exists in the incidence of renal osteodystrophy between Asian and Western countries in end-stage renal disease (ESRD) patients,renal osteodystrophy,renal disease
502844764,7/13/2014 22:20:47,,1322206571,7/13/2014 22:20:15,instagc,1,23149109,USA,NC,Durham,75.189.206.205,107,177,,,127,190,RENAL OSTEODYSTROPHY,RENAL DISEASE,RENAL OSTEODYSTROPHY,107-113,171-177-183-191-167,end stage RENAL DISEASE (ESRD),The purpose of the present study is to investigate whether an ethnic difference exists in the incidence of renal osteodystrophy between Asian and Western countries in end-stage renal disease (ESRD) patients.,107 113,177 183,107,177,127,190,1,RO-cause_of,900407,The purpose of the present study is to investigate whether an ethnic difference exists in the incidence of renal osteodystrophy between Asian and Western countries in end-stage renal disease (ESRD) patients,renal osteodystrophy,renal disease
502844764,7/13/2014 22:24:45,,1322210044,7/13/2014 22:24:27,gifthulk,1,22552178,AUS,5,Adelaide,14.2.7.227,107,177,,,127,190,RENAL OSTEODYSTROPHY,RENAL DISEASE,RENAL OSTEODYSTROPHY,107-113,177-183,RENAL DISEASE,The purpose of the present study is to investigate whether an ethnic difference exists in the incidence of renal osteodystrophy between Asian and Western countries in end-stage renal disease (ESRD) patients.,107 113,177 183,107,177,127,190,1,RO-cause_of,900407,The purpose of the present study is to investigate whether an ethnic difference exists in the incidence of renal osteodystrophy between Asian and Western countries in end-stage renal disease (ESRD) patients,renal osteodystrophy,renal disease
502844764,7/13/2014 22:27:07,,1322212392,7/13/2014 22:26:52,clixsense,1,26889820,GBR,C3,Shelford,92.18.120.203,107,177,,,127,190,RENAL OSTEODYSTROPHY,RENAL DISEASE,RENAL OSTEODYSTROPHY,107-113,167-171-177-183-191,end stage RENAL DISEASE (ESRD),The purpose of the present study is to investigate whether an ethnic difference exists in the incidence of renal osteodystrophy between Asian and Western countries in end-stage renal disease (ESRD) patients.,107 113,177 183,107,177,127,190,1,RO-cause_of,900407,The purpose of the present study is to investigate whether an ethnic difference exists in the incidence of renal osteodystrophy between Asian and Western countries in end-stage renal disease (ESRD) patients,renal osteodystrophy,renal disease
502844765,7/13/2014 21:53:48,,1322183293,7/13/2014 21:53:33,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,178,158,,,202,174,CONTACT HYPERSENSITIVITY,HYPERSENSITIVITY,CONTACT HYPERSENSITIVITY,178-186,158,HYPERSENSITIVITY,Injection of antigen into the anterior chamber of the eye results in the induction of suppressed systemic cell-mediated responses as measured by delayed-type hypersensitivity or contact hypersensitivity (CHS.,178 186,158,178,158,202,174,-1,RO-cause_of,900135,Injection of antigen into the anterior chamber of the eye results in the induction of suppressed systemic cell-mediated responses as measured by delayed-type hypersensitivity or contact hypersensitivity (CHS,contact hypersensitivity,hypersensitivity
502844765,7/13/2014 21:54:46,,1322184150,7/13/2014 21:54:16,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,178,158,,,202,174,CONTACT HYPERSENSITIVITY,HYPERSENSITIVITY,CONTACT HYPERSENSITIVITY,178-186,142-158-178-186,by HYPERSENSITIVITY contact hypersensitivity,Injection of antigen into the anterior chamber of the eye results in the induction of suppressed systemic cell-mediated responses as measured by delayed-type hypersensitivity or contact hypersensitivity (CHS.,178 186,158,178,158,202,174,-1,RO-cause_of,900135,Injection of antigen into the anterior chamber of the eye results in the induction of suppressed systemic cell-mediated responses as measured by delayed-type hypersensitivity or contact hypersensitivity (CHS,contact hypersensitivity,hypersensitivity
502844765,7/13/2014 21:57:59,,1322187135,7/13/2014 21:57:14,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,178,158,,,202,174,CONTACT HYPERSENSITIVITY,HYPERSENSITIVITY,Injection of antigen anterior chamber suppressed systemic cell mediated delayed type hypersensitivity or CONTACT HYPERSENSITIVITY,0-10-13-30-39-86-97-106-111-153-158-175-178-186-145,0-10-13-30-39-86-97-106-111-145-153-158-175-178-186,Injection of antigen anterior chamber suppressed systemic cell mediated delayed type HYPERSENSITIVITY or contact hypersensitivity,Injection of antigen into the anterior chamber of the eye results in the induction of suppressed systemic cell-mediated responses as measured by delayed-type hypersensitivity or contact hypersensitivity (CHS.,178 186,158,178,158,202,174,-1,RO-cause_of,900135,Injection of antigen into the anterior chamber of the eye results in the induction of suppressed systemic cell-mediated responses as measured by delayed-type hypersensitivity or contact hypersensitivity (CHS,contact hypersensitivity,hypersensitivity
502844765,7/13/2014 21:59:02,,1322188029,7/13/2014 21:57:51,prodege,1,17932518,GBR,Y2,Pwllheli,95.151.166.224,178,158,,,202,174,CONTACT HYPERSENSITIVITY,HYPERSENSITIVITY,CONTACT HYPERSENSITIVITY,178-186,158,HYPERSENSITIVITY,Injection of antigen into the anterior chamber of the eye results in the induction of suppressed systemic cell-mediated responses as measured by delayed-type hypersensitivity or contact hypersensitivity (CHS.,178 186,158,178,158,202,174,-1,RO-cause_of,900135,Injection of antigen into the anterior chamber of the eye results in the induction of suppressed systemic cell-mediated responses as measured by delayed-type hypersensitivity or contact hypersensitivity (CHS,contact hypersensitivity,hypersensitivity
502844765,7/13/2014 22:01:12,,1322190402,7/13/2014 22:00:57,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,178,158,,,202,174,CONTACT HYPERSENSITIVITY,HYPERSENSITIVITY,CONTACT HYPERSENSITIVITY,178-186,145-153-158,delayed type HYPERSENSITIVITY,Injection of antigen into the anterior chamber of the eye results in the induction of suppressed systemic cell-mediated responses as measured by delayed-type hypersensitivity or contact hypersensitivity (CHS.,178 186,158,178,158,202,174,-1,RO-cause_of,900135,Injection of antigen into the anterior chamber of the eye results in the induction of suppressed systemic cell-mediated responses as measured by delayed-type hypersensitivity or contact hypersensitivity (CHS,contact hypersensitivity,hypersensitivity
502844765,7/13/2014 22:01:14,,1322190444,7/13/2014 22:00:58,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,178,158,,,202,174,CONTACT HYPERSENSITIVITY,HYPERSENSITIVITY,hypersensitivity or CONTACT HYPERSENSITIVITY (CHS.,158-175-178-186-203,158-175-178-186-203,HYPERSENSITIVITY or contact hypersensitivity (CHS.,Injection of antigen into the anterior chamber of the eye results in the induction of suppressed systemic cell-mediated responses as measured by delayed-type hypersensitivity or contact hypersensitivity (CHS.,178 186,158,178,158,202,174,-1,RO-cause_of,900135,Injection of antigen into the anterior chamber of the eye results in the induction of suppressed systemic cell-mediated responses as measured by delayed-type hypersensitivity or contact hypersensitivity (CHS,contact hypersensitivity,hypersensitivity
502844765,7/13/2014 22:01:27,,1322190591,7/13/2014 22:01:05,bitcoinget,1,24792414,USA,IA,Independence,166.181.80.204,178,158,,,202,174,CONTACT HYPERSENSITIVITY,HYPERSENSITIVITY,CONTACT HYPERSENSITIVITY,178-186,145-158-153,delayed type HYPERSENSITIVITY,Injection of antigen into the anterior chamber of the eye results in the induction of suppressed systemic cell-mediated responses as measured by delayed-type hypersensitivity or contact hypersensitivity (CHS.,178 186,158,178,158,202,174,-1,RO-cause_of,900135,Injection of antigen into the anterior chamber of the eye results in the induction of suppressed systemic cell-mediated responses as measured by delayed-type hypersensitivity or contact hypersensitivity (CHS,contact hypersensitivity,hypersensitivity
502844765,7/13/2014 22:05:21,,1322193720,7/13/2014 22:04:50,prodege,1,28255346,GBR,L9,Sheffield,2.125.183.137,178,158,,,202,174,CONTACT HYPERSENSITIVITY,HYPERSENSITIVITY,CONTACT HYPERSENSITIVITY (CHS.,178-186-203,145-152-153-158,delayed - type HYPERSENSITIVITY,Injection of antigen into the anterior chamber of the eye results in the induction of suppressed systemic cell-mediated responses as measured by delayed-type hypersensitivity or contact hypersensitivity (CHS.,178 186,158,178,158,202,174,-1,RO-cause_of,900135,Injection of antigen into the anterior chamber of the eye results in the induction of suppressed systemic cell-mediated responses as measured by delayed-type hypersensitivity or contact hypersensitivity (CHS,contact hypersensitivity,hypersensitivity
502844765,7/13/2014 22:10:20,,1322197708,7/13/2014 22:10:15,clixsense,1,24763049,GBR,,,86.133.47.213,178,158,,,202,174,CONTACT HYPERSENSITIVITY,HYPERSENSITIVITY,type hypersensitivity or CONTACT HYPERSENSITIVITY,153-158-175-178-186,142-145-153-158-175-178-186,by delayed type HYPERSENSITIVITY or contact hypersensitivity,Injection of antigen into the anterior chamber of the eye results in the induction of suppressed systemic cell-mediated responses as measured by delayed-type hypersensitivity or contact hypersensitivity (CHS.,178 186,158,178,158,202,174,-1,RO-cause_of,900135,Injection of antigen into the anterior chamber of the eye results in the induction of suppressed systemic cell-mediated responses as measured by delayed-type hypersensitivity or contact hypersensitivity (CHS,contact hypersensitivity,hypersensitivity
502844765,7/13/2014 22:11:43,,1322198961,7/13/2014 22:11:18,instagc,1,23149109,USA,NC,Durham,75.189.206.205,178,158,,,202,174,CONTACT HYPERSENSITIVITY,HYPERSENSITIVITY,type hypersensitivity or CONTACT HYPERSENSITIVITY,158-175-178-186-153,145-153-158-175-178-186,delayed type HYPERSENSITIVITY or contact hypersensitivity,Injection of antigen into the anterior chamber of the eye results in the induction of suppressed systemic cell-mediated responses as measured by delayed-type hypersensitivity or contact hypersensitivity (CHS.,178 186,158,178,158,202,174,-1,RO-cause_of,900135,Injection of antigen into the anterior chamber of the eye results in the induction of suppressed systemic cell-mediated responses as measured by delayed-type hypersensitivity or contact hypersensitivity (CHS,contact hypersensitivity,hypersensitivity
502844766,7/13/2014 21:57:09,,1322186386,7/13/2014 21:56:55,instagc,1,28301350,GBR,K4,Plymouth,89.242.63.62,17,30,,,26,61,DYSPLASIA,CARCINOMA IN SITU OF THE CERVIX,DYSPLASIA carcinoma,17-30,17-30-40-43-48-51-55,dysplasia CARCINOMA IN SITU OF THE CERVIX,In patients with dysplasia or carcinoma in situ of the cervix the test was positive in over 80%.,17,30 40 43 48 51 55,17,30,26,61,-1,RO-disease_has_finding,901672,In patients with dysplasia or carcinoma in situ of the cervix the test was positive in over 80%,dysplasia,carcinoma in situ of the cervix
502844766,7/13/2014 21:58:16,,1322187338,7/13/2014 21:57:57,bitcoinget,1,21704174,NLD,7,Beverwijk,83.81.75.251,17,30,,,26,61,DYSPLASIA,CARCINOMA IN SITU OF THE CERVIX,DYSPLASIA,17,30-40-43-48-51-55,CARCINOMA IN SITU OF THE CERVIX,In patients with dysplasia or carcinoma in situ of the cervix the test was positive in over 80%.,17,30 40 43 48 51 55,17,30,26,61,-1,RO-disease_has_finding,901672,In patients with dysplasia or carcinoma in situ of the cervix the test was positive in over 80%,dysplasia,carcinoma in situ of the cervix
502844766,7/13/2014 22:01:01,,1322190225,7/13/2014 21:59:40,prodege,1,17932518,GBR,Y2,Pwllheli,95.151.166.224,17,30,,,26,61,DYSPLASIA,CARCINOMA IN SITU OF THE CERVIX,DYSPLASIA,17,30-40-43-48-51-55,CARCINOMA IN SITU OF THE CERVIX,In patients with dysplasia or carcinoma in situ of the cervix the test was positive in over 80%.,17,30 40 43 48 51 55,17,30,26,61,-1,RO-disease_has_finding,901672,In patients with dysplasia or carcinoma in situ of the cervix the test was positive in over 80%,dysplasia,carcinoma in situ of the cervix
502844766,7/13/2014 22:03:52,,1322192547,7/13/2014 22:03:28,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,17,30,,,26,61,DYSPLASIA,CARCINOMA IN SITU OF THE CERVIX,DYSPLASIA or carcinoma in situ of the cervix,17-27-30-40-43-48-51-55,30-40-43-48-51-55-62-66-71,CARCINOMA IN SITU OF THE CERVIX the test was,In patients with dysplasia or carcinoma in situ of the cervix the test was positive in over 80%.,17,30 40 43 48 51 55,17,30,26,61,-1,RO-disease_has_finding,901672,In patients with dysplasia or carcinoma in situ of the cervix the test was positive in over 80%,dysplasia,carcinoma in situ of the cervix
502844766,7/13/2014 22:05:09,,1322193554,7/13/2014 22:04:37,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,17,30,,,26,61,DYSPLASIA,CARCINOMA IN SITU OF THE CERVIX,In patients with DYSPLASIA or carcinoma in situ of the cervix,0-3-12-17-27-30-40-43-48-51-55,0-12-17-27-30-40-43-48-51-55-62-66-71-3,In patients with dysplasia or CARCINOMA IN SITU OF THE CERVIX the test was,In patients with dysplasia or carcinoma in situ of the cervix the test was positive in over 80%.,17,30 40 43 48 51 55,17,30,26,61,-1,RO-disease_has_finding,901672,In patients with dysplasia or carcinoma in situ of the cervix the test was positive in over 80%,dysplasia,carcinoma in situ of the cervix
502844766,7/13/2014 22:07:34,,1322195446,7/13/2014 22:07:17,clixsense,1,27871219,NLD,7,Amsterdam,87.210.207.223,17,30,,,26,61,DYSPLASIA,CARCINOMA IN SITU OF THE CERVIX,DYSPLASIA,17,30-40-43-48-51-55,CARCINOMA IN SITU OF THE CERVIX,In patients with dysplasia or carcinoma in situ of the cervix the test was positive in over 80%.,17,30 40 43 48 51 55,17,30,26,61,-1,RO-disease_has_finding,901672,In patients with dysplasia or carcinoma in situ of the cervix the test was positive in over 80%,dysplasia,carcinoma in situ of the cervix
502844766,7/13/2014 22:07:45,,1322195663,7/13/2014 22:07:12,prodege,1,28255346,GBR,L9,Sheffield,2.125.183.137,17,30,,,26,61,DYSPLASIA,CARCINOMA IN SITU OF THE CERVIX,DYSPLASIA,17,30-40-43-48-51-55,CARCINOMA IN SITU OF THE CERVIX,In patients with dysplasia or carcinoma in situ of the cervix the test was positive in over 80%.,17,30 40 43 48 51 55,17,30,26,61,-1,RO-disease_has_finding,901672,In patients with dysplasia or carcinoma in situ of the cervix the test was positive in over 80%,dysplasia,carcinoma in situ of the cervix
502844766,7/13/2014 22:17:57,,1322203896,7/13/2014 22:17:42,clixsense,1,10842668,GBR,,,80.189.187.36,17,30,,,26,61,DYSPLASIA,CARCINOMA IN SITU OF THE CERVIX,DYSPLASIA,17,30-40-43-48-51-55,CARCINOMA IN SITU OF THE CERVIX,In patients with dysplasia or carcinoma in situ of the cervix the test was positive in over 80%.,17,30 40 43 48 51 55,17,30,26,61,-1,RO-disease_has_finding,901672,In patients with dysplasia or carcinoma in situ of the cervix the test was positive in over 80%,dysplasia,carcinoma in situ of the cervix
502844766,7/13/2014 22:25:22,,1322210639,7/13/2014 22:24:45,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,17,30,,,26,61,DYSPLASIA,CARCINOMA IN SITU OF THE CERVIX,DYSPLASIA,17,30-40-43-48-51-55,CARCINOMA IN SITU OF THE CERVIX,In patients with dysplasia or carcinoma in situ of the cervix the test was positive in over 80%.,17,30 40 43 48 51 55,17,30,26,61,-1,RO-disease_has_finding,901672,In patients with dysplasia or carcinoma in situ of the cervix the test was positive in over 80%,dysplasia,carcinoma in situ of the cervix
502844766,7/13/2014 22:26:44,,1322211991,7/13/2014 22:26:31,prodege,1,2143114,CAN,BC,Vancouver,24.84.160.12,17,30,,,26,61,DYSPLASIA,CARCINOMA IN SITU OF THE CERVIX,DYSPLASIA,17,30-40-43-48-51-55,CARCINOMA IN SITU OF THE CERVIX,In patients with dysplasia or carcinoma in situ of the cervix the test was positive in over 80%.,17,30 40 43 48 51 55,17,30,26,61,-1,RO-disease_has_finding,901672,In patients with dysplasia or carcinoma in situ of the cervix the test was positive in over 80%,dysplasia,carcinoma in situ of the cervix
502844767,7/13/2014 21:49:54,,1322180111,7/13/2014 21:49:35,instagc,1,28301350,GBR,K4,Plymouth,89.242.63.62,81,32,,,85,45,PAIN,ACETAMINOPHEN,PAIN,81,32-81,ACETAMINOPHEN pain,"She is given a prescription for acetaminophen with codeine to take as needed for pain the week before surgery, and she is instructed to take her atenolol the morning of surgery with a sip of water.",81,32,81,32,85,45,1,RO-may_treat,907827,"She is given a prescription for acetaminophen with codeine to take as needed for pain the week before surgery, and she is instructed to take her atenolol the morning of surgery with a sip of water",pain,acetaminophen
502844767,7/13/2014 21:59:22,,1322188389,7/13/2014 21:59:04,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,81,32,,,85,45,PAIN,ACETAMINOPHEN,PAIN,81,32,ACETAMINOPHEN,"She is given a prescription for acetaminophen with codeine to take as needed for pain the week before surgery, and she is instructed to take her atenolol the morning of surgery with a sip of water.",81,32,81,32,85,45,1,RO-may_treat,907827,"She is given a prescription for acetaminophen with codeine to take as needed for pain the week before surgery, and she is instructed to take her atenolol the morning of surgery with a sip of water",pain,acetaminophen
502844767,7/13/2014 22:02:50,,1322191776,7/13/2014 22:02:31,elite,1,28397222,GBR,,,31.49.231.211,81,32,,,85,45,PAIN,ACETAMINOPHEN,PAIN,81,32,ACETAMINOPHEN,"She is given a prescription for acetaminophen with codeine to take as needed for pain the week before surgery, and she is instructed to take her atenolol the morning of surgery with a sip of water.",81,32,81,32,85,45,1,RO-may_treat,907827,"She is given a prescription for acetaminophen with codeine to take as needed for pain the week before surgery, and she is instructed to take her atenolol the morning of surgery with a sip of water",pain,acetaminophen
502844767,7/13/2014 22:04:41,,1322193252,7/13/2014 22:04:22,neodev,1,28175665,CAN,ON,Brampton,99.228.31.59,81,32,,,85,45,PAIN,ACETAMINOPHEN,"as needed for PAIN the week before surgery,",67-70-77-81-86-90-95-102,32-46-51,ACETAMINOPHEN with codeine,"She is given a prescription for acetaminophen with codeine to take as needed for pain the week before surgery, and she is instructed to take her atenolol the morning of surgery with a sip of water.",81,32,81,32,85,45,1,RO-may_treat,907827,"She is given a prescription for acetaminophen with codeine to take as needed for pain the week before surgery, and she is instructed to take her atenolol the morning of surgery with a sip of water",pain,acetaminophen
502844767,7/13/2014 22:15:15,,1322201743,7/13/2014 22:14:49,prodege,1,28255346,GBR,L9,Sheffield,2.125.183.137,81,32,,,85,45,PAIN,ACETAMINOPHEN,PAIN,81,32-46-51,ACETAMINOPHEN with codeine,"She is given a prescription for acetaminophen with codeine to take as needed for pain the week before surgery, and she is instructed to take her atenolol the morning of surgery with a sip of water.",81,32,81,32,85,45,1,RO-may_treat,907827,"She is given a prescription for acetaminophen with codeine to take as needed for pain the week before surgery, and she is instructed to take her atenolol the morning of surgery with a sip of water",pain,acetaminophen
502844767,7/13/2014 22:16:22,,1322202687,7/13/2014 22:16:09,clixsense,1,10842668,GBR,,,80.189.187.36,81,32,,,85,45,PAIN,ACETAMINOPHEN,PAIN,81,32,ACETAMINOPHEN,"She is given a prescription for acetaminophen with codeine to take as needed for pain the week before surgery, and she is instructed to take her atenolol the morning of surgery with a sip of water.",81,32,81,32,85,45,1,RO-may_treat,907827,"She is given a prescription for acetaminophen with codeine to take as needed for pain the week before surgery, and she is instructed to take her atenolol the morning of surgery with a sip of water",pain,acetaminophen
502844767,7/13/2014 22:23:13,,1322208532,7/13/2014 22:22:56,gifthulk,1,22552178,AUS,5,Adelaide,14.2.7.227,81,32,,,85,45,PAIN,ACETAMINOPHEN,PAIN,81,32,ACETAMINOPHEN,"She is given a prescription for acetaminophen with codeine to take as needed for pain the week before surgery, and she is instructed to take her atenolol the morning of surgery with a sip of water.",81,32,81,32,85,45,1,RO-may_treat,907827,"She is given a prescription for acetaminophen with codeine to take as needed for pain the week before surgery, and she is instructed to take her atenolol the morning of surgery with a sip of water",pain,acetaminophen
502844767,7/13/2014 22:24:27,,1322209659,7/13/2014 22:23:25,clixsense,1,21875134,GBR,,,91.125.61.83,81,32,,,85,45,PAIN,ACETAMINOPHEN,take as needed for PAIN,62-67-70-77-81,32-46-51,ACETAMINOPHEN with codeine,"She is given a prescription for acetaminophen with codeine to take as needed for pain the week before surgery, and she is instructed to take her atenolol the morning of surgery with a sip of water.",81,32,81,32,85,45,1,RO-may_treat,907827,"She is given a prescription for acetaminophen with codeine to take as needed for pain the week before surgery, and she is instructed to take her atenolol the morning of surgery with a sip of water",pain,acetaminophen
502844767,7/13/2014 22:24:40,,1322209986,7/13/2014 22:24:24,clixsense,1,26889820,GBR,C3,Shelford,92.18.120.203,81,32,,,85,45,PAIN,ACETAMINOPHEN,PAIN,81,32,ACETAMINOPHEN,"She is given a prescription for acetaminophen with codeine to take as needed for pain the week before surgery, and she is instructed to take her atenolol the morning of surgery with a sip of water.",81,32,81,32,85,45,1,RO-may_treat,907827,"She is given a prescription for acetaminophen with codeine to take as needed for pain the week before surgery, and she is instructed to take her atenolol the morning of surgery with a sip of water",pain,acetaminophen
502844767,7/13/2014 22:26:05,,1322211287,7/13/2014 22:25:51,prodege,1,2143114,CAN,BC,Vancouver,24.84.160.12,81,32,,,85,45,PAIN,ACETAMINOPHEN,PAIN,81,32,ACETAMINOPHEN,"She is given a prescription for acetaminophen with codeine to take as needed for pain the week before surgery, and she is instructed to take her atenolol the morning of surgery with a sip of water.",81,32,81,32,85,45,1,RO-may_treat,907827,"She is given a prescription for acetaminophen with codeine to take as needed for pain the week before surgery, and she is instructed to take her atenolol the morning of surgery with a sip of water",pain,acetaminophen
502844768,7/13/2014 21:54:10,,1322183649,7/13/2014 21:53:49,clixsense,1,19803139,NLD,11,Leiden,82.139.76.131,175,95,,,181,129,TUMORS,DIETHYLENETRIAMINEPENTAACETIC ACID,TUMORS,175,95-125,DIETHYLENETRIAMINEPENTAACETIC ACID,Antibodies modified on the oligosaccharides with either a peptide labeled with iodine-125 or a diethylenetriaminepentaacetic acid chelate with indium-111 localize into target tumors more efficiently than the same antibody radiolabeled on either tyrosines or lysines.,175,95 125,175,95,181,129,1,RO-may_diagnose,906990,Antibodies modified on the oligosaccharides with either a peptide labeled with iodine-125 or a diethylenetriaminepentaacetic acid chelate with indium-111 localize into target tumors more efficiently than the same antibody radiolabeled on either tyrosines or lysines,tumors,diethylenetriaminepentaacetic acid
502844768,7/13/2014 21:54:29,,1322183845,7/13/2014 21:52:55,instagc,1,19686223,CAN,BC,Surrey,154.20.155.106,175,95,,,181,129,TUMORS,DIETHYLENETRIAMINEPENTAACETIC ACID,Antibodies oligosaccharides peptide iodine 125 diethylenetriaminepentaacetic acid chelate indium 111 localize into target TUMORS than antibody radiolabeled tyrosines or lysines.,0-27-58-79-86-95-125-130-143-150-154-163-168-175-199-213-222-245-255-258,0-27-58-79-86-95-125-130-143-150-154-163-168-175-213-222-245-258,Antibodies oligosaccharides peptide iodine 125 DIETHYLENETRIAMINEPENTAACETIC ACID chelate indium 111 localize into target tumors antibody radiolabeled tyrosines lysines.,Antibodies modified on the oligosaccharides with either a peptide labeled with iodine-125 or a diethylenetriaminepentaacetic acid chelate with indium-111 localize into target tumors more efficiently than the same antibody radiolabeled on either tyrosines or lysines.,175,95 125,175,95,181,129,1,RO-may_diagnose,906990,Antibodies modified on the oligosaccharides with either a peptide labeled with iodine-125 or a diethylenetriaminepentaacetic acid chelate with indium-111 localize into target tumors more efficiently than the same antibody radiolabeled on either tyrosines or lysines,tumors,diethylenetriaminepentaacetic acid
502844768,7/13/2014 21:56:26,,1322185674,7/13/2014 21:56:12,elite,1,28503042,USA,OK,Oakwood,64.250.220.169,175,95,,,181,129,TUMORS,DIETHYLENETRIAMINEPENTAACETIC ACID,TUMORS,175,95-125,DIETHYLENETRIAMINEPENTAACETIC ACID,Antibodies modified on the oligosaccharides with either a peptide labeled with iodine-125 or a diethylenetriaminepentaacetic acid chelate with indium-111 localize into target tumors more efficiently than the same antibody radiolabeled on either tyrosines or lysines.,175,95 125,175,95,181,129,1,RO-may_diagnose,906990,Antibodies modified on the oligosaccharides with either a peptide labeled with iodine-125 or a diethylenetriaminepentaacetic acid chelate with indium-111 localize into target tumors more efficiently than the same antibody radiolabeled on either tyrosines or lysines,tumors,diethylenetriaminepentaacetic acid
502844768,7/13/2014 22:03:19,,1322192166,7/13/2014 22:02:50,neodev,1,28175665,CAN,ON,Brampton,99.228.31.59,175,95,,,181,129,TUMORS,DIETHYLENETRIAMINEPENTAACETIC ACID,localize into target TUMORS more efficiently,154-163-168-175-182-187,95-125-130-138-143-150,DIETHYLENETRIAMINEPENTAACETIC ACID chelate with indium 111,Antibodies modified on the oligosaccharides with either a peptide labeled with iodine-125 or a diethylenetriaminepentaacetic acid chelate with indium-111 localize into target tumors more efficiently than the same antibody radiolabeled on either tyrosines or lysines.,175,95 125,175,95,181,129,1,RO-may_diagnose,906990,Antibodies modified on the oligosaccharides with either a peptide labeled with iodine-125 or a diethylenetriaminepentaacetic acid chelate with indium-111 localize into target tumors more efficiently than the same antibody radiolabeled on either tyrosines or lysines,tumors,diethylenetriaminepentaacetic acid
502844768,7/13/2014 22:03:27,,1322192218,7/13/2014 22:02:36,clixsense,1,25402344,CAN,ON,Wawa,24.109.124.45,175,95,,,181,129,TUMORS,DIETHYLENETRIAMINEPENTAACETIC ACID,localize into target TUMORS more efficiently than,154-163-168-175-182-187-199,86-90-93-95-125-130-138-143,125 or a DIETHYLENETRIAMINEPENTAACETIC ACID chelate with indium,Antibodies modified on the oligosaccharides with either a peptide labeled with iodine-125 or a diethylenetriaminepentaacetic acid chelate with indium-111 localize into target tumors more efficiently than the same antibody radiolabeled on either tyrosines or lysines.,175,95 125,175,95,181,129,1,RO-may_diagnose,906990,Antibodies modified on the oligosaccharides with either a peptide labeled with iodine-125 or a diethylenetriaminepentaacetic acid chelate with indium-111 localize into target tumors more efficiently than the same antibody radiolabeled on either tyrosines or lysines,tumors,diethylenetriaminepentaacetic acid
502844768,7/13/2014 22:06:18,,1322194519,7/13/2014 22:05:50,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,175,95,,,181,129,TUMORS,DIETHYLENETRIAMINEPENTAACETIC ACID,TUMORS,175,95-125-130,DIETHYLENETRIAMINEPENTAACETIC ACID chelate,Antibodies modified on the oligosaccharides with either a peptide labeled with iodine-125 or a diethylenetriaminepentaacetic acid chelate with indium-111 localize into target tumors more efficiently than the same antibody radiolabeled on either tyrosines or lysines.,175,95 125,175,95,181,129,1,RO-may_diagnose,906990,Antibodies modified on the oligosaccharides with either a peptide labeled with iodine-125 or a diethylenetriaminepentaacetic acid chelate with indium-111 localize into target tumors more efficiently than the same antibody radiolabeled on either tyrosines or lysines,tumors,diethylenetriaminepentaacetic acid
502844768,7/13/2014 22:16:08,,1322202432,7/13/2014 22:15:53,clixsense,1,10842668,GBR,,,80.189.187.36,175,95,,,181,129,TUMORS,DIETHYLENETRIAMINEPENTAACETIC ACID,TUMORS,175,95-125,DIETHYLENETRIAMINEPENTAACETIC ACID,Antibodies modified on the oligosaccharides with either a peptide labeled with iodine-125 or a diethylenetriaminepentaacetic acid chelate with indium-111 localize into target tumors more efficiently than the same antibody radiolabeled on either tyrosines or lysines.,175,95 125,175,95,181,129,1,RO-may_diagnose,906990,Antibodies modified on the oligosaccharides with either a peptide labeled with iodine-125 or a diethylenetriaminepentaacetic acid chelate with indium-111 localize into target tumors more efficiently than the same antibody radiolabeled on either tyrosines or lysines,tumors,diethylenetriaminepentaacetic acid
502844768,7/13/2014 22:19:11,,1322205060,7/13/2014 22:18:47,prodege,1,28255346,GBR,L9,Sheffield,2.125.183.137,175,95,,,181,129,TUMORS,DIETHYLENETRIAMINEPENTAACETIC ACID,target TUMORS,168-175,95-125-130-138-143,DIETHYLENETRIAMINEPENTAACETIC ACID chelate with indium,Antibodies modified on the oligosaccharides with either a peptide labeled with iodine-125 or a diethylenetriaminepentaacetic acid chelate with indium-111 localize into target tumors more efficiently than the same antibody radiolabeled on either tyrosines or lysines.,175,95 125,175,95,181,129,1,RO-may_diagnose,906990,Antibodies modified on the oligosaccharides with either a peptide labeled with iodine-125 or a diethylenetriaminepentaacetic acid chelate with indium-111 localize into target tumors more efficiently than the same antibody radiolabeled on either tyrosines or lysines,tumors,diethylenetriaminepentaacetic acid
502844768,7/13/2014 22:21:42,,1322207287,7/13/2014 22:21:01,clixsense,1,26889820,GBR,C3,Shelford,92.18.120.203,175,95,,,181,129,TUMORS,DIETHYLENETRIAMINEPENTAACETIC ACID,TUMORS,175,95-125,DIETHYLENETRIAMINEPENTAACETIC ACID,Antibodies modified on the oligosaccharides with either a peptide labeled with iodine-125 or a diethylenetriaminepentaacetic acid chelate with indium-111 localize into target tumors more efficiently than the same antibody radiolabeled on either tyrosines or lysines.,175,95 125,175,95,181,129,1,RO-may_diagnose,906990,Antibodies modified on the oligosaccharides with either a peptide labeled with iodine-125 or a diethylenetriaminepentaacetic acid chelate with indium-111 localize into target tumors more efficiently than the same antibody radiolabeled on either tyrosines or lysines,tumors,diethylenetriaminepentaacetic acid
502844768,7/13/2014 22:24:26,,1322209610,7/13/2014 22:24:02,gifthulk,1,22552178,AUS,5,Adelaide,14.2.7.227,175,95,,,181,129,TUMORS,DIETHYLENETRIAMINEPENTAACETIC ACID,TUMORS,175,95-125,DIETHYLENETRIAMINEPENTAACETIC ACID,Antibodies modified on the oligosaccharides with either a peptide labeled with iodine-125 or a diethylenetriaminepentaacetic acid chelate with indium-111 localize into target tumors more efficiently than the same antibody radiolabeled on either tyrosines or lysines.,175,95 125,175,95,181,129,1,RO-may_diagnose,906990,Antibodies modified on the oligosaccharides with either a peptide labeled with iodine-125 or a diethylenetriaminepentaacetic acid chelate with indium-111 localize into target tumors more efficiently than the same antibody radiolabeled on either tyrosines or lysines,tumors,diethylenetriaminepentaacetic acid
